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cArdiometAbolic heAlth
Cardiometabolic health plays an important role in healthy aging and longevity. Despite improvements 
in prevention, the prevalence of type 2 diabetes (T2D) continues to increase, and cardiovascular 
disease (CVD) remains the leading cause of death worldwide.1, 2 Addressing risk factors of T2D and 
CVD would help to further improve prevention, but this requires a better understanding of the etiol-
ogy of these cardiometabolic diseases. One of the major risk factors for CVD and T2D is obesity.3 In 
addition, dyslipidemia, defined as decreased high-density lipoprotein-cholesterol (HDL-C), elevated 
low-density lipoprotein-cholesterol (LDL-C), and/or elevated triacylglycerol (TAG) concentrations,4 
is recognized as a prominent risk factor for CVD.5, 6 Cardiometabolic risk factors such as obesity 
and dyslipidemia, are not only important for cardiometabolic disease risk in adulthood, but already 
during childhood. Several studies have shown that the development of cardiometabolic risk factors 
already begins in early life and that these risk factors track into adulthood.7-9 As the prevalence of 
overweight and obesity is rising among children, these children are also at higher risk of obesity, T2D, 
and CVD in adulthood.10 Therefore, gaining knowledge about factors that may influence cardiometa-
bolic health across different stages of the life course is very relevant for early prevention of T2D and 
CVD.11
ePigenetic influences on cArdiometAbolic heAlth
Both T2D and CVD are influenced by environmental and genetic factors. Several genome-wide 
association studies (GWAS) have identified loci that explain a fraction of the variance in T2D and 
CVD or their related risk factors.12, 13 Beyond this, the role of epigenetic determinants is increasingly 
recognized as a potential important link between environmental exposure and disease risk. Thus, 
epigenetic determinants may be a benchmark to capture the influences of environmental exposures 
and disease risk in cardiometabolic health.14 Epigenetics refers to the mechanisms that affect gene 
expression, without changing the sequence of DNA.15 The best understood and most studied epi-
genetic mechanism is DNA methylation, the attachment of a methyl group to a CpG site. Several 
prominent risk factors for T2D and CVD, including dyslipidemia and obesity may be regulated by 
DNA methylation. Expanding this knowledge can help to further unravel our understanding of un-
derlying mechanisms that are leading to T2D and CVD. Recently, epigenome-wide association studies 
(EWAS) have become available, providing further insights into the DNA methylation alterations as-
sociated with complex traits and diseases, and providing an opportunity to identify epigenetic profiles 
that underlie these traits and disease. The study of epigenetic markers is emerging as a promising 
molecular strategy for risk stratification for complex diseases, and, when implemented, it could have a 
sizable public health and clinical impact.16 Epidemiological studies have mainly investigated the rela-
tion between DNA methylation and cardiometabolic risk factors using a candidate-gene approach, 
reporting that lipid concentrations are associated with DNA methylation of several CpG sites, such as 
APOE and ABCA1.17, 18 In addition to the candidate-gene approach, gene-specific DNA methylation 
was also studied for the whole genome. Results of these EWASs confirmed associations of known 
lipid-associated genes, such as ABCG1, but novel CpG sites were also identified. To date, only a few 
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studies have examined blood lipids in relation to differentially methylated sites on a genome-wide 
level.19-21 However, these studies have mainly been performed in patient populations, while only one 
study has been performed within a population-based study. Although promising results have been 
reported in the field of epigenetics and dyslipidemia, our understanding of the role of epigenetics in 
regulating cardiometabolic risk in the general population is still limited.
the role of nutrition in dnA methylAtion And cArdio­
metAbolic heAlth
Considering that DNA methylation is reversible and can be influenced by environmental factors, 
future therapies targeting the epigenome may be a novel strategy to prevent and treat dyslipidemia, 
obesity, and subsequently decreasing the risk of T2D and CVD. Nutrition is one of the environ-
mental factors which can affect DNA methylation, and consequently several health outcomes.22-24 
Some nutrients are directly involved in methylation of DNA, such as vitamin B2, vitamin B6, vitamin 
B12, folate and methionine, which are also known as methyl donor nutrients. These nutrients act as 
co-factors in the one-carbon metabolism, resulting in the forming of s-adenosylmethionine (SAM), 
which is the primary methyl donor.25 Deficiency of these methyl donor nutrients could cause dys-
regulation of DNA methylation and may lead to disturbed energy and lipid metabolism, increasing 
the risk of cardiometabolic diseases.26-28 Findings from animal studies show that DNA methylation is 
prone to modification by external factors in early life. The effect of methyl donor nutrients on DNA 
methylation was studied for example in agouti mice, which are genetically predisposed to diabetes 
and obesity. When these mice received methyl donor nutrient supplementation during pregnancy, 
their offspring were at lower risk of obesity and diabetes compared to the offspring of which their 
mothers did not receive methyl donor nutrients.29 This difference in phenotype was caused by differ-
ential DNA methylation. Results from other animal studies showed that supplementation of methyl 
donor nutrients affected DNA methylation and subsequenlty reduced liver fat accumulation,30 and 
have a protective effect on the development of obesity.31, 32 In addition to methyl donor nutrients, also 
other nutrients, such as protein and fatty acids, may have an effect on DNA methylation. For example, 
offspring of pigs fed a low-protein diet during gestation had lower DNA methylation at cardiometa-
bolic genes compared to those fed a high-protein diet.33-35 Furthermore, also high-fat diets have been 
shown to alter DNA methylation at metabolic genes in mice.36 The influence of nutrition on DNA 
methylation has also been studied in humans, both during pregnancy or in other lifecourse stages, 
such as adolescence and adulthood. These studies suggest  that higher intake of methyl donor nutri-
ents, such as folate or vitamin B12, is associated with differential DNA methylation.25 However, there 
is still a lot of inconsistency in these results and further studies are needed to elucidate these associa-
tions. As epigenetic mechanisms may be affected by nutrition, more research should be performed 
on epigenetic therapy strategies to reduce the high burden of T2D and CVD, establishing potential 
novel therapeutic and preventive strategies in cardiometabolic risk.37 Due to the modifiability of diet, 
optimizing nutrition is an eminently suitable strategy for prevention of cardiometabolic diseases.
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objectiVes
The overall aim of this thesis was to investigate associations between nutritional factors, DNA 
methylation, and cardiometabolic health in children as well as adults. (Figure 1.1.). Therefore, the 
following objectives were:
1. To investigate nutritional factors associated with DNA methylation.
2. To identify differentially methylated CpG sites in relation to cardiometabolic risk factors.
3. To examine associations between nutrition and cardiometabolic risk factors in childhood.
4. To examine associations between nutrition and cardiometabolic diseases in adulthood.
study PoPulAtions
The studies presented in this thesis were embedded in the Generation R Study, The Rotterdam Study, 
the B-PROOF Study, Nurses’ Health Study, Nurses’ Health Study II, and Health Professionals Follow-
Up Study.
The generation r study
The Generation R Study is a population-based prospective cohort from early fetal life onward in 
Rotterdam, the Netherlands.38 Pregnant women with a delivery date between April 2002 and January 
2006 were enrolled in the study, and data on follow-up in early childhood was available for 7,893 
children. In this thesis, we included data on dietary intake in early childhood and growth, body com-
position and cardiometabolic health during follow-up. Food intake was assessed when the children 
had a median age of 1 year using a 211-item semi-quantitative food frequency questionnaire (FFQ), 
which was specifically designed for this age group.39 Growth, including height, weight, and BMI were 
measured repeatedly during routine visits to Child Health Centers up to the age of 4 years. At the 
age of 6 years, children visited our research center in Erasmus Medical Center for a detailed physical 
examination.40 During this visit we measured not only height, weight, and BMI, but also body fat 
mass and fat-free mass, and blood samples were obtained to determine concentrations of insulin, 
TAG, total cholesterol, HDL-cholesterol, LDL-cholesterol, and C-peptide.
 
DNA methylation 
Cardiometabolic 
health  
Nutrition 
Objective 2 Objective 1 
Objectives 3 & 4 
figure 1.1. Overview of objectives included in this thesis
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The rotterdam study
The Rotterdam Study is a large prospective, population-based cohort aimed at assessing the occur-
rence of and risk factors for chronic diseases (cardiovascular, endocrine, hepatic, neurological, oph-
thalmic, psychiatric, dermatological, oncological, and respiratory) in the middle-aged and elderly.41 
A total of 14,926 subjects, living in the well-deﬁned Ommoord district in the city of Rotterdam in the 
Netherlands are included in this study. The first sub-cohort, Rotterdam Study-I (RS-I), started in 1990 
and comprised of 7,983 subjects with age 55 years or above. The second sub-cohort (RS-II), started in 
2000 and included 3,011 subjects who had reached an age of 45 years since 1989. The third sub-cohort, 
Rotterdam Study-III (RS-III), started in 2006 and consisted of 3,932 subjects aged 45 years and above. 
Dietary intake was measured at baseline visits of all three cohorts using validated semi-quantitative 
FFQs. During the visits to the research center, BMI and waist circumference were measured and 
participants had blood samples taken to determine concentrations of triglycerides, HDL-C, and total 
cholesterol. DNA methylation was measured in a random sample of 1,454 participants from the third 
visit of the second cohort (RS-II-3) and first and second visit of the third cohort (RS-III-1, RS-III-2).
The b-Proof study
In Chapter 5.1 baseline data of the B-PROOF (B-vitamins for the Prevention Of Osteoporotic 
Fractures) study were used. The B-PROOF study is a multi-center, randomized, placebo-controlled, 
double-blind intervention study, investigating the effect of a 2-year daily oral vitamin B12 (500 µg) 
and folic acid (400 µg) supplementation on fracture incidence. The study was conducted in three 
research centers in the Netherlands: VU University Medical Center (Amsterdam), Wageningen 
University (Wageningen), and Erasmus Medical Center (Rotterdam). This study included 2919 
individuals, aged 65 years and older with elevated homocysteine levels (12 - 50 µmol/l).42 At baseline, 
venous blood samples were obtained and serum folate, vitamin B12, methylmalonic acid (MMA), and 
holo-transcobalamin (HoloTC) were determined.42, 43 Furthermore, height, weight, and BMI were 
measured, and in a subsample of participants from the Amsterdam and Rotterdam region (n=1227) 
body fat mass and fat-free mass were measured by Dual Energy X-ray assessment (DXA). Dietary 
data were collected in a subsample of the Wageningen region (n=603), using a Food Frequency 
Questionnaire (FFQ).
nurses’ health study, nurses’ health study ii, and health Professionals 
follow-up study
Data from three prospective cohort studies in the USA were used in chapter 5.2 of this thesis: the 
Nurses’ Health Study (NHS), Nurses’ Health Study II (NHS2), and the Health Professionals’ Follow-
Up Study (HPFS). The NHS started in 1976 with 121,701 female nurses aged 30-55 years, the NHS2 
started in 1989 with 116,430 female nurses aged 25-42 years, and the HPFS started in 1986 with 
51,529 male health professionals aged 40-75 years. In all three cohorts, information on lifestyle and 
medical history was obtained by questionnaires at baseline and every 2 years during follow-up, with 
a response rate of ~90% per cycle. For the study included in this thesis, we used data on diet and dia-
betes. Dietary data were collected every 2-4 years using a validated semi-quantitative FFQ consisting 
of ~130 food items.44, 45 Participants in all three cohorts were asked whether they were diagnosed with 
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diabetes by a physician every two years. Participants who self-reported physician diagnosed diabetes 
were sent a supplementary questionnaire to confirm diagnosis.46, 47
thesis outline
Chapter 2 provides an overview of the current evidence on the associations of different nutrients 
with DNA methylation in humans across all stages of the life course (i.e. during pregnancy, infancy, 
childhood, adolescence, and adulthood).
Chapter 3 focuses on associations of DNA methylation and cardiometabolic risk factors. Chapter 
3.1 provides an overview of the current literature on the association between DNA methylation and 
lipid levels. In Chapter 3.2 results of an EWAS on lipid levels in the Rotterdam Study are presented. 
Chapter 3.3 presents the findings of an EWAS on BMI and WC in the Rotterdam Study and replica-
tion of these findings in a USA-based study.
Chapter 4 focuses on associations of nutrition in early childhood with cardiometabolic health 
in children at school age from The Generation R Study. In Chapter 4.1 the associations of intake of 
methyl donor nutrients, including vitamin B6, vitamin B12, folate, and methionine with growth and 
body composition are described. Chapter 4.2 describes the association between protein intake and 
repeatedly measured growth. Chapter 4.3 presents associations between protein intake and detailed 
body composition. Chapter 4.4 describes associations of different types of fatty acids with body 
composition and cardiometabolic health in childhood.
Chapter 5 focuses on associations between nutrition and cardiometabolic health in adults. Chap-
ter 5.1 presents the associations of folate and vitamin B12 with body composition in the B-PROOF 
study. Chapter 5.2 studied the role of methyl donor nutrients and the risk of diabetes using data 
from the Nurses’ Health Study, Nurses’ Health Study II, and Health Professionals Follow-Up Study. 
Chapter 5.3 presents the associations between macronutrient intake and the risk of CHD in The 
Rotterdam Study.
In Chapter 6, the main findings are discussed as well as the methodological considerations, impli-
cations, and recommendation for future studies.
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Chapter 2.1
AbstrAct
Background and objectives: DNA methylation can be modified by environmental factors, including 
nutrition. In order to gain more insight in effects of nutrients on DNA methylation, we conducted a 
systematic review on the relation between nutrients and DNA methylation in humans across the life 
course.
Methods: The literature search was designed by an experienced biomedical information specialist. Six 
bibliographic databases (Embase.com, Medline (Ovid), Web-of-Science, PubMed, Cochrane Central 
and Google Scholar) were searched. We selected studies that examined the association between nutri-
ents (blood levels; dietary intake; or dietary supplements) and DNA methylation (global, site specific, 
or genome-wide) in humans of any age, with no restrictions on year of publication, language, or study 
design. Abstract screening, full text selection, and data extraction was performed by two independent 
reviewers, with a third reviewer available to solve any disagreements.
Results: We identified 3774 references, of which 98 studies met all inclusion criteria. The majority was 
performed in adult study populations, and folate was the main nutrient of interest. Several candidate 
gene and epigenome-wide association studies reported differential DNA methylation of CpG sites 
in response to folate (e.g. IGF2, H19, HOX), fatty acids (e.g. PPRAGC1A, TNFα), and vitamin D 
(CYP24A1). Some of these observed associations were specific to life course stage (e.g. IGF2 in early 
life) and tissue (e.g. opposite directions for PPRAGC1A in muscle versus fat tissue).
Conclusions: To date, promising results have been reported in the field of nutrition and DNA meth-
ylation in humans at different stages across the life-course; especially for nutrients known to be in-
volved in one-carbon metabolism, including folate, but also others, such as fatty acids and vitamin D. 
Studies on other nutrients, such as other macronutrients and several minerals are still scare. Further 
large-scale studies of high quality are needed to expand our understanding on the role of nutrition in 
DNA methylation and its effects on health and disease.
2.1 Nutrients & DNA methylation: A systematic review
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introduction
DNA methylation is prone to modification by environmental factors, including nutrition. The suscep-
tibility of change in DNA methylation in response to nutrition is particularly high during early life.1 
Nevertheless, nutrition has also been reported to be associated with DNA methylation in other stages 
of the life course, for instance, during adolescence and adulthood.2
Nutrients that are known to be involved in DNA methylation through their role in one-carbon 
metabolism are B-vitamins and methionine. However, also other nutrients such as fatty acids, pro-
tein, and vitamin D, are suggested to have an effect on DNA methylation.3 To date, many studies have 
been carried out investigating the role of nutrition on DNA methylation, in animal studies as well as 
human studies. Although evidence from animal studies demonstrates that nutrition has effects on 
DNA methylation, findings from studies in humans are inconsistent.4
In order to gain more insight in effects of several nutrients on DNA methylation across the life-
course, a clear overview of the current knowledge is of importance. Identifying which nutrients affect 
DNA methylation, either globally or at specific CpG sites, will provide insight in the mechanisms 
that are responsible for the effect of nutrition on several health outcomes. Therefore, we conducted 
a comprehensive systematic review on the relationship between status and intake of nutrients with 
DNA methylation in humans across the life course.
methods
This systematic review was performed and reported in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) statement.5
literature search
A literature search was designed for six electronic databases by an experienced biomedical informa-
tion specialist. The search engines Embase.com (Medline and Embase), Medline (Ovid), Cochrane 
Central, Web-of-Science, PubMed, and Google Scholar were searched from inception until May 10th 
2016 (date last searched) to identify published studies that examined the association between nutri-
ents and DNA methylation. The full search strategies of all databases are provided in Supplement 
2.1.1.
study selection and inclusion criteria
We selected studies that examined the association between nutrients (blood levels; dietary intake; 
and/or dietary supplements) and DNA methylation (global, site specific, and/or genome-wide) 
in humans. We excluded studies that were performed among patients with chronic diseases (e.g. 
Alzheimer’s disease, diabetes, anorexia nervosa, cardiovascular diseases, etc.) and case reports (n<5). 
No restrictions were set on year of publication, language, or study design. We excluded studies on 
caloric intake, alcohol intake, glucose levels, triglyceride levels, and cholesterol levels as these were 
outside the scope of our review. Two reviewers screened the retrieved titles and abstracts and selected 
eligible studies according to predefined selection criteria independently of each other (Supplement 
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2.1.2). Discrepancies between the two reviewers were resolved through discussion, with an arbitrator 
available if no consensus was reached. We retrieved full texts for studies that satisfied all selection 
criteria. These full-text articles were evaluated in detail once more by two investigators against the 
selection criteria.
data extraction
A structured database was developed prior to the data extraction. Detailed characteristics of indi-
vidual studies were extracted including study design, study size, country, characteristics of the study 
population, and details on exposure and outcome assessment. In addition, we extracted information 
on covariate adjustments, and conclusions. The association of each nutrient with each methylation 
measure, either global or genome-wide site-specific or gene-specific, was extracted separately to 
report each specific analysis. Gene-specific studies examining multiple loci were considered per gene 
separately.
Quality analysis
The quality of included studies was evaluated by two reviewers using a predefined scoring system. 
This quality score (QS) was previously developed for its use in systematic reviews and meta-analyses 
including studies with various study designs.6 A score of 0, 1 or 2 points was allocated to each of the 
following five items: 1) study design; 2) size of the population for analysis; 3) quality of the methods 
used for exposure assessment or appropriate blinding of an intervention; 4) quality of the methods 
used for outcome assessment; and 5) adjustment for potential confounders or adequate randomiza-
tion of an intervention. The combined scores resulted in a total QS between 0 and 10 points, with 10 
representing the highest quality. Details on the QS are presented in Supplement 2.1.3.
3 results
characteristics of the included studies
From the literature search we identified 3,774 unique references, of which 3,523 were excluded after 
screening of title and abstract based on the selection criteria. Of the 251 remaining references, full-
texts were retrieved and reviewed, of which 98 studies met all criteria and were included in this sys-
tematic review (Figure 2.1.1). Of the included studies, 25 studies investigated the association between 
maternal nutrition and offspring DNA methylation, nine studies were carried out during infancy, 
childhood, or adolescence, and 70 studies were performed in adults (Table 2.1.1, Figure 2.1.2). Most 
studies examined associations between nutrients and gene-specific DNA methylation, of which the 
majority focused on folate as nutrient of interest. Summaries of the findings of all included studies 
are presented below per nutrient or nutrient groups and per life stage (Tables 2.1.2-2.1.18). Detailed 
information of population characteristics, DNA methylation assessment, confounder adjustment, 
and description of results is included in the online supplementary material. 
2.1 Nutrients & DNA methylation: A systematic review
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Records excluded based on title 
and abstract  
n = 3,523 
 
Records given full text detailed 
assessment  
n = 251 
Full-text articles excluded  
 
n = 153 
Studies included  
n = 98 
  
Records screened  
n =3,774 
  
Unique records identified through 
database searching  
n = 3,774 
figure 2.1.1. Flow chart of included studies
Vitamin A, α-carotene, and β-carotene
Vitamin A in infancy, childhood, and adolescence and DNA methylation
Perng et al. (QS: 6) showed that higher plasma vitamin A levels in children aged 5 to 12 years were 
associated with global DNA hypomethylation in blood.7
Vitamin A in adulthood and DNA methylation
Piyathilake et al. (QS: 6) observed no association between plasma vitamin A levels and global DNA 
methylation in either PBMCs or cervical cells.8 Bollati et al (QS: 6) investigated the association of 
intake of α-carotene, β-carotene, and retinol with methylation of CD14, Et-1, HERV-w, iNOS and 
TNFα in blood. Th ey observed an association of higher intake of β-carotene with hypermethylation 
of HERV-w and higher intake of β-carotene and retinol was associated with hypomethylation of 
TNFα. However, no signifi cant association was observed for the other genes.9 Stidley et al (QS: 6) did 
not fi nd an association of α-carotene, β-carotene, and retinol intake with methylation index of genes 
(p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) in sputum.10
Vitamin b1
Vitamin B1 in adulthood and DNA methylation
Marques-Rocha et al. (QS: 5) showed that higher vitamin B1 intake was associated with global DNA 
hypomethylation in blood.11
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table 2.1.1. Number of studies per category of life course stage, nutrient group, and DNA 
methylation type
maternal nutrition 
& offspring dnA 
methylation
infant, child, & adolescent 
nutrition & dnA 
methylation
Adult nutrition & dnA 
methylation
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Micronutrients
Vitamin A, 
α-carotene, and 
β-carotene
0 0 0 0 1 1 0 0 3 1 2 0 4
Vitamin b1 0 0 0 0 0 0 0 0 1 1 0 0 1
Vitamin b2 1 0 1 0 0 0 0 0 5 5 0 0 6
Vitamin b3 1 0 1 0 0 0 0 0 1 1 0 0 2
Vitamin b6 1 0 1 0 0 0 0 0 11 11 1 0 12
folate 16 6 7 4 3 3 1 0 43 34 12 1 59
Vitamin b12 4 2 2 0 2 1 1 0 22 18 7 0 26
Vitamin c 0 0 0 0 0 0 0 0 5 1 4 0 5
Vitamin d 3 0 2 1 3 1 2 1 5 3 3 0 10
Vitamin e 0 0 0 0 0 0 0 0 4 1 3 0 4
choline & 
betaine
2 2 1 0 0 0 0 0 3 3 1 0 3
minerals and 
trace
elements
0 0 0 0 1 1 0 0 7 6 2 0 8
combined 
nutrients
1 0 0 1 0 0 0 0 6 3 2 1 7
bioactive 
compounds
0 0 0 0 0 0 0 0 6 1 5 0 6
Macronutrients
fat and fatty acids 5 2 3 1 2 0 0 2 18 4 10 5 25
carbohydrates & 
fiber
2 1 1 0 0 0 0 0 6 4 3 0 8
Protein & amino 
acids
2 1 1 0 0 0 0 0 7 5 3 0 9
total 25 9 13 6 9 4 4 3 70 42 26 7 98
2.1 Nutrients & DNA methylation: A systematic review
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Vitamin b2
Maternal vitamin B2 and offspring DNA methylation
Azzi et al. (QS: 6) showed that higher vitamin B2 intake during pregnancy was associated with hyper-
methylation of ZAC1 in cord blood.12
Vitamin B2 in adulthood and DNA methylation
Five studies (QS: 3-5) investigated the association between vitamin B2 intake and global DNA meth-
ylation in blood or colonic tissue,11, 13-16 of which only one study found that higher vitamin B2 intake 
was associated with DNA hypermethylation in blood.11 In addition, Figueiredo et al. (QS: 4) found 
no association between vitamin B2 levels in plasma with global methylation in colonic tissue.13 Zhang 
et al. (QS: 5) showed that vitamin B2 intake was not associated with methylation of IL-6 in blood.16
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figure 2.1.2. Distribution of studies (N=98) per category of life course stage, nutrient group, and 
DNA methylation outcome type. Choline; includes choline and betaine, Minerals; include miner-
als and trace elements, CN; combined nutrients, BC; bioactive compounds, Carbs; carbohydrates.
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Vitamin b3
Maternal vitamin B3 and offspring DNA methylation
Azzi et al. (QS: 6) showed that vitamin B3 intake during pregnancy was not associated with methyla-
tion of ZAC1 in cord blood.12
Vitamin B3 in adulthood and DNA methylation
Marques-Rocha et al. (QS: 5) showed that higher vitamin B3 intake was associated with global DNA 
hypomethylation in blood.11
Vitamin b6
Maternal vitamin B6 and offspring DNA methylation
Azzi et al. (QS: 6) reported that vitamin B6 intake during pregnancy was not associated with methyla-
tion of ZAC1 in cord blood.12
Vitamin B6 in adulthood and DNA methylation
Eight studies (QS: 3-5) investigated the association between vitamin B6 intake with global DNA 
methylation in blood or colonic tissue,7, 13-19 and only one study found an association and reported 
that higher vitamin B6 intake was associated with global hypomethylation in blood.17 Two other 
studies (QS: 4 and 6) investigated the association of vitamin B6 levels in plasma and venous blood 
with global DNA methylation in blood or colonic tissue, but did not find any association.13, 20 An 
intervention study by Hübner et al. (QS: 3), showed that vitamin B6 supplementation had no effect 
on global DNA methylation in blood.21 Zhang et al. (QS: 5) showed that vitamin B6 intake was not 
associated with methylation of IL-6 in blood.16
folate
Maternal folate and offspring DNA methylation
Sixteen unique studies investigated the association between maternal folate and offspring DNA meth-
ylation, six at a global level, seven gene-specific, and four at a genome-wide level. Of the four studies 
investigating global DNA methylation in cord blood (QS: 2-6), one found that an increased dietary 
folate as well as RBC folate were associated with global hypomethylation,22 whereas the other three 
studies reported no significant association with folate.23-25 In contrast, studies investigating DNA 
methylation in other fetal tissues, including placenta, brain and heart, showed that maternal folate 
levels were associated with global hypermethylation.26, 27 Four studies investigated the association 
between levels or intake of maternal folate and IGF2 methylation in offspring (QS: 5-7). Three of these 
studies measured methylation in cord blood. In these studies, higher folate intake was shown to be 
associated with IGF2 hypermethylation,22 and no association was observed between serum folate and 
DNA methylation.28 RBC folate showed association with IGF2 hypermethylation in one study,29 and 
no association in another study.22 One observational study found IGF2 hypermethylation in offspring 
at 12-18 months in mothers who used folate supplements during pregnancy compared to those of 
2.1 Nutrients & DNA methylation: A systematic review
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mothers who did not.30 Furthermore, Hoyo et al. (QS: 5 and 7) found an association of maternal folate 
supplements and erythrocytes with H19 hypomethylation in cord blood.29, 31 Maternal intake and 
erythrocyte folate were found to be associated with PEG3 hypomethylation in cord blood,22, 29 whereas 
no association was found with maternal RBC folate (QS: 5-7).22 Furthermore, maternal erythrocyte 
folate was also associated with hypermethylation of PEG1/MEST and hypomethylation of PEG10/
SGCE in cord blood (QS: 7).29 Maternal erythrocyte folate was associated with hypomethylation of 
MEG3, MEG3-IG (intergenic), NNAT and PLAGL1 promoters in cord blood (QS:7).29 Van Mil et al. 
showed that supplement use and venous blood levels of folate were associated with NR3C1 hyper-
methylation, and higher folate supplement use was associated with 5-HTT hypomethylation in cord 
blood (QS: 6 and 7).32 Furthermore, no associations were observed between maternal folate intake or 
RBC and SNRPN or ZAC1 methylation in cord blood (QS: 5 and 6).12, 22
Of the four studies investigating maternal folate levels and epigenome-wide DNA methylation in 
cord blood, three used Illumina 450K arrays and identified several CpG sites. Amarasekera et al. (QS: 
4, N=23) found seven differentially methylated regions, of which ZFP57 was validated using Seque-
nom EpiTyper platform.33 Joubert et al. (QS: 8, N=1988) identified 443 CpG sites annotated to 320 
genes, of which some novel genes included APC2, GRM8, SLC16A12, OPCML, PRPH, LHX1, KLK4 
and PRSS21.34 Gonseth et al. (QS: 6, N=347) found that maternal folate intake was associated with 
three CpG sites annotated to genes TFAP2A, STX11 and CYS1.35 The fourth EWAS (QS: 6, N=200) 
did not find associations between maternal folate levels and genome-wide DNA methylation.36
Folate in infancy, childhood, and adolescence and DNA methylation
Three unique studies investigated the association between folate levels and global DNA methyla-
tion during infancy or childhood, of which one also examined gene-specific DNA methylation. Two 
studies (QS:4 and 5) examined the association between folate levels and global DNA methylation 
in cord blood: Haggerty et al. showed that RBC folate was associated with global hypomethylation 
whereas Fryer et al. observed no association.22, 24 Perng et al. (QS: 4) studied the association between 
erythrocyte folate and global methylation in children aged 5-12 years, but found no association.7 Hag-
gerty et al. (QS: 6) also examined the association between RBC folate and DNA methylation of IGF2, 
PEG3 and SNRPN in cord blood. In line with their findings for maternal folate and offspring DNA 
methylation, they found that RBC folate at birth was also associated with IGF2 hypermethylation, 
PEG3 hypomethylation and no difference in SNRPN methylation.22
Folate in adulthood and DNA methylation
There were 41 unique studies that investigated the association between folate and adult DNA meth-
ylation. Thirty-three studies examined DNA methylation at a global level, 12 gene-specific, and one at 
a genome-wide level. In observational studies that measured DNA methylation in blood, folate intake 
was associated with DNA hypomethylation in one study (QS: 5),14 DNA hypermethylation in three 
studies (QS: 3-5),16, 18, 37 but no difference in methylation was observed in majority of the studies (QS: 
1-6).15, 17, 19, 23, 38, 39 Blood levels of folate were associated with DNA hypomethylation in one study (QS: 
6),40 whereas DNA hypermethylation in six studies (QS: 4-6).20, 41-45 A few studies showed no differ-
ence in methylation (QS: 3-6).19, 46-48 Overall, dietary intake and levels of folate in these observational 
studies tend to be more often associated with global DNA hypermethylation than hypomethylation. 
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In contrast, intervention studies with folate supplements showed an effect of folate on DNA hypo-
methylation in three studies (QS: 2-8),49-51 DNA hypermethylation in two studies (QS: 3),52, 53 and no 
effect on methylation in three studies (QS: 3-8).21, 54, 55 The direction of effect in these intervention 
studies were contradictory to those shown in the observational studies. In studies that measured 
DNA methylation in colonic tissue, folate intake was associated with global DNA hypomethylation 
on one side of the colon (QS: 3),13 whereas folate in blood levels13, 56-58 and colonic tissue56 showed no 
association with DNA methylation (QS: 4-6). Furthermore, Llanos et al. measured DNA methylation 
in breast tissue and observed no association with folate levels from plasma and breast tissue (QS: 6).59 
In an intervention study, Aarabi et al. found a significant association between folate supplements and 
DNA hypomethylation (QS: 4).60
Two studies investigated the association between levels or intake of folate and methylation in IGF2 
and H19. In contrast to the studies that examined the same genes in maternal-offspring,22, 29-31 Hanks 
et al. (QS: 7) did not find an association between folate in serum, RBC and colonic tissue with IGF2 
methylation in adults.56 In addition, in an intervention study by Aarabi et al. (QS: 5), no effect was 
observed between folate supplements and methylation in H19.60
Higher folate intake was associated with promotor hypomethylation of TNFα and methylation 
index of genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) in blood 
and sputum, respectively. However, no association was observed with promoter TLR2, CD14, Et-
1, HERV-w, iNOS and IL-6 methylation in blood (QS: 5-6).9, 16, 61 Dhillon et al. (QS: 5) showed no 
significant association between folate intake and GSTM1 methylation in serum. However, when 
analysis was stratified for MTHFR genotype, low folate intake was associated with lower methylation 
of GSTM1 methylation for CT and TT group only.62 Two studies investigated the association of levels 
of folate in serum, RBC, plasma, and colonic tissue with gene-specific methylation in colonic tissue or 
rectal mucosa (QS: 6-7). Hypermethylation of MYOD, SFRP1, SFRP2 and methylation index of genes 
(HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, ESR1, MYOD, N33) was observed with higher folate 
levels. However, no significant associations were observed for methylation of individual genes: APC, 
MYOD1, MLH1, N33, SOX17 and/or ESR1.56, 58 Ottini et al. (QS: 5) reported that higher folate levels 
in plasma were associated with hypomethylation of methylation index of genes (p16, FHIT, RAR, 
CDH1, DAPK1, hTERT, RASSF1A, MGMT, BRCA1 and PALB2).63
Some studies observed associations for nutrient levels in a tissue specific manner. Tapp et al. (QS: 
6) investigated the association of folate levels with HPP1 and WIF1 methylation in rectal mucosa. 
They observed hypermethylation of HPP1 and WIF1 in association with plasma folate levels, but 
not with RBC folate levels.58 Hanks et al. (QS: 7) examined the association between folate levels and 
MGMT methylation in colonic tissue. They observed hypomethylation of MGMT in association with 
serum folate levels, but not with folate levels in RBC and colonic tissue.56 In women with HPV, plasma 
folate levels were associated with HPV 16 hypermethylation (promoter) in blood (QS: 5).64 In healthy 
women, plasma and breast folate levels were associated with hypomethylation of p16INK4a (QS: 7).65 
In intervention studies, folate supplementation had no effect on ESR1 and MLH1 methylation in 
colonic mucosa, and DLK1/GTL2, MEST, SNRPN, PLAGL1 and KCNQ1OT1 methylation in sperm 
(QS: 5 and 7).60, 66 Song et al. (QS: 4) performed an EWAS of folate levels in breast tissue in women, 
and found two differentially methylated CpG sites. One CpG site near JAG2 was hypomethylated and 
another CpG site near DNAJC2 was hypermethylated.67
2.1 Nutrients & DNA methylation: A systematic review
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Vitamin b12
Maternal vitamin B12 and offspring DNA methylation
Two studies investigated the association of intake and serum levels of vitamin B12 with global DNA 
methylation in cord blood (QS: 5 and 6). Higher serum levels of vitamin B12 were associated with 
hypermethylation,25 whereas no difference in methylation was observed with higher vitamin B12 
intake.23 For the gene-specific studies, Ba et al. (QS: 6) showed that higher vitamin B12 levels in serum 
were associated with IGF2 promoter hypomethylation in cord blood.28 Azzi et al. (QS: 6) showed that 
higher vitamin B12 intake during pregnancy was associated with hypermethylation of ZAC1 in cord 
blood.12
Vitamin B12 in infancy, childhood, and adolescence and DNA methylation
In children aged 5 to 12 years, no association was observed between plasma vitamin B12 levels and 
global DNA methylation in blood (QS: 4).7 In cord blood, McKay et al. (QS: 7) showed that higher 
serum vitamin B12 levels were associated with hypomethylation of IGFBP3.25
Vitamin B12 in adulthood and DNA methylation
Eight studies (QS: 3-6) found no association between vitamin B12 intake and global DNA methyla-
tion.14-19, 23, 38 Also for vitamin B12 levels in plasma or serum, no associations were found with global 
DNA methylation in blood, colonic tissue or rectal mucosa in eight studies (QS: 3-6).13, 19, 20, 46-48, 57, 58 
However, in one study (QS: 6), plasma vitamin B12 levels were associated with global hypermeth-
ylation in blot clots.68 An intervention study (QS: 3) showed that vitamin B12 supplements had no 
effect on global DNA methylation in blood.69 For gene-specific studies, vitamin B12 intake was not 
associated with methylation of CD14, Et-1, HERV-w, iNOS, TNFα, IL-6, and TLR2 in blood (QS: 
5-6).9, 16, 61 In addition, Tapp et al (QS: 6) found no association between vitamin B12 levels in plasma 
and methylation of HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, ESR1, MYOD, N33 and methylation 
index of these genes.58 Al-Ghnaniem et al. (QS: 6) observed that vitamin B12 levels in venous blood 
were associated with hypomethylation of ERα in colonic mucosa.70 Furthermore, plasma vitamin B12 
levels were associated with hypermethylation of HPV 16 (QS: 5) and no difference in methylation 
index of genes (p16, FHIT, RAR, CDH1, DAPK1, hTERT, RASSF1A, MGMT, BRCA1 and PALB2) 
(QS: 3).63, 64
Vitamin c
Vitamin C in adulthood and DNA methylation
Piyathilake et al. (QS: 6) investigated the association between plasma vitamin C levels and global 
DNA methylation in PBMCs and cervical cells, but did not find a significant association.8 Two stud-
ies (QS: 6) investigated the association between vitamin C intake and gene-specific promoter DNA 
methylation. One study found that higher intake of vitamin C was associated with hypomethylation of 
PON1 in venous blood,71 whereas the other study did not find an association of vitamin C intake with 
methylation index of genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) 
in sputum.10 Furthermore, Bollati et al (QS: 6) investigated the association of intake of ascorbic acid 
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with methylation of CD14, Et-1, HERV-w, iNOS and TNFα in blood, but no significant association 
was observed.9 Piyathilake et al. (QS: 5) found no association between vitamin C levels in plasma and 
HPV 16 methylation in blood.64
Vitamin d
Vitamin D and offspring DNA methylation
One study (QS: 5) found that higher maternal vitamin D levels in plasma was associated with hy-
pomethylation of RXRA in umbilical cord tissue,72 whereas another study (QS: 4) did not find an 
association between maternal vitamin D levels in serum and CYP24A1 methylation in placenta.73 
Mozhui et al (QS: 6) conducted an EWAS of vitamin D levels, but found no significant CpG site 
associations in cord blood.36
Vitamin D in infancy, childhood, and adolescence and DNA methylation
For vitamin D, Zhu et al. (QS: 7) found that plasma vitamin D levels as well as an intervention with 
vitamin D supplementation were associated with global hypermethylation in blood.74 In neonates, 
Novakovic et al (QS: 4) found no association between serum vitamin D levels and CYP24A1 meth-
ylation in placenta.73 Zhu et al. (QS: 4) investigated the associated between plasma vitamin D levels 
and gene-specific methylation in blood among children around 16 years of age. Higher vitamin D 
levels were found to be associated with hypomethylation of CYP2R1, hypermethylation of CYP24A1, 
and differential methylation in opposite directions of two CpG sites annotated to DHCR7.75 In an 
EWAS of vitamin D levels, Zhu et al. (QS: 5) identified two differentially methylated CpG sites: higher 
vitamin D levels were associated with hypomethylation of DOI3 and hypermethylation of MAPRE2.75
Vitamin D in adulthood and DNA methylation
Three studies, of which two were cross-sectional (QS: 5) and one intervention (QS: 3) found no effect 
of vitamin D supplementation or vitamin D levels in plasma or serum on global DNA methylation 
in blood or rectal mucosa.21, 58, 76 In gene-specific studies, Bollati et al (QS: 6) found no association 
between vitamin D intake and promoter methylation of CD14, Et-1, HERV-w, iNOS and TNFα.9 
Tapp et al. (QS: 6) investigated the association between plasma vitamin D levels and gene-specific 
methylation of HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, ESR1, MYOD and N33 in rectal mucosa. 
They found that higher vitamin D levels were associated with hypomethylation of index of these genes 
and also individual genes such as APC, WIF1 and MYOD. No association was found for the other 
individual genes.58 Furthermore, Ashktorab et al. (QS: 7) found no significant association between 
serum vitamin D levels and DKK1 methylation in blood.77
Vitamin e
Vitamin E in adulthood and DNA methylation
Piyathilake et al. (QS: 6) observed that higher levels of plasma vitamin E were associated with global 
hypomethylation in PBMCs, but not with global methylation in cervical cells.8 In a gene-specific 
study, Stidley et al (QS: 6) did not find an association of vitamin E intake with methylation index of 
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any of the studied genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) in 
sputum.10
choline and betaine
Maternal choline and betaine and offspring DNA methylation
Boeke et al. (QS: 6) showed that choline and betaine intake during pregnancy were associated with 
global DNA hypomethylation in cord blood.23 In contrast, Jiang et al. (QS: 6), in an intervention 
study, reported that higher supplemental choline intake during pregnancy was associated with global 
DNA hypermethylation in placenta, but not in cord blood.78 For gene-specific studies, an intervention 
study by Jiang et al. (QS: 5) showed that higher supplemental choline intake during pregnancy was 
associated with hypermethylation of promoter CRH and NR3C1 in placenta. In contrast to placental 
tissue, in cord blood promoter CRH and NR3C1 were hypomethylation in response to a higher 
supplemental choline intake. No effect of choline supplementation was observed in methylation of 
GNAS-AS1, IGF2, IL-10, or LEP in placenta or cord blood.78
Choline and betaine in adulthood and DNA methylation
Shin et al. (QS: 3) showed that choline supplementation was associated with global DNA hyper-
methylation in blood, but only for subjects with the MTHFR 677CC genotype.79 However, another 
intervention study (QS: 4) showed no effect of choline supplementation on global DNA methylation 
in blood.78 In addition, in a cross-sectional study by Boeke et al. (QS: 6) choline and betaine intake 
was not associated with global DNA methylation in blood in pregnant women.23 In an intervention 
study by Jiang et al. (QS: 5) a higher supplemental choline intake was not associated with methylation 
of promoter CRH and NR3C1 in blood among pregnant women.78
minerals and trace elements
Minerals and trace elements in infancy, childhood, and adolescence and DNA 
methylation
In a cross-sectional study among children aged 5 to 12 years, Perng et al (QS: 4) investigated the as-
sociation of plasma levels of ferritin and serum levels of zinc with global DNA methylation in blood, 
but no significant associations were observed.7
Minerals and trace elements in adulthood and DNA methylation
Marques-Rocha et al. (QS: 5) showed that higher intakes of both copper and iron were associated 
with global DNA hypermethylation in blood.11 In contrast, Gomes et al (QS: 3) reported that higher 
intakes of magnesium were associated with DNA hypomethylation in blood.17 Two studies (QS: 3 
and 5) examined associations between zinc intake and global DNA methylation in blood, but both 
observed no significant associations.17, 38 Furthermore, Tapp et al. (QS: 5) reported that higher plasma 
levels of selenium were associated with global DNA hypermethylation in rectal mucosa, but only in 
women.58 McChelland et al. (QS: 6) reported that higher serum levels of phosphate were associated 
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with global DNA hypomethylation in blood.80 In an intervention study by Hubner et al. (QS: 3) no 
effect was observed of calcium supplementation on global DNA methylation in blood.21
For gene-specific studies, Shimazu et al. (QS: 6) investigated the associations of salt intake with 
methylation of miR-124a-3, EMX1 and NKX6-1 in gastric mucosa, but observed no significant as-
sociations.81 Tapp et al. (QS: 6) examined associations of plasma selenium levels with methylation of 
HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, ESR1, MYOD, N33 and an index of these genes. They 
observed that higher levels of selenium were associated with hypermethylation of N33, but only in 
males. No significant associations were observed for the other genes or index.58
combined nutrients
Maternal combined vitamins and minerals and offspring DNA methylation
In an intervention study, Khulan et al. examined the effect of maternal micronutrient supplementa-
tion on genome-wide DNA methylation in cord blood and peripheral blood during infancy (QS:6).82 
In cord blood 14 CpG sites were identified in males and 21 CpG sites in females, with no overlap 
between the two. In addition, in infant blood 108 CpG sites were identified in males and 106 CpG 
sites in females, with only 5 (XIRP1, MEOX1, GNA11, C1orf54, KRTAP21-1) in agreement between 
male and female infants. Within each sex a significant proportion of the identified CpG sites in cord 
bloods were also observed in infants (males 7/14: MEOX1, SPAG4L, SPATA22, NRN1L, C1orf54, PIP, 
PTPN20B; females 8/21: HSPC176, XIRP1, BPIL1, MGMT, CHIT1, C14orf152, KLRC2, DEFB123).
Combined vitamins and minerals in adulthood and DNA methylation
Two studies investigated the association between folate and vitamin B12 combined with global DNA 
methylation. Piyathilake et al. (QS: 6) reported that vitamin B12 and folate plasma was associated 
with global hypermethylation in PBMCs, but not in cervical cells.8 However, in an intervention study 
by Fenech et al. (QS: 6) vitamin B12 and folate supplements had no effect on global DNA methyla-
tion.46 Pusceddu et al. (QS:5) studied the effect of vitamin B12, vitamin B6, folate, vitamin D and 
calcium supplementation on global DNA methylation After intervention LINE-1 hypermethylation 
was observed.83 For gene-specific studies, Stidley et al. (QS: 6) observed that intake of multivita-
mins was associated with hypomethylation of methylation index (p16, MGMT, DAPK, RASSF1A, 
PAX5α, PAX5β, GATA4, and GATA5).10 In an intervention study by Zhou et al. (QS: 5), vitamin D 
and calcium supplementation led to hypomethylation of CYP24A1, but had no effect on CYP2R1, 
CYP27A1, and CYP27B1.84 Kok et al. studied the effect of vitamin B12 and folate supplementations 
on epigenome-wide DNA methylation (QS: 8). After intervention 162 CpG sites were identified as 
compared to baseline. Comparisons of folic acid and vitamin B12 versus placebo revealed one CpG 
sites (cg19380919) and 6 differentially methylated regions (DMRs), with pronounced changes in DI-
RAS3, ARMC8, and NODAL. In addition, serum levels of folate and vitamin B12 were related to DNA 
methylation of 173 and 425 regions, respectively, including several members of the developmental 
HOX genes.85
2.1 Nutrients & DNA methylation: A systematic review
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bioactive compounds
Bioactive compounds in adulthood and DNA methylation
Bollati et al (QS: 6) investigated the association of intake carotenoids, polyphenols, and flavonoids 
with methylation of CD14, Et-1, HERV-w, iNOS and TNFα in blood. They observed an association of 
higher intake of carotenoids with hypermethylation of HERV-w and with hypomethylation of TNFα. 
However, no significant association was observed for the other genes.9 De la Iglesia et al. (QS: 6) 
observed that that lycopene intake was associated with PON1 hypomethylation.71 Zhong et al. (QS: 6) 
reported that flavonoid intake was associated with TLR2 hypomethylation.61 Stidley et al (QS: 6) did 
not find an association of carotene, lutein, zeaxanthin, and lycopene intake with methylation index of 
genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) in sputum.10
fat and fatty acids
Maternal fat and fatty acids and offspring DNA methylation
Rerkasem et al. (QS: 3) found no association between total fat intake during pregnancy and global 
DNA methylation in blood of children around 20 years of age.86 Godfrey et al. (QS: 3) also found no 
association between total fat intake during pregnancy and methylation of RXRA and eNOS in cord 
blood.87 For individual fatty acids, an intervention study by Lee et al. (QS: 8) found that ω-3 PUFA 
supplementation during pregnancy had an effect on global hypermethylation in cord blood.88 In the 
same study, Lee et al. (QS: 8) investigated gene-specific DNA methylation and found that ω-3 PUFA 
supplementation during pregnancy had an effect on hypermethylation of IGF2, but no association 
was found for methylation of IFNγ, TNFα, IL-13, GATA3, STAT3, IL-10 and FOXP3 in cord blood.88 
In an intervention by Amarasekera et al. (QS: 8), no significant effects of ω-3 PUFA were found on 
genome-wide DNA methylation in cord blood.89
Fat and fatty acids in infancy, childhood, and adolescence and DNA methylation
Voisin et al. (QS: 5) conducted an EWAS and identified four, 130, 158 and 16 CpG sites in blood 
significantly associated with intake of total fat, (MUFA+PUFA)/SFA, MUFA/SFA and PUFA/SFA, 
respectively, in children around the age of 10 years.90 On the other hand, in an intervention study by 
Lind et al. (QS: 8) found no epigenome-wide CpG site associations of ω-3 PUFA supplementation as 
fish oil.91
Fat and fatty acids in adulthood and DNA methylation
Total fat: Four studies (QS: 3-4) investigated the association between total fat intake and global DNA 
methylation in blood, of which two found that higher fat intake was associated with global DNA 
hypomethylation,17, 19 whereas the other two studies did not find an association.15, 16 Gómez-Uriz et al. 
(QS: 4) found that total fat intake was associated with TNFα hypomethylation in blood.92 However, 
Bollati et al. and Zhang et al (QS: 5 and 6) investigated the association of intake of total fat with 
methylation of CD14, Et-1, HERV-w, iNOS, TNFα and IL-6 in blood, but no significant association 
was observed.9, 16 In addition, Stidley et al. (QS: 6) found no association of total fat as well as animal 
fat intake with methylation index of genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, 
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and GATA5) in sputum.10 Brøns and Gillberg et al. (QS: 6) investigated the effect of high fat overfeed-
ing in healthy men on promoter PPARGC1A methylation.93, 94 They found that high fat overfeeding 
in men with normal birthweight was associated with PPARGC1A hypomethylation in muscle tis-
sue,93 whereas high fat overfeeding in men with low birthweight was associated with PPARGC1A 
hypermethylation in subcutaneous adipose tissue.94 In an EWAS by Irvin et al. (QS: 8) fatty acids were 
not associated with epigenome-wide DNA methylation after correcting for multiple testing.69 In an 
intervention study among healthy men, Jacobsen and Gillberg et al (QS: 6) investigated the effect of 
high fat overfeeding on epigenome-wide DNA methylation. They observed that high fat overfeeding 
affected methylation at 652 CpG sites (including in CDK5, IGFBP5 and SLC2A4) in subcutaneous 
adipose tissue.95 Furthermore, change in DNA methylation of 7,909 CpG sites (including, DNM2, 
MGMT, SLC2A3/GLUT3, MRC1 and ACAT2) in skeletal muscle biopsies was observed in response 
to high fat overfeeding. Within the same study, it was shown that these changes in genome-wide DNA 
methylation were more pronounced in participants with a low birth weight, compared to those with 
a normal birthweight.96
Individual fatty acids: Zhang et al. (QS: 4) found no association between PUFA intake and global 
DNA methylation in blood.15, 16 For methylation measured in blood, one study found that higher 
ω-6 PUFA intake was associated with hypomethylation of TNFα,97 and another study found that 
higher PUFA intake was associated with hypermethylation of CLOCK.98 However, Zhang et al (QS: 
5) and Bollati et al (QS: 6) observed no association of intake of total PUFA and ω-3 PUFA with 
methylation of CD14, Et-1, HERV-w, iNOS, TNFα and IL-6 in blood.9, 16 Furthermore, Ma et al. (QS: 
7) found that higher ω-3 PUFA levels in erythrocytes were associated with hypomethylation of IL-6 
promoter.99 In another study by Ma et al. (QS: 7), higher levels of erythrocyte EPA were associated 
with hypomethylation of ABCA1 promoter. In addition, higher erythrocyte ALA was associated with 
hypomethylation of APOE for the CC genotype, whereas higher erythrocyte ALA was associated with 
hypermethylation of APOE for the AA genotype.100 In an EWAS by Aslibekyan et al. (QS:6), higher 
levels of ω-3 PUFA in erythrocytes were associated with 27 CpG sites (including NAV1, CCL17, 
ACTA2/FAS and AHRR) in blood. Zhang et al. (QS: 4) found no association between MUFA intake 
and global DNA methylation in blood.15, 16 Milagro et al. (QS: 4) found that higher intake of MUFA 
was associated with hypomethylation of CLOCK in blood.98 However, Zhang et al. (QS: 5) and Bollati 
et al (QS: 6) investigated the association of intake of MUFA with methylation of CD14, Et-1, HERV-w, 
iNOS, TNFα and IL-6 in blood, but no significant association was observed.9, 16 Zhang et al. (QS: 4) 
observed that higher SFA intake was associated with global DNA hypomethylation when methylation 
was measured using pyrosequencing,15 whereas no association was observed when methylation was 
measured using PCR technique.16 Zhang et al. (QS: 5) and Bollati et al (QS: 6) investigated the associa-
tion of intake of SFA with methylation of CD14, Et-1, HERV-w, iNOS, TNFα and IL-6 in blood, but 
no significant association was observed.9, 16
carbohydrates and fiber
Maternal carbohydrates and fiber and offspring DNA methylation
Rerkasem et al. (QS: 3) investigated the association between intake of carbohydrates during pregnancy 
and global DNA methylation in their offspring around the age of 20 years, but observed no significant 
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association.86 Godfrey et al. (QS: 3) explored the association between carbohydrate intake during 
pregnancy and gene-specific promoter DNA methylation in cord tissue. They observed that higher 
intake of carbohydrate was associated with RXRA hypomethylation, but no significant association 
was observed with eNOS methylation.87
Carbohydrates and fiber in adulthood and DNA methylation
Four studies investigated the association between carbohydrate intake and global DNA methylation in 
blood. One study (QS:3) reported that higher intake of carbohydrate was associated with global DNA 
hypomethylation,17 whereas the other three studies (QS:4) observed no significant associations.15, 16, 19 
Three studies (QS: 4-6) were conducted on the association of carbohydrate and fiber intake and gene-
specific DNA methylation in blood, of which one observed that carbohydrate intake was associated 
with hypermethylation of BMAL1,101 but in the other two studies no significant associations were 
observed with CD14, Et-1, HERV-w, iNOS, TNFα, and IL-6.9, 16
Protein and amino acids
Maternal protein and amino acids and offspring DNA methylation
Rerkasem et al. (QS: 3) observed no associations between intake of protein during pregnancy and 
global DNA methylation in their offspring around the age of 20 years.86 Godfrey et al. (QS: 3) found 
no association of protein intake during pregnancy with promoter methylation of RXRA or eNOS in 
cord tissue.87
Protein and amino acids in adulthood and DNA methylation
Three studies (QS: 3-4) investigated the association between protein intake and global DNA methyla-
tion in blood, but no significant associations were observed.15-17 In addition, the four studies (QS: 3-4) 
that explored associations between methionine intake and global DNA methylation in blood showed 
no significant associations.15, 16, 18, 38 Two studies (QS: 5 and 6) investigated associations of protein 
intake and methylation of CD14, Et-1, HERV-w, iNOS, TNFα, and IL-6 in blood, but reported no 
significant associations.9, 16 Similarly, two studies (QS: 5 and 6) that examined the associations of 
methionine intake with IL-6 and TLR2 promoter methylation in blood showed no significant as-
sociations.16, 61
discussion
This is the first systematic review on nutrients and DNA methylation in humans. This review included 
studies examining associations between all nutrients with different types of methylation outcomes in 
all life-course stages. The majority of the studies performed on this topic investigated the association 
of folate, other B-vitamins, or fatty acids with DNA methylation, whereas studies for other nutrients 
are scarce or even absent, such as for vitamin K. The evidence so far shows that folate and fatty acids 
are associated with DNA methylation on a global, gene-specific, and genome-wide level. Several can-
didate gene and epigenome-wide association studies reported differential DNA methylation of CpG 
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sites in response to folate (e.g. IGF2, H19, HOX), fatty acids (e.g. PPRAGC1A, TNFα), and vitamin D 
(CYP24A1). Some of these observed associations were specific to life course stage (e.g. IGF2 in early 
life) and tissue (e.g. opposite directions for PPRAGC1A in muscle vs. fat tissue). However, some of the 
directions of these associations are inconsistent across the different studies. Reasons that may explain 
these discrepancies in findings include the differences in the type of tissue used to measure nutrient 
levels as well as DNA methylation and differences across life course stages.
dnA methylation across the life course
Age affects methylation patterns via transcriptional regulation.102 Evidence from our systematic 
review suggests age-specific differences in folate associations with global DNA methylation in blood. 
In early life, higher folate intakes and levels were associated with global DNA hypomethylation,22 
whereas during adulthood higher folate intakes and levels were associated with DNA hypermeth-
ylation.16, 18, 20, 37, 41-45 This pattern could not be observed for the other nutrients due to the limited 
number of studies across the different life course stages or null associations, but similar patterns for 
other nutrients could be possible. Indeed, some studies on gene-specific DNA methylation observed 
similar age-specific differences. Methylation of some genes in blood may be specifically prone to en-
vironmental influences during early life. For example, evidence from our systematic literature review 
shows that during pregnancy, at birth and during childhood, higher folate intake and levels were 
associated with IGF2 hypermethylation.22, 29, 30 However, when this association was studied in adults, 
no significant associations were observed.56 Possibly, methylation of this gene is no longer susceptible 
to changes during adulthood. Similarly, higher choline intake during pregnancy was associated with 
CRH and NR3C1 hypomethylation in cord blood, but no association was found within pregnant 
women.78 Several studies included in our review suggested that IGF2 methylation could also be af-
fected by vitamin B12 and PUFAs.28, 103 Higher folate during pregnancy and at birth was associated 
with PEG3 hypomethylation in cord blood.22, 29 Due to the absence of studies in adults, we cannot 
determine age-related associations in relation to these nutrients. Future studies should be conducted 
in order to establish the life course patterns of these nutrients on DNA methylation.
dnA methylation across nutrients
We were interested in exploring how different nutrients may affect methylation of the same genes, 
because this can be indicative of which genes are susceptible to nutritional influences in general. 
As it is difficult to compare findings across studies due to the different population structure, lab 
techniques, batch effects and analytical methods used, we compared the associations of different 
nutrients with methylation of the same genes within the same study to discard the bias caused by 
heterogeneity. From these studies that explored associations between multiple individual nutrients 
and gene-specific methylation for the same genes and same tissues, we observed that genes such 
as CD14, eNOS, ESR1, Et-1, IL-6, iNOS, N33 and SOX17 were not susceptible to any nutritional 
influence.9, 16, 58, 87 Methylation of some other genes, such as APC, HERV-w, HPP1, RXRA, TLR2, 
SFRP1, SFRP2 and methylation index of genes (p16, FHIT, RAR, CDH1, DAPK1, hTERT, RASSF1A, 
MGMT, BRCA1 and PALB2) showed susceptibility to only one nutrient.9, 58, 61, 87 This suggests that 
methylation of these genes could be responsive to one particular nutrient due to a certain pathway in 
which they are involved. However, for certain other genes, such as CLOCK, HPV 16, MYOD, PON1, 
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TNFα, WIF1, ZAC1, and methylation indexes of genes (HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, 
ESR1, MYOD and N33; p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4 and GATA5), meth-
ylation was susceptible to multiple nutrients.9, 10, 12, 58, 64, 71, 98 Of these genes, HPV 16 and ZAC1 were 
hypermethylated in association with folate, vitamin B2 or vitamin B12, but not other nutrients,12, 64 
suggesting a possible role in one-carbon metabolism. Overall, these findings suggest that methylation 
of some genes are susceptible to nutritional influences in general, whereas methylation of other genes 
are only responsive to specific nutrients.
dnA methylation across nutrient tissues
The tissue used to measure nutrient exposure might contribute to the nutrient-methylation association. 
For certain types of tissues it may be easier to detect associations of nutrients with DNA methylation, 
due to a better reflection of long-term status of these nutrients.104 Within studies that investigated the 
association between folate from different tissues or intake and same gene-specific methylation using 
same methylation tissue, we observed that some genes (H19 and p16INK4a,29, 31, 65 MYOD, NR3C1_a, 
SFRP1, SFRP2 and methylation index (HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, ESR1, MYOD, 
N33)) showed differential methylation in association with folate regardless of the source: for plasma, 
RBC and dietary folate.32, 58 However, methylation of HPP1, MGMT, PEG3, and WIF1 consistently 
showed no association with RBC folate, but showed differential methylation in association with 
plasma, serum or dietary folate within the same studies.22, 56, 58 Even though RBC folate has shown 
associations that are in line with other folate tissues in most studies, these four studies have shown 
discrepancies in their findings, which might be explained by the difference in reflection of long-term 
folate status between RBC and other tissue of folate.105
dnA methylation across methylation tissues
In addition to levels from different tissues or methods used to measure intake of nutrients, tissue-
specificity in DNA methylation is an important factor to take into account when interpreting findings 
of the studies included in this review. A few studies explored associations of specific nutrients with 
gene-specific DNA methylation measured in different tissues within the same subjects. For example, 
an intervention study by Jiang et al. showed opposite directions of association between choline intake 
during pregnancy and CRH or NR3C1 methylation in placenta versus cord blood, which shows 
that associations may differ between tissues.78 Another intervention study showed tissue-specific 
PPARGC1A methylation in muscle biopsy and subcutaneous adipose tissue in opposite directions in 
association with high-fat overfeeding diet.93, 94
dnA methylation of replicable genes
Replication of results across different study populations is of utmost importance in order to confirm 
findings. In this systematic review, we identified different studies examining same nutrient and gene-
specific methylation associations within the same stage of the life course. Different measures of folate 
during pregnancy were associated with hypomethylation of PEG3 and hypermethylation of IGF2 in 
offspring, and these findings were replicated across different studies.22, 29, 30 Methylation of TNF-α 
was not replicable across studies, possibly due to differences in population characteristics. One study 
46
Chapter 2.1
explored this association in normal-weight young women, whereas the other study explored this 
association in overweight older adults, which may explain the non-replicability.9, 97
genome-wide dnA methylation
In this systematic review, we identified five EWASs of folate, of which four studies were conducted in 
relation to maternal nutrition and offspring DNA methylation,33-36 and one study in relation to nutri-
tion in adulthood and DNA methylation.67 We investigated whether any genes of which methylation 
showed significant associations in gene-specific studies in relation to folate, were also found to be 
genome-wide significant in these EWASs. In line with the gene-specific study of Hoyo et al., who 
found an association of maternal folate supplements and erythrocytes with H19 hypomethylation 
in cord blood,29, 31 Joubert et al. in their EWAS of maternal plasma folate also found genome-wide 
significant hypomethylation of H19.34 Furthermore, this EWAS found hypomethylation of SNRPN 
which showed null association in relation to folate intake in a gene-specific study.22 Two EWASs of 
vitamin D levels were conducted by Mozhui et al. 36 and Zhu et al.,75 but the former found null associa-
tion and the later showed no comparison in genes with previous gene-specific studies.
methodological considerations
In this systematic review, a comprehensive overview is provided on the current evidence on associa-
tions between nutrients and DNA methylation in humans of all ages and during all life stages. We 
included studies examining nutrient intake from diet and supplements, as well as nutrient levels mea-
sured in blood or other tissues. Furthermore, we included studies using different tissues to measure 
DNA methylation, which enabled us to provide more insight on tissue-specific DNA methylation. 
The literature was designed by an experienced biomedical information specialist and multiple search 
engines were used, limiting the probability of undetected references. Furthermore, the selection 
process was performed by two independent reviewers. In order to objectively measure study quality, 
we used a quality score based on a predefined scoring system developed for systematic reviews. Study 
quality was determined by five study characteristics: study design, sample size, quality of exposure 
assessment, quality of outcome assessment, and confounder adjustment.
Overall, most studies are of medium to high quality. A majority of studies (28%) have a quality 
score 6 and 77% of the studies were of the quality score 5 or above. However, many studies did not 
properly adjust for confounding. Even though age, sex, and lifestyle covariates were often taken into 
account, other factors important in DNA methylation studies, such as leukocyte proportion, were 
rarely included in the models. Lack of adjustment for these covariates may have led to spurious find-
ings. As the majority of the included studies were of observational nature, causal inference from these 
studies is not possible. Only a few studies tested for effect modification by sex of genetic variation. 
This should be considered in future studies, as some studies show that associations may be different 
for males and females or different genotypes, such as MTHFR. There were a few EWASs included in 
our review, enabling the possibility to identify novel CpG sites in relation to certain nutrients. Nev-
ertheless, with this type of approach caution must be taken when interpreting the results. As EWAS 
follows a hypothesis-free approach, significant findings could be the result of false positives caused 
by multiple testing. To solve this issue, several statistical methods could be used, such as Bonferroni 
correction or false detection rate (FDR). Furthermore, in these type of studies that use a hypothesis-
2.1 Nutrients & DNA methylation: A systematic review
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free approach, there is a need for replication. Therefore, to ensure that findings are true-positives, a 
discovery and a replication cohort should be used. Even though almost all EWAS included in this 
review used a proper method for multiple testing, not all studies included a replication cohort in 
their study. Therefore, findings from these studies still need to be replicated in other cohorts in order 
to confirm that novel CpG sites identified in EWAS are true positives. On the other hand, the EWAS 
approach is also prone to type II error, or false-negatives. Usually, this is caused by lack of power due 
to a small sample size. Out of the included studies that used EWAS, only five had a sample size of >100 
participants. Possibly, potential associations between nutrients and genome-wide DNA methylation 
may have been overlooked in studies with a small sample size.
conclusions
To date, promising results have been reported in the field of nutrition and DNA methylation in 
humans at different stages across the life-course. In particular, nutrients known to be involved in 
one-carbon metabolism, such as folate, have been shown to be related to DNA methylation at a global, 
gene-specific and genome-wide level. In addition, also other nutrients, such as fatty acids, are sug-
gested to be involved in DNA methylation. However, further large-scale studies of high quality are 
needed to expand our understanding on the role of nutrition in DNA methylation and its effects on 
health and disease.
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table 2.1.4. Study characteristics and results: Vitamin B2. 
first author, year study design n country exposure 
assesment
genes tissue direction 
results
Qs
mAternAl offsPring relAtionshiP
gene-sPecific
Azzi, 2014 Cross-
sectional
2002 France FFQ & 24h 
recall
ZAC1 Cord blood Hyper 6
Adulthood              
globAl              
Marques-Rocha, 
2016
Cross-
sectional
156 Brazil 72h food 
record
NA WBCs Hyper 5
Ono, 2012 Cross-
sectional
384 Japan FFQ & 24h 
recall
NA Blood No 5
Zhang 2012 Cross-
sectional
165 USA FFQ NA WBCs No 4
Zhang, 2011 Cross-
sectional
149 USA FFQ NA Peripheral 
blood 
leukocytes
No 4
Figueiredo, 2009 Cross-
sectional
388 North 
America
FFQ NA biopsie 
from right 
and left 
colon
NA 
(Quartiles)
3
Figueiredo, 2009 Cross-
sectional
388 North 
America
Plasma NA biopsie 
from right 
and left 
colon
NA 
(Quartiles)
4
table 2.1.5. Study characteristics and results: Vitamin B3. 
first author, year study 
design 
n country exposure 
assesment
genes tissue direction 
results
Qs
mAternAl offsPring relAtionshiP
gene-sPecific
Azzi, 2014 Cross-
sectional
2002 France FFQ & 24h 
recall
ZAC1 Cord blood No 6
Adulthood              
globAl              
Marques-Rocha, 
2016
Cross-
sectional
156 Brazil 72h food 
record
NA WBCs Hypo 5
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table 2.1.6. Study characteristics and results: Vitamin B6. 
first author, year study 
design 
n country exposure 
assesment
genes tissue direction 
results
Qs
mAternAl offsPring relAtionshiP
gene-sPecific
Azzi, 2014 Cross-
sectional
2002 France FFQ & 24h 
recall
ZAC1 Cord blood No 6
Adulthood              
globAl              
Gomes, 2012 Cross-
sectional
126 Brazil 24h recall on 
3 different 
days
NA Venous blood Hypo 3
Ono, 2012 Cross-
sectional
384 Japan FFQ & 24h 
recall
NA Blood No 5
Huang, 2012 Cross-
sectional
493 USA FFQ NA Blood No 3
Perng, 2014 Cross-
sectional
987 USA FFQ NA Blood No 3
Zhang, 2011 Cross-
sectional
149 USA FFQ NA Peripheral 
blood 
leukocytes
No 4
Ulrich, 2012 Cross-
sectional
173 USA FFQ NA Lymphocytes No 4
Zhang 2012 Cross-
sectional
165 USA FFQ NA WBCs No 4
Figueiredo, 2009 Cross-
sectional
388 North 
America
FFQ NA biopsie from 
right and left 
colon
NA 
(Quartiles)
3
Figueiredo, 2009 Cross-
sectional
388 North 
America
Plasma NA biopsie from 
right and left 
colon
NA 
(Quartiles)
4
Friso, 2002 Cross-
sectional
292 Italy Venous 
blood  
NA Whole blood No 6
Hübner, 2013 Intervention 
(non-
blinded)
50 Germany Supplements NA Blood No 3
 gene-sPecific              
Zhang 2012 Cross-
sectional
165 USA FFQ IL-6 WBCs No 5
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table 2.1.9. Study characteristics and results: Vitamin C. 
first author, year study design n country exposure 
assesment
genes tissue direction 
results
Qs
Adulthood              
globAl              
Piyathilake, 2011 Cross-
sectional
376 USA Plasma NA PBMC No 6
Piyathilake, 2011 Cross-
sectional
376 USA Plasma NA Cervical 
cells
No 6
 gene-sPecific              
Bollati, 2014 Cross-
sectional
165 Italy FFQ CD14 Blood No 6
Bollati, 2014 Cross-
sectional
165 Italy FFQ Et-1 Blood No 6
Bollati, 2014 Cross-
sectional
165 Italy FFQ HERV-w Blood No 6
Bollati, 2014 Cross-
sectional
165 Italy FFQ iNOS Blood No 6
Bollati, 2014 Cross-
sectional
165 Italy FFQ TNFα Blood No 6
Stidley, 2010 Cross-
sectional
1101 USA FFQ Index (p16, 
MGMT, 
DAPK, 
RASSF1A, 
PAX5α, 
PAX5β, 
GATA4, 
and 
GATA5)
Sputum No 6
Piyathilake, 2014 Cross-
sectional
315 USA Plasma HPV 16 Blood No 5
de la Iglesia, 2014 Intervention 
(non-blinded)
47 Spain 48 h 
weighed 
food record
PON1 Venous 
blood
Hypo 6
2.1 Nutrients & DNA methylation: A systematic review
67
Ch
ap
te
r 2
.1
table 2.1.10. Study characteristics and results: Vitamin D
first author, year study design n country exposure 
assesment
genes tissue direction 
results
Qs
mAternAl offsPring relAtionshiP
gene-sPecific              
Novakovic, 2016 Cross-
sectional
68 Canada Serum CYP24A1 Placenta No 4
Harvey, 2014 Cross-
sectional
230 UK Plasma RXRA umbilical 
cord
Hypo 5
genome-wide            
Mozhui, 2015 Cross-
sectional
147 USA Plasma/
Serum
NA Cord blood 
from buffy 
coats
No 6
childhood            
globAl            
Zhu, 2016 Cross-
sectional
454 USA Plasma NA Peripherial 
Blood
Hyper 6
Zhu, 2016 Intervention 
(double-
blinded)
58 USA Supplements NA Peripherial 
Blood
Hyper 7
 gene-sPecific              
Zhu, 2013 Cross-
sectional
22 USA Plasma DHCR7 Whole blood 
leukocytes
Opposite 4
Zhu, 2013 Cross-
sectional
22 USA Plasma CYP2R1 Whole blood 
leukocytes
Hypo 4
Zhu, 2013 Cross-
sectional
22 USA Plasma CYP24A1 Whole blood 
leukocytes
Hyper 4
Novakovic, 2016 Cross-
sectional
68 Canada Serum CYP24A1 Placenta No 4
genome-wide            
Zhu, 2013 Cross-
sectional
22 USA Plasma NA Whole blood 
leukocytes
Hyper/
Hypo
5
 Adulthood            
 globAl            
Tapp, 2013 Cross-
sectional
185 UK Plasma NA Rectal 
mucosa
No 5
Nair-Shalliker, 
2014
Cross-
sectional
208 Australia Serum NA Lymphocytes No 5
Hübner, 2013 Intervention 
(non-
blinded)
50 Germany Supplements NA Blood No 3
 gene-sPecific              
Bollati, 2014 Cross-
sectional
165 Italy FFQ CD14 Blood No 6
Bollati, 2014 Cross-
sectional
165 Italy FFQ Et-1 Blood No 6
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table 2.1.10. Study characteristics and results: Vitamin D (continued)
first author, year study design n country exposure 
assesment
genes tissue direction 
results
Qs
Bollati, 2014 Cross-
sectional
165 Italy FFQ HERV-w Blood No 6
Bollati, 2014 Cross-
sectional
165 Italy FFQ iNOS Blood No 6
Bollati, 2014 Cross-
sectional
165 Italy FFQ TNFα Blood No 6
Ashktorab, 2011 Cross-
sectional
187 USA Serum DKK1 Whole blood No 7
Tapp, 2013 Cross-
sectional
185 UK Plasma Index 
(HPP1, 
APC, 
SFRP1, 
SFRP2, 
SOX17, 
WIF1, 
ESR1, 
MYOD, 
N33)
Rectal 
mucosa
Hypo 6
Tapp, 2013 Cross-
sectional
185 UK Plasma HPP1 Rectal 
mucosa
No 6
Tapp, 2013 Cross-
sectional
185 UK Plasma APC Rectal 
mucosa
Hypo 6
Tapp, 2013 Cross-
sectional
185 UK Plasma SFRP1 Rectal 
mucosa
No 6
Tapp, 2013 Cross-
sectional
185 UK Plasma SFRP2 Rectal 
mucosa
No 6
Tapp, 2013 Cross-
sectional
185 UK Plasma SOX17 Rectal 
mucosa
No 6
Tapp, 2013 Cross-
sectional
185 UK Plasma WIF1 Rectal 
mucosa
Hypo 6
Tapp, 2013 Cross-
sectional
185 UK Plasma ESR1 Rectal 
mucosa
No 6
Tapp, 2013 Cross-
sectional
185 UK Plasma MYOD Rectal 
mucosa
Hypo 6
Tapp, 2013 Cross-
sectional
185 UK Plasma N33 Rectal 
mucosa
No 6
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table 2.1.11. Study characteristics and results: Vitamin E. 
first author, year study design n country exposure 
assesment
genes tissue direction 
results
Qs
Adulthood            
globAl            
Piyathilake, 2011 Cross-sectional 376 USA Plasma NA PBMC Hypo 6
Piyathilake, 2011 Cross-sectional 376 USA Plasma NA Cervical 
cells
No 6
 gene-sPecific
Bollati, 2014 Cross-sectional 165 Italy FFQ CD14 Blood No 6
Bollati, 2014 Cross-sectional 165 Italy FFQ Et-1 Blood No 6
Bollati, 2014 Cross-sectional 165 Italy FFQ HERV-w Blood No 6
Bollati, 2014 Cross-sectional 165 Italy FFQ iNOS Blood No 6
Bollati, 2014 Cross-sectional 165 Italy FFQ TNFα Blood No 6
de la Iglesia, 2014 Intervention 
(non-blinded)
47 Spain 48 h 
weighed 
food record
PON1 Venous 
blood
Hypo 6
Stidley, 2010 Cross-sectional 1101 USA FFQ Index (p16, 
MGMT, 
DAPK,
RASSF1A, 
PAX5α, 
PAX5β, 
GATA4, 
and 
GATA5)
Sputum No 6
table 2.1.12. Study characteristics and results: Choline and betaine
nutritional 
exposure
first 
author, 
year
study design n country exposure 
assesment
genes tissue direction 
results
Qs
mAternAl offsPring relAtionshiP
globAl                
Choline Boeke, 2012 Cross-
sectional
534 USA FFQ NA Cord 
blood
Hypo 6
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
NA Placenta Hyper 4
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
NA Cord 
blood
No 4
Betaine Boeke, 2012 Cross-
sectional
534 USA FFQ NA Cord 
blood
Hypo 6
gene-sPecific
70
Chapter 2.1
table 2.1.12. Study characteristics and results: Choline and betaine (continued)
nutritional 
exposure
first 
author, 
year
study design n country exposure 
assesment
genes tissue direction 
results
Qs
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
CRH Cord 
blood
Hypo 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
NR3C1 Cord 
blood
Hypo 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
GNAS-
AS1
Cord 
blood
No 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
IGF2 Cord 
blood
No 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
IL10 Cord 
blood
No 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
LEP Cord 
blood
No 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
CRH Placenta Hyper 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
NR3C1 Placenta Hyper 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
GNAS-
AS1
Placenta No 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
IGF2 Placenta No 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
IL10 Placenta No 5
2.1 Nutrients & DNA methylation: A systematic review
71
Ch
ap
te
r 2
.1
table 2.1.12. Study characteristics and results: Choline and betaine (continued)
nutritional 
exposure
first 
author, 
year
study design n country exposure 
assesment
genes tissue direction 
results
Qs
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
LEP Placenta No 5
Adulthood
globAl                
Choline Boeke, 2012 Cross-
sectional
534 USA FFQ NA Blood No 6
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
NA Blood No 4
Choline Shin, 2010 Intervention 
(non-blinded)
60 USA Intervention 
(12-wk of 
300, 550, 
1100, or 
2200 mg/d)
NA Leukocytes Hyper 3
Betaine Boeke, 2012 Cross-
sectional
534 USA FFQ NA Blood No 6
gene-
sPecific
               
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
CRH Blood No 5
Choline Jiang, 2012 Intervention 
(non-blinded)
24 USA 12-wk 
controlled 
feeding 
study
NR3C1 Blood No 5
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suPPlementAry mAteriAl
supplement 2.1.1. Details on the search strategy for each of the databases
references identified unique references identified
Embase.com 2337 2294
Medline Ovid 1547 249
Web of science 1714 943
Cochrane 87 19
PubMed publisher 149 133
Google scholar 200 136
total 5874 3774
embase.com 2337
(diet/exp OR ‘dietary intake’/exp OR ‘food intake’/de OR ‘caloric density’/exp OR ‘caloric intake’/
exp OR ‘carbohydrate intake’/exp OR ‘diet restriction’/exp OR ‘dietary reference intake’/exp OR 
‘electrolyte intake’/exp OR ‘fat intake’/exp OR ‘fluid intake’/exp OR ‘food deprivation’/exp OR 
‘mineral intake’/exp OR ‘protein intake’/exp OR ‘vitamin intake’/exp OR ‘vitamin blood level’/exp 
OR ‘diet supplementation’/exp OR ‘mineral supplementation’/exp OR ‘vitamin supplementation’/
exp OR supplementation/de OR ‘nutrition’/de OR ‘child nutrition’/de OR ‘diet therapy’/exp OR 
‘food intake’/exp OR ‘infant nutrition’/exp OR ‘maternal nutrition’/de OR nutrient/exp OR ‘nu-
tritional status’/exp OR (diet OR nutrition OR ((dietar* OR food* OR beverage* OR alcohol* OR 
mineral* OR nutrient* OR micronutrient* OR macronutrient* OR vitamin* OR calor* OR energ* 
OR protein* OR fat OR folic-acid* OR folate* OR vegetabl* OR fruit* OR cholin* OR methionin* 
OR betain* OR fatty-acid* OR pufa OR pufas OR mufa OR mufas OR safa OR safas OR sfa OR 
sfas) NEAR/6 (intake* OR ingest* OR supplement* OR consum* OR restrict* OR depriv* OR level 
OR concentration OR blood OR plasma OR serum OR pattern*)) OR fasting OR ((well OR under) 
NEXT/1 nourish*) OR ((well OR under) NEXT/1 nourish*)):ab,ti) AND (‘DNA methylation’/exp 
OR (((dna OR ‘long interspersed’ OR gene OR genes) NEAR/6 (demethylat* OR methylat* OR 
hypermethylat* OR hypomethylat*))):ab,ti) NOT ([animals]/lim NOT [humans]/lim) AND (‘ob-
servational study’/exp OR ‘cohort analysis’/exp OR ‘longitudinal study’/exp OR ‘retrospective study’/
exp OR ‘prospective study’/exp OR ‘health survey’/de OR ‘health care survey’/de OR ‘epidemiologi-
cal data’/de OR ‘case control study’/de OR ‘cross-sectional study’/de OR ‘correlational study’/de OR 
‘population research’/de OR ‘family study’/de OR ‘major clinical study’/de OR ‘multicenter study’/
de OR ‘comparative study’/de OR ‘follow up’/de OR ‘clinical study’/de OR ‘clinical article’/de OR 
‘clinical trial’/exp OR ‘randomization’/exp OR ‘intervention study’/de OR ‘open study’/de OR ‘com-
munity trial’/de OR ‘review’/exp OR ‘systematic review’/exp OR (((observation* OR epidemiolog* 
OR famil* OR comparativ* OR communit*) NEAR/6 (stud* OR data OR research)) OR cohort* 
OR longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* NEAR/3 (stud* 
OR survey)) OR (health* NEAR/3 survey*) OR ((case OR cases OR match*) NEAR/3 control*) OR 
(cross NEXT/1 section*) OR correlation* OR multicenter* OR multi-center* OR follow-up* OR 
followup* OR clinical* OR trial OR random* OR review* OR meta-analy*):ab,ti) NOT ([Confer-
ence Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
medline ovid  1547
(exp Diet/ OR exp “Eating”/ OR “Recommended Dietary Allowances”/ OR “food deprivation”/ 
OR vitamins/bl OR “Dietary Supplements”/ OR “Nutritional Physiological Phenomena”/ OR exp 
“Diet Therapy”/ OR “Maternal Nutritional Physiological Phenomena”/ OR “nutritional status”/ OR 
(diet OR nutrition OR ((dietar* OR food* OR beverage* OR alcohol* OR mineral* OR nutri-
ent* OR micronutrient* OR macronutrient* OR vitamin* OR calor* OR energ* OR protein* OR 
2.1 Nutrients & DNA methylation: A systematic review
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fat OR folic-acid* OR folate* OR vegetabl* OR fruit* OR cholin* OR methionin* OR betain* 
OR fatty-acid* OR pufa OR pufas OR mufa OR mufas OR safa OR safas OR sfa OR sfas) ADJ6 
(intake* OR ingest* OR supplement* OR consum* OR restrict* OR depriv* OR level OR con-
centration OR blood OR plasma OR serum OR pattern*)) OR fasting OR ((well OR under) ADJ 
nourish*) OR ((well OR under) ADJ nourish*)).ab,ti.) AND (“DNA Methylation”/ OR (((dna OR 
“long interspersed” OR gene OR genes) ADJ6 (demethylat* OR methylat* OR hypermethylat* OR 
hypomethylat*))).ab,ti.) NOT (exp animals/ NOT humans/) AND (“observational study”/ OR exp 
“Epidemiologic Studies”/ OR “health surveys”/ OR “multicenter study”/ OR exp “clinical study”/ 
OR “Random Allocation”/ OR “review”/ OR (((observation* OR epidemiolog* OR famil* OR com-
parativ* OR communit*) ADJ6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR 
retrospectiv* OR prospectiv* OR population* OR (national* ADJ3 (stud* OR survey)) OR (health* 
ADJ3 survey*) OR ((case OR cases OR match*) ADJ3 control*) OR (cross ADJ section*) OR cor-
relation* OR multicenter* OR multi-center* OR follow-up* OR followup* OR clinical* OR trial 
OR random* OR review* OR meta-analy*).ab,ti.) NOT (letter OR news OR comment OR editorial 
OR congresses OR abstracts).pt.
cochrane  87
((diet OR nutrition OR ((dietar* OR food* OR beverage* OR alcohol* OR mineral* OR nutrient* 
OR micronutrient* OR macronutrient* OR vitamin* OR calor* OR energ* OR protein* OR fat OR 
folic-acid* OR folate* OR vegetabl* OR fruit* OR cholin* OR methionin* OR betain* OR fatty-
acid* OR pufa OR pufas OR mufa OR mufas OR safa OR safas OR sfa OR sfas) NEAR/6 (intake* 
OR ingest* OR supplement* OR consum* OR restrict* OR depriv* OR level OR concentration OR 
blood OR plasma OR serum OR pattern*)) OR fasting OR ((well OR under) NEXT/1 nourish*) 
OR ((well OR under) NEXT/1 nourish*)):ab,ti) AND ((((dna OR ‘long interspersed’ OR gene OR 
genes) NEAR/6 (demethylat* OR methylat* OR hypermethylat* OR hypomethylat*))):ab,ti)
web of science  1714
TS=(((diet OR nutrition OR ((dietar* OR food* OR beverage* OR alcohol* OR mineral* OR 
nutrient* OR micronutrient* OR macronutrient* OR vitamin* OR calor* OR energ* OR protein* 
OR fat OR folic-acid* OR folate* OR vegetabl* OR fruit* OR cholin* OR methionin* OR betain* 
OR fatty-acid* OR pufa OR pufas OR mufa OR mufas OR safa OR safas OR sfa OR sfas) NEAR/5 
(intake* OR ingest* OR supplement* OR consum* OR restrict* OR depriv* OR level OR concen-
tration OR blood OR plasma OR serum OR pattern*)) OR fasting OR ((well OR under) NEAR/1 
nourish*) OR ((well OR under) NEAR/1 nourish*))) AND ((((dna OR “long interspersed” OR gene 
OR genes) NEAR/5 (demethylat* OR methylat* OR hypermethylat* OR hypomethylat*)))) AND 
((((observation* OR epidemiolog* OR famil* OR comparativ* OR communit*) NEAR/5 (stud* OR 
data OR research)) OR cohort* OR longitudinal* OR retrospectiv* OR prospectiv* OR population* 
OR (national* NEAR/2 (stud* OR survey)) OR (health* NEAR/2 survey*) OR ((case OR cases OR 
match*) NEAR/2 control*) OR (cross NEAR/1 section*) OR correlation* OR multicenter* OR 
multi-center* OR follow-up* OR followup* OR clinical* OR trial OR random* OR review* OR 
meta-analy*)) NOT ((animal* OR rat OR rats OR mouse OR mice OR murine) NOT (human* OR 
patient*))) AND DT=(article)
Pubmed publisher 149
(Diet[mh] OR “Eating”[mh] OR “Recommended Dietary Allowances”[mh] OR “food 
deprivation”[mh] OR vitamins/bl[mh] OR “Dietary Supplements”[mh] OR “Nutritional Physi-
ological Phenomena”[mh] OR “Diet Therapy”[mh] OR “Maternal Nutritional Physiological 
Phenomena”[mh] OR “nutritional status”[mh] OR (diet OR nutrition OR ((dietar*[tiab] OR 
food*[tiab] OR beverage*[tiab] OR alcohol*[tiab] OR mineral*[tiab] OR nutrient*[tiab] OR 
micronutrient*[tiab] OR macronutrient*[tiab] OR vitamin*[tiab] OR calor*[tiab] OR energ*[tiab] 
OR protein*[tiab] OR fat OR folic-acid*[tiab] OR folate*[tiab] OR vegetabl*[tiab] OR fruit*[tiab] 
96
Chapter 2.1
OR cholin*[tiab] OR methionin*[tiab] OR betain*[tiab] OR fatty-acid*[tiab] OR pufa OR pufas 
OR mufa OR mufas OR safa OR safas OR sfa OR sfas) AND (intake*[tiab] OR ingest*[tiab] OR 
supplement*[tiab] OR consum*[tiab] OR restrict*[tiab] OR depriv*[tiab] OR level OR concen-
tration OR blood OR plasma OR serum OR pattern*[tiab])) OR fasting OR well nourish*[tiab] 
OR under nourish*[tiab])) AND (“DNA Methylation”[mh] OR (((dna OR “long interspersed” 
OR gene OR genes) AND (demethylat*[tiab] OR methylat*[tiab] OR hypermethylat*[tiab] OR 
hypomethylat*[tiab])))) NOT (animals[mh] NOT humans[mh]) AND (“observational study”[mh] 
OR “Epidemiologic Studies”[mh] OR “health surveys”[mh] OR “multicenter study”[mh] OR 
“clinical study”[mh] OR “Random Allocation”[mh] OR “review”[mh] OR (((observation*[tiab] OR 
epidemiolog*[tiab] OR famil*[tiab] OR comparativ*[tiab] OR communit*[tiab]) AND (stud*[tiab] 
OR data OR research)) OR cohort*[tiab] OR longitudinal*[tiab] OR retrospectiv*[tiab] OR 
prospectiv*[tiab] OR population*[tiab] OR (national*[tiab] AND (stud*[tiab] OR survey)) OR 
(health*[tiab] AND survey*[tiab]) OR ((case OR cases OR match*[tiab]) AND control*[tiab]) OR 
(cross section*[tiab]) OR correlation*[tiab] OR multicenter*[tiab] OR multi-center*[tiab] OR fol-
low-up*[tiab] OR followup*[tiab] OR clinical*[tiab] OR trial OR random*[tiab] OR review*[tiab] 
OR meta-analy*[tiab])) NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] OR 
congresses[pt] OR abstracts[pt]) AND publisher[sb]
google scholar
diet| nutrition| dietary| nutrients| micronutrients| macronutrients| vitamins| ”folic acid”| folate| vegetables| 
fruit| choline “dna demethylation| methylation| hypermethylation| hypomethylation”
2.1 Nutrients & DNA methylation: A systematic review
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supplement 2.1.2. Detailed selection criteria
Inclusion
criteria
 1. Any study design
  → Including cross-sectional studies, case-control studies, cohort studies or intervention studies.
 2. Studies investigating associations of dietary factors with DNA methylation.
  → Nutrients:
Including nutrient levels (in blood or other tissues); intake of nutrients; or dietary supplements.
  → DNA methylation:
Including global DNA methylation, gene specific DNA methylation, or genome-wide DNA 
methylation.
 3. Studies conducted at any age or life stage (e.g., during pregnancy, childhood, adulthood, etc.)
 4. No language or date restriction
Exclusion
criteria
 1. Studies not carried out in humans
 2. In vitro studies
 3. Studies conducted only in patients with chronic diseases (cancer, diabetes, CHD, etc.)
Note: some studies have healthy control groups and report associations within these groups separately, 
these should be included.
 4. Letters, reviews, opinions papers, guidelines, case-reports (n<5), editorials
 5. Studies examining only the following exposures:
   a. eating disorders;
   b. alcohol dependency/alcoholism ;
   c.  weight loss (unless the weight-loss intervention is solely a restricted diet, not combined with 
other lifestyle changes).
   d. Dietary patterns or food groups without examining individual nutrients
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supplement 2.1.3. Quality score
Two independent reviewers evaluated the quality of included studies using the following quality 
score. The score is composed of 5 items, and each item was allocated 0, 1 or 2 points. This allowed 
a total score between 0 and 10 points, 10 representing the highest quality. The following items are 
included in the score:
1. study design
0 for cross-sectional studies
1 for longitudinal studies (including repeated measurements)
2 for interventional studies
2. Population
Global and candidate gene studies
0 if n<30
1 if n 30 to 100
2 if n>100
EWAS studies
0 if n<300
1 if n 300 to 1000
2 if n>1000
3. exposure
Observational studies
0 if the study used no appropriate standard diet or nutrient concentration assessment method (see 
below) or if not reported
1 if the study used food records, a 24h recall or an FFQ
2 if the study used blood levels
Interventional studies
0 if the intervention diet was not described or not blinded
1 if the intervention diet was adequately single-blinded
2 if the intervention is adequately double-blinded
4. outcome
0 Global DNA methylation
1 Gene-specific DNA methylation
2 Genome-wide DNA methylation
5. Adjustments
0 if findings are not controlled for potential confounders*
1 if findings are controlled for at least basic confounders: age and sex, and multiple testing in case of 
an EWAS
2 if an intervention study is adequately randomized or if findings are controlled for additional 
confounders (on top of those described above), such as: technical covariates, WBC, BMI, smoking, 
alcohol, etc.
* ‘Controlled for’ includes: adjustment for in the statistical analyses (e.g. with multivariable regression); 
stratification in the analyses (e.g. men and women separately); or restriction or narrow selection criteria of 
study participants on this covariate.
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The role of DNA methylation in 
dyslipidaemia: A systematic review.
braun kVe*, Voortman T*, Dhana K, Troup J, Bramer WM, Troup J, Chowdhury R, 
Dehghan A, Muka T, Franco OH. The role of DNA methylation in dyslipidaemia: A 
systematic review. Progress in Lipid Research. 2016;64:178-91.
*Denotes equal contribution
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AbstrAct
Epigenetic mechanisms, including DNA methylation and histone modifications might be involved in 
the regulation of lipid concentration variability and may thereby contribute to the cardiovascular risk 
profile. We aimed to systematically review studies investigating the association between epigenetic 
marks and plasma concentrations of triacylglycerol, total cholesterol, low-density lipoprotein-choles-
terol, and high-density lipoprotein-cholesterol. Six medical databases were searched until September 
3rd 2015, reference lists were screened, and experts in the field were contacted. Of the initially identi-
fied 757 references, 31 articles reporting on 23 unique studies met all our inclusion criteria. These 
studies included data on 8,027 unique participants. Overall, no consistent associations were observed 
between global DNA methylation and blood lipids. Candidate gene and epigenome-wide association 
studies reported epigenetic regulation of several genes to be related with blood lipids, of which results 
for ABCG1, CPT1A, TNNT1, MIR33B, SREBF1, and TNIP were replicated. To date, no studies have 
been performed on histone modification in relation to blood lipids. Promising results have been 
reported in the field of epigenetics and dyslipidaemia, however, further rigorous studies are needed 
to expand our understanding on the role of epigenetics in regulating human’s blood lipid levels and 
its effects on health and disease.
3.1 DNA methylation & dyslipidaemia: A systematic review
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introduction
Dyslipidaemia, defined as decreased high-density lipoprotein-cholesterol (HDL-C), elevated low-
density lipoprotein-cholesterol (LDL-C), and/or elevated triacylglycerol (TAG) concentrations,1, 2 is 
recognized as a prominent risk factor for cardiovascular disease (CVD)3 and is associated with many 
other metabolic disturbances.4
Dyslipidaemia is caused by environmental factors, such as an unhealthy diet and lack of exercise.5 
In addition, genetic factors have a strong influence on blood lipid concentrations and lipid metabo-
lism.6 Genome wide-association studies have identified several common genetic variants that explain 
up to 12% of the inter-individual variability in plasma blood lipids.7 Beyond this, there is evidence 
that epigenetic mechanisms, that have been recognized recently as a potential important link between 
environmental exposure and disease risk,8, 9 may account for lipoprotein profile variability and may 
thereby influence risk of CVD.10-12 Epigenetics refers to changes in gene activity and expression 
without alterations in DNA sequence. Epigenetic changes occur during development and differentia-
tion, or in response to environmental factors, such as smoking, diet and physical activity. The best 
understood epigenetic mechanisms that regulate these non-genetic alterations are attachment of a 
methyl group to the cytosine-guanine dinucleotide (CpG) of DNA (DNA methylation) and changes 
in histone proteins associated with DNA (histone modifications). These epigenetic processes occur 
under the influence of environmental factors and influence packaging and interpreting the genome 
and thus altering gene expression, and may subsequently affect disease risk.13 Epigenetics is therefore 
considered a bridge between genotype and phenotype.
In epidemiological studies, DNA methylation is studied as either methylation at single genes, or as 
global DNA methylation. The latter refers to global analysis of DNA methylation across the entire ge-
nome in a given cell. Global DNA methylation in blood cells has been used as epigenetic biomarkers for 
predicting disease risk, including cardiovascular disease and type 2 diabetes.14, 15 In addition to global 
methylation, previous studies have reported that DNA methylation at specific genes are related to blood 
lipid concentrations, including methylation at genes that are known to be involved in dyslipidaemia, such 
as APOE, LPL and ABCG1.14, 16, 17 It has been suggested that epigenetics is a promising area in science 
that can help to obtain a better understanding of the aetiology of dyslipidaemia, as well as a promising 
molecular strategy for disease risk stratification. To date, however, there is no comprehensive assessment 
of the current evidence for the role of DNA methylation and histone modifications on plasma lipids profile.
Therefore, we conducted a systematic review of all available evidence in humans on the association 
of DNA methylation and histone modifications with plasma concentrations of triacylglycerol (TAG), 
total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-
cholesterol (HDL-C). A critical appraisal of current limitations in the field is also presented.
methods
literature search
The search engines Embase.com (Medline and Embase), Medline (Ovid), Web-of-Science, PubMed, 
Cochrane Central and Google Scholar were searched from inception until September 3rd 2015 (date 
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last searched) to identify published studies that examined the association between epigenetic marks 
and blood cholesterol or TAG levels. The search was designed by an experienced biomedical infor-
mation specialist. The search terms related to the exposure included epigenetics, DNA methylation, 
histone and CpG, and were combined with the terms TAG, TC, LDL-C, and HDL-C. We did not apply 
any language restriction, but we restricted the search to studies on humans. The full search strategies 
of all databases are provided in Supplement 3.1.1.. In order to identify potential additional studies, 
we checked the reference lists of studies included and contacted other experts in the field.
study selection and inclusion criteria
We selected studies that examined the association between epigenetic marks (global, site specific or 
genome-wide methylation of DNA, or histone modifications) and plasma lipids (TAG, TC, LDL-
C, and HDL-C) in humans. Two independent reviewers screened the retrieved titles and abstracts 
and selected eligible studies according to the selection criteria (Supplement 3.1.2.). Discrepancies 
between the two reviewers were resolved through discussion, with an arbitrator available if no 
consensus was reached. We retrieved full texts for studies that satisfied all selection criteria. These 
full-text articles were evaluated in detail once more by two investigators against the selection criteria.
data extraction
Data extraction was performed using a predesigned form. Extracted information included study 
design, characteristics of the study population, location of the study, and level of confounder adjust-
ment. Furthermore, for each study the tissue type and methods used to determine DNA methylation, 
specific CpG sites (for candidate gene studies), directions of the associations were reported.
results
After deduplication, we identified 757 potentially relevant citations (Figure 3.1.1). Based on the titles 
and abstracts, full texts of 44 articles were selected for more detailed evaluation. Of those, 31 articles 
reporting results of 23 unique studies met all our eligibility criteria and were therefore included in the 
analysis (Tables 3.1.1-3.1.5).
characteristics of the included studies
Detailed characteristics of these studies are summarized in Table 3.1.1-3.1.5. All included studies 
were of cross-sectional design. Combined, the studies included data on 8,027 unique participants. Six 
studies included participants from China, five studies from Canada, and the rest included participants 
from USA, Italy, Iran, Egypt, Germany, Japan and Spain (Table 3.1.1-3.1.5). Of the 23 unique studies, 
one study examined solely on LDL-C as outcome, one study examined only HDL-C, whereas the rest 
of the studies included two or more types of blood lipids.
3.1 DNA methylation & dyslipidaemia: A systematic review
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global dnA methylation
Global DNA methylation refers to the overall genome-wide content of methylated cytosines within 
CpG sites. Th e majority of CpG sites (about 80%) are found in repetitive sequences (multiple copies 
of DNA that are normally methylated), such as Alu and long-interspersed nuclear element (LINE-1) 
and correlate with total genomic methylation content.18-20 Methylation of these repetitive elements is 
widely used as a surrogate measure for global DNA methylation.21, 22 Other methods (e.g., Lumino-
metric Methylation Assay, LUMA and the [3H]-methyl acceptance based method) to assess global 
genomic DNA methylation are primarily based on the digestion of genomic DNA by restriction 
enzymes HpaII and MspI.23
Global DNA methylation and triacylglycerol
Th ree studies examined global DNA-methylation assessed at LINE-1 elements or 5hmC methylation 
in relation to TAG levels (Table 3.1.1). One study assessed global DNA methylation in blood and 
found a positive association with TAG.24 In line with this, another study reported that 5-hmC meth-
ylation levels were positively correlated with TAG blood levels.25 Th e third study found no association 
of LINE-1 methylation in visceral adipose tissue with TAG.26
 
 
Records excluded based on title 
and abstract  
n = 713 
 
Records given full text detailed 
assessment  
n = 44 
Full-text articles excluded  
 
n = 13 
Studies included  
n = 31 
(based on 23 unique studies) 
  
Records screened  
n = 757 
  
Unique records identified through 
database searching  
n = 757 
figure 3.1.1. Flow chart of included studies
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Global DNA methylation and total cholesterol
There were three studies that examined global DNA methylation in relation to TC (Table 3.1.1). All 
three studies assessed global methylation in blood.24, 27, 28 One study assessed global DNA methylation 
in LINE-1 elements and found higher levels of global methylation with increasing levels of TC.24 
Similarly, another study reported 5hmC methylation levels to positively correlate with TC.28 The last 
study used restriction enzymes HpaII and MspI to assess global methylation and found no associa-
tion with TC.27
table 3.1.1. Global DNA methylation and plasma lipid levels
Author Population tissue methods Adjustment Association
TAG
Turcot V et al. 
201226
Canada , n=186, 35.1 
± 7.7 y,
Visceral 
Adipose tissue
LINE-1 
methylation
Age, sex and smoking 
and waist circumference
No association
Pearce MS et 
al. 201224
UK, n=228, 49-51 y PB LINE-1 
methylation
Sex Positive 
association
Nicoletti CF et 
al. 201528
Multiple countries, 
n=45, 43.1 ± 7.9 y, W.
Blood 5hmC (%) Positive 
association
Total Cholesterol
Pearce MS et 
al. 201224
UK, n=228, 49-51 y PB LINE-1 
methylation
Sex Positive 
association
Nicoletti CF et 
al. 201528
Multiple countries, 
n=45, 43.1 ± 7.9 y, W.
Blood 5hmC (%) Positive 
association
Kato S et al. 
201227
Japan, n=44, 59 ± 
12 y
PB HpaII/MspI 
ratio
No association
LDL-C
Cash HL et al. 
201129
USA, n=355, 32.0 
± 3.7 y
Peripheral 
Lymphocyte
LINE-1 Age, sex, BMI, HDL-C Inverse 
association
Pearce MS et 
al. 2012 24
UK, n=228, 49-51 y, 
M and W
PB LINE-1 Sex Positive 
association
HDL-C
Cash HL et al. 
201129
USA, n=355, 32.0 
± 3.7 y
Peripheral 
Lymphocyte
LINE-1 Age, sex, BMI, LDL-C Positive 
association
Pearce MS et 
al. 201224
UK, n=228, 49-51 y PB LINE-1 Sex Inverse 
association
Turcot V et al. 
201226
Canada, n=186, 35.1 
± 7.7 y
Visceral 
Adipose tissue
LINE-1 Age, sex and smoking 
and waist circumference
No association
Kato S et al. 
201227
Japan, n=44, 59 ± 12, PB HpaII/MspI 
ratio
No association
HDL-C:LDL-C ratio
Pearce MS et 
al. 201224
UK, n=228, 49-51 y, 
M and W
PB LINE-1 Sex Inverse 
association
M, men; PB, peripheral blood; W, women; y, years.
3.1 DNA methylation & dyslipidaemia: A systematic review
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Global DNA methylation and low-density lipoprotein-cholesterol
Global DNA methylation assessed at LINE-1 elements in blood in relation to LDL-C was examined 
in two studies (Table 3.1.1). Interestingly, the abovementioned study that found a positive association 
of global methylation and HDL-C (see section 3.2.1), observed an inverse association between global 
methylation and LDL-C,29 whereas one of the other studies that reported an inverse association for 
HDL-C (see section 3.2.1) found a positive association for LDL-C.24 The first study reported that 
the inverse association between global methylation and LDL-C was statistically significant only in 
women.
Global DNA methylation and high-density lipoprotein-cholesterol
Four studies assessed global DNA methylation in relation to HDL-C (Table 3.1.1). Two studies assessed 
global methylation in LINE-1 elements in blood, but showed contradictory results. One study reported 
a positive association between global methylation and HDL-C, which after stratification by sex was 
significant only in men.29 In contrast, the other study reported an inverse association.24 Another study 
assessed global methylation in LINE-1 elements in visceral adipose tissue and reported no significant 
association with HDL-C.26 Similarly, a study using restriction enzymes HpaII and MspI found no 
significant association between global methylation and HDL-C.27
candidate gene studies
Most of the studies on DNA methylation and blood lipids have used a hypotheses-driven, candidate 
gene approach. With this approach, only epigenetic marks at certain genes are investigated, that have 
been selected based on knowledge from previous genetic studies or based on knowledge about the 
biological function of the specific gene.
Methylation of candidate genes and triacylglycerol
There were 15 studies that examined methylation sites in or near known candidate genes for varia-
tions in TAG (Table 3.1.2). One study assessed DNA methylation in placenta,30, 31 one in visceral adi-
pose tissue32 and the remaining studies examined blood cells. Overall, these studies found positive 
correlations between TAG and overall methylation at NPC1 and IGF2, and methylation at several 
CpG sites at FIAM in blood; and negative correlations with overall DNA methylation at MCP-1 and 
methylation at MMP9-CpG2, LIPC-CpG2, GCK-CpG2 and GCK-CpG4 in blood cells. Three studies 
showed sex-specific associations between different methylated regions and TAG: in women, there was 
a positive association between DNA methylation at PLA2G7,12 or BCL11A with TAG,33 and a negative 
association of methylation at ABCG1-CpG3 with TAG, whereas in men, no associations were found.10 
The latter study also showed that DNA methylation at LIPC-CpG2 was negatively correlated with 
TAG in men but not in women. No associations were found between TAG and DNA methylation 
at SCARB1,10 PLTP,10 CETP,10 LPL,10 CD14,34 TCF7L2,35 MTHFR,36 APOE,37 ABCG1,38 GALNT2,38 
HMGCR,38 DPP4,32 CD14,34 Et-1,34 HERV-W,34 iNOS,34 or TNF-α.34 Finally, one study (reported in two 
articles30, 31) included pregnant women and found a negative correlation between TAG concentrations 
in cord blood and methylation levels of the ABCA1 gene in placenta, whereas no association was 
found with methylation at the LPL gene.
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Chapter 3.1
Methylation of candidate genes and total cholesterol
We identified 14 studies that examined methylation sites in, or near, candidate genes for blood lipids 
in relation to TC (Table 3.1.3). All studies assessed DNA methylation in blood, and one study as-
sessed DNA methylation in both blood and adipose tissue.39 Overall, these studies found a higher 
degree of methylation of FIAM, ABCG1, PLA2G7, NPC1 and MTHFR and lower levels of methylation 
of DPP4 in the peripheral blood with higher levels of plasma TC. Furthermore, higher methylation 
of APOE-CpG-7, COL14A1-CpG2, LEP and ADIPOQ; and lower methylation levels of APOE-
CpG1, 2, 10, 12, 13, ABCG1-CpGC3 and TCF7L2-CpG27 were associated with higher levels of TC. 
No associations were found between TC and DNA methylation at IGF2, ABCA1, MCP-1, GALNT2, 
HMGCR and BCL11A. There were two studies investigating the association between DNA methyla-
tion at ABCG1 and TC: one study found an inverse association between ABCG1-CpG3 and TC in 
men,10 whereas the other study reported no association between overall methylation at this gene and 
TC in either sex.38
Methylation of candidate genes and low-density lipoprotein-cholesterol
Fourteen studies investigated methylation sites in or near known candidate genes for blood lipids in 
relation to LDL-C (Table 3.1.4). Ten studies used blood cells to assess DNA methylation, one study 
examined visceral adipose tissue, one study used placenta, and two studies used combinations of these 
tissues. These studies found that higher overall methylation at ABCA1,10 TNF-α,34 LEP, ADIPOQ,39 
MTHFR,36 and several CpG sites at FIAM,40 and lower overall methylation at ADRB310 and NPC141 
were associated with higher LDL-C concentrations. LDL-C was also found to be positively correlated 
to methylation at MMP9-CpG1,42 APOE-CpG9,37 and GCK-CpG3,43 and negatively correlated with 
methylation at MMP9-CpG442 and TCF7L2-CpG27.35 No significant associations were reported 
for LDL-C concentration in relation to methylation at CD14,34 Et-1,34 HERV-W,34 iNOS,34 IGF2,44 
MCP-1,45 ABCG1,38 GALNT2,38 HMGCR,38 or DPP4.32 Finally, one study examined DNA methylation 
at LPL and ABCA1 genes in placenta of pregnant women in relation to LDL-C and reported null 
associations.30, 31
Methylation of candidate genes and high-density lipoprotein-cholesterol
The association of DNA methylation in or near known candidate genes for blood lipids with HDL-
C concentrations was investigated in 13 unique studies (Table 3.1.5). Ten studies assessed DNA 
methylation in blood and the other three studies examined methylation in several tissues, including 
placental tissue and visceral adipose tissue. Overall, these studies found that a lower degree of meth-
ylation of FIAM,40 ABCA1,46 NPC1,41 MTHFR,36 LEP,39 ADIPOQ,39 and higher levels of methylation of 
LPL47 and DPP448 genes in the peripheral blood were associated with higher levels of plasma HDL-C. 
No associations were found between HDL-C and DNA methylation at CD14,34 Et-1,34 HERV-W,34 
iNOS,34 TNF-α,34 TCF7L2,35 IGF2,44 MCP-1,45 APOE,37 ABCG1,38 GALNT2,38 or HMGCR.38 Two stud-
ies showed sex-specific associations between HDL-C and DNA methylation at PLTP,10 CETP,47 and 
LIPC-CpGA210: these associations were all significant in men but not in women.
3.1 DNA methylation & dyslipidaemia: A systematic review
115
Ch
ap
te
r 3
.1
ta
bl
e 
3.
1.
3.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
to
ta
l c
ho
le
ste
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
 
ch
ar
ac
te
ri
st
ic
s
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
c
an
di
da
te
 g
en
e 
ap
pr
oa
ch
W
u 
L 
et
 a
l. 
20
15
40
C
ro
ss
-s
ec
tio
na
l
C
hi
na
, n
=9
8,
 8
-1
8 
y
PB
L
M
as
sA
R
R
AY
 p
la
tfo
rm
FI
AM
 g
en
e 
pr
om
ot
er
, 3
6 
C
pG
 
sit
e
Ag
e,
 g
en
de
r, 
BM
I
Po
sit
iv
e 
as
so
ci
at
io
n
H
ou
de
 A
 e
t 
al
. 2
01
53
9
C
ro
ss
-s
ec
tio
na
l
C
an
ad
a,
 n
=7
3,
 3
4,
7 
± 
7.
1 
y
Bl
oo
d,
 
su
bc
ut
an
eo
us
 
ad
ip
os
e 
tis
su
e,
 a
nd
 
vi
sc
er
al
 a
di
po
se
 
tis
su
e
Py
ro
se
qu
en
ci
ng
LE
P 
an
d 
AD
IP
O
Q
Ag
e,
 se
x 
an
d 
w
ai
st 
gi
rt
h.
As
so
ci
at
io
n 
w
ith
 A
D
IP
O
Q
-
C
pG
E3
 (d
ire
ct
io
n 
no
t r
ep
or
te
d)
G
ua
y 
et
 a
l.,
 
20
14
10
C
ro
ss
-s
ec
tio
na
l 
stu
dy
C
an
ad
a,
 n
=9
8,
 n
=6
1 
m
en
 4
6.
3 
±1
.7
 y,
 a
nd
 
n=
37
 w
om
en
 3
6.
9±
2.
0 
y, 
un
tre
at
ed
 F
H
 
pa
tie
nt
s
Bl
oo
d 
le
uc
oc
yt
es
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g
Pr
im
ar
y: 
AB
C
G
1,
 
LI
PC
, P
LT
P 
an
d 
SC
AR
B1
sec
on
da
ry
: A
BC
A1
, 
C
ET
P,
 a
nd
 L
PL
Ag
e,
 w
ai
st 
ci
rc
um
fe
re
nc
e,
 
bl
oo
d
pr
es
su
re
, f
as
tin
g 
pl
as
m
a 
lip
id
s a
nd
 
gl
uc
os
e 
le
ve
ls
M
en
,
N
eg
at
iv
e 
as
so
ci
at
io
n 
fo
r A
BC
G
1-
C
pG
C
3
W
om
en
:
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
ns
G
ua
y 
SP
 e
t 
al
. 2
01
54
2
C
ro
ss
-s
ec
tio
na
l 
stu
dy
C
an
ad
a,
 n
=5
0,
 5
3.
8 
± 
1.
5 
y, 
m
en
PB
L
Bi
su
lfi
te
-p
yr
os
eq
ue
nc
in
g
C
O
L1
4A
1
Ag
e,
 B
M
I a
nd
 
gl
uc
os
e 
le
ve
ls
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r 
C
O
L1
4A
1-
C
pG
2
G
ua
y 
et
 a
l.,
 
20
14
67
C
as
e-
co
nt
ro
l f
or
 
C
AD
C
an
ad
a,
 n
= 
88
 (3
8 
ca
se
s, 
50
 c
on
tro
ls)
, 
m
ed
ia
n 
ag
e 
61
 y,
 M
, 
C
au
ca
sia
n,
 a
ll 
re
cr
ui
te
d 
fro
m
 p
at
ie
nt
s w
ho
 
un
de
rw
en
t h
ea
rt
 
su
rg
er
y
Bl
oo
d 
le
uc
oc
yt
es
Bi
s-
py
ro
se
qu
en
ci
ng
AB
C
A1
Ag
e,
 C
AD
 st
at
us
 
an
d 
m
ed
ic
at
io
n
O
ld
er
 m
en
 (≥
61
 y
ea
rs
)
Po
sit
iv
e 
as
so
ci
at
io
n
Yo
un
ge
r m
en
 (<
61
 y
ea
rs
)
no
 si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
n
Jia
ng
 e
t a
l.,
 
20
13
12
C
as
e-
co
nt
ro
l f
or
 
C
H
D
C
hi
na
, n
=7
2,
 c
as
es
: 
n=
36
 , 
ag
e 
62
.5
 ±
5.
5 
y, 
co
nt
ro
ls:
 n
= 
36
, 6
1.
7 
±5
.2
 y
Bl
oo
d
Bi
su
lp
hi
te
py
ro
se
qu
en
ci
ng
PL
A2
G
7 
ge
ne
 
pr
om
ot
or
Ag
e,
 h
ist
or
y 
of
 
sm
ok
in
g,
 d
ia
be
te
s, 
hy
pe
rt
en
sio
n
W
om
en
:
po
sit
iv
e 
as
so
ci
at
io
n
M
en
:
no
 si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
n
116
Chapter 3.1
ta
bl
e 
3.
1.
3.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
to
ta
l c
ho
le
ste
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
 (c
on
tin
ue
d)
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
 
ch
ar
ac
te
ri
st
ic
s
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
Af
za
li 
et
 a
l. 
20
13
41
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r C
V
D
Ir
an
, n
=1
00
, 5
9.
9±
12
.1
 
y
Pe
rip
he
ra
l b
lo
od
 
le
uk
oc
yt
es
N
es
te
d-
m
et
hy
la
tio
n 
sp
ec
ifi
c 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
m
et
ho
d
N
C
P1
Po
sit
iv
e 
as
so
ci
at
io
n
C
an
iv
el
l e
t 
al
. 2
01
43
5
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r T
2D
Sp
ai
n,
 n
=1
86
, 
67
.9
±1
0.
5 
y
W
ho
le
 b
lo
od
Se
qu
en
om
 E
pi
T
YP
ER
 
sy
ste
m
TC
F7
L2
Ag
e,
 g
en
de
r, 
BM
I, 
ph
ys
ic
al
 a
ct
iv
ity
, 
sm
ok
in
g 
sta
tu
s a
nd
 
w
ai
st 
ci
rc
um
fe
re
nc
e
Po
sit
iv
e 
as
so
ci
at
io
n 
(C
pG
 2
7)
D
eo
da
ti 
et
 a
l. 
20
13
44
C
ro
ss
-s
ec
tio
na
l 
stu
dy
Ita
ly,
 n
=8
5,
 1
1.
5 
± 
2.
2 
y
Bl
oo
d 
ly
m
ph
oc
yt
es
M
et
hy
l-P
ro
fil
er
 D
N
A 
M
et
hy
la
tio
n 
qP
C
R
 A
ss
ay
 
(S
AB
io
sc
ie
nc
es
)
IG
F2
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
G
ha
tta
s e
t a
l. 
20
14
36
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r e
nd
-
sta
ge
 re
na
l c
as
es
Eg
yp
t, 
n=
96
, 3
0-
70
 y
Pe
rip
he
ra
l b
lo
od
Ep
iT
ec
h 
Bi
su
lfi
te
 
co
nv
er
sio
n 
ki
t
M
T
H
FR
Po
sit
iv
e 
as
so
ci
at
io
n
H
ou
de
 A
 e
t 
al
. 2
01
33
1
C
ro
ss
-s
ec
tio
na
l 
stu
dy
C
an
ad
a,
 n
=1
00
, 
20
-3
9 
y
W
Pl
ac
en
ta
 a
nd
 c
or
d 
bl
oo
d
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g
AB
C
A1
 g
en
e 
pr
om
ot
or
, 2
2 
C
pG
 
sit
es
Ag
e,
 B
M
I, 
TA
G
 
at
 fi
rs
t t
rim
es
te
r 
an
d 
hi
sto
ry
 o
f 
ge
sta
tio
na
l d
ia
be
te
s
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
Li
u,
 Z
. H
. e
t 
al
. 2
01
24
5
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r d
ia
be
te
s
C
hi
na
, n
=4
7,
 
51
.4
6±
14
.1
1 
y
Pe
rip
he
ra
l b
lo
od
Bi
su
lfi
te
 m
od
ifi
ca
tio
n
M
C
P-
1 
pr
om
ot
er
s
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
M
a,
 Y
. e
t a
l. 
20
15
37
C
ro
ss
-s
ec
tio
na
l 
stu
dy
U
ni
te
d 
St
at
es
, n
=9
93
, 
47
.8
8 
y
C
D
4+
 T
 c
el
ls
Bi
su
lfi
te
 tr
ea
tm
en
t
AP
O
E,
 1
3 
C
pG
 
sit
es
Pe
di
gr
ee
, s
ex
, 
ce
nt
er
, a
nd
 th
e 
fir
st 
pr
in
ci
pa
l 
co
m
po
ne
nt
 o
f 
ce
llu
la
r p
ur
ity
 
an
d 
po
pu
la
tio
n 
str
uc
tu
re
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r 1
 C
pG
 
sit
e 
(C
pG
 7
) N
eg
at
iv
e 
as
so
ci
at
io
n 
fo
r 5
 C
pG
 si
te
s (
C
pG
 1
,2
,1
0,
12
, 
an
d 
13
)
3.1 DNA methylation & dyslipidaemia: A systematic review
117
Ch
ap
te
r 3
.1
ta
bl
e 
3.
1.
3.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
to
ta
l c
ho
le
ste
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
 (c
on
tin
ue
d)
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
 
ch
ar
ac
te
ri
st
ic
s
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
Pe
ng
, P
. e
t a
l. 
20
14
38
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r C
H
D
C
hi
na
, n
=1
39
, 
59
.3
5±
9.
12
 y
Pe
rip
he
ra
l b
lo
od
Bi
su
lfi
te
 tr
ea
tm
en
t.
AB
C
G
1,
 G
AL
N
T
2 
an
d 
H
M
G
C
R
Ag
e,
 g
en
de
r, 
sm
ok
in
g,
 li
pi
d 
le
ve
l, 
hi
sto
ry
 o
f 
hy
pe
rt
en
sio
n,
 a
nd
 
hi
sto
ry
 o
f d
ia
be
te
s
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
ns
Ta
ng
, L
. e
t a
l 
20
14
33
C
as
es
 c
on
tro
l 
stu
dy
 fo
r d
ia
be
te
s
C
hi
na
, n
=9
6,
 5
9.
1±
 
7.
6 
y
Pe
rip
he
ra
l b
lo
od
So
di
um
 b
isu
lfi
te
BC
L1
1A
, 5
 C
pG
 
sit
es
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
Tu
rc
ot
, V
. e
t 
al
 2
01
14
8
C
ro
ss
-s
ec
tio
na
l 
stu
dy
C
an
ad
a,
 n
=9
2,
 3
4 
± 
0.
7 
y
V
isc
er
al
 a
di
po
se
 
tis
su
e
So
di
um
 b
isu
lfi
te
D
PP
4,
10
2 
C
pG
 
sit
es
Ag
e,
 sm
ok
in
g,
 a
nd
 
BM
I
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
Tu
rc
ot
, V
. e
t 
al
 2
01
33
2
C
ro
ss
-s
ec
tio
na
l 
stu
dy
C
an
ad
a,
 n
=9
2,
 3
4 
± 
0.
7 
y
V
isc
er
al
 a
di
po
se
 
tis
su
e
So
di
um
 b
isu
lfi
te
D
PP
4,
 C
pG
94
 to
 
C
pG
10
2
Ag
e,
 se
x,
 sm
ok
in
g 
an
d 
w
ai
st 
ci
rc
um
fe
re
nc
e
N
eg
at
iv
e 
as
so
ci
at
io
n
g
en
om
e-
w
id
e 
ap
pr
oa
ch
Pf
ei
ffe
rm
 L
 
et
 a
l. 
20
15
11
C
ro
ss
-s
ec
tio
na
l 
stu
dy
G
er
m
an
y,
D
isc
ov
er
y 
se
t: 
K
O
R
A 
F4
, n
=1
77
6,
 
60
.8
 ±
 8
.9
 y
ea
rs
Re
pl
ic
at
io
n 
se
t: 
K
O
R
A 
F3
, n
=4
99
, 
52
.9
 ±
 9
.6
 y
ea
rs
,
In
C
H
IA
N
T
I, 
n=
47
2,
 7
1.
2 
± 
16
.0
 
ye
ar
s,
M
uT
H
ER
 st
ud
y, 
n=
63
4,
 5
9.
4 
± 
9.
0 
ye
ar
s, 
W
W
B,
 a
di
po
se
 
tis
su
e 
an
d 
fib
ro
bl
as
t
In
fin
iu
m
 
H
um
an
M
et
hy
la
tio
n2
7 
Be
ad
Ar
ra
y 
(I
llu
m
in
a)
Ag
e,
 se
x,
 B
M
I, 
sm
ok
in
g,
 a
lc
oh
ol
, 
lip
id
-lo
w
er
in
g 
dr
ug
s, 
ph
ys
ic
al
 
ac
tiv
ity
, h
ist
or
y 
of
 m
yo
ca
rd
ia
l 
in
fa
rc
tio
n,
 c
ur
re
nt
 
hy
pe
rt
en
sio
n,
 
H
bA
1c
 le
ve
ls,
 
C
-r
ea
ct
iv
e 
pr
ot
ei
n 
an
d 
w
hi
te
 b
lo
od
 
ce
ll 
co
un
t
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
ns
FH
, f
am
ili
al
 h
yp
er
ch
ol
est
er
ol
em
ia
; K
O
RA
, C
oo
pe
ra
tiv
e h
ea
lth
 re
sea
rc
h 
in
 th
e R
eg
io
n 
of
 A
ug
sb
ur
g;
 M
uT
H
ER
, M
ul
tip
le 
Ti
ssu
e H
um
an
 E
xp
re
ssi
on
 S
ou
rc
e; 
PB
L,
pe
rip
he
ra
l b
lo
od
 le
uk
oc
yt
es;
 W
B,
 w
ho
le 
bl
oo
d;
 y,
 ye
ar
118
Chapter 3.1
ta
bl
e 
3.
1.
4.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
LD
L-
ch
ol
es
te
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
/A
ge
 
ra
ng
e/
fo
llo
w
-u
p
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
c
an
di
da
te
 g
en
e 
ap
pr
oa
ch
W
u 
L 
et
 a
l. 
20
15
40
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
hi
na
, n
=9
8,
 8
-1
8 
y
PB
L
M
as
sA
R
R
AY
 p
la
tfo
rm
FI
AM
 g
en
e 
pr
om
ot
er
, 
36
 C
pG
 si
te
s
Ag
e,
 g
en
de
r, 
BM
I
Po
sit
iv
e 
as
so
ci
at
io
n
H
ou
de
 A
 e
t 
al
. 2
01
53
9
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=7
3,
 3
4,
7 
± 
7.
1 
y
Bl
oo
d,
 su
bc
ut
an
eo
us
 
ad
ip
os
e 
tis
su
e,
 a
nd
 
vi
sc
er
al
 a
di
po
se
 
tis
su
e
Py
ro
se
qu
en
ci
ng
LE
P 
an
d 
AD
IP
O
Q
Ag
e,
 se
x 
an
d 
w
ai
st 
gi
rt
h.
Po
sit
iv
e 
as
so
ci
at
io
ns
 
fo
r L
EP
 a
nd
 
AD
IP
O
Q
G
ua
y 
SP
 e
t a
l. 
20
15
42
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=5
0,
 5
3.
8 
± 
1.
5 
y, 
M
en
PB
L
Bi
su
lfi
te
-p
yr
os
eq
ue
nc
in
g
M
M
P9
Ag
e 
an
d 
w
ai
st 
ci
rc
um
fe
re
nc
e
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r C
pG
1
N
eg
at
iv
e 
as
so
ci
at
io
n 
fo
r C
pG
4.
G
ua
y 
et
 a
l.,
 
20
14
10
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a 
, n
=6
1 
FH
 
m
en
 a
nd
 n
=3
0 
se
ve
re
ly
 
ob
es
e 
m
en
 (B
M
I >
 
40
 k
g/
m
2)
 w
ith
ou
t 
FH
, w
ho
 u
nd
er
w
en
t 
a 
bi
lio
pa
nc
re
at
ic
 
di
ve
rs
io
n 
w
ith
 
du
od
en
al
 sw
itc
h
Bl
oo
d,
V
isc
er
al
 a
di
po
se
 
tis
su
e
Py
ro
se
qu
en
ci
ng
 (s
od
iu
m
 b
isu
lfi
te
 
co
nv
er
sio
n,
 P
C
R
 a
m
pl
ifi
ca
tio
n,
 
an
d 
se
qu
en
ci
ng
 b
y 
sy
nt
he
sis
 a
ss
ay
)
AD
RB
3 
ge
ne
 p
ro
m
ot
or
N
eg
at
iv
e 
as
so
ci
at
io
n
(in
 su
bg
ro
up
 o
f n
=4
1 
FH
 su
bj
ec
ts 
w
ith
ou
t 
AD
RB
3 
ra
re
 a
lle
le
s)
G
ua
y 
et
 a
l.,
 
20
14
67
C
as
e-
co
nt
ro
l 
fo
r C
AD
C
an
ad
a,
 n
= 
88
 m
en
, 
ca
se
s: 
n=
38
, c
on
tro
ls:
 
50
, m
ed
ia
n 
ag
e 
61
 
y, 
C
au
ca
sia
n 
, a
ll 
re
cr
ui
te
d 
fro
m
 p
at
ie
nt
s 
w
ho
 u
nd
er
w
en
t h
ea
rt
 
su
rg
er
y.
Bl
oo
d 
le
uk
oc
yt
es
Bi
s-
py
ro
se
qu
en
ci
ng
AB
C
A1
Ag
e,
 C
AD
 st
at
us
 a
nd
 
m
ed
ic
at
io
n
In
 o
ld
er
 m
en
 (≥
61
 
ye
ar
s)
:
po
sit
iv
e 
as
so
ci
at
io
n
In
 y
ou
ng
er
 m
en
 (<
61
 
ye
ar
s)
:
no
 si
gn
ifi
ca
nt
 
as
so
ci
at
io
n
3.1 DNA methylation & dyslipidaemia: A systematic review
119
Ch
ap
te
r 3
.1
ta
bl
e 
3.
1.
4.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
LD
L-
ch
ol
es
te
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
 (c
on
tin
ue
d)
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
/A
ge
 
ra
ng
e/
fo
llo
w
-u
p
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
Af
za
li 
et
 a
l. 
20
13
41
C
as
e-
co
nt
ro
l 
stu
dy
Ir
an
, 1
00
, 5
9.
9±
12
.1
 y
Pe
rip
he
ra
l b
lo
od
 
le
uk
oc
yt
es
N
es
te
d-
m
et
hy
la
tio
n 
sp
ec
ifi
c 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
m
et
ho
d.
N
C
P1
Po
sit
iv
e 
as
so
ci
at
io
n
Bo
lla
ti 
et
 a
l. 
20
14
34
C
ro
ss
 
se
ct
io
na
l 
stu
dy
Ita
ly,
 n
=1
65
, 
50
.3
±1
1.
5 
y
W
ho
le
 b
lo
od
Py
ro
m
ar
k 
M
D
 S
ys
te
m
 
(P
yr
os
eq
ue
nc
in
g,
 In
c.
 
W
es
tb
or
ou
gh
, M
A,
 U
SA
).
C
D
14
, E
t-1
, H
ER
V-
W
, 
iN
O
S 
an
d 
T
N
F-
α
Ag
e,
 se
x,
 B
M
I, 
sm
ok
in
g,
 a
nd
 %
 o
f 
ne
ut
ro
ph
ils
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r T
N
Fα
.
N
o 
sig
ni
fic
an
t 
as
so
ci
at
io
ns
 fo
r o
th
er
 
ge
ne
s.
C
an
iv
el
l e
t a
l. 
20
14
35
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r 
T
2D
Sp
ai
n,
 n
=1
86
, 
67
.9
±1
0.
5 
y
W
ho
le
 b
lo
od
Se
qu
en
om
 E
pi
T
YP
ER
 sy
ste
m
TC
F7
L2
Ag
e,
 g
en
de
r, 
BM
I, 
ph
ys
ic
al
 a
ct
iv
ity
, 
sm
ok
in
g 
sta
tu
s a
nd
 
w
ai
st 
ci
rc
um
fe
re
nc
e
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r
C
pG
 2
7
D
eo
da
ti 
et
 a
l. 
20
13
44
C
ro
ss
-
se
ct
io
na
l 
stu
dy
Ita
ly,
 n
=8
5,
 1
1.
5 
± 
2.
2 
y
Bl
oo
d 
ly
m
ph
oc
yt
es
M
et
hy
l-P
ro
fil
er
 D
N
A 
M
et
hy
la
tio
n 
qP
C
R
 A
ss
ay
 
(S
AB
io
sc
ie
nc
es
)
IG
F2
N
o 
sig
ni
fic
an
t 
as
so
ci
at
io
n
G
ha
tta
s e
t a
l. 
20
14
36
C
as
e-
co
nt
ro
l 
stu
dy
 (e
nd
-
sta
ge
 re
na
l 
ca
se
s)
Eg
yp
t, 
n=
96
, 3
0-
70
 y
Pe
rip
he
ra
l b
lo
od
Ep
iT
ec
h 
Bi
su
lfi
te
 c
on
ve
rs
io
n 
ki
t
M
T
H
FR
Po
sit
iv
e 
as
so
ci
at
io
n
H
ou
de
 A
.A
. 
et
 a
l. 
20
14
30
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=1
26
, 2
0-
39
 
y 
, W
om
en
Pl
ac
en
ta
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g 
an
d 
qu
an
tit
at
iv
e 
re
al
-ti
m
e 
PC
R
.
LP
L 
ge
ne
, 3
 C
pG
 si
te
s
Ag
e,
 B
M
I, 
an
d 
hi
sto
ry
 o
f g
es
ta
tio
na
l 
di
ab
et
es
N
o 
sig
ni
fic
an
t 
as
so
ci
at
io
n
H
ou
de
 A
 e
t 
al
. 2
01
33
1
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=1
00
, 2
0-
39
 
y, 
W
om
en
Pl
ac
en
ta
 a
nd
 c
or
d 
bl
oo
d
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g
AB
C
A1
 g
en
e 
pr
om
ot
or
, 
22
 C
pG
 si
te
s
Ag
e,
 B
M
I, 
TA
G
 a
t 
fir
st 
tr
im
es
te
r a
nd
 
hi
sto
ry
 o
f g
es
ta
tio
na
l 
di
ab
et
es
N
o 
sig
ni
fic
an
t 
as
so
ci
at
io
n
120
Chapter 3.1
ta
bl
e 
3.
1.
4.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
LD
L-
ch
ol
es
te
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
 (c
on
tin
ue
d)
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
/A
ge
 
ra
ng
e/
fo
llo
w
-u
p
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
Li
u,
 Z
. H
. e
t 
al
. 2
01
24
5
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r 
di
ab
et
es
C
hi
na
, n
=4
7,
 
51
.4
6±
14
.1
1 
y
Pe
rip
he
ra
l b
lo
od
Bi
su
lfi
te
 m
od
ifi
ca
tio
n
M
C
P-
1 
pr
om
ot
er
s
N
o 
sig
ni
fic
an
t 
as
so
ci
at
io
n
M
a,
 Y
. e
t a
l. 
20
15
37
C
ro
ss
-
se
ct
io
na
l 
stu
dy
U
SA
, n
=9
93
, 4
7.
88
 y
C
D
4+
 T
 c
el
ls
Bi
su
lfi
te
 tr
ea
tm
en
t
AP
O
E,
 1
3 
C
pG
 si
te
s
Pe
di
gr
ee
, s
ex
, c
en
te
r, 
an
d 
th
e 
fir
st 
pr
in
ci
pa
l 
co
m
po
ne
nt
 o
f
ce
llu
la
r p
ur
ity
 a
nd
 
po
pu
la
tio
n 
str
uc
tu
re
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r C
pG
 9
Pe
ng
, P
. e
t a
l. 
20
14
38
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r 
C
H
D
C
hi
na
, n
=1
39
, 
59
.3
5±
9.
12
 y
Pe
rip
he
ra
l b
lo
od
Bi
su
lfi
te
 tr
ea
tm
en
t
AB
C
G
1,
 G
AL
N
T
2 
an
d 
H
M
G
C
R
Ag
e,
 g
en
de
r, 
sm
ok
in
g,
 
lip
id
 le
ve
l, 
hi
sto
ry
 o
f 
hy
pe
rt
en
sio
n,
 a
nd
 
hi
sto
ry
 o
f d
ia
be
te
s
N
o 
sig
ni
fic
an
t 
as
so
ci
at
io
ns
Tu
rc
ot
, V
. e
t 
al
 2
01
33
2
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=9
2,
 3
4 
± 
0.
7 
y
V
isc
er
al
 a
di
po
se
 
tis
su
e
So
di
um
 b
isu
lfi
te
D
PP
4,
 C
pG
94
 to
 
C
pG
10
2
Ag
e,
 se
x,
 sm
ok
in
g,
 
an
d 
w
ai
st 
ci
rc
um
fe
re
nc
e
N
o 
sig
ni
fic
an
t 
as
so
ci
at
io
n
Xu
, L
. e
t a
l 
20
14
43
C
as
es
 c
on
tro
l 
stu
dy
 fo
r 
C
H
D
C
hi
na
, n
=7
2,
 a
ge
 n
ot
 
re
po
rt
ed
Pe
rip
he
ra
l b
lo
od
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g
G
C
K,
 4
 C
pG
 si
te
s
Ag
e,
 h
ist
or
y 
of
 
sm
ok
in
g,
 d
ia
be
te
s, 
an
d 
hy
pe
rt
en
sio
n
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r 1
 C
pG
 si
te
g
en
om
e-
w
id
e 
ap
pr
oa
ch
3.1 DNA methylation & dyslipidaemia: A systematic review
121
Ch
ap
te
r 3
.1
ta
bl
e 
3.
1.
4.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
LD
L-
ch
ol
es
te
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
 (c
on
tin
ue
d)
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
/A
ge
 
ra
ng
e/
fo
llo
w
-u
p
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
Pf
ei
ffe
rm
 L
 e
t 
al
. 2
01
51
1
C
ro
ss
-
se
ct
io
na
l 
stu
dy
G
er
m
an
y, 
D
isc
ov
er
y 
se
t: 
K
O
R
A 
F4
, 
n=
17
76
, 6
0.
8 
± 
8.
9 
ye
ar
s
Re
pl
ic
at
io
n 
se
t: 
K
O
R
A 
F3
, n
=4
99
, 
52
.9
 ±
 9
.6
 y
ea
rs
, 
In
C
H
IA
N
T
I, 
n=
47
2,
 7
1.
2 
± 
16
.0
 
ye
ar
s, 
an
d 
M
uT
H
ER
 
stu
dy
, n
=6
34
, 5
9.
4 
± 
9.
0 
ye
ar
s, 
w
om
en
 
on
ly
W
B,
 a
di
po
se
 ti
ss
ue
 
an
d 
fib
ro
bl
as
t
In
fin
iu
m
 H
um
an
M
et
hy
la
tio
n4
50
 
Be
ad
C
hi
p 
(I
llu
m
in
a)
Ag
e,
 se
x,
 B
M
I, 
sm
ok
in
g,
 a
lc
oh
ol
, 
lip
id
-lo
w
er
in
g 
dr
ug
s, 
ph
ys
ic
al
 a
ct
iv
ity
, 
hi
sto
ry
 o
f m
yo
ca
rd
ia
l 
in
fa
rc
tio
n,
 c
ur
re
nt
 
hy
pe
rt
en
sio
n,
 H
bA
1c
 
le
ve
ls,
 C
-r
ea
ct
iv
e 
pr
ot
ei
n 
an
d 
w
hi
te
 
bl
oo
d 
ce
ll 
co
un
t
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r T
N
IP
1
FH
, f
am
ili
al
 h
yp
er
ch
ol
est
er
ol
em
ia
; K
O
RA
, C
oo
pe
ra
tiv
e h
ea
lth
 re
sea
rc
h 
in
 th
e R
eg
io
n 
of
 A
ug
sb
ur
g;
 M
uT
H
ER
, M
ul
tip
le 
Ti
ssu
e H
um
an
 E
xp
re
ssi
on
 S
ou
rc
e; 
PB
L,
pe
rip
he
ra
l b
lo
od
 le
uk
oc
yt
es;
 W
B,
 w
ho
le 
bl
oo
d;
 y,
 ye
ar
122
Chapter 3.1
ta
bl
e 
3.
1.
5.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
H
D
L-
ch
ol
es
te
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
/A
ge
 r
an
ge
/f
ol
lo
w
-u
p
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
c
an
di
da
te
 g
en
e 
ap
pr
oa
ch
W
u 
L 
et
 
al
. 2
01
54
0
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
hi
na
, n
=9
8,
 8
-1
8 
y
PB
L
M
as
sA
R
R
AY
 p
la
tfo
rm
FI
AM
 g
en
e 
pr
om
ot
er
, 3
6 
C
pG
 si
te
s
Ag
e,
 g
en
de
r, 
BM
I
N
eg
at
iv
e 
as
so
ci
at
io
n
H
ou
de
 
A 
et
 a
l. 
20
15
39
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=7
3,
 3
4,
7 
± 
7.
1 
y
Bl
oo
d,
 
su
bc
ut
an
eo
us
 
ad
ip
os
e 
tis
su
e,
 
an
d 
vi
sc
er
al
 
ad
ip
os
e 
tis
su
e
Py
ro
se
qu
en
ci
ng
LE
P 
an
d 
AD
IP
O
Q
Ag
e,
 se
x 
an
d 
w
ai
st 
gi
rt
h.
As
so
ci
at
io
n 
w
ith
 L
EP
-
C
pG
7 
(d
ire
ct
io
n 
no
t 
re
po
rt
ed
)
G
ua
y 
et
 a
l.,
 
20
14
10
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a 
, n
=9
8 
un
tre
at
ed
 F
H
 
pa
tie
nt
s, 
m
en
: n
=6
1,
 4
6.
3 
±1
.7
 y,
 
w
om
en
: n
= 
37
, 3
6.
9±
2.
0y
Bl
oo
d 
le
uc
oc
yt
es
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g
Pr
im
ar
y: 
AB
C
G
1,
 
LI
PC
, P
LT
P 
an
d 
SC
AR
B1
sec
on
da
ry
: A
BC
A1
, 
C
ET
P,
 a
nd
 L
PL
Ag
e,
 w
ai
st 
ci
rc
um
fe
re
nc
e,
 
bl
oo
d
pr
es
su
re
, f
as
tin
g 
pl
as
m
a 
lip
id
s a
nd
 g
lu
co
se
 le
ve
ls
M
en
:
N
eg
at
iv
e 
as
so
ci
at
io
n 
fo
r 
LI
PC
-C
pG
A2
 P
LT
P-
C
pG
C
W
om
en
:
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
ns
G
ua
y 
et
 a
l.,
 
20
12
46
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a 
, n
=9
7,
 m
en
: n
=5
9,
 4
5.
6 
± 
1.
7 
y, 
w
om
en
: n
=3
8,
 3
6.
9 
± 
1.
9 
y
C
au
ca
sia
n 
su
bj
ec
ts 
w
ith
 fa
m
ili
al
 
hy
pe
rc
ho
le
ste
ro
le
m
ia
 (F
H
), 
al
l w
ith
 
sa
m
e 
LD
LR
 g
en
e 
m
ut
at
io
n
Bl
oo
d 
le
uc
oc
yt
es
Py
ro
se
qu
en
ci
ng
 (s
od
iu
m
 
bi
su
lfi
te
 c
on
ve
rs
io
n,
 
PC
R
 a
m
pl
ifi
ca
tio
n,
 a
nd
 
se
qu
en
ci
ng
 b
y 
sy
nt
he
sis
 
as
sa
y)
AB
C
A1
 g
en
e 
pr
om
ot
or
Ag
e,
 g
en
de
r, 
w
ai
st 
ci
rc
um
fe
re
nc
e,
 fa
sti
ng
 
tr
ig
ly
ce
rid
es
N
eg
at
iv
e 
as
so
ci
at
io
n
G
ua
y 
et
 a
l.,
 
20
13
47
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=9
8,
 m
en
: 6
1,
 4
6.
3 
±1
.7
 
y, 
w
om
en
: n
=3
7,
 3
6.
9 
± 
2.
0 
y
U
nt
re
at
ed
 F
H
 p
at
ie
nt
s
Bl
oo
d 
le
uc
oc
yt
es
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g
LD
LR
, C
ET
P,
 
LC
AT
 a
nd
 L
PL
 
ge
ne
 p
ro
m
ot
or
s
Ag
e,
 g
en
de
r, 
w
ai
st 
ci
rc
um
fe
re
nc
e,
 fa
sti
ng
 
tr
ig
ly
ce
rid
es
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r L
PL
M
en
:
N
eg
at
iv
e 
as
so
ci
at
io
n 
fo
r 
C
ET
P
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
ns
 
fo
r L
C
AT
 o
r L
D
LR
Af
za
li 
et
 
al
. 2
01
34
1
C
as
e-
co
nt
ro
l 
stu
dy
Ir
an
, n
=1
00
, 5
9.
9±
12
.1
 y
Pe
rip
he
ra
l 
bl
oo
d 
le
uk
oc
yt
es
N
es
te
d-
m
et
hy
la
tio
n 
sp
ec
ifi
c 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
m
et
ho
d
N
C
P1
N
eg
at
iv
e 
as
so
ci
at
io
n
3.1 DNA methylation & dyslipidaemia: A systematic review
123
Ch
ap
te
r 3
.1
ta
bl
e 
3.
1.
5.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
H
D
L-
ch
ol
es
te
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
 (c
on
tin
ue
d)
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
/A
ge
 r
an
ge
/f
ol
lo
w
-u
p
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
Bo
lla
ti 
et
 
al
. 2
01
43
4
C
ro
ss
 
se
ct
io
na
l 
stu
dy
Ita
ly,
 n
=1
65
, 5
0.
3±
11
.5
 y
W
ho
le
 b
lo
od
Py
ro
m
ar
k 
M
D
 S
ys
te
m
 
(P
yr
os
eq
ue
nc
in
g,
 In
c.
 
W
es
tb
or
ou
gh
, M
A,
 U
SA
)
C
D
14
, E
t-1
, 
H
ER
V-
W
, i
N
O
S 
an
d 
T
N
F-
α
Ag
e,
 se
x,
 B
M
I, 
sm
ok
in
g,
 
an
d 
%
 o
f n
eu
tro
ph
ils
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
ns
C
an
iv
el
l 
et
 a
l. 
20
14
35
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r 
T
2D
Sp
ai
n,
 n
=1
86
, 6
7.
9±
10
.5
 y
W
ho
le
 b
lo
od
Se
qu
en
om
 E
pi
T
YP
ER
 
sy
ste
m
TC
F7
L2
Ag
e,
 g
en
de
r, 
BM
I, 
ph
ys
ic
al
 
ac
tiv
ity
, s
m
ok
in
g 
sta
tu
s a
nd
 
w
ai
st 
ci
rc
um
fe
re
nc
e.
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
D
eo
da
ti 
et
 a
l. 
20
13
44
C
ro
ss
-
se
ct
io
na
l 
stu
dy
Ita
ly,
 n
=8
5,
 1
1.
5 
± 
2.
2 
y
Bl
oo
d 
ly
m
ph
oc
yt
es
M
et
hy
l-P
ro
fil
er
 D
N
A 
M
et
hy
la
tio
n 
qP
C
R
 A
ss
ay
 
(S
AB
io
sc
ie
nc
es
)
IG
F2
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
G
ha
tta
s 
et
 a
l. 
20
14
36
C
as
e-
co
nt
ro
l 
stu
dy
 (e
nd
-
sta
ge
 re
na
l 
ca
se
s)
Eg
yp
t, 
n=
96
, 3
0-
70
 y
Pe
rip
he
ra
l 
bl
oo
d
Ep
iT
ec
h 
Bi
su
lfi
te
 
co
nv
er
sio
n 
ki
t
M
T
H
FR
N
eg
at
iv
e 
as
so
ci
at
io
n
H
ou
de
 
A.
A.
 e
t 
al
. 2
01
43
0
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=1
26
, 2
0-
39
 y,
 W
om
en
Pl
ac
en
ta
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g 
an
d 
qu
an
tit
at
iv
e 
re
al
-ti
m
e 
PC
R
LP
L 
ge
ne
, 3
 C
pG
 
sit
es
Ag
e,
 B
M
I, 
TA
G
 a
t fi
rs
t 
tr
im
es
te
r, 
an
d 
hi
sto
ry
 o
f 
ge
sta
tio
na
l d
ia
be
te
s
N
eg
at
iv
e 
as
so
ci
at
io
n
H
ou
de
 
A 
et
 a
l. 
20
13
31
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=1
00
, 2
0-
39
 y,
 W
om
en
Pl
ac
en
ta
 a
nd
 
co
rd
 b
lo
od
Bi
su
lfi
te
 p
yr
os
eq
ue
nc
in
g
AB
C
A1
 g
en
e 
pr
om
ot
or
, 2
2 
C
pG
 si
te
s
Ag
e,
 B
M
I, 
TA
G
 a
t fi
rs
t 
tr
im
es
te
r a
nd
 h
ist
or
y 
of
 
ge
sta
tio
na
l d
ia
be
te
s
N
eg
at
iv
e 
as
so
ci
at
io
n
Li
u,
 Z
. 
H
. e
t a
l. 
20
12
45
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r 
di
ab
et
es
C
hi
na
, n
=4
7,
 5
1.
46
±1
4.
11
 y
Pe
rip
he
ra
l 
bl
oo
d
Bi
su
lfi
te
 m
od
ifi
ca
tio
n
M
C
P-
1 
pr
om
ot
er
s
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
M
a,
 Y
. e
t 
al
. 2
01
53
7
C
ro
ss
-
se
ct
io
na
l 
stu
dy
U
ni
te
d 
St
at
es
, n
=9
93
, 4
7.
88
 y
C
D
4+
 T
 c
el
ls
Bi
su
lfi
te
 tr
ea
tm
en
t
AP
O
E,
 1
3 
C
pG
 
sit
es
Pe
di
gr
ee
, s
ex
, c
en
te
r, 
an
d 
th
e 
fir
st 
pr
in
ci
pa
l 
co
m
po
ne
nt
 o
f c
el
lu
la
r 
pu
rit
y 
an
d 
po
pu
la
tio
n 
str
uc
tu
re
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
124
Chapter 3.1
ta
bl
e 
3.
1.
5.
 S
pe
ci
fic
 g
en
e 
m
et
hy
la
tio
n 
an
d 
H
D
L-
ch
ol
es
te
ro
l: 
ge
ne
 a
nd
 g
en
om
e-
w
id
e 
ap
pr
oa
ch
es
 (c
on
tin
ue
d)
A
ut
ho
r
st
ud
y 
de
si
gn
Po
pu
la
ti
on
/A
ge
 r
an
ge
/f
ol
lo
w
-u
p
t
is
su
e 
ty
pe
m
et
ho
ds
m
et
hy
la
ti
on
 si
te
s
A
dj
us
tm
en
ts
m
ai
n 
fin
di
ng
Pe
ng
, 
P. 
et
 a
l. 
20
14
38
C
as
e-
co
nt
ro
l 
stu
dy
 fo
r 
C
H
D
C
hi
na
, n
=1
39
, 5
9.
35
±9
.1
2 
y
Pe
rip
he
ra
l 
bl
oo
d
Bi
su
lfi
te
 tr
ea
tm
en
t
AB
C
G
1,
 
G
AL
N
T
2 
an
d 
H
M
G
C
R
Ag
e,
 g
en
de
r, 
sm
ok
in
g,
 
lip
id
 le
ve
l, 
hi
sto
ry
 o
f 
hy
pe
rt
en
sio
n,
 a
nd
 h
ist
or
y 
of
 d
ia
be
te
s
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
ns
Tu
rc
ot
, 
V.
 e
t a
l 
20
11
48
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=9
2,
 3
4 
± 
0.
7 
y
V
isc
er
al
 
ad
ip
os
e 
tis
su
e
So
di
um
 b
isu
lfi
te
D
PP
4,
 1
02
 C
pG
 
sit
es
Ag
e,
 sm
ok
in
g,
 a
nd
 B
M
I
Po
sit
iv
e 
as
so
ci
at
io
n
Tu
rc
ot
, 
V.
 e
t a
l 
20
13
32
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=9
2,
 3
4 
± 
0.
7 
y
V
isc
er
al
 
ad
ip
os
e 
tis
su
e
So
di
um
 b
isu
lfi
te
D
PP
4,
 C
pG
94
 to
 
C
pG
10
2
Ag
e,
 se
x,
 sm
ok
in
g 
an
d 
w
ai
st 
ci
rc
um
fe
re
nc
e
N
o 
sig
ni
fic
an
t a
ss
oc
ia
tio
n
g
en
om
e-
w
id
e 
ap
pr
oa
ch
Pf
ei
ffe
rm
 
L 
et
 a
l. 
20
15
11
C
ro
ss
-
se
ct
io
na
l 
stu
dy
G
er
m
an
y, 
D
isc
ov
er
y 
se
t: 
K
O
R
A 
F4
, n
=1
77
6,
 6
0.
8 
± 
8.
9 
ye
ar
s
Re
pl
ic
at
io
n 
se
t: 
K
O
R
A 
F3
, n
=4
99
, 
52
.9
 ±
 9
.6
 y
ea
rs
, I
nC
H
IA
N
T
I, 
n=
47
2,
 7
1.
2 
± 
16
.0
 y
ea
rs
, a
nd
 
M
uT
H
ER
 st
ud
y, 
n=
63
4,
 5
9.
4 
± 
9.
0 
ye
ar
s, 
w
om
en
 o
nl
y
W
B,
 a
di
po
se
 
tis
su
e 
an
d 
fib
ro
bl
as
t
In
fin
iu
m
 
H
um
an
M
et
hy
la
tio
n2
7 
Be
ad
Ar
ra
y 
(I
llu
m
in
a)
Ag
e,
 se
x,
 B
M
I, 
sm
ok
in
g,
 
al
co
ho
l, 
lip
id
-lo
w
er
in
g 
dr
ug
s, 
ph
ys
ic
al
 a
ct
iv
ity
, 
hi
sto
ry
 o
f m
yo
ca
rd
ia
l 
in
fa
rc
tio
n,
 c
ur
re
nt
 
hy
pe
rt
en
sio
n,
 H
bA
1c
 le
ve
ls,
 
C
-r
ea
ct
iv
e 
pr
ot
ei
n 
an
d 
w
hi
te
 b
lo
od
 c
el
l c
ou
nt
D
isc
ov
er
y 
se
t:
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r 
5 
C
pG
 si
te
s l
oc
at
ed
 in
 
AB
C
G
1,
 S
RE
BF
1,
 a
nd
 
C
PT
1A
Re
pl
ic
at
io
n:
Al
l r
es
ul
ts 
fro
m
 d
isc
ov
er
y 
co
ho
rt
 w
er
e 
re
pl
ic
at
ed
G
ua
y 
et
 a
l.,
 
20
12
50
C
ro
ss
-
se
ct
io
na
l 
stu
dy
C
an
ad
a,
 n
=2
1 
m
en
 w
ith
 F
H
, 1
0 
w
ith
 lo
w
 H
D
L-
c,
 a
ge
 4
4.
2±
3.
7 
y, 
an
d 
11
 w
ith
 h
ig
h 
H
D
L-
c,
 6
0.
0 
±3
.0
 y
Re
pl
ic
at
io
n,
 n
=2
76
 F
H
 su
bj
ec
ts
Bl
oo
d 
le
uc
oc
yt
es
In
fin
iu
m
 
H
um
an
M
Et
hy
la
tio
n2
7 
Be
ad
C
hi
p 
an
d 
va
lid
at
io
n 
fo
r 
se
ve
n 
ge
ne
s w
ith
 b
isu
lfi
te
 
D
N
A 
py
ro
se
qu
en
ci
ng
Ag
e,
 g
en
de
r, 
w
ai
st 
ci
rc
um
fe
re
nc
e,
 fa
sti
ng
 
tr
ig
ly
ce
rid
es
D
isc
ov
er
y 
co
ho
rt
:
40
9 
di
ffe
re
nt
ia
lly
 
m
et
hy
la
te
d 
C
pG
 si
te
s 
id
en
tifi
ed
Re
pl
ic
at
io
n 
co
ho
rt
:
Po
sit
iv
e 
as
so
ci
at
io
n 
fo
r 
T
N
N
T
1 
re
pl
ic
at
ed
FH
, f
am
ili
al
 h
yp
er
ch
ol
est
er
ol
em
ia
; K
O
RA
, C
oo
pe
ra
tiv
e h
ea
lth
 re
sea
rc
h 
in
 th
e R
eg
io
n 
of
 A
ug
sb
ur
g;
 M
uT
H
ER
, M
ul
tip
le 
Ti
ssu
e H
um
an
 E
xp
re
ssi
on
 S
ou
rc
e; 
PB
L,
pe
rip
he
ra
l b
lo
od
 le
uk
oc
yt
es;
 W
B,
 w
ho
le 
bl
oo
d;
 y,
 ye
ar
3.1 DNA methylation & dyslipidaemia: A systematic review
125
Ch
ap
te
r 3
.1
epigenome-wide analyses
Epigenome-wide association studies (EWAS) have recently become available, in which methylation 
levels of all measurable CpG sites are tested in relation to a phenotype or biological trait. This ap-
proach provides the opportunity to identify novel CpG sites in relation to disease phenotypes. In 
contrast to the candidate gene approach, this approach is hypothesis-free. This relatively new method 
provides many new opportunities, but also new challenges arise with the introduction of this method. 
For instance, due to the possibility to measure a large amount of CpG sites, this introduces a multiple 
testing issue, and an appropriate adjustment is necessary to avoid false positive results. Since this is a 
hypothesis free approach, results obtained in a first study (a discovery cohort) can be used to generate 
hypotheses, that subsequently need to be tested in a replication cohort.
Epigenome-wide analyses and blood lipids
Three studies examined blood lipids-associated differentially methylated sites in blood. One study 
investigated solely TAG,49 one study solely HDL-C,50 and the other study investigated TAG, TC, LDL-
C and HDL-C simultaneously (Tables 3.1.2-3.1.5).11 This latter study, using samples from blood, 
adipose tissue and fibroblasts, found no CpG site to be associated with TC concentrations (Table3.1. 
3).11 The same study identified 11 CpG sites, located in ABCG1 (3 CpGs), MIR33B (1 CpGs), SREBF1 
(1CpG), CPT1A (1 CpG), TXNIP (1CpG), APOA5 (1 CpG), TNIP1(1 CpG), and 2 other CpGs with 
no gene annotation (cg07504977, cg07815238), that were associated with either HDL-C, LDL-C, 
or TAG (Tables 3.1.2., 3.1.3. and 3.1.5.). Associations between ABCG1, SREBF1, and CPT1A and 
HDL-C were replicated in other blood samples or adipose tissues. The association between TNIP1 
and LDL-C was also replicated. Furthermore, associations between MIR33B, ABCG1, and one CpG 
site not annotated to a gene and TAG concentrations were replicated in other blood samples and in 
adipose and skin tissue. Irvin et al.49 investigating DNA methylation at CD4+ T cells reported four 
CpG sites (cg00574958, cg17058475, cg01082498, and cg09737197) in intron 1 of carnitine palmi-
toyltransferase 1A (CPT1A) to positively correlate with TAG levels (P=1.6×10–26 to 1.5×10–9): DNA 
methylation at CPT1A cg00574958 explained 11.6% and 5.5% of the variation in TAG in the discov-
ery and replication cohorts, respectively. Another study performed EWAS for HDL-C and identified 
409 differentially methylated loci in the discovery cohort, without correction for multiple testing.50 
Pathway analyses showed that 37 of these differentially methylated loci were involved in pathways 
related to lipid metabolism. One of the top hits, a CpG site located in the promoter of the TNNT1 
gene, was replicated: TNNT1 methylation levels were positively correlated with HDL-C levels.
generAl discussion
The present work is the first to systematically review the currently available evidence on the association 
of DNA methylation and histone modifications with plasma lipid levels. Overall, the scarce evidence 
suggests no consistent association between global DNA methylation with blood concentrations of 
triacylglycerol or cholesterol. Several studies did report that DNA methylation at specific individual 
genes was associated with concentrations of one or more blood lipids, suggesting a role of epigenetics 
in blood lipids levels. However, most studies were of relatively small size and replication is lacking 
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for most results. Care must thus be taken in the interpretation of the specific findings and further 
studies are required. Furthermore, there is lack of evidence on the role of histone modifications in 
dyslipidaemia.
summary and interpretation of main findings
Only four studies examined the association between global DNA methylation and specific blood 
lipids and reported contradictory results.24, 26, 27, 29 These findings are in line with other studies show-
ing no consistent association between global DNA methylation and other health outcomes, such 
as cardiovascular disease and type 2 diabetes.8, 9 Global methylation may not be specific enough 
as a measure of epigenetics to predict health, as methylation may have different effects at different 
positions in the DNA. For example, hypermethylation of promoter CpG islands has been linked to 
reduced expression of the associated gene,51 whereas hypermethylation of the body of the gene is 
associated with increased gene expression.52 Therefore, gene-specific methylation may provide better 
insight on the association of epigenetic modifications and health.
In the current review, several studies were identified that examined the association between 
methylation of individual genes, either in the full genome or focused on specific genes, with blood 
lipids. The majority of these studies used a candidate-gene approach, i.e., they studied methylation at 
genes for which previous studies suggested that their genetic code is associated with blood lipid levels. 
These candidate-gene studies reported that epigenetic regulation of FIAM, PLA2G7, NPC1, MTHFR, 
DPP4, IGF2, BCL11A, LEP, ADIPOQ, APOA5, and ABCG1 were associated with lipid levels. Future 
studies are needed to replicate these findings.
In addition to the candidate-gene approach, gene-specific DNA methylation can also be studied 
for the whole genome. Only three studies were identified that examined this genome-wide DNA 
methylation in relation to blood cholesterol or TAG levels.11, 49, 50 Their results confirmed some as-
sociations of known lipid-associated genes, such as ABCG1, but also identified new potential epi-
genetic predictors of blood lipids levels. ABCG1, CPT1A, TNNT1, MIR33B, SREBF1, and TNIP was 
associated with concentrations of TC, TAG, LDL-C and HDL-C. Blood lipid levels in relation to DNA 
methylation at ABCG1, CPT1A, TNNT1, MIR33B, SREBF1, and TNIP were replicated.
No studies were identified that studied histone modification in relation to blood cholesterol or 
TAG levels. We previously also identified a scarcity of studies examining this epigenetic mark in 
relation to cardiovascular disease and type 2 diabetes.8, 9 Modification of histones associated with 
specific genes, and in particular histone acetylation, may play a role in controlling eukaryotic gene 
expression.53 Histone modifications can also affect processes such as transcription, mitosis and 
chromosome stability.53 More studies are thus needed to explore the potential relation of histone 
modifications with health.
underlying mechanisms
DNA methylation, the addition of a methyl group to the 5’ position of cytosine in a dinucleotide 
CpG site, is an important mechanism in gene expression regulation.54 Until recently, it was believed 
that loss of DNA methylation promotes gene expression.55 However, recent studies have shown that 
underlying mechanisms are more complex, and that the association of DNA methylation with gene 
expression depends on where within the gene sequence the methylation occurs.51
3.1 DNA methylation & dyslipidaemia: A systematic review
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Studies included in this systematic review report that differentially methylated CpG sites anno-
tated to FIAM, PLA2G7, NPC1, MTHFR, DPP4, IGF2, BCL11A, LEP, ADIPOQ, APOA5, ABCG1, 
CPT1A, TNNT1, MIR33B, SREBF1, and TNIP were associated with concentrations of TC, TAG, 
LDL-C and HDL-C. Of all these CpG sites that were reported to be related to blood lipid levels, 
CpG sites annotated to ABCG1, CPT1A, TNNT1, MIR33B, SREBF1, and TNIP were replicated. An 
overview of these replicated genes with a description of the protein these genes encode is provided in 
Table 3.1.6. Methylation at ABCG1 was reported to be associated with lipid levels in a candidate-gene 
study.10 Additionally, methylation of this gene in relation to TAG and HDL-C levels was identified and 
replicated in an EWAS.11 ABCG1 encodes for ATP-binding cassette sub-family G member 1 protein, 
and is known to be involved in lipid homeostasis as cholesterol transporter.56 The other replicated 
CpG sites, including CPT1A, TNNT1, MIR33B, SREBF1, and TNIP were not previously reported by 
candidate gene studies, but identified by EWAS. The majority of these CpG sites are located in genes 
that are involved in cholesterol and lipid metabolism. For example, CPT1A gene, encodes for carnitine 
palmitoytransferase-1, which has an important role of transporting long-chain fatty acids in mito-
chondria.57 MIR33B, a non-coding microRNA, is involved in regulation of cholesterol biosynthesis by 
SREBF1, which encodes for sterol-regulatory-element-binding-proteins (SREBP).58 TNIP encodes for 
TNFa-induced protein 3 (TNFAIP3)-interacting protein 1, which regulates transcriptional activity of 
PPAR and RAR.59
table 3.1.6. Description of genes at which methylation levels are associated with blood lipid levels.
gene common name encodes for function
ABCG1 ATP-binding cassette 
transporter 8
ATP-binding cassette sub-family G 
member 1 protein
Macrophage cholesterol and 
phospholipid transporter
CPT1A Carnitine 
palmitoytransferase-1A
Carnitine palmitoytransferase-1 Transporting long-chain fatty acids 
in mitochondria.
TNNT1 Troponin T Type 1 Troponin subunit protein Regulates striated muscle 
contraction in response to 
intracellular calcium concentrations
MIR33B MicroRNA 33b Non-coding RNA Regulation of cholesterol 
biosynthesis by SREBP
SREBF1 Sterol regulatory element-
binding transcription 
factor 1
Sterol-regulatory-element-binding-
proteins (SREBP)
Activate the uptake and synthesis of 
cholesterol and active the synthesis 
of fatty acids
TNIP TNFa-induced protein 3 (TNFAIP3)-
interacting protein 1
Regulation of multiple receptor-
mediated activity of PPAR and RAR
Quality of the included studies and directions for future research
The current evidence suggests that epigenetic changes at certain genes may play a role in the devel-
opment of dyslipidaemia, but quality of the included studies should be taken into account in the 
interpretation of the their findings. There are several components that determine the quality of the 
studies, such as design, sample size, use of tissue, confounder adjustment, and replication.
We identified 23 unique studies that examined the association between DNA methylation and 
blood cholesterol and TAG levels, but all had a cross-sectional design. Therefore it is not possible to 
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draw inferences on the temporal relation between DNA methylation and blood lipids. Furthermore, 
many of the included studies were of limited sample size and may have been underpowered to detect 
associations. Considering that DNA methylation is tissue-specific, tissue used for analyses in the 
included studies is another quality aspect that should be to be taken into account when interpreting 
the results. Most studies used blood tissue, which is one of the most accessible tissues. For examining 
associations with blood lipids, blood might be the appropriate tissue to measure DNA methylation. 
However, not all CpG sites related to lipid concentrations may be methylated in blood, but rather 
in adipose or liver tissue. Therefore, some CpG sites may have been overlooked in studies that only 
investigated blood. An another important quality aspect in epigenetic studies is adjustment for 
confounders. In contrast to genetics, epigenetic studies are prone to confounding. For instance, since 
the majority of the studies used whole blood to measure DNA methylation,10-12, 31, 33-36, 38, 40-47, 50, 60, 61 
results may have been confounded by cell type proportion.62 Although some studies adjusted for 
measured or estimated cell type proportions,11, 34 several studies did not which may have resulted 
in spurious findings.10, 12, 31, 33, 35, 36, 38, 40-47, 50, 60, 61 Besides cell type proportion, there are many other 
potential confounding factors in the association between DNA methylation and lipid levels, such as 
age, sex, BMI, medication, alcohol consumption, and smoking. Of all studies included, only one study 
adjusted for all these covariates.63 Finally, although all EWASs included in our review performed 
replication of their findings in independent cohorts, replication is still lacking for results from the 
candidate-gene studies.
Therefore, more research is needed in order to draw stronger conclusions on the likely complex 
association between epigenetics and blood lipids. More specifically, more studies should examine 
gene-specific DNA methylation in genome-wide analyses in large samples and findings from these 
studies should be replicated in other populations. Furthermore, longitudinal studies are needed to 
examine temporal relation of epigenetics with blood lipids, i.e., whether differences in epigenetic 
marks may predict changes in blood lipid levels and subsequently cardiometabolic disease risk. If 
these studies confirm that epigenetic marks may predict blood lipids levels, methylation profiling may 
be used to identify individuals at high risk of dyslipidaemia and cardiometabolic disease before actual 
changes are detectable in lipid levels.64 Additionally, these results forthcoming these future studies 
may be used to identify pathways underlying the development of dyslipidaemia and cardiometabolic 
disease and provide insight in better preventive strategies. As methylation of DNA, in contrast to 
the DNA sequence, can be modified by several other environmental factors, the association between 
DNA methylation and cholesterol and TAG levels might be due to potential environmental influ-
ences, such as nutrition, smoking, and exercise.65, 66 Since blood lipids are also influenced by many 
of these lifestyle factors, methylation may be a possible mediator between these external factors and 
cholesterol and TAG levels. New findings from studies on DNA methylation, lifestyle and lipids may 
thus provide further insight in underlying pathways and how to treat and prevent dyslipidaemia.
conclusions
The present systematic review suggests that DNA methylation at specific genes is associated with 
blood cholesterol and TAG levels. However, most studies were small and of relatively small size and 
replication is lacking. Future studies using larger sample sizes, longitudinal data, relevant tissues, and 
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appropriate confounder adjustment are needed to establish whether differences in epigenetic marks 
are associated with changes in blood lipid levels and subsequently cardiometabolic disease risk.
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suPPlementAry mAteriAl
supplement 3.1.1. search strategy 
embase.com
(epigenetics/exp OR ‘DNA methylation’/exp OR ‘histone modification’/exp OR ‘s adenosylmethio-
nine’/exp OR ‘CpG island’/exp OR (((histone* OR dna OR ‘long interspersed’) NEAR/3 (acetylat* 
OR demethylat* OR methylat* OR phosphorylat* OR ubiquitinat* OR modif*)) OR ‘s adenosylme-
thionine’ OR cpg OR epigenetic* OR epigenomic*):ab,ti) AND (‘lipid blood level’/exp OR (((lipid* 
OR cholester* OR triacylglycerol* OR triglyceride* OR HDL* OR LDL* OR VLDL* OR VHDL*) 
NEAR/6 (level* OR blood OR serum OR plasma* OR concentration*)) OR hypercholesterol*):ab,ti) 
NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR 
[Note]/lim OR [Editorial]/lim)
medline ovid
(Epigenomics/ OR DNA methylation/ OR S-Adenosylmethionine/ OR CpG Islands/ OR (((histone* 
OR dna OR long interspersed) ADJ3 (acetylat* OR demethylat* OR methylat* OR phosphorylat* OR 
ubiquitinat* OR modif*)) OR s adenosylmethionine OR cpg OR epigenetic*).ab,ti.) AND  (exp lipids/
bl OR (((lipid* OR cholester* OR triacylglycerol* OR triglyceride* OR HDL* OR LDL* OR VLDL* 
OR VHDL*) ADJ6 (level* OR blood OR serum OR plasma* OR concentration*)) OR hypercholes-
terol*).ab,ti.) NOT (exp animals/ NOT humans/) NOT (letter OR news OR comment OR editorial 
OR congresses OR abstracts).pt.
cochrane 
((((histone* OR dna OR ‘long interspersed’) NEAR/3 (acetylat* OR demethylat* OR methylat* OR 
phosphorylat* OR ubiquitinat* OR modif*)) OR ‘s adenosylmethionine’ OR cpg OR epigenetic* OR 
epigenomic*):ab,ti) AND ((((lipid* OR cholester* OR triacylglycerol* OR triglyceride* OR HDL* 
OR LDL* OR VLDL* OR VHDL*) NEAR/6 (level* OR blood OR serum OR plasma* OR concentra-
tion*)) OR hypercholesterol*):ab,ti) 
web-of-science
TS=(((((histone* OR dna OR “long interspersed”) NEAR/2 (acetylat* OR demethylat* OR methylat* 
OR phosphorylat* OR ubiquitinat* OR modif*)) OR “s adenosylmethionine” OR cpg OR epigenetic* 
OR epigenomic*)) AND ((((lipid* OR cholester* OR triacylglycerol* OR triglyceride* OR HDL* OR 
LDL* OR VLDL* OR VHDL*) NEAR/5 (level* OR blood OR serum OR plasma* OR concentra-
tion*)) OR hypercholesterol*)) NOT ((animal* OR rat OR rats OR mouse OR mice OR murine) NOT 
human*)) AND dt=(article)
Pubmed publisher 
(Epigenomics[mh] OR DNA methylation[mh] OR S-Adenosylmethionine[mh] OR CpG Islands[mh] 
OR (((histone*[tiab] OR dna OR long interspersed) AND (acetylat*[tiab] OR demethylat*[tiab] OR 
methylat*[tiab] OR phosphorylat*[tiab] OR ubiquitinat*[tiab] OR modif*[tiab])) OR “s adenosylme-
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thionine” OR cpg OR epigenetic*[tiab])) AND  (lipids/bl[mh] OR (((lipid*[tiab] OR cholester*[tiab] 
OR triacylglycerol*[tiab] OR triglyceride*[tiab] OR HDL*[tiab] OR LDL*[tiab] OR VLDL*[tiab] OR 
VHDL*[tiab]) AND (level*[tiab] OR blood OR serum OR plasma*[tiab] OR concentration*[tiab])) 
OR hypercholesterol*[tiab])) NOT (animals[mh] NOT humans[mh]) NOT (letter[pt] OR news[pt] 
OR comment[pt] OR editorial[pt] OR congresses[pt] OR abstracts[pt]) AND (publisher[sb] OR 
inprocess [sb])
google scholar
“histone|dna methylation|modification”|epigenetics  “lipid|cholesterol|triacylglycerol|triglyceride le
vel|levels|blood|serum|plasma|concentration”|”blood|plasma lipids|cholesterol”|hypercholesterolem
ia|hypercholesterolaemia
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supplement 3.1.2. selection criteria
Inclusion criteria:
1. Include randomized controlled trials studies, clinical trials, intervention studies, cohort, case-
control or cross-sectional studies.
2. Include studies that evaluate DNA methylation (either global, site-specific or genome-wide 
methylation of DNA) and histone modifications
3. Include studies that evaluate the association of DNA-methylation or histone modifications with 
at least one of the following outcomes: 
·	 Hypercholesterolemia 
·	 Total Cholesterol
·	 HDL-cholesterol
·	 Triglycerides
·	 LDL
4. Include studies conducted in humans. 
5. Include studies conducted in all ages 
6. No language or date restriction.
Exclusion criteria
1. Exclude abstracts, cost effectiveness studies, letters to the editor, conference proceedings, system-
atic reviews or meta-analyses. 
2. Exclude studies conducted in animals. 
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 Epigenome-wide association study 
(EWAS) on lipids: the Rotterdam Study.
Based on:
braun kVe, Dhana K, de Vries PS, Voortman T, van Meurs JBJ, Uitterlinden AG, 
Hofman A, Hu FB, BIOS consortium, Franco OH, Dehghan A. Epigenome-wide 
association study (EWAS) on lipids: the Rotterdam Study. Clinical Epigenetics. 
2017;9:15.
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AbstrAct
Background: DNA methylation is a key epigenetic mechanism that is suggested to be associated 
with blood lipid levels. We aimed to identify CpG sites at which DNA methylation levels are associ-
ated with blood levels of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C), and total cholesterol in 725 participants of the Rotterdam Study, a 
population-based cohort study. Subsequently, we sought replication in a non-overlapping set of 760 
participants.
Results: Genome-wide methylation levels were measured in whole blood using the Illumina 
Methylation 450 array. Associations between lipid levels and DNA methylation beta-values were 
examined using linear mixed-effect models. All models were adjusted for sex, age, smoking, white 
blood cell proportions, array number, and position on array. A Bonferroni corrected p-value lower 
than 1.08×10−7 was considered statistically significant. Five CpG sites annotated to genes including 
DHCR24, CPT1A, ABCG1, and SREBF1, were identified and replicated. Four CpG sites were associated 
with triglycerides, including CpG sites annotated to CPT1A (cg00574958 and cg17058475), ABCG1 
(cg06500161), and SREBF1 (cg11024682). Two CpG sites were associated with HDL-C, including 
ABCG1 (cg06500161), and DHCR24 (cg17901584). No significant associations were observed with 
LDL-C or total cholesterol.
Conclusions: We report an association of HDL-C levels with methylation of a CpG site near DHCR24, 
a protein coding gene involved in cholesterol biosynthesis, which has previously been reported to be 
associated with other metabolic traits. Furthermore, we confirmed previously reported associations 
of methylation of CpG sites within CPT1A, ABCG1, and SREBF1 and lipids. These results provide 
insight in the mechanisms that are involved in lipid metabolism.
3.2 Epigenome-wide association study (EWAS) on lipids
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bAckground
Genetics is an important determinant of lipid levels which may affect lipid levels by changing expres-
sion levels of the genes.1 Gene expression levels, however, are also regulated by DNA methylation, 
which is one of the most studied mechanism in the field of epigenetics, and may therefore have an 
effect on lipid levels.2 In contrast to the DNA sequence, DNA methylation is dynamic over time and 
responsive to the environment, therefore, DNA methylation could also change in response to blood 
lipid levels.3
A few studies using candidate gene approaches have reported that DNA methylation at several loci, 
such as APOE and ABCA1, are associated with lipid levels.4, 5 In addition, epigenome-wide association 
studies (EWAS) have recently become available, providing the possibility to identify associations be-
tween blood lipid levels and DNA methylation at novel loci.3 To date, EWAS have identified associations 
between differentially methylated genes at a few novel loci, such as TNNT1, CPT1A, and ABCG1, and 
blood lipid levels.6-8 However, so far most studies investigating the association between DNA methyla-
tion and lipids have been performed in patient populations, while only one study has been performed 
within a population-based study. As DNA methylation may vary across different states of health, further 
population-based studies are needed to explore these associations in the general population.
In this study we aimed to investigate the association between blood DNA methylation levels and 
blood levels of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), and total cholesterol in of 725 participants of the Rotterdam Study, a population-
based cohort study. Subsequently, we sought replication in a non-overlapping set of 760 participants.
results
Participant characteristics
Participant characteristics of the discovery cohort (n=725) and the replication cohort (n=760) are 
presented in Table 3.2.1. Levels of triglycerides and total cholesterol were similar in both cohorts. 
Mean levels of HDL were slightly lower in the discovery cohort compared to the replication cohort 
(1.4 vs. 1.5 mmol/L, p<0.001). Mean levels of LDL-C were higher in the discovery cohort compared to 
the replication cohort (3.9 vs. 3.7 mmol/L, p=0.02). The mean age was significantly higher (p<0.001) 
in the replication cohort (59.9 ± 8.2 years) compared to the discovery cohort (67.7 ± 5.9 years). In 
the discovery cohort, 26% of the population were current smokers, whereas in the replication cohort, 
this was 10% (p<0.001).
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discovery panel
The associations between DNA methylation probes and blood lipid levels are presented in Man-
hattan plots (Figure 3.2.1 and Figure 3.2.2). Table 3.2.2 shows the Bonferroni significant CpGs. 
We identified five CpG sites associated with triglyceride levels. These CpG sites were annotated to 
CPT1A (cg00574958 and cg17058475), ABCG1 (cg06500161), SREBF1 (cg11024682), and DHCR24 
(cg17901584). CpG sites annotated to CPT1A and DHCR24 were negatively associated with 
triglycerides, whereas CpG sites annotated to ABCG1 and SBREF1 were positively associated with 
triglycerides. We identified three CpG sites associated with HDL-C. These CpG sites were annotated 
to ABCG1 (cg06500161), DHCR24 (cg17901584), and one CpG site that was not annotated to a gene 
(cg14816825). The CpG site annotated to DHCR24 was positively associated with HDL-C, the other 
two CpG sites were negatively associated with HDL-C. We did not find significantly associated CpG 
sites for LDL-C and total cholesterol levels in the discovery cohort.
replication panel
Of the five CpG sites significantly associated with triglycerides in the discovery cohort, four replicated 
in the replication cohort, including CPT1A (cg00574958 and cg17058475), ABCG1 (cg06500161), 
and SREBF1 (cg11024682). Of the three CpG sites significantly associated with HDL-C in the discov-
ery cohort, two replicated in the replication cohort, including ABCG1 (cg06500161), and DHCR24 
(cg17901584). Results from the discovery and replication cohort were combined using fixed effects 
meta-analyses.
table 3.2.1. Participant characteristics
discovery1 replication1 P value2
N 725 760
Gender (male) 336 (46%) 324 (42%) 0.14
Age (years) 59.9 ± 8.2 67.7 (5.9) <0.001
BMI (kg/m2) 27.6 ± 4.6 27.8 (4.2) 0.48
Obesity (BMI>30) 173 (24%) 194 (26%) 0.54
Waist circumference 93.7 ± 12.8 94.4 ± 12.0 0.318
Current smoking (yes) 197 (27%) 79 (10%) <0.001
Triglycerides (mmol/L) 1.3 [0.9-1.8] 1.3 [1.0-1.7] 0.66
HDL-cholesterol (mmol/L) 1.4 (0.41) 1.5 (0.44) <0.001
LDL-cholesterol (mmol/L) 3.9 (1.00) 3.7 (0.95) 0.001
Total cholesterol (mmol/L) 5.6 (1.07) 5.5 (1.03) 0.26
Lipid lowering medication (yes) 191 (26%) 238 (31%) <0.001
CHD 42 (6%) 61 (8%) 0.003
DM 72 (10%) 94 (12%) 0.13
1Values are presented as mean ± SD, median [IQR], or N (%).
2 Characteristics of the discovery cohort and replication cohort were compared with ANOVA
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figure 3.2.1. Manhattan plot epigenome-wide associations between genome wide DNA meth-
ylation and triglycerides.
figure 3.2.2. Manhattan plot epigenome-wide associations between genome wide DNA meth-
ylation and HDL-C.
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meta analyses
In order to test potential confounding, additional models with adjustment for lipid-lowering medica-
tion, waist circumference, and other lipids were performed in the combined analyses. Some of the 
effect estimates decreased in strength, but overall the results remained similar to those of model 
1 (Table 3.2.3). Furthermore, results from meta-analyses revealed seven new CpG sites associated 
with triglycerides, including TXNIP, TMEM49, SLC7A11, and KCNA3. An additional 55 CpG sites 
were associated with HDL-C, Methylation of four CpG sites were associated with total cholesterol, 
including, CpGs annotated to IFFO1, ABCG1, and DHCR24 (Supplementary Table 3.2.1).
Additional analyses
Since lipid levels might be affected by dietary fat intake, we explored whether intake of total fat, 
poly-unsaturated fatty acids (PUFA), mono-unsaturated fatty acids (MUFA) and saturated fatty 
acids (SFA) was associated with DNA methylation of significantly replicated CpG sites, using linear 
regression models. From these models we observed no significant association between fat intake and 
methylation of DHCR24, SREBF1, ABCG1, or CPT1A (Supplementary Table 3.2.2). To test if there 
was an interaction between lipid-lowering medication or fat intake and the CpG site located in the 
DHCR24 gene on blood lipid levels, interaction terms were added to the regression model. However, 
none of these interaction terms were significant. Sensitivity analyses in which we replaced beta-values 
with M-values showed similar results (Supplementary Table 3.2.3).
table 3.2.2. Epigenome-wide associations between genome wide DNA methylation and lipid levels.1
cpg site chromosome Position
discovery replication
gene
regression 
coefficient P2
regression 
coefficient P2
Tr
ig
ly
ce
rid
es
cg00574958 11 68607622 -0.0206 1.23×10−15 -0.0114 7.24×10−13 CPT1A
cg06500161 21 43656587 0.0149 5.02×10−11 0.0201 1.46×10−15 ABCG1
cg11024682 17 17730094 0.0135 3.40×10−10 0.0172 3.27×10−11 SREBF1
cg17901584 1 55353706 -0.0162 1.56×10−08 -0.0068 9.54×10−02 DHCR24
cg17058475 11 68607737 -0.0183 9.84×10−08 -0.0118 1.71×10−06 CPT1A
H
D
L-
C cg06500161 21 43656587 -0.0202 1.84×10
−12 -0.0189 3.29×10−12 ABCG1
cg14816825 11 12128203 -0.0143 6.31×10−08 -0.0051 1.15×10−01 NA3
cg17901584 1 55353706 0.0196 6.44×10−08 0.0142 1.03×10−03 DHCR24
Values are regression coefficients based on linear mixed models and reflect differences in methylation beta 
values per increase in HDL-C or log transformed triglycerides unit.
1Models are adjusted for age, gender, current smoking, leukocyte proportions, array number, and position 
on array.
2Level of significance: p<1.08×10−07 (discovery cohort), p<7.14×10−03 (replication).
3Not annotated.
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methylation risk scores
The methylation risk score was calculated using eight CpG sites for triglycerides and seven CpG 
sites for HDL-C, based on current and previously reported findings.(7, 8) Correlation coefficients of 
these CpG sites are presented in Supplementary Table 3.2.4 and Supplementary Table 3.2.5. For 
triglycerides, 9% of the variance was explained by the methylation risk score. For HDL-C, 5 % of the 
variance was explained by the methylation risk score (Supplementary Table 3.2.6). To test whether 
the association between methylation risk scores and lipids differed by lipid lowering medication use, 
interaction terms were tested. For both triglycerides as HDL-C, none of the interaction terms were 
significant. The difference in levels of triglycerides and HDL-C per quartile of methylation risk score 
are presented in Figure 3.2.3 and Figure 3.2.4. HDL-C levels decrease as quartiles of methylation 
risk score increase. Triglyceride levels increased from the first quartile to the second quartile, but 
remained similar for the third quartile and fourth quartile.
expression levels
The associations between DNA methylation of ABCG1 and CPT1A and there expression levels are 
presented in Supplementary Table 3.2.7. Of the four genes of which the significantly associated CpG 
sites were annotated, only data on expression levels for CPT1A and ABCG1 passed quality control. 
For CPT1A, expression (ILMN_1696316) was negatively associated with methylation of CPT1A at 
both identified CpG sites (cg00574958: p=7.6×10−4, cg17058475: p= 5.1×10−3). Expression of ABCG1 
at two of the five transcripts (ILMN_1794782 and ILMN_2329927) were negatively associated with 
methylation of the ABCG1 CpG site (p=6.6×10−14 and 3.7×10−11).
table 3.2.3. Associations between genome wide DNA methylation and lipid levels (meta-analyses).1
ProbeID
model 22 model 33 model 44
Gene
Regression 
coefficient P5
Regression 
coefficient P5
Regression 
coefficient P5
T
G
cg00574958 -0.0142 2.6×10−26 -0.0114 1.9×10−16 -0.0161 1.5×10−22 CPT1A
cg06500161 0.0167 1.4×10−24 0.0153 3.9×10−18 0.0151 7.0×10−14 ABCG1
cg11024682 0.0147 3.0×10−19 0.0124 8.4×10−13 0.0138 1.0×10−11 SREBF1
cg17058475 -0.0146 3.1×10−13 -0.0120 8.8×10−09 -0.0196 9.2×10−16 CPT1A
cg17901584 -0.013 1.9×10−08 -0.0104 2.5×10−05 -0.012 2.5×10−05 DHCR24
H
D
L-
C cg06500161 -0.0187 9.5×10
−23 -0.0166 9.5×10−16 -0.0116 2.5×10−07 ABCG1
cg14816825 -0.0104 3.2×10−07 -0.0145 3.8×10−07 -0.0127 1.7×10−07 NA6
cg17901584 0.0164 2.4×10−09 0.0128 1.3×10−05 0.0116 3.6×10−04 DHCR24
Values are regression coefficients based on linear mixed models and reflect differences in methylation beta 
values per increase in HDL-C or log transformed triglycerides unit.
1All models are adjusted for age, gender, current smoking, leukocyte proportions, array number, and posi-
tion on array.
2Model 2: model1 + lipid lowering medication use.
3Model 3: model1 + waist circumference.
4Model 4: model1 + other lipids.
5Level of significance: p<7.14×10−03.
6 Not annotated
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figure 3.2.3. Methylation risk score in quartiles and levels of triglycerides.
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figure 3.2.4. Methylation risk score in quartiles and levels of HDL-C.
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discussion
The current study reports the results of an epigenome-wide association study of fasting triglycerides, 
HDL-C, LDL-C and total cholesterol blood levels. We identified and replicated a CpG site near 
DHCR24 to be related with HDL-cholesterol. Moreover, we confirmed former reports that methyla-
tion of CpG sites within ABCG1 are associated with HDL-C, and methylation of CpG sites within 
CPT1A, ABCG1, and SREBF1 were associated with triglycerides. The majority of these associations 
were independent of several potentially confounding factors, such as use of lipid lowering medica-
tion, waist circumference, or other lipid traits. The differentially methylated CpG sites combined in 
a methylation risk score explained up to 9% of the variance in triglycerides and 5% of the variance 
in HDL-C.
We observed that methylation of a CpG site (cg17901584) annotated to the DHCR24 gene was 
associated with HDL-cholesterol. This CpG site is located within 1 Kb upstream of the DHCR24 
gene (Figure 3.2.5). The DHCR24 gene encodes for the cholesterol biosynthesis enzyme 3-hydroxys-
terol-24 reductase, which catalyzes the conversion of desmosterol to cholesterol.9, 10 Mutations in the 
DHCR24 gene may cause desmosterolosis, an autosomal recessive disease characterized by high levels 
of desmosterol.11 Since DHCR24 is involved in the cholesterol metabolism, an association between 
methylation in this gene and HDL-C is plausible. However, to date, it is not clear how methylation of 
DHCR24 is involved in sterol regulation. It has been suggested that regulation of DHCR24 expression 
is mediated by sterol-regulatory-element-binding-proteins (SREBP) in response to cholesterol avail-
ability.12 We observed in meta-analysis of the discovery and replication cohort that methylation of a 
CpG site in the SREBF1 gene, which encodes for SREBP, was associated with HDL-C levels. These 
findings suggest that mechanisms in which these two genes are involved might interact. Unfortunately, 
as the probes for these genes did not pass quality control, we did not have data on expression levels of 
these genes to further investigate this hypothesis. Moreover, the DHCR24 gene is located near PCSK9, 
which is associated with cholesterol levels.1 Therefore, the association we observed between DHCR24 
methylation and HDL-C might be due to SNP variation in PCSK9. However, when we adjusted our 
models on HDL-C for the top SNP from GWAS, the association remained similar (data not shown). 
To our knowledge, an association between methylation of cg17901584 (DHCR24) and HDL-C has 
not been previously reported. However, an EWAS performed by Dekkers et al. showed that another 
CpG site located in the DHCR24 gene, cg2716885, was associated with LDL-C levels.13 Although there 
are no previous studies that report an association between methylation of cg17901584 (DHCR24) 
and HDL-C, previous studies reported associations between methylation of this CpG site with waist 
circumference and phosphatidylcholine (PC ae C36:5).14-16 In additional models we adjusted for 
waist circumference, where we indeed observed a decrease in strength compared to the main model. 
However, the association stayed significant. Two scenarios may explain these results. A higher waist 
circumference may affect lipid levels and consequently modify DNA methylation. Alternatively, waist 
circumference could be a confounding factor since metabolic traits are highly correlated. Due to the 
cross-sectional design of our study, it is difficult to make strong conclusions whether waist circumfer-
ence is a confounder or a precursor in this association.
In addition to our novel finding, we also replicated findings previously reported by the GOLDN 
study.7 In line with findings from GOLDN, we observed a significant negative association between 
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two CpG sites (cg00574958 and cg17058475) located in the CPT1A gene and triglycerides. Carnitine 
palmitoytransferase-1, which is encoded by the CPT1A gene, has an important role of transporting 
long-chain fatty acids in mitochondria. In order to obtain more knowledge on the epigenetic mecha-
nisms of CPT1A, we explored expression levels of this gene in relation to methylation. Similar to 
findings from the GOLDN study, we observed a negative association between DNA methylation and 
expression levels of one probe, suggesting that increased methylation at CPT1A decreases expression 
of this gene.7
Furthermore, some of the findings previously reported by KORA were also replicated.8 In line 
with findings from KORA, we also found a significant negative association between a CpG site 
(cg06500161), located in the ABCG1 gene and HDL-C. We also found a significant positive associa-
tion between CpG sites located in ABCG1 (cg06500161) and SBREF1 (cg11024682) and triglycerides. 
Although these findings regarding triglycerides correspond to findings from KORA, the CpG sites in 
ABCG1 and SBREF1 differed from the CpG sites found in our study. To further explore the epigenetic 
mechanisms of ABCG1, we investigated whether DNA methylation of the CpG sites at ABCG1 was 
associated with gene expression. Similar to KORA, we observed a negative correlation between DNA 
methylation at CpG sites annotated to ABCG1 with two mRNA expression probes.8 In our study 
ILMN_1794782 showed the strongest negative correlation (r=-0.30) with methylation of ABCG1 
(cg06500161), which was also reported by the authors from KORA as one of the most strongly 
related transcripts to ABCG1 methylation. These results are in agreement with a mediatory role of 
gene ABCG1 expression in the association between DNA methylation and lipid levels. In addition to 
lipid levels, other studies have also demonstrated an association between methylation levels at CpG 
sites located in CPT1A, ABCG1, and SREBF1 with other cardiometabolic traits, such as myocardial 
infarction, BMI, waist circumference, insulin and several metabolomic traits.8, 14, 15, 17 These previously 
reported findings and our current results suggest that methylation of these genes are involved in 
metabolic mechanisms, and may be potential therapeutic targets for cardiovascular and metabolic 
related diseases.
Results from the discovery and replication cohort were combined in meta-analysis, which revealed 
a large amount of additional differentially methylated CpG sites that are associated with HDL-C levels. 
These additional findings include several CpG sites annotated to genes that were previously reported 
in GWAS on lipid levels, such as LDLR and CMIP.1 LDLR, Low-Density Lipoprotein Receptor, is a 
protein coding gene, and mutations in this gene can cause familial hypercholesterolemia.18 CMIP en-
codes a c-Maf inducing protein, which is involved in T-cell signaling pathway, and this gene is known 
to be associated with speech impairment.19 However, less is known on the role of CMIP in cholesterol 
metabolism. Considering previously reported and current findings, there might be a genetic effect as 
well as an epigenetic effect of these genes on HDL-C levels. Nevertheless, these findings should be 
interpreted with caution, as results of our meta-analyses are not replicated by other studies yet.
This study has several strengths and limitations that should be considered with the interpretation 
of the currently reported results. The strength of this study is the availability of genome-wide DNA 
methylation data in a large sample of adults from the general population and an internal replication 
set. Although we had a large sample size, more loci can be identified with even larger sample sizes. 
To illustrate, when the results from the discovery and replication cohort were combined in meta-
analysis, an additional set of 55 new significant associations for HDL-C were observed (Supplemen-
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tary Table 3.2.1), which emphasizes the benefits of using a larger sample size in EWAS. A limitation 
of this study is the use of whole blood samples to determine DNA methylation levels, whereas DNA 
methylation is cell type specific. When methylation is studied as a consequence of lipid levels, then 
leukocytes are relevant tissue. However, when the aim is to study methylation sites that are causal of 
lipid levels, leukocytes might not be relevant tissue. Therefore, certain important CpG sites could have 
been overlooked in our study. Nevertheless, previous studies have demonstrated that results can be 
replicated across tissues, suggesting that the use of blood tissue is not necessarily a major issue.14, 20 
Moreover, associations may have been overlooked be due to the type of measurements used in our 
study. Levels of LDL-C in our study were calculated with use of the Friedewald formula,21 which may 
not have been specific enough to identify an association between genome-wide DNA methylation 
and LDL-C. Results from another study performed within the GOLDN study showed that methyla-
tion of two CpG sites in the CPT1A gene are associated with LDL-C and VLDL-C.22 These results 
overlap with our findings of triglycerides, but we did not identify CpG sites associated with LDL. This 
discrepancy in results may be due to a more detailed quantification of lipids by NMR spectroscopy 
in the GOLDN study. In our current study we used beta-values to analyze methylation levels. Since it 
has been suggested that there could be heteroscedasticity for CpG sites with very low or high meth-
ylation, the use of M-values is recommended. These M-values represent the Logit transformation of 
the beta-values and are considered to have a better detection rate and true positive rate.23 In order 
to explore whether this could have affected our results, we performed additional analyses in which 
we replaced beta-values with M-values. However, these sensitivity analyses showed that results were 
similar for beta-values and M-values (Supplementary Table 3.2.3), which suggests that in our study 
heteroscedasticity may not be an issue. Due to the cross-sectional design we cannot determine the 
temporal direction of the association between DNA methylation and blood lipids. Furthermore, the 
observed associations could be explained by an unidentified common factor, as residual confounding 
is always an issue in observational studies. Another possibility is that the results may be confounded 
by differences in cell type proportion. In order to avoid this source of confounding, we adjusted all 
analyses for measured or estimated cell type proportions.24 Finally, our replication cohort had a 7.8 
years higher mean age compared to the discovery cohort, which could have resulted in differences 
in association between DNA methylation and lipid levels. However, when we tested our models for 
interaction with age we did not find any evidence that the strength of associations was affected by age.
conclusion
In conclusion, we report an association of HDL-C levels with methylation of a CpG site near DHCR24, 
a protein coding gene involved in cholesterol biosynthesis. This CpG site has previously been reported 
to be associated with other metabolic traits, such as waist circumference. In addition, we replicated 
associations previously reported by other studies. These results provide insight in the mechanisms 
that are involved in cholesterol and lipid metabolism, and identify potential new therapeutic targets. 
Future studies should include a larger sample size and further investigate the independency and 
causality of the observed associations.
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methods
design and subjects
This study was embedded within the Rotterdam Study, a population-based cohort study in Rotterdam, 
the Netherlands. The design of The Rotterdam Study has been previously described in detail else-
where.25 Briefly, residents of Ommoord, a district in Rotterdam, aged 45 years and older were invited 
to participate. The Rotterdam Study includes three sub-cohorts. We used data from the baseline and 
second visit of the third cohort (RSIII-1 and RSIII-2)¸ the third visit from the second cohort (RSII-3).
discovery panel
We used the data from RSIII-1 as the discovery panel: between February 2006 and December 2008, 
3,932 participants were examined. EWAS measurements were performed on a random subset of 731 
subjects, of whom 725 had fasting blood samples available and were included in the current analyses.
replication panel
We sought replication in a set of 767 participants from RSII-3 and RSIII-2. Between February 2011 and 
February 2012, 1,887 participants from RSII-3 were examined. Between March 2012 and December 
2013, approximately 3,000 participants from RSIII-2 were examined. From the participants included 
in the replication study, 760 had fasting blood samples available and were included for analyses. None 
of the participants included in the replication study were included in the discovery cohort.
dnA methylation
DNA was extracted from whole blood (stored in EDTA tubes) by standardized salting out methods. 
Genome-wide methylation levels were measured using the Illumina Infinium Human Methyla-
tion450 Beadchip (Illumina Inc., San Diego, CA).26 Briefly, samples (500 ng of DNA per sample) were 
bisulfite-treated with use of the Zymo EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA). 
Thereafter, the samples were hybridized to the arrays according to the protocol of the manufacturer. 
During quality control in RSIII-1, samples showing incomplete bisulfite treatment were excluded 
(n=5) as were samples with a low detection rate (<99%) (n=7), and gender swaps (n=4). Probes with 
a detection p-value >0.01 in >1% of the samples, were filtered out.27-29 In RSII-3 and RSIII-2, outlying 
samples were checked using the first two principal components obtained using principal component 
analysis (PCA). None of the samples failed the quality control checks, indicating high quality data. 
Per individual probe, participants with methylation levels higher than three times the inter-quartiles 
range (IQR) were excluded. The methylation proportion of a CpG site was reported as a beta-value 
ranging from 0 to 1.30 We used the genome coordinates provided by Illumina (GRCh37/hg19) to 
identify independent loci.
mrnA expression data
Total RNA was isolated (PAXGene Blood RNA kits - Qiagen) from whole blood (PAXGene Tubes 
– Becton Dickinson). All RNA samples were analyzed using the Labchip GX (Calliper) according to 
manufacturer’s instructions, to ensure a constant high quality of RNA preparations. Samples with an 
RNA quality score >7 were amplified and labeled (Ambion TotalPrep RNA) and hybridized to the 
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Illumina HumanHT12v4 Expression Beadchips, as described by the manufacturers protocol. RNA 
samples were processed at the Genetic Laboratory of Internal Medicine, Erasmus University Medical 
Centre Rotterdam. The dataset including 881 expression samples from RSIII-1 is available at GEO 
(Gene Expression Omnibus) public repository under the accession GSE338828. Gene expression 
data was quantile-normalized to the median distribution and log2-transformed. Probe and sample 
means were centered to zero. Genes were considered significantly expressed when detection p-values 
calculated by Genome Studio were less than 0.05 in more than 10% of all discovery samples, which 
added to a total number of 21,238 probes. The eQTL-mapping pipeline was used to perform quality 
control.31
blood lipids
All participants had blood samples taken during the visits to the research center. From the blood 
samples, concentrations of triglycerides, HDL-C, and total cholesterol were measured using an 
automated enzymatic method. LDL-C was calculated using the Friedewald formula (total cholesterol 
– HDL-C – triglycerides/5).21 Participants with non-fasting blood samples were excluded from the 
current analyses (n=6).
covariates
Height and weight were measured during the centre visit and BMI was calculated (kg/m2). During 
home visit interviews, data on tobacco smoking, dietary intake, and medication use were collected. 
Information on smoking history was acquired from questionnaires, and categorized as never, former 
or current smoking. Nutritional data was collected using semi-quantitative FFQs, and information 
on intake of different types of fatty acids were obtained. Fat intake was reported as total fat, PUFA, 
MUFA, and SFA. Information regarding the use of lipid lowering medication was derived from both 
structured home interviews and linkage to pharmacy records.
statistical analysis
Triglyceride level was log-transformed using a natural-log to obtain a normal distribution. The as-
sociations between lipid levels and DNA methylation beta-values were examined using linear mixed-
effect models.
discovery
All models were adjusted for sex, age, smoking (current, former, or never), white blood cell propor-
tions, and technical covariates (model 1). Gender, age, and smoking were added to the model as fixed 
effects. To correct for cell mixture distribution, leukocyte proportions (CD8+ T-cells, CD4+ T-cells, 
NK-cells, B-cells, monocytes, and granulocytes) were estimated using the Houseman method and 
were added to the model as fixed effects.24 Technical covariates included array number and position 
on the array, and these were added to the models as random effects. To account for multiple testing, 
we used a Bonferroni corrected p-value of 1.08×10−7 (0.05/463,456 probes).
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replication
Identified probes were replicated using the same models as in the discovery cohort, further adjusted 
for the cohort. The adjustment for cell counts (monocytes, granulocytes and lymphocytes) was based 
on lab measurements rather than houseman estimates. For the replication we applied a Bonferroni-
corrected significance threshold of 6.25×10−3 (0.05/8 probes).
meta-analyses
To combine results from the discovery and replication cohort, fixed effects meta-analyses were per-
formed in METAL, using an inverse variance weighted method. In subsequent analyses, models were 
further adjusted for lipid-lowering medication use (model 2), waist circumference (model 3), and 
other lipids (model 4).
Additional analyses
Lipid levels may be affected by dietary fat intake, and this might be mediated through DNA meth-
ylation. Therefore, we explored associations between different types of fatty acid intake and DNA 
methylation at significantly replicated CpG sites. To account for potential measurement error and 
confounding by total energy intake, we used the residual method to adjust the fatty acid intake for 
total energy intake. Briefly, linear regression analyses were used with energy intake as independent 
variable and fatty acid intake as dependent variable to calculate energy-adjusted intake of individual 
fatty acids for each subject. We regressed out the estimated leukocyte proportions, age, sex, array 
number, and position on array on the beta-values of the CpG sites using linear mixed models. The 
associations between energy-adjusted fatty acid intakes and the residuals of the DNA methylation 
beta-values were examined using linear regression models. All models were adjusted for sex, age, 
total energy intake (kcal/d), and smoking. Furthermore, to test if there was an interaction between 
lipid-lowering medication or fat intake and methylation at novel loci on lipids, interaction terms were 
added to the regression model, with one of the lipid traits as the outcome. In post-hoc analyses, we 
adjusted our models on HDL-C for the PCSK9 genotype, as DHCR24 and PCSK9 are located near 
each other. In these analyses, the top SNP from GWAS (rs17111503) was added this to our main 
model (model 1). As it is recommended to use M-values due to heteroscedasticity in beta-values, we 
performed additional analyses in which we replaced beta-values with M-values for comparison.23
methylation risk score
A methylation risk score was calculated based on CpG sites that were associated with the phenotypes, 
using both newly identified CpG sites in the current study as well as the ones previously reported for 
the corresponding trait.7, 8 First, CpG sites were checked for correlation and CpGs were pruned giving 
priority to the most significant CpGs reported by the largest studies using a correlation coefficient 
cut-off of 0.6. Second, linear regression analyses were performed in the replication cohort, using 
the lipids as dependent variable and the included CpG sites as independent variables. Models were 
adjusted for age, sex, blood cell counts, and technical covariates. The effect estimates were used to 
build the methylation risk score using data from the discovery panel. With the use of linear regression 
models, we calculated the lipids variance explained by the methylation risk score.
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functional analyses
Considering that DNA methylation can have an effect on the expression of genes, we explored the 
association between DNA methylation at the statistically significant CpG sites identified by EWAS 
and mRNA expression of the corresponding genes. The DNA methylation proportions and mRNA 
expression levels of these genes were checked for association using linear mixed models, which were 
adjusted for age, sex, smoking, white blood cell proportions, and technical covariates (array number 
and position on array).
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suPPlementAry mAteriAl
supplementary table 3.2.1. Statistically significant associations in meta-analyses from discov-
ery and replication cohort between genome wide DNA methylation and lipid levels.
Probeid chr pos effect P gene
triglycerides cg00574958 11 68607622 -0.0139 5.07×10−26 CPT1A
cg06500161 21 43656587 0.0173 1.42×10−25 ABCG1
cg11024682 17 17730094 0.0150 2.85×10−20 SREBF1
cg17901584 1 55353706 -0.0131 1.52×10−08 DHCR24
cg17058475 11 68607737 -0.0140 1.53×10−12 CPT1A
cg19693031 1 145441552 -0.0133 6.72×10−08 TXNIP
cg24174557 17 57903544 -0.0145 7.00×10−10 TMEM49
cg06690548 4 139162808 -0.0089 3.91×10−08 SLC7A11
cg27243685 21 43642366 0.0085 9.90×10−15 ABCG1
cg01176028 21 43653234 0.0123 1.22×10−08 ABCG1
cg13925011 1 111216387 -0.0097 1.26×10−08 KCNA3
cg06734985 11 26849501 -0.0129 5.19×10−08 NA3
hdl-c cg06500161 21 43656587 -0.0195 4.16×10−24 ABCG1
cg17901584 1 55353706 0.0170 5.78×10−10 DHCR24
cg06017212 17 1478463 -0.0109 1.67×10−09 SLC43A2
cg11969813 17 79816559 -0.0161 2.04×10−08 P4HB
cg21088259 17 81039990 -0.0121 4.92×10−09 METRNL
cg01101459 1 234871477 -0.0137 1.21×10−09 NA3
cg14468090 3 129032864 -0.0110 2.96×10−10 NA3
cg26313301 19 11219615 -0.0056 3.28×10−08 LDLR
cg08174890 4 9558077 0.0088 3.74×10−09 MIR548I2
cg03031932 16 81547138 -0.0106 2.82×10−11 CMIP
cg02578470 3 127320670 -0.0141 2.53×10−09 MCM2
cg07730360 3 128845626 -0.0110 2.91×10−09 NA3
cg08132940 7 1081526 -0.0160 2.46×10−08 C7orf50
cg27243685 21 43642366 -0.0105 2.79×10−16 ABCG1
cg11024682 17 17730094 -0.0137 1.10×10−12 SREBF1
cg07091481 10 82169149 -0.0131 5.26×10−08 C10orf58
cg07691624 3 9886198 -0.0083 7.04×10−09 RPUSD3
cg14939082 10 104535990 -0.0135 2.22×10−08 C10orf26
cg00521255 5 139726689 -0.0116 2.82×10−08 HBEGF
cg20214535 21 43619310 -0.0099 8.45×10−08 ABCG1
cg07565956 17 7381288 -0.0102 1.21×10−08 ZBTB4
cg20605134 6 15400462 -0.0104 8.01×10−08 JARID2
cg25217710 1 156609523 -0.0086 1.87×10−08 NA3
cg00805360 10 135091210 -0.0142 2.49×10−10 ADAM8
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supplementary table 3.2.1. Statistically significant associations in meta-analyses from discovery 
and replication cohort between genome wide DNA methylation and lipid levels. (continued)
Probeid chr pos effect P gene
cg13876650 1 26146005 -0.0085 1.30E×10−08 FAM54B
cg02797539 17 72740524 -0.0109 4.02×10−08 RAB37
cg06372475 10 73534286 -0.0080 6.08×10−08 C10orf54
cg25877299 17 80273290 -0.0142 4.26×10−09 CD7
cg04262505 2 217850623 0.0088 8.55×10−08 NA3
cg08352115 17 66356057 -0.0097 7.93×10−08 ARSG
cg21113318 14 92983645 -0.0096 9.72×10−09 RIN3
cg26943120 4 5472116 -0.0213 3.60×10−09 STK32B
cg11849692 10 103875969 -0.0099 3.48×10−08 LDB1
cg03074946 12 120687694 -0.0122 2.74×10−09 PXN
cg27269962 7 127540997 -0.0082 4.50×10−08 SND1
cg09473207 6 155079453 -0.0118 8.72×10−10 RBM16
cg07175797 16 50317656 -0.0109 9.64×10−11 NA3
cg27366162 17 66375195 -0.0128 1.72×10−08 ARSG
cg12179380 8 142084624 -0.0104 2.45×10−08 NA3
cg26468878 5 112501418 0.0098 7.36×10−08 MCC
cg09256683 17 34313637 0.0077 9.50×10−08 CCL14
cg06151145 4 48346434 -0.0136 2.44×10−08 SLAIN2
cg06710464 17 79047695 -0.0096 5.39×10−08 BAIAP2
cg23799393 10 60588674 0.0069 6.29×10−09 BICC1
cg04061506 2 48137261 -0.0115 4.20×10−08 NA3
cg05457221 10 134272437 -0.0090 5.42×10−08 NA3
cg26405097 6 15428301 -0.0157 1.88×10−09 JARID2
cg06876354 2 121020189 -0.0100 3.57×10−10 RALB
cg00819078 5 16615081 -0.0152 2.35×10−18 FAM134B
cg10127660 8 21996234 -0.0107 2.57×10−08 REEP4
cg05045598 1 6418521 -0.0123 4.58×10−08 ACOT7
cg15483436 14 105857208 -0.0068 1.23×10−09 PACS2
cg18805734 12 31453901 -0.0072 4.23×10−08 FAM60A
cg26640901 10 104536035 -0.0104 4.82×10−08 C10orf26
cg13139542 2 8242815 -0.0071 1.73×10−08 NA3
cg08788930 8 142201685 -0.0116 8.11×10−08 DENND3
total cholesterol cg17281677 12 6658557 -0.0035 5.57×10−08 IFFO1
cg25536676 1 55353327 0.0044 7.77×10−08 DHCR24
cg06500161 21 43656587 -0.0043 3.66×10−08 ABCG1
cg17475467 1 55316769 -0.0023 8.97×10−08 DHCR24
1Models adjusted for age, gender, current smoking, houseman estimated leukocyte proportions, array num-
ber, and position on array (model 1).
2Only hits that are statistically significant (p<1.08×10−07) in the combined analyses are shown in the table
3 Not annotated.
3.2 Epigenome-wide association study (EWAS) on lipids
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supplementary table 3.2.2. Associations between DNA methylation at significant CpG sites 
and fatty acid intake.1
Probeid gene effect P
total fat cg17901584 DHCR24 -0.00002 0.78
cg11024682 SREBF1 -0.00001 0.89
cg06500161 ABCG1  0.00003 0.61
cg00574958 CPT1A -0.00011 0.10
cg17058475 CPT1A -0.00005 0.60
sfA2 cg17901584 DHCR24 -0.00011 0.53
cg11024682 SREBF1  0.00003 0.80
cg06500161 ABCG1  0.00008 0.55
cg00574958 CPT1A -0.00019 0.22
cg17058475 CPT1A  0.00024 0.28
mufA2 cg17901584 DHCR24 -0.00011 0.53
cg11024682 SREBF1 -0.00009 0.48
cg06500161 ABCG1  0.00004 0.77
cg00574958 CPT1A -0.00023 0.13
cg17058475 CPT1A -0.00019 0.38
PufA2 cg17901584 DHCR24 -0.00011 0.55
cg11024682 SREBF1  0.00000 0.98
cg06500161 ABCG1  0.00003 0.82
cg00574958 CPT1A -0.00018 0.29
cg17058475 CPT1A -0.00036 0.13
Values are regression coefficients based on linear mixed models and reflect differences in methylation beta 
values per increase in triglycerides or HDL-C unit.
1Models adjusted for age, gender, current smoking, and total energy intake.
2PUFA, poly-unsaturated fatty acids; MUFA, mono-unsaturated fatty acids; SFA, saturated fatty acids.
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supplementary table 3.2.3. Statistically significant associations from the discovery cohort 
between lipid levels and genome wide DNA methylation Beta-values compared to M-values.
Probeid chr pos
m-value1,2
P4effect3
TG cg00574958 11 68607622 -0.1925 2.09E×10−16
cg06500161 21 43656587  0.1042 1.51E×10−10
cg11024682 17 17730094  0.0799 2.96E×10−10
cg17058475 11 68607737 -0.1630 2.59E×10−08
cg17901584 1 55353706 -0.1061 2.64E×10−08
HDL-C cg06500161 21 43656587 -0.1406 7.78E×10−12
cg14816825 11 12128203 -0.1123 1.48E×10−07
cg17901584 1 55353706  0.1368 1.46E×10−08
1Values are regression coefficients based on linear mixed models and reflect differences in methylation M-
values per increase in HDL-C or log transformed triglycerides unit.
2M-value=log2(Beta/(1-Beta))
3Models are adjusted for age, gender, current smoking, leukocyte proportions, array number, and position 
on array.
4Level of significance: p<1.08×10−07
supplementary table 3.2.4. Correlations between CpG sites included in the triglycerides 
methylation risk score.
cg
00
57
49
58
cg
07
50
49
77
cg
20
54
45
16
cg
07
39
72
96
cg
07
81
52
38
cg
06
50
01
61
cg
11
02
46
82
cg00574958 1 -0.07 -0.03 -0.04 0.12 -0.24 -0.15
cg07504977 - 1 -0.35 0.17 -0.35 0.02 0.03
cg20544516 - - 1 0.14 0.43 0.24 0.30
cg07397296 - - - 1 0.18 0.22 0.15
cg07815238 - - - - 1 0.19 0.17
cg06500161 - - - - - 1 0.32
cg11024682 - - - - - - 1
Correlation coefficients were based on Pearson correlation r2
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supplementary table 3.2.5. Correlations between CpG sites included in the HDL-C methyla-
tion risk score.
cg
06
50
01
61
cg
19
69
30
31
cg
11
02
46
82
cg
00
57
49
58
cg
27
24
36
85
cg
14
81
68
25
cg
17
90
15
84
cg06500161 1 -0.07 0.32 -0.24 0.48 0.05 -0.01
cg19693031 - 1 0.15 0.24 -0.01 0.26 0.01
cg11024682 - - 1 -0.15 0.43 0.35 0.26
cg00574958 - - - 1 -0.09 -0.13 0.15
cg27243685 - - - - 1 -0.01 0.27
cg14816825 - - - - - 1 -0.32
cg17901584 - - - - - - 1
Correlation coefficients were based on Pearson correlation r2
supplementary table 3.2.6. Lipid variation explained by methylation risk score, age, and sex.1
Triglycerides HDL-C
MRS2 0.09 0.05
Age 0.002 0.001
Sex 0.02 0.17
Age + sex 0.026 0.173
MRS + age + sex 0.10 0.21
1Variance explained by the methylation scores (multiple R2, adjusting for age and sex) was calculated using 
a linear regression models
2MRS, methylation risk score.
supplementary table 3.2.7. Correlations between DNA methylation at significant CpG sites 
and expression probes.1
cpg site1 gene location2 expression probe n correlation 
coefficients
P
cg00574958 CPT1A 5’UTR ILMN_1696316 713 -0.12 2.0 × 10−03
cg17058475 CPT1A 5’UTR ILMN_1696316 712 -0.09 1.4 × 10−02
cg06500161 ABCG1 Body ILMN_1695968 712 -0.02 5.6 × 10−01
cg06500161 ABCG1 Body ILMN_1794782 712 -0.30 2.2 × 10−16
cg06500161 ABCG1 Body ILMN_2262362 712 -0.06 1.1 × 10−01
cg06500161 ABCG1 Body ILMN_2329927 712 -0.18 1.9 × 10−06
1Correlation coefficients are based on pearson correlation test of methylation beta values and expression 
probe unit.
2 Annotation according to genome coordinates provided by Illumina (GRCh37/hg19)
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AbstrAct
We conducted an epigenome-wide association study (EWAS) on obesity-related traits. We used data 
from two prospective, population-based cohort studies: the Rotterdam Study (RS) and the Athero-
sclerosis Risk in Communities (ARIC) Study. We used RS (n=1,454) as the discovery panel and ARIC 
(n=2,097) as replication panel. Linear mixed-effect models were used to assess the cross-sectional 
association between genome-wide DNA methylation in leukocytes with body mass index (BMI) and 
waist circumference (WC) adjusting for sex, age, smoking, leukocyte proportions, array number and 
position on array. The two latter were modelled as random effects. Fourteen CpGs were associated 
with BMI and 26 CpGs with WC in RS after Bonferroni-correction (P <1.07 × 10−7), of which 12 
and 14 CpGs replicated in ARIC Study, respectively. The most significant novel CpGs were located 
at MSI2 (cg21139312) and LARS2 (cg18030453) and were associated both with BMI and WC. CpGs 
at BRDT, PSMD1, IFI44L, MAP1A, and MAP3K5 were associated with BMI. CpGs at LGALS3BP, 
MAP2K3, DHCR24, CPSF4L, and TMEM49 were associated with WC. We report novel associations 
of methylation at MSI2 and LARS2 with obesity-related traits. These results provide further insight in 
mechanisms underlying obesity-related traits, which can enable identification of new biomarkers in 
obesity-related chronic diseases.
3.3 Epigenome-wide association study (EWAS) on obesity-related traits
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introduction
Obesity is an important risk factor for cardiovascular disease, diabetes, some cancers, and musculoskel-
etal disorders.1-3 Evidence suggests that obesity is not only dependent on lifestyle factors, but is a result 
of interactions between genes and lifestyle.4, 5 Epigenetics has been proposed as a molecular mechanism 
that can affect the expression of genes by environmental influences and potentially could describe 
further the link between obesity and its complications.6 Nevertheless, unlike genetics, DNA methylation 
is dynamic overtime, therefore change in DNA methylation could also be a consequence of obesity.
Epigenetics is the study of heritable variation in gene function that is not a result of a change in 
DNA sequence.7 One of the best studied epigenetic mechanisms is DNA methylation, the attach-
ment of a methyl group to a cytosine nucleotide of CpG dinucleotides. DNA methylation has varying 
functions at different locations in the human genome, including regulation of gene expression.8 To 
date, epigenome-wide association studies (EWAS) have identified several differentially methylated 
CpG regions related to body mass index (BMI) - the most widely used measure of obesity - and waist 
circumference (WC).9-11 These few studies were performed in either patient populations, specific 
ethnic groups, or young adults. However, information among the older adults from population-based 
studies are scarce. In older adults and elderly, biological mechanisms involved in body weight and 
body composition may be different compared to younger adults.12 Therefore, it is crucial to explore 
the relationship of obesity to epigenetic variation in older adults.
We performed a cross-sectional EWAS of DNA methylation in blood leukocytes for BMI and WC 
in subjects from the Rotterdam Study (RS), and replicated our findings in the Atherosclerosis Risk in 
Communities (ARIC) Study.
methods
study population
The RS is a large prospective, population-based cohort study aimed at assessing the occurrence of 
and risk factors for chronic diseases (cardiovascular, endocrine, hepatic, neurological, ophthalmic, 
psychiatric, dermatological, oncological, and respiratory) in the elderly.13 The study comprises 14,926 
subjects in total, living in the well-deﬁned Ommoord district in the city of Rotterdam in the Neth-
erlands. In 1989, the first cohort, Rotterdam Study-I (RS-I), was established and comprised of 7,983 
subjects with age 55 years or above. In 2000, the second cohort, Rotterdam Study-II (RS-II) was 
included with 3,011 subjects who had reached an age of 55 years since 1989. In 2006, the third cohort, 
Rotterdam Study-III (RS-III) was further included with 3,932 subjects with age 45 years and above. 
The discovery panel for the current analysis consisted of a random sample of 1,454 participants from 
the first and second visit of the third cohort (RS-III-1, RS-III-2) and third visit of the second cohort 
(RS-II-3). We sought replication of the identified CpG sites in the ARIC Study, which is described in 
detail elsewhere.14 Briefly, the ARIC Study is a prospective cohort study of cardiovascular disease in 
adults. Between 1987 and 1989, 7,082 men and 8,710 women aged 45-64 were recruited from four US 
communities. Methylation data was available in a subset of 2,097 African American participants.10 
RS and ARIC study protocols were approved by Institutional Review Boards at each participating 
university and all participants provided written informed consent.
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Anthropometric measures and covariates
Height and weight were measured with the participants standing without shoes and heavy outer gar-
ments. WC was measured at the level midway between the lower rib margin and the iliac crest with 
participants in standing position without heavy outer garments and with emptied pockets, breathing 
out gently. Hip circumference was recorded as the maximum circumference over the buttocks. BMI 
was calculated as weight divided by height squared (kg/m2), and WHR was calculated as WC divided 
by hip circumference.15 Information on current and past smoking behavior was acquired from ques-
tionnaires.
dnA methylation data
DNA was extracted from whole peripheral blood (stored in EDTA tubes) by standardized salting out 
methods. Genome-wide DNA methylation levels were measured using the Illumina Human Methyla-
tion 450K array.16 In short, samples (500ng of DNA per sample) were first bisulfite treated using the 
Zymo EZ-96 DNA-methylation kit (Zymo Research, Irvine, CA, USA). Next, samples were hybrid-
ized to the arrays according to the manufacturers’ protocol. The methylation percentage of a CpG site 
was reported as a beta-value ranging between 0 (no methylation) and 1 (full methylation). The data 
preprocessing was additionally performed in both datasets using an R programming pipeline which 
is based on the pipeline developed by Tost & Toulemat,17 which includes additional parameters and 
options to preprocess and normalize methylation data directly from idat files. We excluded probes 
which had a detection p-value >0.01 in >95% of samples. 11,648 probes at X and Y chromosomes 
were excluded to avoid gender bias. The raw beta values were then background corrected and normal-
ized using the DASEN option of the WateRmelon R-package.18 Per individual probe, participants with 
methylation levels higher than three times the inter-quartiles range (IQR) were excluded.
statistical analyses
The characteristics of the discovery and replication population are presented as mean for continuous 
variables and proportion for the categorical variables. In the discovery stage, we modeled cross-sectional 
associations between Dasen normalized beta-values of the CpG sites as outcome and BMI or WC as 
exposure using linear mixed effect models adjusting for age, sex, smoking, white blood cell proportions, 
array number (65 arrays) and position on array (12 positions; a combination of row number and column 
number). We performed an independent analysis in individuals from RS-III-1, from RS-III-2, and from 
RS-II-3. We then performed a fixed effects meta-analysis on the estimates of these three cohorts using 
the inverse-variance weighted method implemented in METAL combining RS-III-1 with RS-III-2 and 
RS-II-3.19 Technical covariates (array number and position on array) were modeled as random effects. 
For the RS-III-1 we estimated leukocyte proportions (B-cells, CD4+ T-cells, CD8+ T-cells, granulocytes, 
monocytes and NK-cells) by a formula developed by Houseman and implemented in the minfi package 
in R.20, 21 For RS-II-3 and RS-III-2 we used white blood cell counts (WBC), i.e. lymphocytes, monocytes, 
and granulocytes, which were assessed with a Coulter AcT diff2 Hematology Analyzer. We corrected for 
multiple testing using a robust Bonferroni corrected P-value of 1.07 × 10−7 as the threshold for signifi-
cance (0.05/463,456 probes). The probes identified in the discovery analysis were tested for replication 
in the independent samples from the ARIC study. A Bonferroni corrected P-value of 0.05 divided by 
the number of significant findings in the discovery study was used as a threshold of significant replica-
3.3 Epigenome-wide association study (EWAS) on obesity-related traits
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tion. Finally, we checked all identified CpG sites for cross-reaction or polymorphism.22 A CpG site was 
considered polymorphic when a SNP with a minor allele frequency of >0.01 resided at the position of 
the cytosine or guanine nucleotide, or within 10 bp from the CpG site within the probe binding site.23
methylation risk score
A methylation risk score was calculated based on CpG sites that were associated with the phenotypes. 
The effect estimates were used to build the methylation risk score using data from the discovery panel. 
Linear regression analyses were performed in using BMI or WC as outcome variable and the included 
CpG sites as exposure variables. With the use of linear regression models we calculated the lipids 
variance explained by the methylation risk score.
results
Table 3.3.1 summarizes the characteristics of participants in the studies. RS is entirely comprised of 
Europeans, whereas the ARIC study included only African Americans. Compared to RS (mean age 
63.7 (8.1)), the participants in ARIC were on average younger (mean age 56.2 (5.7)) and comprised 
more women (63% in ARIC vs. 55% in RS)). The respective mean values of BMI in RS and ARIC 
study were 27.6 kg/m2 and 30.1 kg/m2. The mean values of WC were 93.7 cm and 101.3 cm in RS and 
ARIC, respectively.
table 3.3.1. Characteristics of study populations
rs (n=1,450) Aric (n=2,097)
Age, years 63.7 (8.1) 56.2 (5.7)
Gender, women 55.9 63.6
Race, %
European 100 0
African American 0 100
BMI (kg/m2) 27.7 (4.4) 30.1 (6.1)
BMI status
Normal weight 28.9 17.6
Overweight 46.5 37.6
Obese 24.6 43.8
WC (cm) 93.7 (12.9) 101.3 (15.1)
Smoking status
Current smoker 18.8 24.4
Current nonsmoker 81.2 75.6
Diabetes, % 11 26
Values are mean (SD) or percentage.
ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; RS, Rotterdam Study; WC, waist 
circumference.
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Table 3.3.2 and Table 3.3.3 present the CpG sites associated with BMI and WC in both popula-
tions. Using the Bonferroni-corrected statistical significance level of 1.07 × 10−7 we identified 14 CpG 
sites associated with BMI (Supplementary Table 3.3.1) and 26 CpG sites with WC (Supplementary 
Table 3.3.2) in RS. The identified CpG sites for BMI and WC are presented in Manhattan plots (Fig-
ure 3.3.1 and Figure 3.3.2). In the ARIC Study we successfully replicated 12 out of 14 BMI related 
CpG sites (P <3.57 × 10−3) (Table 3.3.2) and 13 out of 26 WC related CpG sites (P <1.92 × 10−3) (Table 
3.3.3). Among these, eight BMI-related CpG sites and 11 WC-related CpG sites were novel. The most 
significant novel CpG sites were located at MSI2 (cg21139312) and LARS2 (cg18030453) both for 
BMI and WC. For MSI2 methylation, we observed an increase of 0.0009 (P 4.5 × 10−10) and 0.0004 (P 
5.9 × 10−12) with every increase of BMI (kg/m2) and WC (cm), respectively. For LARS2 methylation, 
an increase of 0.0009 (P 4.5 × 10−10) was observed with every unit increase of BMI, and an increase of 
0.0003 (P 8.8 × 10−08) with every unit increase of WC. Additionally, for BMI other novel CpGs were 
located in the BRDT (cg03421440) and MAP1A (cg15159104) genes. For WC, the other top novel 
CpG sites were located in TMEM49 (cg24174557) and LGALS3BP (cg04927537) genes. In addition 
to these novel findings, we confirmed previous reported CpG sites including CPT1A, ABCG1 and 
SREBF1 associated with BMI and WC. The scatterplots of the association between the replicated 
CpG sites are shown in Supplementary Figure 3.3.1 and Supplementary Figure 3.3.2. Figure 3.3.3 
summarizes successfully replicated findings for BMI and WC and highlights the overlapping loci 
table 3.3.2. CpG methylation sites associated with BMI in RS at level of genome-wide signifi-
cance (P <1.08 × 10−7) and successfully replicated at ARIC (P <3.57 × 10−3)
Probeid chr gene
mean (sd) 
methylation
discovery Panel (rs)
replication Panel 
(Aric) %Variance 
explainedbeta P beta P
cg00574958 11 CPT1A 0.19 (0.04) -0.0011 6.2 ×10−15 -0.0029 3.2 × 10−12 1.9
cg00851028 1 NA 0.72 (0.04) 0.0010 5.4 × 10−08 0.0038 9.0 × 10−04 0.4
cg03421440 1 BRDT 0.71 (0.07) -0.0015 3.2 × 10−08 -0.0043 1.3 × 10−03 0.3
cg06096336 2 PSMD1 0.64 (0.05) 0.0016 4.3 × 10−08 0.0058 5.5 × 10−04 1.0
cg06500161 21 ABCG1 0.71 (0.03) 0.0011 1.7 × 10−09 0.0081 1.5 × 10−13 0.3
cg06872964 1 IFI44L 0.62 (0.06) 0.0015 4.8 × 10−08 0.0100 4.3 × 10−07 0.4
cg11024682 17 SREBF1 0.55 (0.04) 0.0013 6.6 × 10−15 0.0068 9.6 × 10−09 0.1
cg15159104 15 MAP1A 0.48 (0.05) 0.0010 3.2 × 10−08 0.0048 5.1 × 10−06 0.0
cg15903032 10 NA 0.57 (0.04) 0.0010 7.6 × 10−08 0.0037 2.8 × 10−03 0.2
cg18030453 3 LARS2 0.72 (0.04) 0.0009 4.5 × 10−09 0.0028 1.7 × 10−03 0.1
cg21139312 17 MSI2 0.89 (0.03) 0.0009 4.5 × 10−10 0.0028 1.2 × 10−06 2.0
cg21506299 6 MAP3K5 0.23 (0.06) -0.0010 3.5 × 10−08 -0.0019 2.8 × 10−03 1.1
Betas shows the regression coefficients based on linear mixed models and reflect differences in methylation 
beta values per increase in BMI unit.
Models are adjusted for age, gender, current smoking, leukocyte proportions, array number, and position on 
array.
ARIC, Atherosclerosis Risk in Communities; BMI, Body Mass Index; NA, Not Annotated; RS, Rotterdam 
Study.
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figure 3.3.1. Manhattan plot epigenome-wide associations between genome wide DNA meth-
ylation and BMI.
figure 3.3.2. Manhattan plot epigenome-wide associations between genome wide DNA meth-
ylation and WC.
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including ABCG1, MSI2, LARS2, SREBF1, and CPT1A. To test for genomic inflation we calculated 
the lambda for the EWAS on BMI and WC, and created QQ-plots. The lambda was 1.487 and 1.556 
for the EWAS on BMI and WC, respectively. The QQ-plot are shown in Supplementary Figure 3.3.3 
and Supplementary Figure 3.3.4.
We calculated a methylation risk score based on the 12 CpG sites for BMI and 14 CpG sites for WC 
that were identified and replicated in the current study. For BMI, 2.0% of the variance was explained 
by the methylation risk score, whereas for WC the variance explained was 6.4%.
table 3.3.3. CpG methylation sites associated with WC in RS at level of genome-wide signifi-
cance (P < 1.08 × 10−7) and successfully replicated at ARIC (P <1.92 × 10−3)
Probeid chr gene
mean (sd) 
methylation
discovery Panel (rs)
replication Panel 
(Aric) %Variance 
explainedbeta P beta P
cg00574958 11 CPT1A 0.19 (0.04) -0.0005 1.2 × 10−17 -0.0034 5.8 × 10−17 3.3
cg00851028 1 NA 0.72 (0.04)  0.0004 6.0 × 10−09  0.0043 1.2 × 10−04 0
cg04927537 17 LGALS3BP 0.57 (0.05)  0.0006 7.0 × 10−08  0.0093 7.0 × 10−08 1.6
cg05899984 12 NA 0.84 (0.03)  0.0003 8.1× 10−08  0.0038 5.7 × 10−06 2.9
cg06500161 21 ABCG1 0.71 (0.03)  0.0005 2.4 × 10−12  0.0096 4.4 × 10−19 0.8
cg11024682 17 SREBF1 0.55 (0.04)  0.0005 2.9 × 10−15  0.0080 3.5 × 10−12 1.2
cg13139542 2 NA 0.89 (0.02)  0.0002 6.0 × 10−08  0.0029 4.7 × 10−06 0
cg15416179 17 MAP2K3 0.14 (0.03) -0.0002 9.1 × 10−08 -0.0019 2.6 × 10−04 3.6
cg17901584 1 DHCR24 0.68 (0.07) -0.0005 1.7 × 10−08 -0.0080 8.3 × 10−08 2.0
cg18030453 3 LARS2 0.72 (0.04)  0.0003 8.8 × 10−08  0.0029 8.6 × 10−04 0
cg18772573 17 CPSF4L 0.85 (0.03)  0.0003 7.3 × 10−08  0.0039 2.8 × 10−05 0
cg21139312 17 MSI2 0.89 (0.03)  0.0004 5.9 × 10−12  0.0028 6.1 × 10−07 8.2
cg24174557 17 TMEM49 0.38 (0.07) -0.0005 1.1 × 10−08 -0.0059 5.3 × 10−05 0
Betas shows the regression coefficients based on linear mixed models and reflect differences in methylation 
beta values per increase in WC unit.
Models are adjusted for age, gender, current smoking, leukocyte proportions, array number, and position on 
array.
ARIC, Atherosclerosis Risk in Communities; NA, Not Annotated; RS, Rotterdam Study; WC, waist 
circumference
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discussion
This study used an EWAS approach to identify novel differentially methylated genes for obesity-
related traits in older adults. The EWAS analysis in RS provided numerous novel loci associated with 
BMI and WC, of which many findings successfully replicated in ARIC. Our most significant CpG 
sites associated with both BMI and WC were located at the MSI2 and LARS2 genes. Additionally, CpG 
sites at BRDT and MAP1A were associated with BMI, and CpG sites at TMEM49 and LGALS3BP were 
associated with WC. Moreover, we confirmed previous findings that methylation at CPT1A, ABCG1, 
and SREBF1 are associated with BMI and WC.
Previous EWAS on obesity traits were conducted in population-based studies including ARIC 
and Genetics of Lipid Lowering Drugs and Diet Network Study (GOLDN),9, 10 and in individuals 
with history of myocardial infarction or healthy blood donors from the Cardiogenics Consortium.11 
Similar to our findings, ARIC and GOLDN reported an inverse association between CpG site at 
CPT1A and BMI,9, 10 and positive associations of CpGs at ABCG1 and SREBF1 with BMI and WC.10 
The Cardiogenics Consortium, however, reported only a positive association between three CpG sites 
at HIF3A with BMI in both blood and adipose tissue DNA in European adults.11 These CpGs sites at 
HIF3A did not achieve the threshold for statistical significance in our study. However, CpGs sites at 
HIF3A were replicated by ARIC in DNA blood.10 This discrepancy may be due to difference in the 
prevalence of obesity and comorbidities in our study (25% obese, 11% diabetes, 7 % CHD) compared 
with ARIC (44% obese, 26% diabetes) and Cardiogenics Consortium (4% diabetes, 52% MI).
The known loci, CPT1A, ABCG1, and SREBF1 are involved in regulation of lipids, lipoprotein 
metabolism and insulin sensitivity.24-26 Specifically, the CPT1A gene encodes for carnitine palmitoy-
transferase-1, which is a mitochondrial protein involved in fatty acid metabolism and lipoprotein 
subfraction.25, 27 The ABCG1 gene encodes for ATP-binding cassette sub-family G member 1 protein 
and is involved in the transport of cholesterol and phospholipids in macrophages.28 Finally, the 
SREBF1 gene encodes for sterol regulatory element-binding transcription factor 1, which is known 
to promote adipocyte differentiation and signaling of insulin action.26 Although it has been shown 
previously that these loci are associated with obesity-related traits, it is still important to replicate 
these findings across different study population. Since the EWAS approach is hypothesis-free, find-
ings are prone to be false-positive. By replicating previously reported results, we can say with more 
certainty that these CpG sites are true-positive findings.
In addition to confirming these previously identified loci, we have identified and replicated novel 
CpG sites located in the gene body of the MSI2 (cg21139312) and LARS2 (cg18030453) gene, which 
were associated with both BMI and WC. The CpG site at MSI2 gene explained 2.2% of variation in 
BMI and 8.2% of variation in WC. MSI2 encodes RNA-binding proteins and plays a central role in 
posttranscriptional gene regulation.29 A genome-wide association study in pigs suggested that MSI2 
is associated with eating behaviors, including number of visits to feeder per day.30 Moreover, another 
study performed in mice reported that MSI2 is linked with the proliferation and maintenance of stem 
cells in the central nervous system.31 This study suggested that during neurogenesis MSI2 expression 
persisted in a subset of neuronal lineage cells, such as parvalbumin-containing GABA neurons in 
the neocortex.29, 31 GABA receptors are involved in controlling feeding behavior, reinforcing the role 
of MSI2 in obesity. The other novel locus associated with both BMI and WC, LARS2, encodes an 
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enzyme that catalyzes aminoacylation of mitochondrial tRNALeu.32 A previous post-mortem study 
showed that LARS2 expression (human leucyl-tRNA synthetase 2, mitochondrial NM015340) was 
increased in brain tissue of patients with bipolar disorder compared to controls.33 Considering that 
bipolar disorder is associated with obesity, overweight, and abdominal obesity,34 methylation of MSI2 
and LARS2 could play a role in disturbances in eating behaviors, and consequently BMI and WC. 
However, further studies are warranted to establish the temporality and the pathway of the associa-
tions. Even though previous studies have investigated the association between DNA methylation and 
anthropometrics, this study is the first report an association between DNA methylation of several 
CpG sites, including MSI2 and LARS2, with BMI and WC. One possible explanation of discrepan-
cies between findings of our current study compared to previous similar studies, is the difference 
in population characteristics. Study populations from previous studies consisted of mixed ethnic 
groups, participants of younger age, or at high disease risk.11, 35-37 Considering that our discovery 
cohort consisted of an ethnic homogenous group of older adults from the general population of Rot-
terdam, underlying mechanisms may differ from other population groups.
In this study we conducted an EWAS in a European population and replicated the findings in Af-
rican Americans. Epidemiologic studies have reported large disparities across racial/ethnic groups in 
the development of obesity.38 For example, in the current study the rates of obesity were significantly 
lower in Europeans (24.6%) than in African Americans (43.8%). However, despite the differences in 
ethnicity and prevalence of obesity between our studies, most of our CpGs sites (86.7%) successfully 
replicated in ARIC. This may indicate that, in contrast to genetic studies where replication across 
ethnic groups is challenging due to differences in LD pattern, epigenetic findings could more easily 
be translated across ethnic groups.
The strength of the current study includes the large sample size with available data on DNA 
methylation and the ability to replicate our findings in different ethnic population. However, the 
results of this study must be interpreted in light of several limitations. We used whole blood samples 
for the quantification of DNA methylation, whereas adipose tissue may be a more relevant tissue 
in examining obesity. In this case, important CpG sites may not have been identified in our study. 
Unlike in genetic studies, unraveling the direction of the association between DNA methylation and 
phenotypes in epigenetic epidemiology remains challenging. Due to the cross-sectional design and 
the nature of our variables, which are responsive to the environment and dynamic over time, a tem-
poral direction of the association between DNA methylation and anthropometric measures cannot 
be determined. As previous studies have shown that change in DNA methylation is a consequence of 
BMI for the majority of CpG sites, this may be the most likely direction for the associations observed 
in the current study as well.37 However, longitudinal studies are required to confirm the direction 
of the associations between DNA methylation and anthropometrics. Another possibility is that our 
findings could be explained by third common factors. For instance, associations may be confounded 
by differences in cell type proportion. In order to avoid this source of confounding, all analyses were 
adjusted for cell type proportions. However, as in any observational study residual confounding, due 
to various lifestyle factors, still remains an issue. Another possibility is that our findings could be 
explained by third common factors. For instance, associations may be confounded by differences 
in cell type proportion. In order to avoid this source of confounding, all analyses were adjusted for 
cell type proportions. However, as in any observational study residual confounding, due to various 
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lifestyle factors, still remains an issue. Furthermore, the QQ plots showed a high genomic inflation. 
Many EWAS studies have reported high genomic inflation.39 Adjustment for potential confounders 
such as technical covariates could decrease the inflation. The correlation between CpGs and the large 
number of findings in EWAS studies are suggested to explain the residual inflation.40 In this study 
we did adequate adjustment for technical covariates. Moreover, the replication of our results in an 
independent population provides further evidence for the robustness of our findings.
In conclusion, we have reported a novel association of increased methylation at the MSI2 and 
LARS2 genes with increased BMI and WC in older adults. Moreover, we confirmed three previously 
identified methylation loci (CPT1A, ABCG1 and SREBF1) suggested to be associated with obesity. 
Further investigations using repeatedly measured genome-wide DNA methylation and obesity-related 
traits are needed to assess causality and to further evolve the growing field of epigenetic epidemiology 
toward novel therapeutic and preventative approaches of obesity and non-communicable related 
disorders.
174
Chapter 3.3 
suPPlementAry mAteriAl
supplementary figure 3.3.1. Scatter plots and regression lines for significantly replicated CpG 
sites and BMI.
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supplementary figure 3.3.2. Scatter plots and regression lines for significantly replicated CpG 
sites and WC.
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supplementary figure 3.3.3. QQ plot for EWAS on BMI.
supplementary figure 3.3.4. QQ plot for EWAS on WC.
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supplementary table 3.3.1. CpG methylation sites associated with BMI in RS (n=1,454).
Probeid chr gene effect P1
cg00574958 11 CPT1A -0.0011 6.22×10−15
cg11024682 17 SREBF1 0.0013 6.61×10−15
cg16778405 16 RAB40C 0.0006 2.52×10−11
cg21139312 17 MSI2 0.0009 4.54×10−10
cg06500161 21 ABCG1 0.0011 1.71×10−09
cg18030453 3 LARS2 0.0009 4.49×10−09
cg08794157 17 PMP22 0.0010 1.01×10−08
cg15159104 15 MAP1A 0.0010 3.15×10−08
cg03421440 1 BRDT -0.0015 3.23×10−08
cg21506299 6 MAP3K5 -0.0010 3.49×10−08
cg06096336 2 PSMD1 0.0016 4.26×10−08
cg06872964 1 IFI44L 0.0015 4.81×10−08
cg00851028 1 NA2 0.0010 5.50×10−08
cg15903032 10 NA2 0.0010 7.55×10−08
Betas shows the regression coefficients based on linear mixed models and reflect differences in methylation 
beta values per increase in BMI unit.
Models are adjusted for age, gender, current smoking, leukocyte proportions, array number, and position on 
array.
1Level of significance: P <1.07 × 10−7
2Not annotated.
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supplementary  table 3.3.2. CpG methylation sites associated with waist circumference in RS 
(n=1,454).
Probeid chr gene effect P1
cg00574958 11 CPT1A -0.0005 1.16×10−17
cg11024682 17 SREBF1 0.0005 2.90×10−15
cg06500161 21 ABCG1 0.0005 2.39×10−12
cg21139312 17 MSI2 0.0004 5.92×10−12
cg16778405 16 RAB40C 0.0002 1.37×10−10
cg00851028 1 NA2 0.0004 5.97×10−09
cg12970155 19 MYADM 0.0008 7.48×10−09
cg24174557 17 TMEM49 -0.0005 1.07×10−08
cg17901584 1 DHCR24 -0.0005 1.69×10−08
cg11969813 17 P4HB 0.0005 1.78×10−08
cg09780767 16 NA2 -0.0003 1.98×10−08
cg03564497 6 TCP10L2 -0.0007 2.44×10−08
cg06690548 4 SLC7A11 -0.0003 2.60×10−08
cg01411912 1 S100A4 -0.0004 3.09×10−08
cg20456243 2 SPEG -0.0004 4.37×10−08
cg05635169 5 NA2 -0.0005 4.39×10−08
cg13139542 2 NA2 0.0002 6.05×10−08
cg04927537 17 LGALS3BP 0.0006 6.99×10−08
cg18772573 17 CPSF4L 0.0003 7.30×10−08
cg03096285 4 MAEA 0.0003 7.90×10−08
cg05899984 12 NA2 0.0003 8.11×10−08
cg18030453 3 LARS2 0.0003 8.84×10−08
cg15416179 17 MAP2K3 -0.0002 9.11×10−08
cg03421440 1 BRDT -0.0006 9.58×10−08
cg06734985 11 NA2 -0.0005 1.00×10−07
cg00945209 17 USP36 -0.0004 1.04×10−07
Betas shows the regression coefficients based on linear mixed models and reflect differences in methylation 
beta values per increase in WC unit.
Models are adjusted for age, gender, current smoking, leukocyte proportions, array number, and position on 
array.
1Level of significance: P <1.07 × 10−7
2Not annotated.
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childhood and body composition at the 
age of 6 years: The Generation R Study
Based on:
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OH, van den Hooven EH. Dietary Intakes of Folic Acid and Methionine in Early 
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AbstrAct
Background: Deficiency of vitamin B-6, vitamin B-12, folate, folic acid and methionine may lead to 
dysregulation of DNA methylation, which might lead to a disturbed energy and lipid metabolism.
Objective: We aimed to explore whether intake of vitamin B-6, vitamin B-12, folate, folic acid and 
methionine at 1 year is associated with measures of growth and body composition at the age of 6 
years.
Methods: This study was performed in 2,922 children participating in The Generation R Study, a 
population-based prospective cohort study. Dietary intakes of vitamin B-6, B-12, folate, folic acid, 
and methionine were assessed at a median age of 12.9 months using a validated food frequency 
questionnaire. At the age of 6 years, height and weight were measured and BMI was calculated. Body 
fat was measured using DXA and body fat percentage and the android:gynoid ratio were calculated. 
Multivariable linear regression analyses were used to study associations between intakes of vitamin 
B-6, vitamin B-12, folate, folic acid and methionine with body composition.
Results: In models adjusted for maternal and child characteristics, children with folic acid intakes in 
the highest tertile had a 0.16 SD lower weight (95%CI -0.31, -0.02) and a 0.14 SD lower BMI (95%CI 
-0.26, -0.01) compared to those in the lowest tertile. Children with vitamin B-12 intakes in the highest 
tertile had a 0.13 SD higher android:gynoid ratio (95%CI 0.00, 0.25) compared to those in the lowest 
tertile. In addition, children with intakes in the highest tertile of methionine had a 0.09 SD higher 
BMI (95%CI 0.01, 0.17), and a 0.12 SD android:gynoid ratio (95%CI 0.02, 0.22). Vitamin B-6 and 
folate intakes were not associated with any of the body composition outcomes measured.
Conclusions: In this population of children, high folic acid intakes were associated with a lower 
body weight and BMI. In contrast, higher methionine intakes were associated with unfavorable body 
composition at the age of 6 years. Future studies should investigate long term consequences of these 
outcomes on health.
4.1 Methyl donor nutrient intake & body composition
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The prevalence of overweight is rising among children, increasing the risk of metabolic syndrome, 
type 2 diabetes, and obesity in adulthood.1, 2 For adequate prevention, it is important to identify fac-
tors that influence the development of overweight in early life. One of the mechanisms that might be 
involved in the early development of overweight is DNA methylation. DNA methylation is a mecha-
nism in which gene expression is altered in response to environmental influences, such as nutrition 
and physical activity.3 For example, there are several nutrients, including vitamin B-6, vitamin B-12 
and folate, which can directly or indirectly act as methyl donors in DNA methylation.4-6 Deficiency 
of these methyl donor nutrients could lead to dysregulation of DNA methylation and might generate 
metabolic disturbances, including disturbed energy and lipid metabolism, and a higher future risk of 
cardiovascular disease.7-9
Considering that DNA methylation might influence the development of overweight, this might be 
particularly important during early life, when epigenetic changes are actively occurring.10-12 Therefore, 
it is possible that methyl donor nutrient intake during critical periods of growth, for instance during 
early childhood, could have an influence on the development of overweight in children. For instance, 
Perng et al. observed that a lower DNA methylation was associated with the development of adiposity 
in 5-12 year old boys, but not in girls.13
Several animal studies have examined the effects of methyl donor nutrient supplementation on 
body composition. Results of these studies suggest that high intakes of methyl donor nutrients could 
have a protective effect on liver fat accumulation,14 and that methyl donor nutrient supplementation 
during pregnancy has a protective effect on the development of obesity in the offspring.15, 16 A recent 
study by Gunanti et al. reported that low serum levels of folate and vitamin B-12 were associated 
with higher BMI and fat mass in Mexican American children aged 8-15 years.17 Furthermore, a few 
other cross-sectional studies investigated the associations between folate and vitamin B-12 and body 
composition in children and adolescents. Results of these studies show that lower levels or intakes of 
vitamin B-12 or folate were associated with unfavorable body composition outcomes, such as a higher 
BMI and waist circumference.18-21 In addition, a few studies suggest that a higher homocysteine level, 
which could be the result of a vitamin B-12 and/or folate deficiency, is associated with unfavourable 
body composition in children.22-24 The aim of this study was to investigate the associations between 
dietary intakes of vitamin B-6, vitamin B-12, folate, folic acid, and methionine in early childhood and 
growth and body composition outcomes at school-age in 2,922 children participating in a prospective 
cohort study.
methods
design and subjects
This study was embedded in the Generation R Study, a population-based prospective cohort study 
from early fetal life onward in Rotterdam, the Netherlands.25 The study was approved by the Medical 
Ethical Committee of Erasmus Medical Center, Rotterdam. Written informed consent was obtained 
from all participating mothers. All children were born between 2002 and 2006 and data on follow-up 
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in early childhood was available for 7,893 children (Figure 4.1.1). A Food Frequency Questionnaire 
(FFQ) to assess infant diet was sent to 5,088 mothers who provided informed consent for postnatal 
follow-up and mastered the Dutch language suffi  ciently.26 Th is FFQ was returned by 3,650 mothers 
(72%). Aft er exclusion of subjects with invalid dietary data and withdrawn consent, information on 
nutrition was available for 3,629 children.26 Of these children, growth and body composition data at 
the age of 6 years were available for 2,922 singleton born children (Figure 4.1.1).
 
 
n= 1,459 excluded due to missing 
information on FFQ (n=1,438) or 
invalid data on FFQ (n=21) 
 
 Children with dietary data at 1 y 
n= 3,629 
 
n= 707 excluded, due to missing 
growth measurements at 6 years 
(n=645) or twin births (n=62) 
Children with follow-up 
measurements at 6 years 
n = 2,922 
 
With data available on: 
Height    n=2,921 
Weight   n=2,921 
BMI   n=2,921 
Body fat %  n=2,857 
Android:gynoid ratio n=2,858 
  
 Children of mothers who received 
an FFQ at 1 y  
n= 5,088 
  
Children available for follow-up 
in early childhood 
n= 7,893 
  
n= 2,805 excluded due to no 
implementation of FFQ at 1 y 
figure 4.1.1. Flowchart: Population for analysis
dietary assessment
Dietary intake of the children was assessed at a median age of 12.9 months (95% range 12.2-18.9) 
using a semi-quantitative FFQ fi lled in by one of the parents, covering the previous month.26 Th is 
FFQ developed for our study population and was modifi ed to include only foods that are frequently 
consumed by children aged 9 to 18 months according to a Dutch national food consumption survey 
in 2002.27 Th e fi nal FFQ consisted of 211 food items and included questions on frequency, quantity, 
type and preparation methods. Th is FFQ was validated against three 24h-recalls, obtained by trained 
4.1 Methyl donor nutrient intake & body composition
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nutritionists, in a representative sample of 32 Dutch children aged 14 months.26 Intraclass correlation 
coefficients for nutrient intakes ranged from 0.36 to 0.74.28 Food frequencies and quantities were 
converted into grams per day using standardized portion sizes. Vitamin B-6, vitamin B-12, folate 
and methionine intakes were calculated using the Dutch Food Composition Table 2006.29 For folate 
intakes we calculated both naturally occurring dietary folate and synthetically produced folic acid, 
which is added to fortified foods. Total dietary folate equivalents (DFE) were calculated taking into 
account the differences in bioavailability of dietary folate and synthetic folic acid (1 DFE = 1 µg 
dietary folate or 0.6 µg folic acid added to food), according to a commonly used formula for DFE.30
growth and body composition outcomes
At a median age of 5.9 years (95% range 5.7-6.6) children visited our research center in the Erasmus 
Medical Center for a detailed physical examination. Height was determined in standing position to the 
nearest millimeter by a Harpenden stadiometer (Holtain Limited, Dyfed, U.K.). Weight was measured 
using a mechanical personal scale (SECA, Almere, the Netherlands). Height and weight were measured 
without shoes and heavy clothing and body mass index (BMI) was calculated (kg/m2). Age- and sex-
specific standard deviation (SD) scores for height, weight, and BMI were obtained using Dutch refer-
ence growth charts.31 Total body, android, and gynoid fat mass were measured using dual-energy X-ray 
absorptiometry (DXA) (iDXA, General Electrics – Lunar, 2008, Madison, WI) using enCORE software 
v.13.6, as described in detail previously.32 Body fat percentage was calculated and android fat mass was 
divided by gynoid fat mass to obtain the ratio. Age- and sex-specific SD scores for body fat percentage 
and android:gynoid ratio were calculated based on data from our study population.
covariates
Maternal height and weight were measured at enrolment and BMI (kg/m2) was calculated. Data on 
maternal age, educational level, household income, parity, and folic acid supplement use were avail-
able from self-administered questionnaires at enrolment. Maternal educational level was categorized 
as no/primary; secondary; or higher education. Net monthly household income was categorized as 
lower than 1,400 euro; 1,400 to 2,200 euro; or higher than 2,200 euro. Parity was categorized as nul-
liparous or multiparous. Smoking and alcohol consumption during pregnancy were assessed using 
questionnaires in each trimester and categorized as never; until pregnancy was known; or continued 
during pregnancy. Folic acid supplement use during pregnancy was categorized as none during early 
pregnancy; during the first 10 weeks of pregnancy; or periconceptional. Child’s methylenetetrahy-
drofolate reductase (MTHFR) variants C677T (rs1801133) and A1298C (rs1801131) were genotyped 
in cord blood.33 Information on child’s sex, ethnicity, gestational age at birth, and birth weight were 
obtained from hospital medical records. Ethnicity was defined as Dutch or non-Dutch according to 
Statistics Netherlands.34 Information on breastfeeding during infancy was obtained with postnatal 
questionnaires and categorized as exclusively for at least 4 months; partially in the first 4 months; or 
never. Infant formula intake at 1 year was obtained from the previously mentioned FFQ. A previously 
defined child diet score was used to quantify overall diet quality at the age of 1 year.35 The diet score 
was calculated for each child using data from the FFQ. Information on child’s screen time (television 
watching and computer use, h/d) and sports participation (yes/no) at the age of 6 years was obtained 
using a questionnaire.
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statistical analysis
To control for confounding by total energy intake, we used the residual method to adjust the intakes 
of vitamin B-6, vitamin B-12, folate, folic acid and methionine for total energy intake.36 In short, linear 
regression analyses were used to calculate energy adjusted intake of vitamin B-6, vitamin B-12, folate, 
folic acid and methionine for each subject, with energy intake as independent variable and intake of 
vitamin B-6, vitamin B-12, folate, folic acid and methionine as dependent variables. Since methionine 
is an amino acid and therefore part of dietary protein, methionine intake was additionally adjusted 
for total protein intake with the residual method. After visual inspection, all outcome variables were 
considered to be normally distributed. Multivariable linear regression models were used to assess 
associations between intake of vitamin B-6, vitamin B-12, folate, folic acid, DFEs and methionine 
with age- and sex-adjusted SD scores for growth and body composition outcomes (height, weight, 
BMI, body fat percentage and android:gynoid ratio). As recommended for dietary intake variables, 
nutrient intakes were analyzed both as continuous variables and categorized into tertiles, with the 
lowest tertile as reference category.36 Potential covariates were selected based on literature or a ≥ 
10% change in effect estimates.37 The adjusted models included maternal age, BMI, education, parity, 
folic acid supplement use, smoking and alcohol consumption during pregnancy; household income; 
child’s ethnicity, birth weight Z-score, breastfeeding during infancy, intake of formula, total energy 
intake, diet quality score, screen time, and participation in sports. Considering that vitamin B-12 only 
occurs in animal foods, models including vitamin B-12 were additionally adjusted for animal protein 
intake. To reduce potential bias due to attrition, missing values of covariates were multiple imputed 
based on the correlation between each variable with missing values and other subject characteristics 
(Supplementary Table 4.1.1). Five independent datasets were generated. Because we found similar 
results, we present results based on the imputed datasets.38 Because the FFQ was developed and vali-
dated for Dutch children, we performed sensitivity analyses in Dutch children only. Previous studies 
suggest that the influence of several nutrients in early life might differ between boys and girls.39, 40 
Furthermore, it is suggested that nutrients involved in the one-carbon metabolism, such as folate, 
might interact with MTHFR polymorphisms.41 To assess if associations between intakes of vitamin 
B-6, vitamin B-12, folate, folic acid and methionine and body composition outcomes differed by sex 
or by MTHFR polymorphisms, we analyzed interaction terms. A statistical interaction was analyzed 
by adding a product of each of the nutrients (e.g. folic acid) and the potential effect modifier (e.g. 
sex) as an independent variable to the linear regression model. The linear regression model in which 
the interaction was tested thus included one of the nutrients, the effect modifier and the interaction 
term of these two variables as independent variables, and one of the outcomes as dependent variables. 
Stratified analyses were performed in case the interaction term was significant (P<0.05). All statisti-
cal analyses were conducted using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA). Results were 
considered statistically significant with a P value < 0.05. Values are presented as mean (± SD), median 
[95%range], n(%) and regression coefficients (95%CI lower limit, upper limit).
4.1 Methyl donor nutrient intake & body composition
191
Ch
ap
te
r 4
.1
results
subject characteristics
Characteristics of the children and their mothers are presented in Table 4.1.1. The majority of the 
children had a Dutch ethnicity (68.7%) and 49.1 % were boys. Mean (± SD) total energy intake at the 
median age of 12.9 months (95% range 12.2-18.9) was 1,310 ± 393 kcal/d. Median intakes of vitamin 
B-6 and vitamin B-12 were comparable to the median intakes among Dutch children aged 2-3 years 
from the general population,42 but intake of DFEs were considerably higher (i.e. 182 µg/d vs. 106 µg/d 
).42 This high DFEs intake in our population was primarily due to added folic acid in infant formula. 
Main sources of vitamin B-12 and methionine in our population were meat, fish, and eggs. Various 
food groups contributed to vitamin B-6 and naturally present folate intake. In non-response analyses, 
we observed that children without FFQ data had a higher BMI and body fat percentage at the age of 
6 years than children with FFQ data (Supplementary Table 4.1.3).
table 4.1.1. Population characteristics (n=2,922)
Characteristics Values1
Child characteristics
Sex, male 1,434 (49.1)
Ethnicity
Dutch 2,007 (68.7) 
Non Dutch 915 (31.3) 
Gestational age at birth (wk) 40.1 [36.0-42.3]
Birth weight (g) 3470 ± 552
Breastfeeding
Exclusively ≥ 4 months 864 (29.6) 
Partially ≥ 4 months 1,708 (58.4) 
Never 350 (12.0) 
Characteristics dietary measurement (1y)
Age filling out FFQ (months) 12.9 [12.2-18.9]
Total energy intake (kcal/d) 1,310 ± 393
Vitamin B-6 intake (mg/d) 1.2 [0.5-2.2]
Vitamin B-12 intake (µg/d) 2.5 [0.7-5.6]
Folate intake
Dietary folate (µg/d) 91 [32-209] 
Added folic acid (µg/d) 430 [0-1420] 
Folate equivalents (µg/d) 182 [67-783] 
Methionine intake (mg/d) 642 [197-1390]
192
Chapter 4.1
table 4.1.1. Population characteristics (n=2,922) (continued)
Characteristics Values1
Characteristics growth measurements (6y)
Age (years) 6.0 ± 0.2
Height (cm) 118 ± 5
Weight (kg) 22.4 ± 3.4
BMI (kg/m2) 16.0 ± 1.6
Body fat percentage (%) 24.2 ± 5.1
Android-gynoid fat ratio 0.24 ± 0.06
Sports participation (yes %) 1291 (44.2)
Screen time (h/d) 1.6 [0.3-4.4]
Maternal characteristics
Age at enrolment (years) 31.5 ± 4.5
BMI at enrolment (kg/m2) 24.4 [18.8-35.6]
Educational level
No or primary education 302 (10.3) 
Secondary 911 (31.2) 
Higher 1,709 (58.5) 
Household income per month
<1,400 euro 414 (14.2) 
1,400-2,200 euro 556 (19.0) 
>2,200 euro 1,952 (66.8) 
Parity
0 1,761 (60.3) 
1 842 (28.8) 
2≤ 319 (10.9) 
Folic acid supplement use
None 469 (16.0) 
First 10 weeks of pregnancy 890 (30.5) 
Periconceptional 1,563 (53.5) 
Smoking during pregnancy
Never 2,277 (78.0) 
Until pregnancy was known 296 (10.1) 
Continued 349 (11.9) 
Alcohol consumption during pregnancy
Never 1,119 (38.3) 
Until pregnancy was known 443 (15.2) 
Continued 1,359 (46.5) 
1Mean ± SD, Median [95% range], or N (%)
4.1 Methyl donor nutrient intake & body composition
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intake of vitamin b-6, vitamin b-12, folate, folic acid and methionine and 
growth and body composition outcomes
Table 4.1.2 shows the covariate-adjusted associations between intake of vitamin B-6, vitamin B-12, 
folate, folic acid and methionine and growth and body composition outcomes. Children with intake 
of vitamin B-12 in the highest tertile had a 0.13 SD higher android:gynoid ratio (95%CI 0.00;0.25) 
compared to children in the lowest tertile. In addition, for the association between vitamin B-12 with 
android:gynoid ratio P for trend was significant (P=0.03). Additional adjustment for saturated fat 
intake did not change this result (data not shown). In contrast, children with intakes of folic acid in 
the highest tertile had a 0.16 SD lower weight (95% CI -0.31; -0.02) and a 0.14 SD lower BMI (95% 
CI -0.26; -0.01) compared to children with intakes in the lowest tertile. In line with this, children 
with intakes of DFEs in the second and highest tertile had a lower weight, -0.10 SD (95%CI -0.19, 
-0.01) and -0.11 SD (95%CI -0.00, -0.22) respectively, compared to children with intakes in the lowest 
tertile. However, intake of DFEs in the third tertile was also associated with a lower height (-0.12 SD 
(95%CI -0.23,-0.01)) compared to intake in the lowest tertile. Children with intakes in the highest 
tertile of methionine had a 0.09 SD higher BMI (95%CI 0.01, 0.17), and a 0.12 SD android:gynoid 
ratio (95%CI 0.02, 0.22). In addition, P for trend was significant for body fat percentage (P=0.03) and 
android:gynoid ratio (P=0.01). In the covariate-adjusted models, vitamin B-6 and folate intakes were 
not associated with body composition outcomes.
Results of the crude analyses are presented in Supplementary Table 4.1.4, showing associations 
in similar directions to the adjusted models. However, in the crude models higher folate and vitamin 
B-12 intakes were associated with a higher weight and BMI. These results were no longer significant 
in the adjusted model.
Additional analyses
Analyses restricted to Dutch children (n=2,002) were similar to those in the whole study population 
(Supplementary Table 4.1.5). Only two out of 30 interaction terms for MTHFR polymorphisms were 
significant (folate and folic acid on height), however, stratification on MTHFR for these two models 
revealed no clear differences in associations (data not shown). Interactions of sex with vitamin B-12, 
folic acid and methionine intake were significant for height and weight (p<0.05), but not for BMI, 
body fat percentage, or android:gynoid ratio. We stratified all analyses for sex (Supplementary Tables 
4.1.6 and 4.1.7), but analysis stratified for sex showed effect estimates in the same direction as the 
whole group. Only for vitamin B-6 intake, results differed between girls and boys. Girls with higher 
vitamin B-6 intake had a lower BMI, while boys had a higher body fat percentage.
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discussion
In this population-based prospective cohort study, we investigated associations between dietary 
intake of vitamin B-6, vitamin B-12, folate, folic acid and methionine in early childhood and growth 
and body composition outcomes at the age of 6 years. We hypothesized that higher intake of vitamin 
B-6, vitamin B-12, folate, folic acid, and methionine were associated with favorable body composition 
outcomes, since these nutrients play a role in DNA methylation, which may be involved in obesity 
risk.13 We observed that folic acid intake in the highest tertile was associated with a lower body weight 
and BMI, which is in line with our hypothesis. However, in contrast to our hypothesis, a higher 
methionine intake was associated with a higher BMI, a higher body fat percentage and a higher 
android:gynoid ratio, and a higher vitamin B-12 intake was associated with a higher android:gynoid 
ratio. Finally, there were no consistent associations between vitamin B-6 intake and any of the body 
composition outcomes in the total group. However, when analyses were stratified for sex, a higher 
vitamin B-6 intake was associated with a higher body fat percentage in boys, but with a lower BMI 
in girls.
Our findings regarding vitamin B-6 are in line with findings of the study by Gunanti et al. in 
Mexican American children, which also did not find an association between vitamin B-6 intake and 
body composition.17 However, two cross-sectional studies in adults reported that vitamin B-6 levels 
were lower in obese subjects or patients with metabolic syndrome compared to controls.43, 44 These 
findings are in concurrence with our finding that a higher vitamin B-6 intake was associated with a 
lower BMI in girls. However, in boys a higher intake was associated with a higher body fat percent-
age. There was no difference in vitamin B-6 intake between boys and girls, suggesting that divergent 
results might be due to sex-specific differences.
In our study, we observed that a folic acid intake in the highest tertile was associated with a lower 
weight and a lower BMI, but not with body fat percentage or android:gynoid ratio. Similar patterns 
of associations were observed for intake of DFEs, probably because folic acid intake was the main 
contributor to the intake of DFEs.30 In line with this, a previous cross-sectional study in Brazilian 
children aged 10-19 years reported that a higher total folate intake was associated with a lower waist 
circumference.19 However, in this latter study no distinction was made between natural folate and 
added folate (folic acid). Moreover, Gunanti et al.,17 Huemer et al.,20 and Gallistl et al.21 observed 
unfavorable body composition outcomes in relation to lower folate levels in children and adolescents 
aged 8-15, 2-17, and 4-17 years, respectively. However, two cross-sectional studies did not observe 
associations between folate levels and overweight in children and adolescents aged 6-17 years.45, 46
In contrast to our results for folic acid, intakes of folate were not associated with any of the body 
composition outcomes. And in sensitivity analyses including Dutch children only, a higher folate 
intake was even associated with a higher BMI (P for trend = 0.03). Only one study reported similar 
results. In this cross-sectional study levels of folate were significantly higher in overweight and obese 
boys compared to boys with a normal weight.18 Potential mechanisms behind these associations 
remain unclear, but may involve DNA synthesis induced by folate. Intake of folate and vitamin B-12 
has been associated with increased DNA synthesis,47 which stimulates growth and might also increase 
BMI.
4.1 Methyl donor nutrient intake & body composition
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In line with this latter mechanism, vitamin B-12 intakes were associated with a higher 
android:gynoid ratio. However, these findings are not in agreement with findings from three previ-
ous studies, which reported higher vitamin B-12 levels among children and adolescents aged 8-15, 
2-17, and 10-19 years with a lower BMI compared to those with higher BMI.17, 18, 20 These conflicting 
results might be explained by the fact that previous studies used blood levels of vitamin B-12, rather 
than dietary vitamin B-12 intakes. Another reason for our unexpected findings might be residual 
confounding. Vitamin B-12 only occurs in animal products, which are usually also high in energy, 
protein and fat. However, we adjusted our models for total energy intake, animal protein intake, diet 
quality and saturated fat. Other possible explanations for this unexpected finding might be other 
mechanisms involved, such as DNA synthesis. As well as folate, vitamin B-12 is also associated with 
an increased DNA synthesis, and this could lead to a stimulated growth, which might explain our a 
higher android:gynoid ratio among children with a higher vitamin B-12 intake. Potential mechanisms 
underlying these associations should be further investigated in future studies.
We observed that a higher methionine intake, independent of total protein intake, was associated 
with a higher BMI, body fat percentage and android:gynoid ratio. Although this is in contrast with 
our hypothesis focusing on DNA methylation, it is in line with a number of previous studies. Results 
from a randomized controlled trial in adults with metabolic syndrome conducted by Plaisance et 
al. suggested that a methionine-restricted diet led to an increase in fat oxidation and decrease in 
intrahepatic lipid content.48 Previous animal studies performed by Hasek et al. and Malloy et al. 
showed that rats fed methionine-restricted diets had limited fat deposition and reduced visceral fat 
mass.49, 50 These results suggest that a potential beneficial effect on body composition of higher DNA 
methylation due to a higher methionine intake might be overruled by other mechanisms, such as 
decreased energy expenditure.49 For methionine, as well as other nutrients, we observed larger effect 
estimates in girls compared to boys. A possible explanation for these different findings may be due to 
differences in adiposity rebound between boys and girls. This onset of rapid growth in body fat occurs 
around the age of 6 years51 and seems to occur earlier in girls than in boys.52
The current study has several strengths and limitations. An important strength is the size of the 
population included and the prospective, population-based design. There was large amount of infor-
mation available on potentially confounding sociodemographic and lifestyle factors of the children 
and their parents. However, residual confounding may still be an issue, as in any observational study. 
For instance, detailed information on physical activity levels of children was not available. However, 
we adjusted for proxies of physical activity, including participation in sports and screen time. In ad-
dition, a diet score was used to control for overall healthy diet. Detailed body fat measurements were 
available by using DXA, which is a more objective measure as compared to several anthropometric 
measures, such as skinfold thickness. We aimed to reduce attrition bias as much as possible. Therefore, 
we used a multiple imputation procedure, which is an appropriate method to deal with missing data.38
A limitation of our study was the fact that the FFQ was only validated for Dutch children, while 
we had a multi-ethnic study population. Furthermore, the FFQ was validated for several nutrients, 
but not for the nutrients used in the current study.26 This might have led to measurement error in 
the assessment of vitamin B-6, vitamin B-12, folate, folic acid and methionine intakes, which may 
have led to random misclassification, and consequently attenuation of effect estimates.53 However, we 
adjusted all the nutrients for energy intake using the nutrient residual method, which has been de-
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scribed by Kipnis et al. as an accurate approach for reducing attenuated effect estimates in nutritional 
epidemiology.54 In addition, we analyzed the nutrient intakes in tertiles to avoid misspecification 
and to decrease the influence of outliers.36 Unfortunately, as the intake tertiles show, the variation 
of vitamin B-6 and vitamin B-12 intake in our population is quite low, which made it less likely to 
find a significant association with body composition outcomes. Furthermore, there might be some 
distortion in calculating the amount of DFEs in human milk. Folate in human milk is considered 
naturally present, but might have the same bioavailability as added folic acid. However, the number 
of children still being breastfed at the age of one year was very small in our population (n=267), 
therefore the impact this error might have on our results is minor. The FFQ was only sent to mothers 
of participating children who mastered the Dutch language sufficiently, of whom 72% returned the 
questionnaire, which may have led to selection bias. We observed that children without FFQ data 
were taller and heavier than children with FFQ data (Supplementary Table 4.1.3). However, this 
would only result in selection bias if the associations between intake of vitamin B-6, vitamin B-12, 
folate, folic acid and methionine and body composition outcomes were different between included 
and excluded participants in the final analysis. Unfortunately, blood levels of nutrients were not avail-
able, which would be a more objective measurement of nutritional status than dietary intake. Also, 
we did not have information on choline intake, which is another important nutrient involved in DNA 
methylation. Finally, an important limitation of our study is that we had no information available 
on DNA methylation. We could therefore not examine whether intake of vitamin B-6, vitamin B-12, 
folate, folic acid and methionine were associated with child body composition via changes in DNA 
methylation, as suggested by animal studies. Future studies in population-based samples of children 
are needed to investigate this effect.
conclusions
Results of this prospective cohort study suggest that high folic acid intake during early childhood 
may be associated with a lower weight and BMI at the age of 6 years. In contrast, a higher methionine 
intake was associated with a higher BMI, body fat percentage and android:gynoid ratio. Future stud-
ies are needed to confirm these findings, to investigate the underlying mechanisms and examine long 
term consequences of these outcomes on health.
4.1 Methyl donor nutrient intake & body composition
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supplementary table 4.1.1. Details of the multiple imputation procedure.
Software used: IBM SPSS Statistics 21
Imputation method and key settings: Markov Chain Monte Carlo (MCMC) method
Number of imputed data sets created: 5
Variable included in the imputation procedure (imputed 
or used as predictors of missing data):
Age at DXA measurement; gender; ethnicity; vitamin 
B-6 intake; vitamin B-12 intake; folate intake; folic acid 
intake; folate equivalents intake; methionine intake; 
height-for-age at age 6; weight-for-age at age 6; BMI-for-
age at age 6; body fat percentage at age 6; android:gynoid 
ratio at age 6; SDS weight at 2, 3,4, 5-10, 10-13, 13-17, 
17-23, 23-29, 29-35, 23-35, 35-44 and 44-56 months; 
SDS height at 2, 3,4, 5-10, 10-13, 13-17, 17-23, 23-29, 
29-35, 23-35, 35-44 and 44-56 months; SDS BMI at 2, 
3,4, 5-10, 10-13, 13-17, 17-23, 23-29, 29-35, 23-35, 
35-44 and 44-56 months; diet score; total protein intake; 
animal protein intake; breastfeeding during infancy; 
formula intake; energy intake; sports participation; 
screen time; maternal age; maternal BMI at enrolment; 
maternal education; family income; parity; folic acid 
supplementation during pregnancy; smoking during 
pregnancy; alcohol consumption during pregnancy.
Variables additionally added as predictors of missing data 
to increase plausibility of missing at random assumption:
Maternal prepregnancy BM;, maternal BMI in second 
trimester; maternal ethnicity; gestational age at intake; 
paternal education; paternal ethnicity; paternal BMI; age 
biological father; gestational age at birth; TV watching 
at 2, 3 and 4 years; marital status; age until child was 
breastfed; age introduction fruit/vegetables; walking to 
school; biking to school; playing outside.
Treatment of non-normally distributed variables: Predictive mean matching
Treatment of binary/categorical variables: Logistic regression models
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supplementary table 4.1.2. Population characteristics before and after imputation (n=2,922).
Characteristics Values before imputation1 Values after imputation1
Child characteristics
Sex, male 1,434 (49.1) NI
Missing - - 
Ethnicity
 Dutch 2,003 2,007 (68.7) 
 Non Dutch 908 915 (31.3) 
Missing 11 (0.4) - 
Gestational age at delivery (wk) 40.1 [36.0-42.3] NI
Missing (%) 4 (0.001) - 
Birth weight (g) 3,470 ± 552 NI
Missing 2 (0.0006) - 
Breastfeeding
Exclusively ≥ 4 months 777 (26.6) 864 (29.6) 
Partially ≥ 4 months 1,639 (56.1) 1,708 (58.4) 
Never 210 (7.2) 350 (12.0) 
Missing 296 (10.1) - 
Characteristics dietary measurement (1y)
Missing -
Age filling out FFQ (months) 12.9 [12.2-18.9] NI 
Missing - - 
Total energy intake (kcal/d) 1,310 ± 393 NI
Vitamin B-6 (mg/d) 1.2 [0.5-2.2] NI
Vitamin B-12 intake (µg/d) 2.5 [0.7-5.6] NI
Folate intake
Dietary folate (µg/d) 91 [32-209] NI 
Added folic acid (µg/d) 430 [0-1,420] NI 
Folate equivalents (µg/d) 182 [67-783] NI 
Methionine (mg/d) 642 [197-1,390] NI
Characteristics growth measurements (6y)
Age (years) 6.0 ± 0.2 NI
Missing - - 
Height (cm) 118 ± 5 NI
Missing 1 - 
Weight (kg) 22.4 ± 3.4 NI
Missing 1 - 
BMI (kg/m2) 16.0 ± 1.6 NI
Missing 1 - 
Body fat percentage (%) 24.2 ± 5.1 NI
Missing 64 (0.02) - 
4.1 Methyl donor nutrient intake & body composition
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supplementary table 4.1.2. Population characteristics before and after imputation (n=2,922). 
(continued)
Characteristics Values before imputation1 Values after imputation1
Android-gynoid fat ratio 0.24 ± 0.06 NI
Missing 64 (0.02) - 
Sports participation (yes %) 1,206 (44.6) 1,291 (44.2)
Missing 215 (0.07) - 
Screen time (h/d) 1.2 [0.3-4.4] 1.6 [0.3-4.4]
Missing 533 (18.2) - 
Maternal characteristics
Age at enrolment (years) 31.5 ± 4.5 NI
Missing - - 
BMI at enrolment (kg/m2) 23.5 [18.8-35.6] 24.4 [18.8-35.6]
Missing 238 (0.08) - 
Highest completed education level
No or primary education 38 (1.3) 302 (10.3) 
Secondary 757 (25.9) 911 (31.2) 
Higher 1,549 (53.0) 1,709 (58.5) 
Missing 578 (19.8) - 
Household income per month
<1,400 euro 315 (10.8) 414 (14.2) 
1,400-2,200 euro 459 (15.7) 556 (19.0) 
>2,200 euro 1,715 (58.7) 1,952 (66.8) 
Missing 433 (14.8) - 
Parity
0 1,724 (59.0) 1,761 (60.3) 
1 815 (27.9) 842 (28.8) 
2≤ 305 (10.4) 319 (10.9) 
 Missing 78 (2.7) - 
Folic acid supplement use
None 310 (10.6) 469 (16.0) 
First 10 weeks of pregnancy 647 (22.1) 890 (30.5) 
Periconceptional 1,182 (40.5) 1,563 (53.5) 
Missing 783 (26.8) - 
Smoking during pregnancy
Never 2,056 (70.4) 2,277 (78.0) 
Until pregnancy was known 263 (9.0) 296 (10.1) 
Continued 312 (10.7) 349 (11.9) 
Missing 291 (10.0) - 
 Alcohol consumption during pregnancy
Never 924 (31.6) 1,119 (38.3) 
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supplementary table 4.1.3. Non response analysis.
With FFQ 12
(n=2,922)
Without FFQ 12
(n=3,757)
P value 3
Age (y) 6.0 ± 0.2 6.4 ± 0.6 <0.01
Height (cm) 118 ± 5 120 ± 7 <0.01
Weight (kg) 22.4 ± 3.4 24.0 ± 4.7 <0.01
BMI (kg/m2) 16.0 ± 1.6 16.4 ± 2.1 <0.01
Body fat percentage(%) 23.9 ± 5.0 25.2 ± 6.0 <0.01
Android:gynoid ratio 0.24 ± 0.06 0.26 ± 0.07 <0.01
1 Differences in growth and body composition outcomes at the age of 6 years between children with and 
without dietary data available at the age of 13 months.
2 Values are means ± SD
3 P values are obtained from independent sample t-tests.
supplementary table 4.1.2. Population characteristics before and after imputation (n=2,922). 
(continued)
Characteristics Values before imputation1 Values after imputation1
Until pregnancy was known 367 (12.6) 443 (15.2) 
Continued 1,116 (38.2) 1,359 (46.5) 
Missing 515 (17.6) - 
1Mean ± SD,
Median [95% range],
or N (%)
Abbreviations: NI, not imputed.
4.1 Methyl donor nutrient intake & body composition
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AbstrAct
Background: High protein intake in infancy might lead to a higher BMI in childhood. However, 
whether these associations differ between different sources of protein is unclear.
Objective: We investigated associations between the intake of total protein, protein from different 
sources, and individual amino acids in early childhood, and repeatedly measured height, weight, and 
BMI up to the age of 9 years.
Methods: This study was performed in 3,564 children participating in the Generation R Study, a 
population-based prospective cohort study in Rotterdam, the Netherlands. Intake of total protein, 
animal protein, vegetable protein and individual amino acids (including methionine, arginine, lysine, 
threonine, valine, leucine, isoleucine, phenylalanine, tryptophan, histidine, cysteine, tyrosine, ala-
nine, asparagine, glutamine, glycine, proline, and serine) at 1 year was assessed using an FFQ. Height 
and weight were measured around the ages of 14, 18, 24, 30, 36, 45 months, 6 years, and 9 years, and 
BMI was calculated.
Results: After adjustment for confounders, linear mixed models showed that a 10 g/d higher total 
protein intake at 1 year was significantly associated with a 0.03 SD higher height (95%CI 0.00; 0.06), a 
0.06 SD higher weight (95%CI 0.03; 0.09), and a 0.05 SD higher BMI (95%CI 0.03; 0.08) up to the age 
of 9 years. Associations were stronger for animal than for vegetable protein intake, but did not differ 
between dairy and non-dairy animal protein, or between specific amino acids.
Conclusion: A higher intake of protein, especially animal protein, at 1 year of age was associated with 
a higher height, weight, and BMI in childhood up to 9 years of age. Future studies should explore the 
role of growth hormones, and investigate if protein intake in early childhood affects health later in life.
4.2 Protein intake & growth trajectories
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introduction
Diet in early childhood plays an important role in development and growth.1 In particular protein 
intake is important, because it provides essential amino acids required for protein synthesis, which 
are necessary for growth.2, 3 When intake is too low, growth during childhood is restricted.4 However, 
in most Western countries protein intake exceeds recommendations and a high protein intake in early 
childhood might lead to increased growth and a higher risk of obesity. This accelerated growth may 
be mediated through hormonal responses.5, 6
Several observational studies have reported that a higher total protein intake in early childhood is 
associated with higher height, weight, and BMI.7, 8 This has also been confirmed in a randomized con-
trolled trial with dairy protein-based infant formula. Results of this study showed that children who 
received a lower-protein formula during infancy had a lower weight and BMI up to 6 years of age than 
children who had received a higher-protein infant formula, but that these children were not different 
with respect to height.9, 10 Some studies suggest that it is not the total amount of protein intake, but 
specific sources, such as animal or dairy protein, that may cause accelerated growth.11, 12 A difference 
in effect of different types of protein might be due to a different amino acid composition in different 
sources of protein. It has been suggested that certain amino acids, such as arginine and lysine, may 
induce a release of growth hormone and insulin, which may lead to accelerated growth.13, 14
Even though previous studies showed an association between early protein intake and growth, so 
far there is only limited evidence on whether associations differ between different sources of protein.15 
Our aim was to explore associations between intake of protein, measured as total protein, different 
sources of dietary protein, and individual amino acids, and repeatedly measured height, weight, and 
BMI up to the age of 9 years in a large prospective cohort within a multi-ethnic study population.
methods
design and subjects
This study was embedded in the Generation R Study, a population-based prospective cohort study 
from fetal life onward in Rotterdam, the Netherlands.16 The study was approved by the Medical Ethi-
cal Committee of Erasmus Medical Center, Rotterdam. Written informed consent was obtained from 
all participating mothers. All children were born between 2002 and 2006, and data on follow-up in 
early childhood was available for 7,893 children. A Food Frequency Questionnaire (FFQ) to assess 
infant diet, including protein intake, was sent to 5,088 mothers who provided informed consent for 
postnatal follow-up and mastered the Dutch language sufficiently.17, 18 This FFQ was returned by 3,650 
mothers (72%). After exclusion of subjects with invalid dietary data (n=21), information on nutrition 
was available for 3,629 children.18 Of these children, growth data, i.e. height, weight and BMI between 
13 months and 9 years was available for 3,564 children (Figure 4.2.1.).
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n= 1,459 excluded due to missing 
information on FFQ (n=1,438) or 
invalid data on FFQ (n=21) 
 
 Children with dietary data at 1 y 
n= 3,629 
 
n = 65 excluded, due to missing 
growth measurements. 
 
 
Children with growth follow-up 
measurements  
n = 3,564 
  
 Children of mothers who received 
an FFQ at 1 y  
n= 5,088 
  
Children available for follow-up 
in early childhood 
n= 7,893 
  
n= 2,805 excluded due to no 
implementation of FFQ at 1 y 
figure 4.2.1. Flowchart: Population for analysis
dietary assessment
Dietary intake of the children was assessed at a median age of 12.9 months (95% range 12.2-18.9) 
using a semi-quantitative FFQ.17 Th is FFQ was modifi ed to include only foods that are frequently 
consumed during the second year of life according to a Dutch national food consumption survey in 
2002.19 Th e fi nal FFQ consisted of 211 food items and included questions on frequency, quantity, type 
of foods consumed, and on preparation methods. Food frequencies and quantities were converted 
into grams per day using standardized portion sizes. Intakes of total protein, animal protein (further 
divided into dairy and non-dairy), and vegetable protein were calculated using the Dutch Food 
Composition Table 2006.20 Amino acid content was calculated from McCance and Widdowson’s food 
composition table, which included chemically analyzed amino acid composition of 150 foods.21 Th e 
FFQ was evaluated against three 24h-recalls, obtained by trained nutritionists, in a representative 
sample of 32 Dutch children aged 14 months. Th is evaluation showed intraclass correlation coef-
fi cients of 0.4 for total energy, 0.7 for total protein, 0.4 for total fat, 0.4 for carbohydrates, and 0.7 for 
dietary fi ber intake.17, 18
growth and body composition outcomes
Data on height, weight, and BMI was collected at eight diff erent time point between the ages of 13 
months and 9 years. At the Child Health Centers, height and weight were measured without shoes 
4.2 Protein intake & growth trajectories
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and heavy clothing during routine visits at median ages of 14 (95% range 13-16), 18 (95% range 
17-21), 24 (95% range 23-28), 30 (95% range 29-34), 36 (95% range 35-40), and 45 (95% range 44-48) 
months. At median ages of 5.9 years (95% range 5.7-6.6) and 9.7 years (95% range 9.4-10.8), children 
visited our research center in the Erasmus Medical Center for a detailed physical examination. Height 
was determined in standing position to the nearest millimeter by a Harpenden stadiometer (Holtain 
Limited, Dyfed, U.K.). Weight was measured using a mechanical personal scale (SECA, Almere, the 
Netherlands). For all time points, body mass index (BMI) was calculated (kg/m2). Age- and sex-
specific standard deviation (SD) scores for height, weight, and BMI were calculated. Overweight was 
determined using cut-off values for BMI according to the Cole criteria.22
covariates
Information on maternal age, educational level (no/primary, secondary or higher), household income 
(<1400, 1400-2200 or >2200 euros/month), parity (0, 1 or ≥2), and folic acid supplement use (start 
preconceptional, start in the first 10 weeks of pregnancy, or never) was obtained through self-ad-
ministered questionnaires at enrollment. Smoking and alcohol consumption during pregnancy were 
assessed with questionnaires in each trimester and categorized as never, until pregnancy was known, 
or continued during pregnancy. At enrollment maternal height and weight were measured during 
early pregnancy and BMI (kg/m2) was calculated. Information on child’s sex, ethnicity, gestational 
age at birth, and birth weight were obtained from hospital medical records. Birth weight Z-scores for 
gestational age were calculated using reference data.23 Ethnicity was defined as Dutch or non-Dutch, 
on the basis of the countries of birth of the parents, according to Statistics Netherlands.24 Information 
on breastfeeding (exclusively for at least 4 months, partially in the first 4 months, or never) was ob-
tained by postnatal questionnaires. A previously defined child diet score was used to quantify overall 
diet quality at the age of 1 year,18 which we previously found to be associated with body composition.25 
The diet score is composed of ten food groups (Supplementary Table 4.2.1), for which the ratio of 
the reported intake and the recommended intake was calculated. For each component the score was 
truncated at 1. The scores for the single components were added together, resulting in an overall 
score that ranged from 0 to 10 on a continuous scale, with a higher score representing a healthier 
diet.18 Information on child’s sports participation (yes/no) and screen time (television watching and 
computer use, h/d) was obtained using a questionnaire at the age of 6 years.
statistical analysis
To account for potential measurement error and confounding by total energy intake, we used the 
residual method to adjust the intake of protein for total energy intake.26 In short, linear regression 
analyses were used to calculate energy adjusted intake of protein for each subject, with energy intake 
as independent variable and protein intake as dependent variable. Similarly, intakes of amino acids 
and the diet score were adjusted for both energy and total protein intake.
To reduce potential bias due to missing values, incomplete data on covariates were multiple 
imputed (m=5 imputations).27 In order to establish covariates to include in our models, we used 
linear regression analyses to examine the associations of total protein, animal protein, and vegetable 
protein intake at the age of 1 year with age- and sex-adjusted SD scores of growth measurements 
(height, weight and BMI) at the age of 9 years, with protein intake as independent variable and growth 
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outcomes as dependent variables. Covariates were added to the model and were selected based a 
10% change in effect estimates and on previous literature. Three multivariable models were used: 
Model 1 (crude) included child’s sex, ethnicity, age at FFQ and energy intake; model 2 (confounders) 
was additionally adjusted for birthweight Z score, breastfeeding, playing sports, household income, 
maternal BMI at enrollment, maternal education, folic acid use during pregnancy and smoking dur-
ing pregnancy; and model 3 (confounders + diet score) was additionally adjusted for the diet score to 
examine if protein intake was related to growth independent of overall diet quality.
Associations between protein intake and total trajectories of growth between the age of 1 and 
9 years were analyzed using linear mixed models. This method allows to use all available repeated 
measurements of either height, weight or BMI simultaneously and takes into account that these 
measurements are correlated within subjects. The fixed effects structure was specified according to 
the previously mentioned models 1, 2 and 3. Likelihood ratio tests were used to determine a suitable 
random effects structure, random intercepts and slopes, which were used in each of the longitudinal 
models. To examine whether protein intake modified growth trajectories, i.e. velocity, we included 
interaction terms between protein intake and age at measurement of the outcome in the fixed effects 
structure. Furthermore, to assess if associations between protein intake and growth outcomes differed 
by sex, ethnicity, age at dietary measurement, or birth year we added interaction terms between the 
potential effect modifier and protein intake to the crude and confounder models. Considering that 
the FFQ was developed for Dutch children, we performed sensitivity analyses in children with a 
Dutch ethnic background only. In addition, sensitivity analyses were performed by stratifying for 
sex, since previous studies suggest that the influence of diet in early life might differ by sex.28, 29 To 
test whether associations differed when protein intake was replaced by fat or carbohydrate intake, 
macronutrient substitution models were performed.
Results were considered statistically significant with a P < 0.05. Statistical analyses were conducted 
using SPSS version 21.0 (IBM Inc., Armonk, NY, USA) and R version 3.1.2 (The R Foundation for 
Statistical Computing, Vienna, Austria).
results
subject characteristics
Characteristics of the children and their mothers are presented in Table 4.2.1. The majority of the 
study population had a Dutch ethnicity (67.7%). Total protein intake at the age of 12.9 months (95% 
range 12.2-18.9) was 42.1 ± 13.4 g/d. This is higher than the recommended intake for this age group,30 
but comparable to observed in other Western populations.7, 8, 31
Mean animal protein intake was 26.5 ± 10.6 g/d, and mean vegetable protein intake was 15.1 ± 
5.9 g/d. At the age of 9 years mean height (cm) was 141.6 ± 6.4, mean weight (kg) was 34.7 ± 6.7, and 
mean BMI (kg/m2) was 17.2 ± 2.5.
4.2 Protein intake & growth trajectories
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table 4.2.1. Population characteristics (n =3564)1
Characteristics Values1
Child characteristics
Sex, female 1816 (51.0)
Ethnicity
Dutch 2415 (67.8)
Non Dutch 1149 (32.2)
Gestational age at birth (wk) 40.1 [35.6 - 42.3]
Birth weight (g) 3446 ± 580
Breastfeeding
Exclusively ≥ 4 months 1005 (28.2)
Partially ≥ 4 months 2263 (63.5)
Never 296 (8.3)
Characteristics at dietary measurement (1y)
Age filling out FFQ (months) 12.9 [12.2 - 18.9]
BMI (kg/m2) 17.4 ± 1.4
Total energy intake (kcal) 1321 ± 413
Total protein intake (g/d) 42.1 ± 13.4
Animal protein intake (g/d) 26.5 ± 10.6
Dairy animal protein (g/d) 17.7 ± 8.3
Non-dairy animal protein intake (g/d) 8.8 ± 5.9
Vegetable protein intake (g/d) 15.1 ± 5.9
Amino acids
Methionine (g/d) 0.68 ± 0.33
Lysine (g/d) 2.04 ± 0.99
Arginine (g/d) 1.64 ± 0.72
Isoleucine (g/d) 1.49 ± 0.67
Leucine (g/d) 2.83 ± 1.12
Valine (g/d) 1.83 ± 0.82
Cysteine (g/d) 0.50 ± 0.19
Phenylalanine (g/d) 1.56 ± 0.67
Tyrosine (g/d) 1.17 ± 0.52
Threonine (g/d) 1.31 ± 0.59
Tryptophan (g/d) 4.12 ± 0.18
Histidine (g/d) 0.93 ± 0.40
Alanine (g/d) 1.45 ± 0.64
Asparagine (g/d) 2.84 ± 1.26
Glutamine (g/d) 6.88 ± 2.85
Glycine (g/d) 1.22 ± 0.52
Proline (g/d) 2.50 ± 1.03
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table 4.2.1. Population characteristics (n =3564)1 (continued)
Characteristics Values1
Serine (g/d) 1.87 ± 0.74
Diet quality score 4.2 ± 1.3
Characteristics at growth measurements (6y)
Age (years) 6.0 ± 0.2
Height (cm) 118.2 ± 5.2
Weight (kg) 22.4 ± 3.4
BMI (kg/m2) 16.0 ± 1.6
Sport participation 1557 (43.7)
Characteristics at growth measurements (9y)
Age (years) 9.7 ± 0.3
Height (cm) 141.6 ± 6.4
Weight (kg) 34.7 ± 6.7
BMI (kg/m2) 17.2 ± 2.5
Maternal characteristics
Maternal age at enrollment (years) 31.4 ± 4.6
Maternal BMI at enrollment (kg/m2) 23.5 [18.8 - 35.4]
Maternal education
No or primary education 238 (6.7)
Secondary 1294 (36.3)
Higher 2033 (57.0)
Household income
<1,400 euro/mo 625 (17.5)
1,400-2,200 euro/mo 686 (19.2)
>2,200 euro/mo 2252 (63.2)
Folic acid supplement use during pregnancy
None 609 (17.1)
First 10 weeks 1101 (30.9)
Periconceptional 1854 (52.0)
Smoking during pregnancy
Never 2764 (77.5)
Until pregnancy was known 356 (10.0)
Continued 444 (12.5)
Alcohol consumption during pregnancy
Never 1417 (39.8)
Until pregnancy was known 561 (15.7)
Continued 1585 (44.5)
1Values represent mean ± SD, Median [95% range], or N(%)
BMI, body mass index; FFQ, food frequency questionnaire.
4.2 Protein intake & growth trajectories
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Protein intake and growth
The results of the linear mixed models are presented in Table 4.2.2. The adjusted models (model 2) 
show that a 10 g/d higher protein intake was associated with an increase in trajectory of height with 
0.03 SDS (95% CI 0.00; 0.06), of weight with 0.06 SDS (95%CI 0.03; 0.09), and of BMI with 0.05 
SDS (95%CI 0.03; 0.08) up to the age of 9 years. This association did not attenuate and remained 
statistically significant after additional adjustment for the diet score (model 3). To illustrate, these 
results correspond to actual units of growth measurements of approximately 0.2 cm for height, 0.4 kg 
for weight, and 0.1 kg/m2 for BMI at the age of 9 years. When analyses were performed for protein 
from animal and vegetable sources, associations between animal protein and growth outcomes were 
stronger than for vegetable protein intake (Table 4.2.2). The results of the analysis in which animal 
protein was further divided into intake from dairy and non-dairy food sources are presented in Table 
4.2.3. Effect estimates for both dairy protein and non-dairy protein were very similar. Supplemen-
tary Table 4.2.2 shows the results from the linear mixed models for intake of amino acids. Except for 
table 4.2.2. Associations of protein intake at the age of 1 year with childhood growth measures 
between the age of 1 and 9 years (n=3564).1
Height
(SDS)
Weight
(SDS)
BMI
(SDS)
Total protein intake (10 g/d)2
Model 1 (crude)4 0.04 (0.01; 0.07)* 0.06 (0.03; 0.09)* 0.06 (0.03; 0.08)*
Model 2 (confounders)5 0.03 (0.00; 0.06)* 0.06 (0.03; 0.09)* 0.05 (0.03; 0.08)*
Model 3 (diet score)6 0.03 (0.01; 0.06)* 0.06 (0.03; 0.09)* 0.05 (0.03; 0.08)*
Animal protein intake (10 g/d)2,3
Model 1 (crude)4 0.03 (0.00; 0.07)* 0.06 (0.03; 0.09)* 0.06 (0.03; 0.09)*
Model 2 (confounders)5 0.03 (0.00; 0.06)* 0.06 (0.03; 0.09)* 0.06 (0.03; 0.08)*
Model 3 (diet score)6 0.04 (0.01; 0.07)* 0.07 (0.04; 0.10)* 0.06 (0.03; 0.09)*
Vegetable protein intake (10 g/d)2,3
Model 1 (crude)4 0.03 (0.00; 0.06)* 0.04 (0.00; 0.07)* 0.02 (-0.01; 0.05)
Model 2 (confounders)5 0.02 (-0.01; 0.05) 0.03 (-0.00; 0.05) 0.02 (-0.01; 0.05)
Model 3 (diet score)6 0.01 (-0.02; 0.04) 0.01 (-0.02; 0.04) 0.01 (-0.02; 0.04)
1Values are regression coefficients and 95% confidence intervals based on linear mixed models and reflect 
differences in growth measures (age- and sex-specific SD scores) per 10 g/d increase in energy-adjusted 
protein intake.
2Total, animal and vegetable protein intake were adjusted for total energy intake using the residual 
method.
3Models including animal protein were adjusted for vegetable protein and vice versa.
4Model 1 is adjusted for child sex , ethnicity, age at dietary measurement and total energy intake at 1 y;
5Model 2 is additionally adjusted for birthweight Z score, breastfeeding, playing sports; household income; 
and maternal BMI at enrollment, maternal education, folic acid use during pregnancy and smoking dur-
ing pregnancy.
6Model 3 is additionally adjusted for diet score
* statistically significant effect estimates.
BMI, body mass index; SDS, standard deviation score.
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serine, higher intakes of all of the individual amino acids were significantly associated with a higher 
weight and BMI. For most amino acids, strengths of the associations were fairly similar, only for 
cysteine and tryptophan the effect estimates were slightly larger compared to the other amino acids: 
a 100 mg/d higher cysteine intake was associated with a 0.038 (95% CI 0.016; 0.060) SDS increase in 
BMI and a 100 mg/d higher intake in tryptophan was associated with a 0.052 (95% CI 0.029; 0.074) 
SDS increase in BMI. Overall for weight and BMI, associations did not differ substantially between 
the essential and non-essential amino acids. Higher intakes of all of the essential amino acids were 
significantly associated with an increase in height. However, some of the non-essential amino acids, 
including cysteine, arginine, glycine and serine, were not significantly associated with height.
Additional analyses
Interactions of protein intake with age at outcome measurement were not statistically significant. This 
suggests that protein intake does not affect the velocity height/weight/BMI. Furthermore, interac-
tions of protein intake with sex, ethnicity, age at FFQ, and birth year were not significant. Sensitivity 
analyses in children with a Dutch ethnic background showed that effect estimates for total and animal 
protein intake in this group were similar to those in the total population, but had slightly wider con-
fidence intervals (Supplementary Table 4.2.3). Food sources of total, animal and vegetable protein 
intake were similar between Dutch only and the total study population (data not shown). Results were 
similar between boys and girls, but effect estimates were slightly stronger for girls compared to boys 
(Supplementary Tables 4.2.4 and 4.2.5). Macronutrient substitution models in which protein intake 
was replaced either with fat or carbohydrate intakes showed similar results (data no shown).
table 4.2.3. Associations of dairy and non-dairy animal protein intake at the age of 1 year with 
childhood growth measures between the age of 1 and 9 years (n= 3564).1
Height
(SDS)
Weight
(SDS)
BMI
(SDS)
Dairy protein intake (10 g/d)2,3
0.04 (-0.01; 0.08) 0.07 (0.03; 0.12)* 0.07 (0.02; 0.11)*
Non-dairy protein intake (10 g/d)2,3
0.04 (-0.02; 0.09) 0.07 (0.02; 0.12)* 0.07 (0.02; 0.12)*
1Values are regression coefficients and 95% confidence intervals based on linear mixed models and reflect 
differences in growth measures (age- and sex-specific SD scores) per 10 g/d increase in energy-adjusted 
protein intake.
2 Dairy and non-dairy protein intake were adjusted for total energy intake using the residual method.
3Models are adjusted for birthweight Z score, breastfeeding, playing sports; household income; and mater-
nal BMI at enrollment, maternal education, folic acid use during pregnancy and smoking during preg-
nancy. Models including dairy animal protein were adjusted for non-dairy animal protein and vice versa.
* statistically significant effect estimates.
BMI, body mass index; SDS, standard deviation score.
4.2 Protein intake & growth trajectories
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discussion
In our multi-ethnic population-based study, a higher protein intake at the age of 1 year was associated 
with a higher height, weight, and BMI up to the age of 9 years. This association was stronger for 
animal protein compared to vegetable protein, but did not differ between dairy and non-dairy animal 
protein. Furthermore, associations were not driven by intake of specific amino acids.
One of the suggested mechanisms that may explain the associations we observed is that protein 
intake stimulates the release of insulin like growth factor (IGF-I) and other growth hormones, which 
in turn results in rapid growth and increased muscle and fat mass. However, we have previously 
shown that this increased BMI at age 6 years is fully driven by an increase in fat mass and not fat-free 
mass.32
Our results are in line with a few previous studies, which also showed that a higher total protein 
intake in early childhood is associated with higher height, weight and BMI in later childhood.7, 8, 31 
In addition, the causal effect of a higher protein intake in early childhood on a higher weight and 
BMI has been confirmed in a randomized controlled trial among 1138 children comparing the effect 
of higher- and lower-protein formula during the first year of life on growth up to 6 years of age.9, 10 
However, in contrast to our results, no difference in height was observed between the lower- and 
higher-protein formula groups in this trial. In our study we found a significant increase in height with 
higher protein intake, although effect estimates were not as strong as those for weight and BMI. A 
possible explanation might be that height is more genetically determined and is less prone to modifi-
cation by external exposures such as diet.33
Our results suggest that the associations between protein intake and growth might be stronger 
for intake of animal protein rather than vegetable protein. This corresponds with findings from two 
previous studies which found that a higher animal protein intake in early life was associated with 
higher BMI later in childhood.11, 34 These different results for animal and vegetable protein intake 
might be due to the higher intake of animal protein (8.0 E%) compared to vegetable protein (4.6 E%) 
in our population and in previous studies.11, 34 Nevertheless, it has also been suggested that protein 
from animal sources specifically stimulate growth. These effects of animal protein intake have been 
ascribed to protein from dairy sources in particular, which has been suggested to have specific growth 
stimulating effects by raising hormonal responses.12, 35 However, when we further separated animal 
protein into intake from dairy and non-dairy animal food sources, effect sizes for both were similar. 
These results indicate that in our population the associations observed between animal protein intake 
and growth were not specifically driven by dairy or non-dairy animal protein.
Another possible explanation for the difference in results regarding animal versus vegetable protein 
might be due to the high proportion of essential amino acids present in animal protein. Axelsson et al. 
suggested that certain specific amino acids (i.e., arginine, lysine, threonine, valine, leucine, isoleucine, 
phenylalanine) might stimulate secretion of insulin and growth hormone, which might mediate the 
association between protein and growth.36 Furthermore, Vught et al. reported that higher arginine 
intake was associated with growth velocity in children aged 7-13 years after 3 years of follow up,14 and 
that a high arginine intake in combination with a high lysine intake was associated with a higher fat 
mass index among 8-10 year old girls after 6 years of follow up.37 However, our results suggested that 
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associations did not differ substantially between essential and non-essential amino acids and were not 
driven by any of the individual amino acids.
The current study has several strengths and limitations. Important strengths of this study are 
the large sample size of the population included, the prospective, population-based study design, 
and the repeated growth measurements obtained by professional staff. Another strength is the large 
amount of information available on potential sociodemographic and lifestyle confounders of the 
children and their parents. We aimed to reduce attrition bias as much as possible. Therefore, we 
used a multiple imputation procedure, which is an appropriate method to deal with missing data 
because it requires the least assumptions and reduces bias when the missing data are not completely 
at random.27 A limitation of this study is the observational nature of the study design, therefore, no 
causal relation can be concluded. As in all observational studies, residual confounding may still be 
an issue, for example by physical activity and pubertal status. The FFQ was only sent to mothers who 
mastered the Dutch language sufficiently, of which 72% filled in and returned the questionnaire. This 
may have led to selection bias. As we previously reported, children without FFQ data had a higher 
height, weight, and BMI compared to the children with FFQ data.38 However, this difference would 
only result in selection bias if associations between protein intake and growth differs between the 
included and excluded participants. Another limitation of this study is that the FFQ was developed 
for Dutch children, whereas our study was conducted in a multi-ethnic study population. However, 
when we performed sensitivity analyses restricted to Dutch children only, results were similar to 
those in the whole group. Furthermore, the FFQ was evaluated for total protein, showing a relatively 
high intraclass correlation coefficient (0.7), but protein from specific sources or amino acids were not 
evaluated. Not all amino acids could be calculated from the FFQ, 18 amino acids were available for 
analysis. Moreover, with the calculation of the amount of amino acids, intakes from breast milk were 
not taken into account because no amino acid composition data was available. However, the number 
of children still being breast fed at the age of 1 year was relatively small (10%), therefore the error due 
to this missing information is probably minimal. Unfortunately, we had no repeated dietary data or 
dietary measurements after the age of 1 year. In addition, data on IGF-I or other growth factors that 
might mediate the association between protein intake and growth were not available in this study.
conclusion
Results of this prospective cohort study support findings from previous studies that a higher intake of 
protein during early childhood is associated with a higher height, weight, and BMI in later childhood. 
Furthermore, our results add to the literature that in particular animal protein is associated with 
growth, but that this is not specifically driven by dairy protein or specific amino acids. Future studies 
should explore the role of growth hormones, and investigate if protein intake in early childhood 
affects health later in life.
4.2 Protein intake & growth trajectories
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suPPlementAry mAteriAl
supplementary table 4.2.1. Diet quality score.
Food group Cut-off level Summary of included items Summary of excluded items
Vegetables ≥100 g Fresh vegetables, frozen or canned 
vegetables
Pickles
Fruit ≥150 g Fresh fruit, canned fruit without 
added sugar
Canned fruit with added sugar, fruit 
juice
Bread and cereals ≥70 g Whole-wheat bread or crackers, 
oatmeal, muesli without added sugar
White bread or crackers, breakfast 
cereals with added sugar
Rice, pasta, potatoes, 
and legumes
≥70 g Boiled or steamed potatoes, whole-
wheat pasta, couscous, whole-grain 
rice, legumes
Fried potatoes, French fries, white 
pasta, white rice
Dairy ≥370 g Whole, semi-skimmed and skimmed 
milk and yogurt without added 
sugars, soy milk without added 
sugars, low-fat and reduced-fat 
cheeses (20+ and 30+)
Milk products with added sugars, 
full-fat cheeses
Meat, eggs and meat 
substitutes
≥35 g Low-fat meat, eggs, tofu, tempeh Fat and processed meat
Fish ≥15 g Fresh or canned fish Fish fingers
Oils and fats ≥25 g Low-fat margarine products(≤16g 
saturated fat and ≤1g trans fat per 
100g), oils, liquid cooking or frying 
fat
Butter, solid cooking or frying fats
Candy and snacks ≤ 20 g/d Ice cream, potato chips, cookies, 
candy bars, fried snacks, cakes
-
Sugar-sweetened 
beverages
≤ 100 g/d Soft drinks, lemonade -
We used a food-based diet score to overall diet quality in the children. The score is composed of eight food 
groups. For each food group, we calculated the ratio of the reported intake and the recommended intake 
(see table below). For each component the score was truncated at 1. The scores for the single components 
were added together, resulting in an overall score that ranged from 0 to 8 on a continuous scale, with 
a higher score representing a healthier diet. The score was adjusted for energy intake using the residuals 
method.
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supplementary table 4.2.2. Associations of amino acid intake at the age of 1 year with child-
hood growth measures between the age of 1 and 9 years (n=3564).
Height (SDS) Weight (SDS) BMI (SDS)
Essential amino acids
Methionine (100 mg/d) 0.013 (0.002; 0.023)* 0.024 (0.015; 0.034)* 0.023 (0.014; 0.032)*
Lysine (100/mg) 0.006 (0.001; 0.010)* 0.010 (0.006; 0.014)* 0.009 (0.005; 0.013)*
Valine (100 mg/d) 0.006 (0.002; 0.010)* 0.010 (0.006; 0.014)* 0.009 (0.006; 0.013)*
Leucine (100 mg/d) 0.006 (0.002; 0.010)* 0.010 (0.006; 0.014)* 0.009 (0.005; 0.013)*
Isoleucine (100 mg/d) 0.008 (0.002; 0.015)* 0.015 (0.009; 0.021)* 0.014 (0.008; 0.019)*
Phenylalanine (100 mg/d) 0.008 (0.002; 0.014)* 0.014 (0.008; 0.020)* 0.013 (0.007; 0.018)*
Threonine (100 mg/d) 0.010 (0.002; 0.017)* 0.017 (0.010; 0.024)* 0.016 (0.009; 0.022)*
Tryptophan (100 mg/d) 0.031 (0.006; 0.056)* 0.057 (0.033; 0.080)* 0.052 (0.029; 0.074)*
Histidine (100 mg/d) 0.014 (0.003; 0.025)* 0.024 (0.014; 0.034)* 0.021 (0.011; 0.031)*
Non-essential amino acids
Cysteine (100 mg/d) 0.020 (-0.004; 0.044) 0.040 (0.017; 0.063)* 0.038 (0.016; 0.060)*
Tyrosine (100 mg/d) 0.011 (0.003; 0.019)* 0.019 (0.012; 0.027)* 0.017 (0.010; 0.025)*
Alanine (100 mg/d) 0.007 (0.001; 0.014)* 0.014 (0.008; 0.021)* 0.013 (0.007; 0.019)*
Arginine (100 mg/d) 0.005 (-0.000; 0.009) 0.009 (0.004; 0.014)* 0.009 (0.004; 0.013)*
Asparagine (100 mg/d) 0.004 (0.000; 0.007)* 0.007 (0.004; 0.010)* 0.006 (0.003; 0.010)*
Glutamine (100 mg/d) 0.002 (0.000; 0.003)* 0.003 (0.002; 0.005)* 0.003 (0.001; 0.004)*
Glycine (100 mg/d)) 0.005 (-0.002; 0.015) 0.013 (0.005; 0.021)* 0.013 (0.005; 0.021)*
Proline (100 mg/d) 0.006 (0.002; 0.009)* 0.009 (0.005; 0.013)* 0.008 (0.004; 0.011)*
Serine (100 mg/d) 0.002 (-0.003; 0.007) 0.003 (-0.002; 0.008) 0.003 (-0.002; 0.007)
1 Values are regression coefficients and 95% confidence intervals based on linear mixed models and reflect 
differences in growth measures (age- and sex-specific SD scores) per 100 mg/d increase in intake.
2 Amino acids were adjusted for energy and protein using the residual method.
3Models are adjusted for birthweight Z score, breastfeeding, playing sports; household income; and 
maternal BMI at enrollment, maternal education, folic acid use during pregnancy and smoking during 
pregnancy.
* statistically significant effect estimates.
BMI, body mass index; SDS, standard deviation score.
4.2 Protein intake & growth trajectories
229
Ch
ap
te
r 4
.2
supplementary table 4.2.3. Associations of protein intake at the age of 1 year with childhood 
growth measures between the age of 1 and 9 years in Dutch children only (n=2433).1
Height
(SDS)
Weight
(SDS)
BMI
(SDS)
Total protein intake* (10 g/d)2
Model 1 (crude)4 0.03 (-0.01; 0.07) 0.07 (0.03; 0.10)* 0.07 (0.04; 0.10)*
Model 2 (confounders)5 0.03 (-0.00; 0.07) 0.07 (0.04; 0.10)* 0.07 (0.04; 0.10)*
Model 3 (diet score)6 0.03 (-0.03; 0.07) 0.07 (0.04; 0.10)* 0.07 (0.04; 0.10)*
Animal protein intake* (10 g/d)2,3
Model 1 (crude)4 0.03 (-0.01; 0.07) 0.06 (0.02; 0.10)* 0.06 (0.03; 0.10)*
Model 2 (confounders)5 0.04 (-0.00; 0.07) 0.07 (0.03; 0.10)* 0.07 (0.03; 0.10)*
Model 3 (diet score)6 0.04 (0.00; 0.07)* 0.07 (0.04; 0.10)* 0.06 (0.03; 0.10)*
Vegetable protein intake* (10 g/d)2,3
Model 1 (crude)4 0.02 (-0.02; 0.07) 0.06 (0.02; 0.10)* 0.07 (0.03; 0.10)*
Model 2 (confounders)5 -0.01 (-0.03; 0.05) 0.05 (0.01; 0.08)* 0.06 (0.02; 0.09)*
Model 3 (diet score)6 0.00 (-0.04; 0.04) 0.04 (0.00; 0.07)* 0.05 (0.02; 0.09)*
1Values are regression coefficients and 95% confidence intervals based on linear mixed models and reflect 
differences in growth measures (age- and sex-specific SD scores) per 10 g/d increase in energy-adjusted 
protein intake.
2Total, animal and vegetable protein intake were adjusted for total energy intake using the residual 
method.
3Models including animal protein were adjusted for vegetable protein and vice versa.
4Model 1 is adjusted for child sex , ethnicity, age at dietary measurement and total energy intake at 1 y;
5Model 2 is additionally adjusted for birthweight Z score, breastfeeding, playing sports; household income; 
and maternal BMI at enrollment, maternal education, folic acid use during pregnancy and smoking dur-
ing pregnancy.
6Model 3 is additionally adjusted for diet score
* statistically significant effect estimates.
BMI, body mass index; SDS, standard deviation score.
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supplementary table 4.2.4. Associations of protein intake at the age of 1 year with childhood 
growth measures between the age of 1 and 9 years in girls (n=1816). 1
Height
(SDS)
Weight
(SDS)
BMI
(SDS)
Total protein intake* (10 g/d)2
Model 1 (crude)4 0.05 (0.00; 0.09)* 0.07 (0.03; 0.11)* 0.06 (0.02; 0.10)*
Model 2 (confounders)5 0.04 (-0.00; 0.08) 0.07 (0.02; 0.11)* 0.06 (0.02; 0.09)*
Model 3 (diet score)6 0.04 (-0.00; 0.08) 0.07 (0.03; 0.10)* 0.06 (0.02; 0.09)*
Animal protein intake* (10 g/d)2,3
Model 1 (crude)4 0.05 (0.00; 0.10)* 0.08 (0.04; 0.13)* 0.07 (0.03; 0.11)*
Model 2 (confounders)5 0.05 (0.01; 0.09)* 0.08 (0.04; 0.12)* 0.07 (0.03; 0.11)*
Model 3 (diet score)6 0.05 (0.01; 0.10)* 0.08 (0.04; 0.13)* 0.07 (0.03; 0.11)*
Vegetable protein intake* (10 g/d)2,3
Model 1 (crude)4 0.04 (-0.01; 0.08) 0.04 (-0.00; 0.08) 0.02 (-0.02; 0.06)
Model 2 (confounders)5 0.02 (-0.02; 0.06) 0.03 (-0.01; 0.07) 0.02 (-0.02; 0.06)
Model 3 (diet score)6 0.02 (-0.03; 0.06) 0.01 (-0.03; 0.05) 0.01 (-0.03; 0.04)
1Values are regression coefficients and 95% confidence intervals based on linear mixed models and reflect 
differences in growth measures (age- and sex-specific SD scores) per 10 g/d increase in energy-adjusted 
protein intake.
2Total, animal and vegetable protein intake were adjusted for total energy intake using the residual 
method.
3Models including animal protein were adjusted for vegetable protein and vice versa.
4Model 1 is adjusted for child sex , ethnicity, age at dietary measurement and total energy intake at 1 y;
5Model 2 is additionally adjusted for birthweight Z score, breastfeeding, playing sports; household income; 
and maternal BMI at enrollment, maternal education, folic acid use during pregnancy and smoking dur-
ing pregnancy.
6Model 3 is additionally adjusted for diet score
* statistically significant effect estimates.
BMI, body mass index; SDS, standard deviation score.
4.2 Protein intake & growth trajectories
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supplementary table 4.2.5. Associations of protein intake at the age of 1 year with childhood 
growth measures between the age of 1 and 9 years in boys (n=1748).1
Height
(SDS)
Weight
(SDS)
BMI
(SDS)
Total protein intake* (10 g/d)2
Model 1 (crude)4 0.03 (-0.02; 0.07) 0.05 (0.01; 0.10)* 0.05 (0.01; 0.09)*
Model 2 (confounders)5 0.02 (-0.02; 0.07) 0.05 (0.01; 0.09)* 0.05 (0.01; 0.09)*
Model 3 (diet score)6 0.03 (-0.02; 0.07) 0.05 (0.01; 0.09)* 0.05 (0.01; 0.09)*
Animal protein intake* (10 g/d)2,3
Model 1 (crude)4 0.02 (-0.02; 0.06) 0.04 (-0.00; 0.09) 0.04 (0.00; 0.08)*
Model 2 (confounders)5 0.02 (-0.02; 0.06) 0.04 (0.00; 0.08)* 0.04 (0.00; 0.08)*
Model 3 (diet score)6 0.02 (-0.02; 0.06) 0.05 (0.01; 0.09)* 0.04 (0.01; 0.08)*
Vegetable protein intake* (10 g/d)2,3
Model 1 (crude)4 0.02 (-0.02; 0.07) 0.04 (-0.01; 0.08) 0.02 (-0.02; 0.07)
Model 2 (confounders)5 0.02 (-0.03; 0.06) 0.03 (-0.02; 0.07) 0.02 (-0.02; 0.06)
Model 3 (diet score)6 0.01 (-0.04; 0.06) 0.02 (-0.03; 0.06) 0.02 (-0.03; 0.06)
1Values are regression coefficients and 95% confidence intervals based on linear mixed models and reflect 
differences in growth measures (age- and sex-specific SD scores) per 10 g/d increase in energy-adjusted 
protein intake.
2Total, animal and vegetable protein intake were adjusted for total energy intake using the residual 
method.
3Models including animal protein were adjusted for vegetable protein and vice versa.
4Model 1 is adjusted for child sex , ethnicity, age at dietary measurement and total energy intake at 1 y;
5Model 2 is additionally adjusted for birthweight Z score, breastfeeding, playing sports; household income; 
and maternal BMI at enrollment, maternal education, folic acid use during pregnancy and smoking dur-
ing pregnancy.
6Model 3 is additionally adjusted for diet score
* statistically significant effect estimates.
BMI, body mass index; SDS, standard deviation score.
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AbstrAct
Background: Previous studies suggest that high protein intake in infancy leads to a higher body mass 
index in later childhood. We examined the associations of total, animal and vegetable protein intake 
in early childhood with detailed measures of body composition at the age of 6 years.
Methods: This study was performed in 2,911 children participating in a population-based cohort 
study. Protein intake at the age of 1 year was assessed with a validated food-frequency questionnaire 
and was adjusted for total energy intake. At the children’s age of 6 years, we measured their anthropo-
metrics and body fat (with dual-energy X-ray absorptiometry). We calculated age- and sex- specific 
SD scores for body mass index (BMI), fat mass index (FMI), and fat-free mass index (FFMI).
Results: After adjustment for confounders, a 10 g/d higher total protein intake at 1 year of age was 
associated with a 0.05 SD (95%CI 0.00, 0.09) higher BMI at age 6 years. This association was fully 
driven by a higher FMI (0.06 SD (95%CI 0.01, 0.11)) and not FFMI (-0.01 SD (95%CI -0.06, 0.05)). 
The associations of protein intake with FMI at 6 years remained significant after adjustment for BMI 
at the age of 1 year. Additional analyses showed that the associations of protein intake with FMI were 
stronger in girls than in boys (p for interaction=0.03), stronger among children who had catch-up 
growth in the first year of life (p for interaction<0.01), and stronger for intake of animal protein (both 
dairy and non-dairy protein) than protein from vegetable sources.
Conclusions: Our results suggest that high protein intake in early childhood is associated with higher 
body fat mass, but not fat-free mass. Future studies are needed to investigate whether these changes 
persist into adulthood and to examine the optimal range of protein intake for infants and young 
children.
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introduction
Protein is an important component of early life nutrition, as it provides essential amino acids required 
for growth. However, a high protein intake in early childhood has been linked to a higher risk of 
obesity.1-3 Whereas in adults a higher total protein intake increases satiety and energy expenditure 
and is thereby beneficial for body weight maintenance,4, 5 different mechanisms may play a role in 
infancy. The early protein hypothesis states that high protein in early childhood is linked to later 
obesity through hormonal responses,1 including enhanced secretion of insulin-like growth factor-1 
(IGF-1),6 which may increase growth and adipogenesis.7 This effect might have a specific risk window 
around the age of 1 year, when most children undergo a transition from milk-based and complemen-
tary feeding to table foods, often coinciding with a sharp increase in protein intake.8 Furthermore, 
previous studies suggested that certain groups of children may be extra sensitive to potential adverse 
effect of high protein intake in early life, for example those who are genetically predisposed to obesity 
or children who experienced catch-up growth in early childhood.2, 9
Although several studies showed that high protein intake in early childhood is associated with 
a higher body mass index (BMI) in later childhood,1, 2, 10 most of these studies did not distinguish 
between body fat and lean mass. Because variation in fat-free mass is an important source of vari-
ability in BMI in infants and children, BMI is considered to be of limited use to measure childhood 
adiposity.11 Therefore, we studied the associations between protein intake at the age of 1 year and 
BMI, fat mass index, and fat-free mass index at the age of 6 years. Furthermore, we evaluated these 
associations in a subgroup of the children for protein intake at the age of 2 years; and we examined 
whether the associations differed by children’s sex, ethnicity, genetic risk score for BMI, birth weight, 
or catch-up growth or by protein source.
subjects And methods
subjects and study design
This study was embedded in the Generation R Study, a population-based prospective cohort study 
from fetal life onward in Rotterdam, the Netherlands.12 Pregnant women were enrolled between 2001 
and 2005 and 7,893 children were available for follow-up studies in early childhood. A questionnaire 
on infant diet was introduced from 2003 onwards, and was sent to 5,088 mothers who provided 
consent for follow-up and had sufficient mastery of the Dutch language (Figure 4.3.1). Complete 
dietary data was available for 3,629 children,13, 14 of whom 2,911 visited the research center at the age 
of 6 years for body composition measurements (Figure 4.3.1). The study was conducted according to 
the Declaration of Helsinki, approved by the Medical Ethics Committee of Erasmus Medical Center, 
Rotterdam, and parents of the children provided written informed consent.
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dietary assessment
Dietary intake was assessed at a median age of 12.9 months (95% range 12.2-18.9), with a semi-
quantitative food-frequency questionnaire (FFQ) consisting of 211 food items and covering the past 
month.13 On the basis of standardized portion sizes and the Dutch Food Composition Table 2006,15 
food frequencies were converted into energy and macronutrient intakes. Protein intake was further 
divided into protein from animal food sources (e.g., meat, fi sh, eggs, and dairy) and from plant 
food sources (e.g., grains, legumes, and soy). Th e FFQ was evaluated against three 24h-recalls in a 
representative sample of 32 Dutch children with a median age of 14 months (95% range 6 to 20) living 
in Rotterdam.13, 14 To evaluate the agreement of the FFQ relative to these 24h-recalls, an intraclass 
correlation coeffi  cient was computed, which was 0.74 for total protein intake.13, 14 An additional FFQ 
around the age of 2 years was implemented in a subgroup of 899 Dutch children.14 Th is questionnaire 
was completed for 844 children (94%) at a median age of 24.9 months (95% range 24.3-27.6),14 of 
 
n= 1,459 excluded due to missing 
information on FFQ (n=1,438) or 
invalid data on FFQ (n=21) 
 
 Children with dietary data at 1 y 
n= 3,629 
 
n= 171 excluded due to loss to 
follow-up (n=137), withdrawal of 
consent (n=34) 
 Children available for follow-up 
at age 6 y 
 n= 3,458 
  
 Children of mothers who received 
an FFQ at 1 y  
n= 5,088 
  
Children available for follow-up 
in early childhood 
n= 7,893 
  
n= 2,805 excluded due to no 
implementation of FFQ at 1 y 
n= 547 excluded due to no visit to 
the research centre (n=474), no 
DXA measurements (n=73) 
Children with body composition 
data available at age 6 y 
n= 2,911 
 
figure 4.3.1. Flowchart: Population for analysis
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whom 698 had body composition measurements taken at the age of 6 years. In total, 649 children had 
dietary data at both 1 and 2 years and body composition at 6 years available.
body composition assessments
Children’s anthropometrics and body composition were measured at a median age of 5.9 years 
(95% range 5.6 to 6.6) by well-trained staff in our research center.12 Height was determined with a 
Harpenden stadiometer (Holtain Limited, Dyfed, U.K.) and weight was measured using a mechanical 
personal scale (SECA, Almere, the Netherlands). Total and regional body fat, lean, and bone mass 
were measured with a dual-energy X-ray absorptiometry (DXA) scanner (iDXA, GE-Lunar, 2008, 
Madison, WI, USA), using enCORE software version 13.6.
We calculated body mass index (BMI) [weight (kg) /height (m)2], fat mass index (FMI) [fat mass 
(kg) /height (m)2], and fat-free mass index (FFMI) [fat-free mass (kg) /height (m)2].16 As secondary 
outcomes we calculated body fat percentage (BF%) [fat mass (kg) /weight (kg)], and android/gynoid 
fat ratio (A/G ratio) [android fat mass (kg) /gynoid fat mass (kg)]. For all outcomes we calculated 
age- and sex-specific SD-scores (SDS) on the basis of the total Generation R study population with 
body composition data at 6 years (n=6,491).12
covariates
We collected information on household income, maternal age, maternal educational level, and 
folic acid supplement use (as a proxy for maternal health-conscious behavior) with questionnaires 
at enrollment in the study.12 Maternal smoking and alcohol consumption during pregnancy were 
assessed using questionnaires in each trimester and both variables were categorized into never; until 
pregnancy was known; or continued during pregnancy. Maternal anthropometrics were measured at 
enrollment in the study at the research center and BMI was calculated.12
Information on child’s sex, gestational age, and birth weight was available from medical records. 
For birth weight, we calculated sex- and gestational age-specific SD-scores.17 Child’s ethnicity (Dutch 
or non-Dutch) was defined as Dutch if both parents were born in the Netherlands.18 For a subgroup of 
1,909 children, we assessed their genetic predisposition to obesity because this may be an effect modi-
fier in the association of protein intake with obesity.19 As described in detail previously,20 cord blood 
samples were genotyped using Illumina Infinium II HumanHap610 Quad Arrays and we calculated a 
weighted genetic risk score for BMI using 29 independent variants.20, 21
We obtained information on breastfeeding in the first 4 months (never, partial, or exclusive) from 
delivery reports and from questionnaires. Timing of introduction of solids in the first year of life was 
obtained from a questionnaire administered at the child’s age of 1 year. Children’s carbohydrate and 
fat intake were measured using the previously mentioned FFQs. A diet score for preschool children 
was used as measure of overall diet quality and was calculated using data obtained with the FFQs.14 
Information on doctor-diagnosed food allergies was obtained with questionnaires at the child’s ages 
of 6 and 12 months. Children’s height and weight were measured at several time points between birth 
and the age of 4 years during routine visits at community health centres,12 and sex- and age-specific 
height, weight, and BMI SD-scores were calculated.22 For the current analyses, we used BMI at the 
age of 12 months and catch-up growth in the first year of life, defined as a weight change in SD scores 
greater than 0.67 between the age of 1 and 12 months.23 Serum insulin levels at age 6 years, which we 
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examined as possible mediator,24 were available for 1,966 children. Non-blood samples were obtained 
at the research center and serum concentrations of insulin were measured with enzymatic methods 
(Cobas 8000, Roche, Almere, the Netherlands).25 Screen time (time spent watching television or using 
a computer), as a proxy for sedentary behavior, and participation in sports (yes/no), as a proxy for 
physical activity, were assessed with a questionnaire at 6 years.
statistical analysis
Because we were interested in the effect of protein independent of its energy content, we adjusted 
dietary intake of protein and the other macronutrients for total energy intake using the nutrient 
residual method.26 For interpretability, predicted protein intake at mean energy intake of our study 
population (1310 kcal/d) was added to the residuals as a constant.
Using natural cubic splines with three knots, we found no indication for non-linear associations 
between protein intake at 1 year and body composition outcomes at 6 years (p>0.1). Therefore, we 
used linear regression models to examine the associations of total, animal, and vegetable protein 
intake with body composition outcomes (BMI, FMI, and FFMI). Because a previous study suggested 
specific associations for dairy protein,8 we performed post hoc analyses in which we further separated 
animal protein into energy-adjusted protein from dairy versus non-dairy sources. Basic models 
included energy-adjusted total protein intake, child’s sex, total energy intake, and age at outcome 
measurement (model 1). For analyses with protein from different sources, total protein intake was 
replaced by energy-adjusted animal protein intake and energy-adjusted vegetable protein, i.e., animal 
and vegetable protein were adjusted for each other. Multivariable models were further adjusted for 
household income; maternal age, education, BMI, and smoking during pregnancy; and for child’s 
ethnicity, birth weight SD-score, breastfeeding, total fat intake, diet quality score, screen time, and 
participation in sports (model 2). The covariates in model 2 were selected on the basis of theory or 
previous literature and were included if they resulted in a change of ≥10% in effect estimates when 
entered individually in model 1. The following covariates were considered, but were not included as 
they did not fulfill this criterion: maternal parity, folic acid supplement use during pregnancy, alcohol 
consumption during pregnancy, child’s timing of introduction of solids, and child’s food allergies. The 
final model was additionally adjusted for child BMI-SDS at 1 year of age to evaluate whether protein 
intake at age 1 year predicted body composition at age 6 years independent of baseline BMI (model 
3).
On the basis of previously published literature, we assessed whether the associations differed by 
sex,24, 27 ethnicity,28 birth weight,29 genetic risk score for BMI,19 catch-up growth,29 or age at dietary 
assessment.8 To examine this, we examined the statistical interaction by adding the product term of 
total protein intake with the potential effect modifier to model 2. Interactions with age and sex were 
evaluated in models with body composition unadjusted for age and sex, respectively.
We performed several sensitivity analyses. Firstly, because the FFQ was developed for Dutch chil-
dren,13 we repeated our analyses restricted to children with a Dutch ethnic background. Secondly, to 
test whether it mattered if protein was consumed at the expense of fat or carbohydrate, we performed 
macronutrient substitution analyses in which we replaced total fat intake by carbohydrate intake, 
or by saturated, monounsaturated, and polyunsaturated fat intake. Thirdly, to examine whether as-
sociations were mediated by differences in insulin levels,24 we additionally adjusted the multivariable 
4.3 Protein intake & body composition
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models for blood insulin levels at 6 years. Fourthly, we examined the direct effect and confounding ef-
fect of catch-up growth in the first year of life by adding this variable to model 2. Finally, we examined 
associations of protein intake at 2 years with body composition at 6 years in the subgroup of children 
(n=698) who had dietary data at this age, using the same models as for protein at 1 year.
To reduce potential bias associated with missing data, we imputed missing values of covariates 
(n=10 imputations),30 according to the Fully Conditional Specification method (predictive mean 
matching) and assuming no monotone missing pattern (Supplementary Table 4.3.1). Analyses were 
performed in each of ten imputed datasets separately and results were pooled. Because we observed 
similar effect estimates in the original and imputed datasets, we present pooled estimates from the 
imputed datasets. Statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, 
NY, USA) and R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
results
subject characteristics
Characteristics of the children and their mothers are presented in Table 4.3.1, for the whole group 
as well as for boys and girls separately. At the age of 1 year, mean (± SD) daily protein intake of the 
children was 41.2 gram (± 12.9), which corresponds to 12.9% of their total energy intake. Although 
this amount is higher than recommended for this age group,31 it is similar to protein intake observed 
in other Western pediatric populations.32, 33 Mean animal protein intake was 8.1 E% (± 2.4) and mean 
vegetable protein intake 4.7 E% (± 1.4). Boys had a higher absolute protein and energy intake than 
girls, but relative protein intake was the same for boys and girls (12.9 E%). At the age of 6 years, boys 
were taller and heavier than girls. Mean BMI was similar, but girls had a higher mean FMI and a lower 
mean FFMI than boys (Table 4.3.1). Subject characteristics before and after multiple imputation are 
presented in Supplementary Table 4.3.2.
table 4.3.1. Subject characteristics1
All
(n=2,911)
boys
(n=1,422)
girls
(n=1,489)
p-value2
Parental characteristics
Maternal age (y) 31.9 (21.7-39.7) 31.8 (21.7-39.9) 31.8 (21.7-39.7) 0.77
Maternal BMI at enrollment (kg/m2) 23.7 (18.9-35.2) 23.4 (18.7-35.2) 23.6 (19.0-36.0) 0.34
Higher maternal education (%) 58.4 60.0 57.3 0.30
High household income (%) 66.9 66.4 67.7 0.40
Smoking during pregnancy (%) 0.06
Never 77.9 78.5 78.0
Until pregnancy was known 10.1 8.7 11.2
Continued 12.0 12.8 10.8
infant characteristics
Girls (%) 51.2 - - -
Dutch ethnicity (%) 68.9 69.4 68.4 0.54
Gestational age at birth (wk) 40.0 (1.7) 40.0 (1.8) 40.1 (1.7) 0.40
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table 4.3.1. Subject characteristics1 (continued)
All
(n=2,911)
boys
(n=1,422)
girls
(n=1,489)
p-value2
Birth weight (g) 3452 (568) 3521 (577) 3387 (553) <0.001
Breastfeeding in the first 4 months (%) 0.92
Exclusive 30.4 30.7 30.1
Partial 60.1 59.9 60.2
Never 9.5 9.4 9.7
child characteristics at 1 year
Body mass index (kg/m2) 17.4 (1.6) 17.6 (1.4) 17.2 (1.3) <0.001
Catch-up growth first year (%) 21.4 22.9 20.0 0.009
Age at dietary measurement (mo) 12.9 (12.2-19.0) 12.9 (12.2-19.1) 12.9 (12.2-18.8) 0.87
Total energy intake (kcal/d) 1265 (676-2207) 1315 (691-2205) 1222 (651-2232) <0.001
Diet quality score3 4.2 (1.3) 4.2 (1.3) 4.1 (1.3) 0.04
Protein intake (g/d)
Total protein 41.8 (12.7) 42.4 (13.3) 40.0 (12.4) <0.001
Animal protein 26.3 (10.2) 26.3 (10.6) 25.1 (10.0) 0.006
Dairy protein4 18.5 (8.3) 18.7 (8.1) 17.6 (8.4) 0.22
Non-dairy animal protein 7.7 (4.7) 7.5 (6.1) 7.3 (5.3) 0.008
Vegetable protein 15.0 (5.6) 15.5 (5.5) 14.4 (5.7) 0.004
Macronutrient composition of the diet
Total protein intake (E%) 12.9 (2.4) 12.9 (2.4) 12.9 (2.4) 0.94
Total fat intake (E%) 28.6 (5.6) 28.6 (5.6) 28.6 (5.6) 0.87
Total carbohydrate intake (E%) 58.4 (6.0) 58.4 (5.9) 58.4 (6.0) 0.95
child characteristics at 6 year visit
Age (y) 5.9 (5.7-6.6) 5.9 (5.7-6.6) 5.9 (5.7-6.6) 0.60
Screen time (h/d) 1.2 (0.3-4.4) 1.3 (0.2-4.5) 1.2 (0.2-4.3) <0.001
Participation in sports (%) 44.3 43.0 45.6 0.15
Height (cm) 118.2 (5.2) 118.5 (5.1) 117.9 (5.2) 0.002
Weight (kg) 22.4 (3.4) 22.5 (3.4) 21.7 (3.4) 0.15
Body mass index (kg/m2) 16.0 (1.6) 16.0 (1.6) 16.0 (1.7) 0.75
Fat mass index (kg/m2) 3.8 (1.2) 3.5 (1.1) 4.2 (1.2) <0.001
Fat-free mass index (kg/m2) 11.9 (0.9) 12.2 (0.8) 11.6 (0.8) <0.001
Body fat percentage (%) 24.2 (16.2-36.4) 21.1 (15.7-33.5) 25.6 (18.8-37.5) <0.001
Android/gynoid fat ratio 0.24 (0.06) 0.24 (0.05) 0.25 (0.06) 0.09
Overweight or obese (%)5 13.5 10.9 16.1 <0.001
1 Values are percentages for categorical variables, means (SD) for continuous variables with a normal 
distribution, or medians (95% range) for continuous variables with a skewed distribution.
2 p-values for differences in means between boys and girls, assessed using independent t-tests for continu-
ous variables with a normal distribution, Mann Whitney U tests for continuous variables with a skewed 
distribution, and chi-square tests for categorical variables.
3 Diet quality score for preschool children with a theoretical range of 0 to 10 (Voortman et al., 2015)
4 Protein from dairy products including dairy-based infant formulas (mean 6.9 g/d) and breast milk 
(mean 0.6 g/d).
5 According to international age- and sex-specific cut-offs for BMI (Cole et al., 2000)
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Protein intake and body composition
Associations between protein intake at age 1 year and body composition at 6 years are presented in 
Table 4.3.2. In confounder-adjusted models (model 2), a 10 g/d higher total protein intake at 1 year 
was associated with a 0.05 SD (95%CI 0.00, 0.09) higher BMI and a 0.06 SD (95%CI 0.01, 0.11) higher 
FMI at 6 years, but not with FFMI (-0.01 SD (95%CI -0.06, 0.05)). The positive association with 
FMI slightly attenuated but remained statistically significant after additional adjustment for baseline 
BMI (model 3). The association of protein intake with BF% was similar to that observed for FMI, 
but protein intake was not associated with A/G fat ratio (Supplementary Table 4.3.3). Associations 
between protein intake and FMI were stronger for animal protein than for vegetable protein intake 
(Table 4.3.2). Post hoc analyses in which we further separated animal protein into protein from dairy 
versus non-dairy sources showed that associations with FMI were similar for protein from dairy (0.04 
SD (95%CI 0.00, 0.08) versus protein from meat, fish, and eggs (0.05 SD (95%CI 0.00, 0.10).
table 4.3.2. Associations of protein intake at the age of 1 year with body composition at the 
age of 6 years (n=2,911).
bmi
(sds)
fmi
(sds)
ffmi
(sds)
Total protein intake (10 g/d)
 Model 1 (crude) 0.06 (0.01, 0.10) 0.06 (0.02, 0.10) 0.02 (-0.03, 0.06)
 Model 2 (confounders) 0.05 (0.01, 0.09) 0.06 (0.02, 0.09) 0.02 (-0.03, 0.06)
 Model 3 (baseline BMI) 0.03 (-0.01, 0.06) 0.05 (0.00, 0.09) -0.01 (-0.05, 0.03)
Animal protein intake (10 g/d)
 Model 1 (crude) 0.05 (0.01, 0.09) 0.06 (0.01, 0.10) 0.01 (-0.03, 0.06)
 Model 2 (confounders) 0.06 (0.01, 0.10) 0.05 (0.01, 0.09) 0.02 (-0.03, 0.07)
 Model 3 (baseline BMI) 0.02 (-0.02, 0.06) 0.05 (0.00, 0.10) -0.02 (-0.06, 0.03)
Vegetable protein intake (10 g/d)
 Model 1 (crude) 0.04 (-0.04, 0.11) 0.02 (-0.06, 0.09) 0.04 (-0.04, 0.12)
 Model 2 (confounders) 0.01 (-0.07, 0.08) -0.01 (-0.08, 0.07) 0.00 (-0.09, 0.08)
 Model 3 (baseline BMI) 0.02 (-0.05, 0.09) 0.00 (-0.07, 0.07) 0.01 (-0.07, 0.09)
Values are based on multivariable linear regression models and reflect differences and 95% confidence 
intervals in body composition outcomes (age- and sex-specific SD scores) per 10 g/d higher energy-adjusted 
protein intake. In our population, a 0.05 SD higher BMI corresponds to an approximately 0.1 kg/m2 
higher BMI (Table 1). Bold values indicate statistically significant effect estimates.
Model 1 is adjusted for child sex, total energy intake at 1 y, and age at body composition measurement. 
Models with animal protein intake (energy-adjusted) are additionally adjusted for vegetable protein 
(energy-adjusted) intake and vice versa.
Model 2 is additionally adjusted for maternal age, pre-pregnancy BMI, educational level, and smoking 
during pregnancy; household income; and child’s ethnicity, birth weight SD-score, breastfeeding in the first 
4 months of life, age at dietary assessment, total fat intake at 1 y, diet quality score at 1 y, screen time at 6 
y, and participation in sports at 6 y.
Model 3 is additionally adjusted for BMI at the age of 1 year
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index.
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stratified analyses
There were significant interactions between protein intake and sex for FMI (p=0.03), but not for BMI 
(p=0.15) or FFMI (p=0.24). After stratifying our analyses for sex, we observed that the association of 
protein intake with FMI was similar in direction, but slightly stronger in girls than in boys (Supple-
mentary Table 4.3.4). We also observed a significant interaction of protein intake with catch-up 
growth in the first year on BMI and FMI at 6 years (p=0.002 and p<0.001, respectively). Results of 
stratified analyses showed that the positive associations between dietary protein and body fat were 
stronger among children who had experienced catch-up growth in the first year of life than among 
those without catch-up growth (Table 4.3.4 and Supplementary Table 4.3.3), whereas protein intake 
was similar in both groups (12.9 E% vs. 13.1 E%). Catch-up growth itself was associated with both fat 
and fat-free mass: after adjustment for confounders (model 2), children who experienced catch-up 
growth had a 0.22 (95%CI 0.13, 0.31) higher FFMI and a 0.26 (95% 0.19, 0.34) higher FMI than chil-
dren who had not had catch-up growth. We observed no interactions of protein intake with ethnicity, 
age at dietary measurement, birth weight, or genetic risk score for BMI on any of the outcomes (p for 
interaction>0.05).
table 4.3.3. Associations of protein intake at the age of 1 year with body composition at the 
age of 6 years, in children with or without catch-up growth in the first year of life (n=2,911).
total protein intake (10 g/d)
bmi
(sds)
fmi
(sds)
ffmi
(sds)
No catch-up growth (n=2,287)
 Model 1 (crude) 0.02 (-0.02, 0.07) 0.02 (-0.02, 0.07) 0.00 (-0.06, 0.05)
 Model 2 (confounders) 0.02 (-0.02, 0.06) 0.02 (-0.02, 0.06) -0.01 (-0.06, 0.05)
 Model 3 (baseline BMI) 0.00 (-0.04, 0.04) 0.01 (-0.03, 0.05) -0.02 (-0.07, 0.02)
Catch-up growth (n=624)
 Model 1 (crude) 0.18 (0.06, 0.29) 0.18 (0.07, 0.30) 0.08 (-0.03, 0.20)
 Model 2 (confounders) 0.18 (0.08, 0.29) 0.19 (0.08, 0.30) 0.09 (-0.02, 0.20)
 Model 3 (baseline BMI) 0.14 (0.04, 0.23) 0.15 (0.05, 0.26) 0.05 (-0.06, 0.15)
Values are based on multivariable linear regression models and reflect differences and 95% confidence 
intervals in body composition outcomes (age- and sex-specific SD scores) per 10 g/d higher energy-adjusted 
protein intake. In our population, a 0.18 SD higher BMI corresponds to an approximately 0.3 kg/m2 
higher BMI (Table 1). Bold values indicate statistically significant effect estimates. P-values for interaction 
between protein intake and catch-up growth were p=0.002 for BMI, p<0.001 for FMI, and p=0.17 for 
FFMI.
Model 1 is adjusted for child sex, total energy intake at 1 y and age at body composition measurement; 
models with animal protein intake are additionally adjusted for vegetable protein intake and vice versa.
Model 2 is additionally adjusted for maternal age, pre-pregnancy BMI, educational level, and smoking 
during pregnancy; household income; and child’s ethnicity, birth weight SD-score, breastfeeding in the first 
4 months of life, age at dietary assessment, total fat intake at 1 y, diet quality score at 1 y, screen time at 6 
y, and participation in sports at 6 y.
Model 3 is additionally adjusted for BMI at the age of 1 y.
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index, SDS, standard 
deviation score.
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sensitivity analyses
We performed several sensitivity analyses, but results remained similar as obtained in the original 
analyses. Analyses restricted to children with a Dutch background revealed similar effect estimates as 
for the whole group (Supplementary Table 4.3.5). Macronutrient substitution models in which we 
replaced total fat intake by either carbohydrate intake or by saturated, monounsaturated and polyun-
saturated fat intake revealed similar effect estimates for protein intake (data not shown). Additional 
adjustment for insulin concentrations at 6 years as potential mediator, or for catch-up growth in the 
first year, did not affect the effect estimates for protein intake on BMI and FMI (data not shown).
Finally, protein intake at age 2 years was slightly higher (13.9 ± 1.9 E%) than at age 1 year,34 but 
among the subgroup with dietary data at both the age of 1 and 2 years (n=649) associations with body 
composition were similar for protein intake at both ages (Supplementary Table 4.3.6).
discussion
Results from this large population-based cohort study suggest that protein intake in early childhood 
is associated with a higher fat mass index, but not with fat-free mass index at school age. These as-
sociations were stronger for protein from animal than from vegetable sources, but did not differ by 
food source of animal protein (i.e., dairy versus non-dairy). Furthermore, associations were slightly 
larger in girls than in boys, and were stronger among children who had experienced catch-up growth 
in the first year of life.
comparison with previous studies
A number of observational studies showed that a higher protein intake in the complementary feeding 
period is associated with a higher BMI in later childhood.1, 35-37 The causal effect of a higher protein 
intake in infancy on a higher BMI in later childhood was also confirmed in a large randomized trial 
in which children received high-protein or lower-protein infant formulas in their first year of life.2 In 
our study, we also found that a higher protein intake at 1 year of age is associated with a higher BMI, 
but we additionally show that it is specifically associated with a higher fat mass, but not with fat-free 
mass index.
To our knowledge, only four previous studies examined protein intake in early life in relation 
to later measures of body fat.1, 3, 38, 39 Mean protein intake in these populations ranged from 13 to 15 
E%, which is close to the 12.9 E% in our study population. In the first study, Rolland-Cachera et al. 
reported that, among 112 French children, protein intake at the age of 2 years was associated with 
a higher BMI and higher subscapular skinfold thickness at the age of 8 years.1 In the second study, 
performed by Hoppe et al., protein intake at 9 months of age was not associated with BF% (assessed 
with DXA) at the age of 10 years in 142 Danish children.38 The absence of an association in this study 
might be explained by the earlier age at which protein intake was measured, as results from the third 
study, performed by Günther et al., suggests that the effect of protein intake on obesity risk may have a 
specific risk window, i.e., around the age of 12 months.8 In this study in 203 German children, higher 
protein intake at the age of 12 months, but not at 6 or 18-24 months, was associated with a higher 
BF% (calculated from skinfold thicknesses) at the age of 7 years.3 However, this relation was no longer 
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present when the children reached young adulthood (18-25 years).40 In the fourth study, neither 
protein intake at 6 months nor at 12 months was associated with fat mass assessed with DXA at the 
age of 4 years in 556 British children.39 In a smaller subgroup of our study population, we observed 
no differences in associations for protein intake at 1 year or 2 years and no interaction between age of 
dietary assessment and protein intake on child body composition. Thus, our results do not confirm 
that the period around the age of 1 year poses a specific risk window for high protein intake.
We observed no associations between protein intake in early childhood and FFMI at age 6 years. 
This is in contrast to findings in adults or older children, in whom several studies reported associations 
between high protein intake and higher FFMI or sparing of FFMI loss during weight loss.41-43 To our 
knowledge, only one previous study has examined the association of protein intake at preschool age 
with measures of later fat-free mass. In this follow-up of 159 children participating in the previously 
mentioned study by Günther et al., Assmann et al. reported that protein intake in early childhood was 
no longer associated with measures of body fat and was not associated with FFMI in young adulthood 
(18-25 years).40 However, higher protein intake between the ages of 9 and 15 years was associated with 
a higher FFMI in young adulthood.40 This association between protein intake and FFMI is in line 
with studies in adults.44-46 Our study further supports the existing literature that suggests that higher 
protein intake in early childhood may have very different effects on body composition than protein 
intake in later life.1
Potential mechanisms
In adults and older children, a higher protein intake seems to increase weight loss while sparing 
fat-free mass.43 A potential underlying mechanism is a higher satiety from high-protein diets, via 
increased release of satiety hormones and consequently a lower energy intake.4, 5 However, a high pro-
tein intake in adults has also been associated with weight loss independent of energy intake, possibly 
because of the high thermic effect of protein resulting in a slightly increased energy expenditure.4
In early childhood, different mechanisms may play a role. The early protein hypothesis postulates 
that high protein in infancy triggers hormonal responses that may cause rapid weight gain in early life 
and persistent changes in later obesity risk.1, 47, 48 Protein intake stimulates the secretion of insulin and 
insulin-like growth factor-1 (IGF-1),6, 24 which may in turn increase growth and adipogenesis7, 49 and 
have a long-term effect on body fat.50 Unfortunately, in our study we did not measure IGF-1 or other 
growth hormone levels at the age of 1 year. We previously observed that protein intake was positively 
associated with insulin concentrations at age 6 years,24 but adjustment for insulin levels had no effect 
on the association between protein intake and FMI in our population, suggesting that insulin at 6 
years does not explain this association.
Associations between protein intake and FMI were stronger for animal than for vegetable protein 
intake. In line with this, a previous study in 2.5-year-old children found that dietary protein from 
animal, but not from vegetable sources, was associated with higher IGF-1 concentrations.7 To our 
knowledge, only one previous study examined protein from different sources in early childhood in 
relation body composition. In line with our results, they found that animal but not vegetable protein 
intake was associated with a higher body fat.8 More specifically, they observed that intake of dairy 
protein, but not meat protein, was associated with a higher BMI and body fat at the age of 7 years.8 
4.3 Protein intake & body composition
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Contrary to these results, additional analyses in our study showed that associations were similar for 
protein intake from dairy sources and from non-dairy animal sources.
It has been previously suggested that certain subgroups may be extra sensitive to the adverse effect 
of high protein intake in early life.2 In our population we observed slightly stronger associations in 
girls than in boys. This may be explained by differences in the IGF-1 axis response to high protein 
intake, which a previous study suggested to be stronger in girls than in boys.27 In line with this, we 
have previously shown associations of protein intake with insulin levels in girls, but not in boys.24 
The observed sex differences may also be related to a difference in timing of adiposity rebound (AR) 
between boys and girls, or to a difference in peak BMI at AR. This period, during which a child’s BMI 
curve starts to rise again after a period of decrease during early childhood, usually occurs between 5 
and 7 years of age,51 corresponding to the age of outcome measurements in our study (6 years). An 
early AR and a higher BMI at AR are associated with an increased risk of obesity.51 A higher intake of 
protein in early childhood has been linked to an earlier AR,1 although not consistently;52 and with a 
higher BMI at AR in girls, but not in boys.52
Our results suggest that growth patterns in infancy may also influence the relation between pro-
tein intake and later body composition, as we observed an interaction between catch-up growth in 
the first year of life –but not with birth weight– and protein intake at 1 year on later BMI and FMI. 
Catch-up growth in early childhood is an important risk factor for later obesity,29, 53, 54 and our results 
suggest that especially children who experienced catch-up growth in the first year of life may have a 
higher risk of obesity with higher protein consumption. These children may already have a ‘thrifty’ 
energy metabolism leading to increased fat accumulation,9 which may be further exacerbated by high 
protein intake. Previous studies also suggested that the effect of protein intake on obesity may be 
stronger in children who are at genetic risk to become obese,19 but we did not find evidence for this 
interaction effect in our population. However, our study may have been underpowered to identify 
such an interaction. Future studies should further examine which children are at increased risk for 
adverse effects of high protein intake in early life.
strengths and limitations
Main strengths of this study are its prospective population-based cohort design, the availability of 
information on many child and parental covariates, and the detailed measurements of body composi-
tion. We not only measured height and weight to calculate BMI, but we also measured body fat and 
fat-free mass with DXA. Because a given BMI can encompass a wide range of fat mass in childhood, 
BMI is considered to be of limited use to measure adiposity in children.11 Although the effect esti-
mates were relatively small and probably without direct consequences for individual children, the 
effects may be relevant on a population level in predicting later obesity.55
Unfortunately, not all children participating in the study were included in the current analyses, 
mainly because of missing dietary data. On average, mothers who filled out the FFQ had a higher 
educational level, a higher household income, and a healthier lifestyle than mothers who did not.14 
For missing values of covariates, we used multiple imputation procedures.30
Strengths of the dietary assessment in our study are that we used an extensive FFQ which was 
developed specifically for our population of young children, and that we calculated not only total 
dietary protein, but also protein from different food sources. A limitation is that there was no dietary 
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data available around the age of 6 years to examine possible confounding or effect modification by 
diet later in childhood. Another limitation of our dietary assessment is that food intake reported 
using an FFQ is subject to substantial measurement error.56 By adjusting for total energy intake, we 
aimed to reduce this measurement error.56, 57 However, when keeping energy intake constant, a higher 
protein intake involves a lower intake of fat and/or carbohydrate. Adjusting our models for either 
total fat, fat subtypes, or carbohydrate intake in macronutrient substitution models resulted in similar 
effect estimates for protein intake, suggesting that for body composition it makes no difference if 
dietary protein is replaced by carbohydrate or by fat in early childhood.
implications
Previously, a large randomized controlled trial showed that a higher protein intake in the first year 
of life leads to a higher BMI in later childhood.2 In our study, we observed that this higher BMI in 
relation to protein intake is specifically explained by a higher fat mass, and not a higher fat-free 
mass. Therefore, results from our study and previous studies combined,1-3 suggest that high protein 
intake in early childhood increases the risk of adiposity. A reduction in protein intake in infancy 
and early childhood may thus be advised to prevent obesity, for example by lowering the amounts of 
protein in infant formula and toddler foods. However, a too low protein intake may restrict growth. 
Therefore future studies should explore what the optimal range of protein intake is for infants and 
young children for optimal growth58 and other aspects of later health.59 Furthermore, future studies 
should explore whether intake of different types of protein or certain amino acids are specifically 
associated with increased adiposity, for example by studying the endocrinal response to different 
protein subtypes. Results from these studies can be used to further optimize dietary recommenda-
tions regarding protein intake in early childhood.
conclusions
In this prospective cohort study, high protein intake in early childhood is associated with higher fat 
mass, but not fat-free mass index in later childhood. This association was stronger for animal protein 
than for vegetable protein, but did not differ for dairy versus non-dairy animal protein. Further 
research should explore the underlying mechanisms and study the optimal amount of protein intake 
needed in infancy and early childhood for optimal growth and body composition.
4.3 Protein intake & body composition
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suPPlementAry mAteriAl
supplementary table 4.3.1. Details of the multiple imputation procedure
Software SPSS version 21 for Windows
Imputation method and key settings Fully conditional specification (Markov chain Monte Carlo method); 
maximum iterations: 20
Number of imputed data sets created 10
Variables included as both predictor variable 
as a variable to be imputed
Maternal age, parity, educational level, and marital status at 
enrollment, gestational age at fatty acid measurement, ethnicity, 
pre-pregnancy BMI, alcohol consumption during pregnancy, smoking 
during pregnancy, folic acid supplement use during early pregnancy, 
energy intake, maternal diet quality score, gestational weight gain, 
maternal BMI at 6y follow-up, maternal educational level and 
employment status at 6 y follow-up; paternal education at enrollment 
and follow-up; household income at enrollment and at follow-up; and 
child’s gestational age at birth, birthweight, birthweight Z-score, sex, 
breastfeeding, food allergies, timing of introduction of solid foods, age 
at follow-up, participation in sports, screen time
Variables included as predictors of missing 
data only
Maternal height and weight pre-pregnancy, in early, mid, and late 
pregnancy, and 6 years after delivery, maternal smoking and alcohol use 
in early, mid, and late pregnancy, serum folate levels in early pregnancy, 
gestational age at intake; paternal age, smoking, employment status, 
and ethnicity; child’s diet quality score, dietary intake of calories, 
total protein, animal protein, vegetable protein, total fat, saturated 
fat, monounsaturated fat, polyunsaturated fat, carbohydrates; height, 
weight and BMI at the ages of 5, 12, 15, 20, 25, 32, 40, and 50 
months; children’s height, weight, BMI, fat mass, fat-free mass, insulin 
levels, C-peptide levels, total, HDL and LDL cholesterol levels, 
triacylglycerol, systolic and diastolic blood pressure, TV watching, 
playing outside, and computer use at the age of 6 years.
Treatment of not normally distributed 
variables
Predictive mean matching
Treatment of binary or categorical variables Logistic regression and multinomial models
Population All children with complete information on dietary intake at 1 year and 
body composition at 6 years (n=2,911)
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supplementary table 4.3.2. Subject characteristics before and after imputation
unimputed imputed
Parental characteristics
Maternal age (y) 31.9 (21.7-39.7) 31.9 (21.7-39.7)
Missing 0.0% -
Maternal BMI at enrollment (kg/m2) 23.5 (18.9-35.6) 23.7 (18.9-35.2)
Missing 8.4% -
Higher maternal education (%) 59.3 58.4
Missing 3.1% -
High household income (%) 66.1 66.9
Missing 15.1% -
Smoking during pregnancy (valid %)
Never 78.1 77.9
Until pregnancy was known 10.2 10.1
Continued 11.7 12.0
Missing 9.8% -
infant characteristics
Girls (%) 51.2 51.2
Missing 0.0% -
Dutch ethnicity (%) 68.9 68.9
Missing 0.4% -
Gestational age at birth (wk) 39.9 (1.8) 40.0 (1.7)
Missing <0.1% -
Birth weight (g) 3452 (567) 3452 (568)
Missing <0.1% -
Breastfeeding in the first 4 months (valid %)
Exclusive 29.2 30.4
Partial 61.5 60.1
Never 9.2 9.5
Missing 10.1% -
child characteristics at 1 year
Body mass index (kg/m2) 17.3 (1.5) 17.4 (1.6)
Missing 16.1% -
Catch-up growth first year (%) 20.9 21.4
Missing 17.8% -
Age at dietary measurement (mo) 12.9 (12.2-19.0) not imputed
Total energy intake (kcal/d) 1265 (676-2207) not imputed
Diet quality score3 4.2 (1.3) not imputed
Protein intake (g/d)
Total protein 41.8 (12.7) not imputed
Animal protein 26.3 (10.2) not imputed
4.3 Protein intake & body composition
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supplementary table 4.3.2. Subject characteristics before and after imputation (continued)
unimputed imputed
Dairy protein4 18.5 (8.3) not imputed
Non-dairy animal protein 7.7 (4.7) not imputed
Vegetable protein 15.0 (5.6) not imputed
Macronutrient composition of the diet
Total protein intake (E%) 12.9 (2.4) not imputed
Total fat intake (E%) 28.6 (5.6) not imputed
Total carbohydrate intake (E%) 58.4 (6.0) not imputed
child characteristics at 6 year visit
Age (y) 5.9 (5.7-6.6) not imputed
Screen time (h/d) 1.2 (0.3-4.4) 1.2 (0.3-4.4)
Missing 18.3% -
Participation in sports (%) 44.9 44.1
Missing 7.3% -
Height (cm) 118.2 (5.2) not imputed
Weight (kg) 22.4 (3.4) not imputed
Body mass index (kg/m2) 16.0 (1.6) not imputed
Fat mass index (kg/m2) 3.8 (1.2) not imputed
Fat-free mass index (kg/m2) 11.9 (0.9) not imputed
Body fat percentage (%) 24.2 (16.2-36.4) not imputed
Android/gynoid fat ratio 0.24 (0.06) not imputed
Overweight or obese (%)5 13.5 not imputed
1 Values are percentages for categorical variables, means (SD) for continuous variables with a normal 
distribution, or medians (95% range) for continuous variables with a skewed distribution.
2 p-values for differences in means between boys and girls, assessed using independent t-tests for continu-
ous variables with a normal distribution, Mann Whitney U tests for continuous variables with a skewed 
distribution, and chi-square tests for categorical variables.
3 Diet quality score for preschool children with a theoretical range of 0 to 10 (Voortman et al., 2015)
4 Protein from dairy products including dairy-based infant formulas (mean 6.9 g/d) and breast milk 
(mean 0.6 g/d).
5 According to international age- and sex-specific cut-offs for BMI (Cole et al., 2000)
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supplementary table 4.3.3. Associations of protein intake at the age of 1 year with body fat 
percentage and android/gynoid ratio at the age of 6 years (n=2,911).
total protein intake (10 g/d)
bf%
(sds)
A/g ratio
(sds)
All children (n=2,911)
Model 1 (crude) 0.06 (0.02, 0.11) 0.03 (-0.01, 0.07)
Model 2 (confounders) 0.06 (0.02, 0.10) 0.04 (-0.01, 0.09)
Model 3 (baseline BMI) 0.05 (0.00, 0.10) 0.04 (-0.02, 0.09)
Girls (n=1,489)
Model 1 (crude) 0.10 (0.03, 0.16) 0.05 (-0.01, 0.11)
Model 2 (confounders) 0.09 (0.02, 0.16) 0.06 (-0.02, 0.14)
Model 3 (baseline BMI) 0.08 (0.01, 0.15) 0.06 (-0.02, 0.14)
Boys (n=1,422)
Model 1 (crude) 0.04 (-0.03, 0.10) 0.01 (-0.05, 0.08)
Model 2 (confounders) 0.05 (-0.02, 0.12) 0.02 (-0.06, 0.09)
Model 3 (baseline BMI) 0.03 (-0.04, 0.09) 0.01 (-0.06, 0.09)
No catch-up growth (n=2,287)
Model 1 (crude) 0.03 (-0.02, 0.08) 0.00 (-0.05, 0.04)
Model 2 (confounders) 0.02 (-0.02, 0.07) -0.01 (-0.06, 0.04)
Model 3 (baseline BMI) 0.01 (-0.03, 0.06) -0.01 (-0.06, 0.03)
Catch-up growth (n=624)
Model 1 (crude) 0.17 (0.06, 0.29) 0.16 (0.04, 0.27)
Model 2 (confounders) 0.17 (0.06, 0.28) 0.16 (0.04, 0.27)
Model 3 (baseline BMI) 0.15 (0.04, 0.26) 0.14 (0.02, 0.26)
Values are based on multivariable linear regression models and reflect differences and 95% confidence 
intervals in body composition outcomes (age- and sex-specific SD scores) per 10 g/d higher energy-adjusted 
protein intake. Bold values indicate statistically significant effect estimates.
Model 1 is adjusted for total energy intake at 1 y and age at body composition measurement; models with 
animal protein intake are additionally adjusted for vegetable protein intake and vice versa.
Model 2 is additionally adjusted for maternal age, pre-pregnancy BMI, educational level, and smoking 
during pregnancy; household income; and child’s ethnicity, birth weight SD-score, breastfeeding in the first 
4 months of life, age at dietary assessment, total fat intake at 1 y, diet quality score at 1 y, screen time at 6 
y, and participation in sports at 6 y.
Model 3 is additionally adjusted for BMI at the age of 1 y.
Abbreviations: BF%, body fat percentage; A/G ratio, android/gynoid fat ratio
4.3 Protein intake & body composition
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supplementary table 4.3.4. Associations of protein intake at the age of 1 year with body com-
position at the age of 6 years, stratified by child sex (n=2,911).
total protein intake (10 g/d)
bmi
(sds)
fmi
(sds)
ffmi
(sds)
Girls (n=1,489)
Model 1 (crude) 0.07 (0.01, 0.13) 0.09 (0.03, 0.15) 0.00 (-0.07, 0.07)
Model 2 (confounders) 0.06 (0.00, 0.12) 0.08 (0.02, 0.13) -0.01 (-0.08, 0.05)
Model 3 (baseline BMI) 0.05 (0.00, 0.11) 0.07 (0.02, 0.12) -0.02 (-0.08, 0.04)
Boys (n=1,422)
Model 1 (crude) 0.05 (-0.01, 0.11) 0.04 (-0.02, 0.10) 0.03 (-0.03, 0.20)
Model 2 (confounders) 0.04 (-0.02, 0.11) 0.05 (-0.02, 0.12) 0.02 (-0.06, 0.10)
Model 3 (baseline BMI) 0.01 (-0.06, 0.07) 0.03 (-0.04, 0.09) -0.02 (-0.09, 0.06)
Values are based on multivariable linear regression models and reflect differences and 95% confidence 
intervals in body composition outcomes (age- and sex-specific SD scores) per 10 g/d higher energy-adjusted 
protein intake. Bold values indicate statistically significant effect estimates. P-values for interaction be-
tween protein intake and sex were p=0.15 for BMI, p=0.03 for FMI, and p=0.24 for FFMI.
Model 1 is adjusted for child sex, total energy intake at 1 y and age at body composition measurement; 
models with animal protein intake are additionally adjusted for vegetable protein intake and vice versa.
Model 2 is additionally adjusted for maternal age, pre-pregnancy BMI, educational level, and smoking 
during pregnancy; household income; and child’s ethnicity, birth weight SD-score, breastfeeding in the first 
4 months of life, age at dietary assessment, total fat intake at 1 y, diet quality score at 1 y, screen time at 6 
y, and participation in sports at 6 y.
Model 3 is additionally adjusted for BMI at the age of 1 y.
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index.
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supplementary table 4.3.5. Associations of protein intake at the age of 1 year with childhood 
body composition at the age of 6 years, in Dutch children only (n=2,006).
total protein intake (10 g/d)
bmi
(sds)
fmi
(sds)
ffmi
(sds)
All children (n=2,006)
Model 1 (crude) 0.08 (0.04, 0.13) 0.06 (0.02, 0.10) 0.08 (0.02, 0.13)
Model 2 (confounders) 0.08 (0.03, 0.14) 0.07 (0.02, 0.12) 0.06 (-0.01, 0.13)
Model 3 (baseline BMI) 0.04 (-0.01, 0.09) 0.04 (-0.01, 0.09) 0.02 (-0.04, 0.08)
Girls (n=1,018)
Model 1 (crude) 0.10 (0.03, 0.16) 0.10 (0.03, 0.16) 0.04 (-0.04, 0.12)
Model 2 (confounders) 0.12 (0.04, 0.20) 0.12 (0.05, 0.20) 0.04 (-0.06, 0.13)
Model 3 (baseline BMI) 0.10 (0.03, 0.17) 0.11 (0.04, 0.18) 0.02 (-0.07, 0.10)
Boys (n=988)
Model 1 (crude) 0.07 (0.01, 0.14) 0.03 (-0.03, 0.08) 0.11 (0.04, 0.19)
Model 2 (confounders) 0.05 (-0.03, 0.12) 0.02 (-0.05, 0.09) 0.08 (-0.01, 0.18)
Model 3 (baseline BMI) -0.01 (-0.08, 0.06) -0.01 (-0.08, 0.05) 0.03 (-0.06, 0.15)
No catch-up growth (n=2,287)
Model 1 (crude) 0.02 (-0.02, 0.07) 0.02 (-0.02, 0.07) 0.00 (-0.05, 0.05)
Model 2 (confounders) 0.02 (-0.04, 0.07) 0.03 (-0.02, 0.08) -0.03 (-0.09, 0.04)
Model 3 (baseline BMI) 0.00 (-0.05, 0.05) 0.02 (-0.03, 0.07) -0.05 (-0.11, 0.01)
Catch-up growth (n=624)
Model 1 (crude) 0.18 (0.06, 0.29) 0.18 (0.06, 0.30) 0.08 (-0.03, 0.20)
Model 2 (confounders) 0.18 (0.05, 0.31) 0.19 (0.06, 0.33) 0.09 (-0.05, 0.22)
Model 3 (baseline BMI) 0.15 (0.03, 0.27) 0.17 (0.04, 0.30) 0.05 (-0.07, 0.17)
Values are based on multivariable linear regression models and reflect differences and 95% confidence 
intervals in body composition outcomes (age- and sex-specific SD scores) per 10 g/d higher energy-adjusted 
protein intake. Bold values indicate statistically significant effect estimates.
Model 1 is adjusted for child sex, total energy intake at 1 y and age at body composition measurement; 
models with animal protein intake are additionally adjusted for vegetable protein intake and vice versa.
Model 2 is additionally adjusted for maternal age, pre-pregnancy BMI, educational level, and smoking 
during pregnancy; household income; and child’s ethnicity, birth weight SD-score, breastfeeding in the first 
4 months of life, age at dietary assessment, total fat intake at 1 y, diet quality score at 1 y, screen time at 6 
y, and participation in sports at 6 y.
Model 3 is additionally adjusted for BMI at the age of 1 y.
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index.
4.3 Protein intake & body composition
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supplementary table 4.3.6. Associations of protein intake at the age of 1 and 2 years with 
childhood body composition at the age of 6 years (n=649).
total protein intake (10 g/d)
bmi
(sds)
fmi
(sds)
ffmi
(sds)
Protein intake at 1 year (n=649)
Model 1 (crude) 0.05 (-0.03, 0.12) -0.01 (-0.08, 0.07) 0.08 (-0.02, 0.18)
Model 2 (confounders) 0.03 (-0.06, 0.13) -0.02 (-0.11, 0.08) 0.07 (-0.04, 0.19)
Model 3 (baseline BMI) 0.00 (-0.09, 0.08) -0.04 (-0.13, 0.04) 0.03 (-0.07, 0.14)
Protein intake at 2 years (n=649)
Model 1 (crude) 0.03 (-0.06, 0.11) -0.03 (-0.11, 0.05) 0.09 (-0.02, 0.20)
Model 2 (confounders) 0.06 (-0.05, 0.16) -0.01 (-0.11, 0.09) 0.10 (-0.02, 0.23)
Model 3 (baseline BMI) -0.02 (-0.11, 0.07) -0.07 (-0.17, 0.02) 0.04 (-0.08, 0.16)
Values are based on multivariable linear regression models and reflect differences and 95% confidence 
intervals in body composition outcomes (age- and sex-specific SD scores) per 10 g/d higher energy-adjusted 
protein intake. Bold values indicate statistically significant effect estimates.
Model 1 is adjusted for total energy intake at age of dietary assessment and for age at body composition 
measurement; models with animal protein intake are additionally adjusted for vegetable protein intake 
and vice versa.
Model 2 is additionally adjusted for maternal age, pre-pregnancy BMI, educational level, and smoking 
during pregnancy; household income; and child’s ethnicity, birth weight SD-score, breastfeeding in the first 
4 months of life, age at dietary assessment, total fat intake at age of dietary assessment, diet quality score at 
age of dietary assessment, screen time at 6 y, and participation in sports at 6 y.
Model 3 is additionally adjusted for BMI at the age of dietary assessment
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index.
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Intake of different types of fatty acids 
in infancy and growth, adiposity, and 
cardiometabolic health up to 6 years of 
age: The Generation R Study
Based on:
Stroobant W*, braun kVe*, Kiefte-de Jong JC, Moll HA, Jaddoe VWV, Brouwer IA, 
Franco OH, Voortman T. Intake of Different Types of Fatty Acids in Infancy Is Not 
Associated with Growth, Adiposity, or Cardiometabolic Health up to 6 Years of Age. 
Journal of Nutrition. 2017;147(3):413-20.
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AbstrAct
Background: Studies in adults indicate that a lower saturated and higher unsaturated fat intake is 
associated with a lower risk for metabolic syndrome and cardiovascular diseases. However, studies 
on fat intake in relation to cardiometabolic health during childhood are scarce. We examined as-
sociations between dietary intake of fatty acids at age 1 year and measures of growth, adiposity and 
cardiometabolic health up to age 6 years.
Methods: This study was performed among 2,927 children participating in the Generation R Study, 
a multiethnic prospective population-based cohort in the Netherlands. We measured children’s total 
fat intake, and intake of saturated (SFA), monounsaturated (MUFA), and polyunsaturated fatty acids 
(PUFA) at their median age of 12.9 months (95%range 12.2-18.9) using a food-frequency question-
naire. We repeatedly measured their height and weight up to age 6 years. At age 6, we measured 
their body fat percentage, diastolic and systolic blood pressure, and serum insulin, triacylglycerol 
and HDL-cholesterol. These outcomes were combined into a cardiometabolic risk factor score. We 
examined associations of fatty acid intake with repeatedly measured height, weight and BMI using 
linear mixed models and with cardiometabolic outcomes using linear regression models, adjusting 
for sociodemographic and lifestyle factors and taking into account macronutrient substitution effects.
Results: In multivariable models, we observed no association of a higher intake of total fat or SFA, 
MUFA, or PUFA with growth, adiposity, or cardiometabolic health when fat was consumed at the 
expense of carbohydrates. In subsequent models, also no associations were observed for a higher 
MUFA or PUFA intake at the expense of SFA with any of outcomes. Results did not differ by sex, 
ethnicity, age, or birth weight.
Conclusions: The results of this study did not support our hypothesis that intake of different types 
of fatty acids was associated with adiposity or cardiometabolic health among children up to 6 years 
of age.
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265
Ch
ap
te
r 4
.4
introduction
Cardiometabolic diseases, such as cardiovascular disease and type 2 diabetes, are highly prevalent. 
Risk factors for these diseases include obesity, dyslipidemia, elevated blood pressure, and insulin 
resistance and a clustering of these risk factors is often referred to as the metabolic syndrome.1 Several 
studies have suggested that the development of cardiometabolic risk factors already begins in early 
life and that these risk factors track during further life.2-4 Therefore, gaining knowledge about factors 
that may influence cardiometabolic health among children is very relevant for early prevention of 
later cardiovascular disease and type 2 diabetes.
Several studies among adults have reported associations for different types of dietary fat intakes 
with cardiometabolic risk factors. Overall, these studies suggest that a lower saturated fatty acid (SFA) 
intake, when replaced by a higher polyunsaturated fatty acid (PUFA) or monounsaturated fatty acid 
(MUFA) intake, may reduce coronary heart disease risk and provide cardiometabolic benefits.5-7 Sug-
gested underlying mechanisms include for example differences in inflammatory responses, changes 
in endothelial function, or changes in lipid metabolism in response to different fatty acids.8 Based 
on these studies, dietary guidelines generally advise to lower SFA intake and increase PUFA intake.9
In contrast to these dietary recommendations for adults, no clear guidelines are available regarding fat 
intake for young children. Nutritional requirements in this period may be different, however, evidence 
on the cardiometabolic health effects of fatty acid intake in early life is scarce.10 A few studies among 
school-aged children have indicated that the intake of different types of fatty acids may be associated 
with certain cardiometabolic risk factors,11-13 but studies on fat intake in early childhood are lacking,14 
whereas early life may be an important period for programming of long-term health.15 Considering the 
divergent effects of different types of fatty acids on cardiometabolic outcomes in previous studies, we 
hypothesized that intake of SFA is negatively associated with cardiometabolic health, and that intake of 
MUFA and PUFA is positively associated with cardiometabolic health. Therefore, the objective of this 
study was to examine the association between the intake of different types of fatty acids in early child-
hood and body composition and cardiometabolic health at 6 years of age, in a prospective cohort study.
methods
study design and subjects
This study was embedded in the Generation R Study, a prospective cohort from fetal life onward 
in Rotterdam, the Netherlands.16 All pregnant women living in the urban area of Rotterdam and 
with an expected delivery date between April 2002 and January 2006 were approached to partici-
pate. Response at baseline was 61% (n=9,778 women). After birth, 7,893 children were available for 
follow-up studies. The study was approved by the Medical Ethical Committee of Erasmus Medical 
Center in Rotterdam and parents of all children provided written informed consent. To determine 
children’s dietary intake, mothers of 5,088 children received a food-frequency questionnaire (FFQ). 
After excluding children whose parents did not return the FFQ and children whose FFQ was not 
completely filled out, complete and valid food intake data was available for 3,629 (72%) children.17, 18 
Of these children, 2,967 visited the research center around the age of 6 years and had data available 
about at least one cardiometabolic outcome (Figure 4.4.1).
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dietary intake assessment
Food intake was assessed between 2003 and 2006 when the children had a median age of 12.9 months 
(95% range: 12.2-18.9), using a semi-quantitative FFQ. Th is questionnaire was completed by the par-
ents or caregivers of the children. Th e FFQ was specifi cally designed for this age group and contained 
 
 
n= 1,459 excluded due to missing 
information on FFQ (n=1,438) or 
invalid data on FFQ (n=21) 
 
 Children with dietary data at 1 y 
n= 3,629 
 
n= 173 excluded due to loss to 
follow-up (n=139), withdrawal of 
consent (n=34) 
Children available for follow-up 
at age 6 y 
 n= 3,456 
  
 Children of mothers who received 
an FFQ at 1 y  
n= 5,088 
  
Children available for follow-up 
in early childhood 
n= 7,893 
  
n= 2,805 excluded due to no 
implementation of FFQ at 1 y 
n= 489 excluded due to no visit to 
the research centre (n=472) or 
missing adiposity or 
cardiometabolic measurements 
(n=17) 
Children with adiposity or 
cardiometabolic outcomes at 6 y 
n = 2,967 
 
With data available on:  
Growth   n=2,967 
Body fat  n=2,911 
Insulin   n=1,998 
Blood pressure   n=2,782 
HDL-cholesterol  n=2,008 
Triglycerides    n=2,003 
Cardiometabolic score  n=1,896 
 
figure 4.4.1. Flowchart of participants included for analysis
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211 food items.17 The FFQ was validated against three 24-hour recalls in 32 children aged 14 months 
living in Rotterdam and interclass correlation coefficients for nutrient intakes ranged from 0.4 to 
0.7.17, 18 With the Dutch Food Composition Database (2006), we calculated intake of total energy, total 
fat, SFA, MUFA, PUFA, n-3 PUFA, and n-6 PUFA.19 Intakes of different types of fat were calculated as 
a percentage of total energy intake. Information on content of trans fat was unfortunately not avail-
able, but was assumed to be low.20, 21 To be able to apply macronutrient substitution models, we also 
calculated intake of other protein and carbohydrates, and we calculated energy from total fat minus 
that from SFAs, MUFAs and PUFAs (i.e., from glycerol, trans fatty acids, sterols, and phospholipids22), 
which amounted to approximately 4% of total energy intake in our study population.
Assessment of anthropometrics, adiposity and cardiometabolic health
Data on height, weight, and BMI were collected at eight different time points between the ages of 1 
and 6 years. Children’s height and weight up to the age of 4 years were measured during routine visits 
to Child Health Centers at median (95% range) ages of 11 (10-13), 14 (13-16), 19 (17-21), 24 (23-28), 
30 (29-34), 36 (35-40), and 45 (44-48) months. At their median age of 6.0 years (95% range: 5.7-6.6), 
we measured the children’s height, weight, body composition, and cardiometabolic health factors in 
our research center at the Erasmus Medical Center.16 Height was determined in standing position to 
the nearest millimeter with a Harpenden stadiometer (Holtain Limited, Dyfed, U.K.). Weight was 
measured using a mechanical personal scale (SECA, Almere, the Netherlands) to the nearest 0.1 kg. 
For each time point, BMI was calculated as total body weight (kg) divided by height (m)2. Overweight 
was determined according to the Cole criteria.23
Body fat mass was measured with a dual-energy x-ray absorptiometry (DXA) scanner (iDXA, 
General Electrics –Lunar, 2008, Madison, WI, USA) and was analyzed with Encore software (version 
13.6).24 Body fat percentage (BF%) was calculated by expressing total fat mass as percentage of total 
body weight; fat mass index (FMI) was calculated as fat mass (kg) divided by height (m)2 and fat-
free mass index (FFMI) as fat-free mass (kg) divided by height (m)2. Blood pressure was measured 
four times at the right brachial artery using a validated automatic sphygmomanometer (Datascope 
Accutorr Plus™, Paramus, USA). The mean of the last three measurements was calculated and used 
for analyses. Non-fasting blood samples were obtained and concentrations of insulin, triacylglycerol 
(TAG), total cholesterol, HDL-cholesterol, LDL-cholesterol, and C-peptide were determined with 
enzymatic methods (using a Cobas 8000 analyzer, Roche, Almere, the Netherlands).16 Quality control 
samples demonstrated intra-assay and inter-assay coefficients of variation ranging from 0.77% to 
1.69%. For all body composition and cardiometabolic outcomes, age- and sex- specific SD-scores 
were calculated on the basis of our study population.
We applied a cardiometabolic risk factor score, modelled following metabolic syndrome-like 
definitions used in adults and adapted for use in pediatric population.25, 26 As described in more 
detail elsewhere, this score consisted of the sum of SD-scores from BF%, SBP, DBP, insulin concen-
trations, TAG concentrations, and the inverse of HDL-cholesterol concentrations,26 with a higher 
cardiometabolic risk factor score reflecting a higher cardiometabolic risk. For our analyses, we chose 
the cardiometabolic risk factor score and its components as primary outcomes of interest, but we 
additionally examined the other cardiometabolic outcomes that were available in our study (i.e., total 
cholesterol, LDL-cholesterol, and C-peptide concentrations).
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covariates
Information on maternal age, parental educational level, net household income, folic acid supple-
ment use during pregnancy, and maternal parity was collected via self-administered questionnaires at 
enrollment in the study. Parental highest finished educational levels were classified into no or primary 
education, middle school or less than 4 years of high school, or higher education. Net household 
income was categorized into less than 1400, 1400 to 2200, or more than 2200 euros per month. 
Parity was categorized into 0, 1, or 2 or more. Information on smoking and alcohol consumption 
during pregnancy was obtained through questionnaires in each trimester and both variables were 
categorized into never, till pregnancy was known, or continued during pregnancy. Maternal food 
intake during first trimester was assessed with an FFQ and overall diet quality was assessed with a 
predefined quality score.27
Information on children’s sex, birth weight, and gestational age was available from obstetric 
records.16 Sex- and gestational age-specific z-scores for birth weight were determined according 
to reference data.28 Child’s ethnic background was defined as Dutch or non-Dutch on the basis of 
the countries of birth of the parents.18 Information on breastfeeding was available from postnatal 
questionnaires and was categorized into never, partially, or exclusively for at least 4 months. Infor-
mation on timing of introduction of solid foods was available from a questionnaire. A previously 
developed diet score was applied to assess overall diet quality of the children at the age of 1 year, 
based on adherence to dietary guidelines for preschool children. Briefly, the ratio of reported and 
recommended intake for ten food groups was calculated, each truncated at 1. The scores of the 10 diet 
score components were summed, resulting in an overall score ranging from 0 to 10 on a continuous 
scale with a higher score representing a better diet quality.18 Screen time (watching television or using 
a computer, hours/day), and participation in sports (yes or no) were assessed with questionnaires 
when the children were 6 years old.
statistical analysis
Associations between the intake of fatty acids and repeatedly measured height, weight and BMI were 
analyzed with linear mixed models. Associations of dietary fatty acid intakes with adiposity and 
cardiometabolic outcomes at the age of 6 years were analyzed with linear regression analyses. To test 
whether exposure variables had a linear relation with the outcomes we applied natural cubic splines 
with 3 degrees of freedom.29 We found indications for a non-linear association only for the relation 
between PUFA intake and the cardiometabolic risk score (P<0.05). Therefore, we also examined the 
associations of quartiles of PUFA intake with cardiometabolic health.
To account for the effect of energy intake and substitution effects of macronutrients in the diet, 
two different multivariable nutrient density substitution models were used.30 We chose to enter all 
nutrients in the model per 5 energy percent (E%) in line with previous studies.6, 31 Firstly, we exam-
ined the association of fat intake at the expense of carbohydrates with cardiometabolic outcomes. 
In order to study this, we included total energy, protein and total fat intake; or total energy, protein, 
SFA, MUFA, and PUFA intake in the same model. Because total carbohydrate intake is the only 
macronutrient left out of this model, coefficients for fat intake can be interpreted as a 5 E% higher 
intake of fat the expense of carbohydrate. Secondly, we examined the association of MUFA and PUFA 
intake at the expense of SFA with cardiometabolic health. In these models, total energy intake and 
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energy from carbohydrate, protein, total fat minus fatty acids, MUFA, and PUFAs were included in 
one model, i.e., all energy sources except for SFA.
In addition to the nutrients, we included child’s sex, ethnicity, and age at filling out the FFQ in our 
basic models. In this model sex, ethnicity, age at filing out the FFQ, and birth weight were also tested 
as possible effect modifiers, but none of the interaction terms were statistically significant (all P>0.05). 
Covariates were selected based on theory and previous studies and were included in the multivariable 
model when adding them to the basic model resulted in changes in effect estimates larger than 10%. 
Based on this criterion, multivariable models were additionally adjusted for the following variables: 
maternal BMI, age, alcohol consumption during pregnancy, smoking during pregnancy, education, 
and parity, household income, birth weight Z-score, breastfeeding, and children’s screen time and 
playing sports. The following covariates were considered but not included because they did not meet 
the 10%-change criterion: folic acid supplement use during pregnancy, maternal diet quality score, 
paternal educational level, timing of introduction of solid foods, and child’s diet quality score. As 
sensitivity analysis, we repeated our models among children with a Dutch ethnic background only, 
because the FFQ was originally designed for Dutch children. Furthermore, we performed sensitiv-
ity analyses in which we replaced protein intake by carbohydrate intake in the models, in order 
to examine fat intake at the expense of protein. Finally, to assess if potential associations with the 
cardiometabolic risk factor score were driven by a single cardiometabolic risk factor, we performed 
sensitivity analyses in which we excluded each cardiometabolic outcome from the cardiometabolic 
score one by one.
To increase statistical power and to reduce bias due to missing data, missing values of covariates 
(ranging from 0 to 19%) were multiple imputed (10 imputations) according to the Fully Conditional 
Specification method using predictive mean matching.32 We report the pooled regression coefficients 
after the multiple imputation procedure. Statistical analyses were performed using SPSS version 
21.0 (IBM Corp., Armonk, NY, USA) and R version 3.1.2 (R Foundation for Statistical Computing, 
Vienna, Austria).
results
subject characteristics
Maternal characteristics, child characteristics, dietary intake and cardiometabolic outcomes are pre-
sented in Table 4.4.1. Most children had a Dutch ethnic background (68.8 %) and had mothers with 
a high educational level (59.4%). Children’s mean (± SD) total energy intake was 1,310 (±388) kcal 
per day and 28.5 (±5.6) E% was derived from fat. The mean intake of SFAs in our population was 11.5 
(±3.6) E%, of MUFAs 9.8 (±3.1) E%, and of PUFAs 5.5 (±1.5) E%. The main food sources contributing 
to SFA intake in our study population were sauces, solid cooking fats, and cakes and pastry. Main food 
sources of MUFA intake were sauces, and cooking fats and oils; and main sources of PUFA intake 
were margarines, liquid cooking fats and oils, and mayonnaise. At the age of 6 years, 404 (13.6%) of 
the children in this study population were overweight or obese. In nonresponse analyses, we observed 
that children without FFQ were slightly taller and heavier at follow-up than children with FFQ data.33
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table 4.4.1. Characteristics of the mothers and children included in the analyses
Population characteristics1
(n=2,967)
Maternal characteristics
Maternal age (years) 31.5 ± 4.5
Maternal BMI at intake (kg/m2) 23.5 (18.8-35.3)
Nulliparous 60.5%
Education level
- No or primary education 5.5%
- Middle school or < 4 years of high school 36.0%
- Higher education 58.6%
Monthly household income
- < € 1400 13.9%
- € 1400 – € 2200 19.4%
- > € 2200 66.6%
Smoking during pregnancy
- Never 77.3%
- Until pregnancy was known 10.7%
- Continued 11.9%
Alcohol consumption during pregnancy
- Never 37.7%
- Until pregnancy was known 16.4%
- Continued 45.9%
Infant characteristics
Sex (% boys) 48.7%
Dutch ethnic background 68.6%
Gestational age at birth (weeks) 40.1 (35.6-42.3)
Birth weight (g) 3,452 ± 569
Breastfeeding
- Exclusive the first 4 months 29.8%
- Partial the first 4 months 59.9%
- Never 10.3%
Child characteristics at dietary assessment
Age at FFQ (months) 12.9 (12.2-18.9)
Total energy intake (kcal) 1,310 ± 388
Total protein intake (E%) 12.9 ± 2.4
Total carbohydrate intake (E%) 58.4 ± 5.9
Total fat intake (E%) 28.5 ± 5.6
- SFA intake (E%) 11.5 ± 3.6
- MUFA intake (E%) 9.8 ± 3.1
- PUFA intake (E%) 5.5 ± 1.5
4.4 Fatty acid intake & growth, adiposity, and cardiometabolic health
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table 4.4.1. Characteristics of the mothers and children included in the analyses (continued)
Population characteristics1
(n=2,967)
Child characteristics at follow-up visit
Age (years) 6.0 (5.7-6.6)
Height (cm) 118 ± 5
Weight (kg) 21.8 (17.4-30.4)
BMI (kg/m2) 16.0 ± 1.6
Screen time (h/d) 1.25 (0.25-4.71)
Participation in sports 44.9%
Body fat percentage (n=2911) 24.2 ± 5.0
Systolic blood pressure (mmHg) (n=2843) 102 ± 8
Diastolic blood pressure (mmHg) (n=2843) 60 ± 7
HDL-cholesterol (mmol/L) (n=2008) 1.34 ± 0.31
Insulin (pmol/L) (n=1998) 115 (18-397)
Triacylglycerol (mmol/L) (n=2003) 0.97 (0.40-2.36)
1Values are given as mean ± SD when continuous variables were normally distributed, as median (95% 
range) for continuous variables with a skewed distribution, and as percentages for categorical variables.
table 4.4.2. Associations between fat intake at the expense of carbohydrates at age 1 year and 
growth between the ages of 1 and 6 years.1,2
Height
(SDS)
n=2967
Weight
(SDS)
n=2967
BMI
(SDS)
n=2967
Total fat intake (5E%) -0.023
(-0.056;0.010)
-0.027
(-0.059;0.007)
-0.003
(-0.030;0.024)
SFA intake (5E%) 0.088
(-0.049;0.225)
0.074
(-0.062;0.211)
0.049
(-0.062;0.159)
MUFA intake (5E%) -0.139
(-0.314;0.035)
-0.102
(-0.275;0.072)
-0.016
(-0.157;0.125)
PUFA intake (5E%) -0.006
( -0.163;0.151)
-0.082
(-0.238;0.074)
-0.094
(-0.221;0.033)
1Values are based on multivariable linear mixed models and reflect differences (95% CI) of the whole tra-
jectory of the anthropometric outcome between the ages of 1 and 6 years (age and sex adjusted SD-scores) 
per 5 E% higher intake of a specific fat intake, at the expense of carbohydrates.
2Models were adjusted for intake of total energy and energy from protein and all types of fats (i.e., all en-
ergy sources except for carbohydrates) to examine macronutrient substitution effects. Models were addition-
ally adjusted for age at FFQ, sex, ethnicity, maternal education, household income, parity, maternal BMI, 
maternal age, smoking during pregnancy, drinking alcohol during pregnancy, breastfeeding, birth weight, 
screen time and playing sports at 6 years of age.
Abbreviations: SDS, Standard deviation score; SFA, saturated fatty acids; MUFA, monounsaturated fatty 
acids; PUFA, polyunsaturated fatty acids; E, energy.
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Associations of fat intake with growth, adiposity and cardiometabolic health
The covariate-adjusted associations for the carbohydrate substitution models are presented in Table 
4.4.2 and Table 4.4.3. A higher total fat intake at the expense of a lower carbohydrate intake in early 
childhood was not associated with any of the anthropometric or cardiometabolic outcomes at the 
ages of 6 years. Similarly, higher intakes of either SFAs, MUFAs, or PUFAs at the expense of carbo-
hydrates were not associated with growth (Table 4.4.2) or cardiometabolic health (Table 4.4.3). For 
analyses with PUFA intake in quartiles also no significant associations or clear non-linear trends were 
observed (data not shown).
Substitution models in which we examined the substitution of SFAs by unsaturated fat showed 
similar results as observed for carbohydrate substitution models: neither MUFA nor PUFA intake 
were associated with any of the anthropometric (data not shown) or cardiometabolic outcomes 
(Table 4.4.4) when consumed at the expense of SFAs.
Associations with cardiometabolic health unadjusted for confounders are shown in Supplemen-
tary Table 4.4.1. In these models, a higher SFA intake was associated with a higher SBP and lower 
insulin concentrations; and a higher MUFA intake was associated with higher insulin levels when 
consumed that the expense of carbohydrates. Other results were similar to those of the adjusted 
model.
Additional analysis
Sensitivity analyses restricted to children with a Dutch ethnic background showed similar associa-
tions between fat intakes, either at the expense of carbohydrates or of SFAs, with cardiometabolic 
health as observed for the whole study population (Supplementary Table 4.4.2). Intake of fatty acids 
was also not associated with other measures of adiposity (FMI or FFMI) or other cardiometabolic 
health outcomes that were not included in the cardiometabolic score (i.e., total cholesterol, LDL-
cholesterol, or C-peptide concentrations) (Supplementary Table 4.4.3).
When we explored substitution of protein instead of carbohydrates we found that a higher total 
fat, PUFA, or MUFA intake at the expense of protein was associated with a lower BF%, but not with 
any of the other outcomes (data not shown). This is in line with results for protein intake, either at 
the expense of fat or carbohydrates, which we described previously.26, 34 Finally, in line with the main 
analysis, in sensitivity analyses in which we excluded each component from the cardiometabolic score 
one by one no significant associations were observed.
discussion
The aim of this study was to examine the associations between intake of total, saturated, monounsatu-
rated and polyunsaturated fat in children in early childhood and their growth and cardiometabolic 
health up to the age of 6 years. Overall, our results show no consistent association between intake of 
total fat or different types of fatty acids, at the expense of either carbohydrates or saturated fat with 
growth or cardiometabolic outcomes.
One large intervention study in children focused on similar outcome variables as our study. This 
Special Turku coronary Risk factor Intervention Project (STRIP) study investigated the influence 
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of low-saturated fat counseling versus no dietary counseling on cardiometabolic health in over one 
thousand children from 7 months of age onwards in Finland. Outcomes that were examined included 
metabolic syndrome, blood pressure, insulin sensitivity and cholesterol levels, and in several follow-up 
studies in later childhood or adolescence a beneficial effect of the intervention was observed for many 
of these cardiometabolic outcomes.13, 35-37 In contrast to the findings of the STRIP study, in our study 
we did not find associations between lower SFA intake and a better cardiometabolic health. However, 
because the intervention in the STRIP study consisted of dietary counseling it is not certain whether 
the effects were caused by a low-saturated fat diet or other effects of the long-term lifestyle advice. 
For example, in one of the analyses in the STRIP study it was shown that the intervention group had 
a lower HOMA-IR, but that actual SFA intake was not significantly associated with HOMA-IR in 
multivariable analyses.37 Additionally, dietary counseling in the STRIP study remained until 20 years 
of age and observed effects may therefore also be caused by dietary changes in later childhood rather 
than in early childhood.
A few observational studies focused on dietary fat intake in young children in relation to their 
weight or BMI. In previous analyses in our study population, Heppe et al. (2013) observed that a 
higher PUFA intake at the age of 1 year was associated with a lower BMI at 4 years of age – an earlier 
follow-up measurement in our cohort.38 Considering that we did not find this association with BMI 
up to the age of 6 years might suggest that the potential effects of fat intake fade away after a longer 
follow-up period. Another possible explanation for our null-findings with BF% may be that the adi-
posity rebound, that occurs around the age of 6 years,39 have obscured a possible inverse association 
between PUFA intake and body fat at this age specifically. In line with our results, Williams et al. 
(2008), who performed a prospective study in 519 children, did not find any significant associations 
between SFA or MUFA intake at 3-4 years of age and BMI at 7-10 years.40 Also Agostoni et al. (2000), 
who measured dietary intake at 1 and 5 years and BMI at 5 years in 147 children, observed that total 
fat, SFA, MUFA or PUFA intake at neither 1 year nor at 5 years were associated with BMI at 5 years of 
age.41 Also in line with our findings, PUFA supplementation in infancy has been shown not to influ-
ence growth.42 No previous studies were identified that examined fat intake in relation to measures of 
body fat in young children.
Two previous studies investigated the association between fatty acid intake with cholesterol 
and TAG concentrations in children. Contrary to our findings, Cowin et al. (2000) observed that a 
higher intake of PUFAs or SFAs at the age of 18 months was associated with a lower HDL-cholesterol 
concentration at the age of 31 months.43 However, this association was only present among girls and 
not among boys. Moreover, among boys, but not girls, a higher total fat intake or SFA intake was 
associated with a higher total cholesterol concentration.43 In our population, we found no significant 
interaction between child sex and fatty acid intake on cardiometabolic health. In line with our results, 
the study of Williams et al. (2008) did not find any association between SFA or MUFA intake at 3-4 
years of age and total cholesterol, HDL-cholesterol and TAG concentrations at 7-10 years.40 However, 
cross-sectional data from the same study population showed that intake of MUFAs, but not SFAs, in 
later childhood were inversely associated with total cholesterol and TAG concentrations.40
In contrast to our hypothesis, in our study no associations were found for lower SFA intake and 
higher MUFA and PUFA intake and better cardiometabolic health. This is in line with a review and 
meta-analysis of studies among adults by Chowdhury et al., who also reported no consistent effects 
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of dietary or circulating SFAs, MUFAs, or PUFAs on cardiovascular disease.44 A possible explanation 
for the fact that we did not find associations might be that different individual fatty acids within the 
subgroups of SFA, MUFA and PUFA, may have different effects on cardiometabolic health. Unfor-
tunately, we could not reliably calculate intake of specific fatty acids from our FFQ data. We also did 
not have information available on trans fatty acids, but intake was assumed to be less than 1% of total 
energy intake based on national food consumption data in the years of our dietary assessment.20, 21 
Although many food items were included in the FFQ, including many detailed subtypes of oils and 
margarines, the intraclass correlation coefficient for total fat intake in a validation study was only 
0.4. This indicates measurement errors in our assessment of fat intake in early childhood. However, 
dietary fat intake remains difficult to estimate and our reference method with 24-hour recalls is also 
not an optimal way to measure this.45 Therefore, it is difficult to judge the quality of the estimates of fat 
intake in our study and whether our exposure measurement was specific enough to detect a potential 
association of fatty acid intake with growth or cardiometabolic health. Future studies should use 
more detailed measurements of fat intake, such as weighed food records or repeated 24-hour recalls, 
or should combine dietary intake data with fatty acid concentrations in for example blood or adipose 
tissue. Especially serum or erythrocyte concentrations of certain n-3 or n-6 PUFAs may provide good 
estimates for dietary intake of fatty acids.46, 47
An important strength compared with other studies is that we accounted for the effect of energy 
intake and macronutrient substitution by using a multivariable nutrient density substitution model. 
By using different substitution models, we could examine the effects of replacing different macro-
nutrients by fatty acids. Finally, a strength of our study is the large number of variables measured 
in this cohort, which made it possible to examine many potential confounders and effect modifiers. 
However, a limitation was that no information was available about the children’s cardiometabolic 
health earlier in childhood or their dietary intake at the age of 6 years. Therefore, it was not possible 
to perform longitudinal analyses or to examine whether fatty acid intake at the age of 6 years was 
associated with cardiometabolic health or diluted a potential effect of fat intake in early childhood.
conclusion
Results from this prospective cohort study show no consistent associations between intakes of total, 
saturated, monounsaturated, or polyunsaturated fat in early childhood with growth or cardiometa-
bolic health outcomes at school age. Because the number of studies examining these associations is 
scarce, future studies are needed to further investigate the associations between intake of different 
types of fat in early childhood and adiposity and cardiometabolic health, preferably with the use of 
more detailed dietary assessment methods and combined with fatty acid biomarkers.
4.4 Fatty acid intake & growth, adiposity, and cardiometabolic health
277
Ch
ap
te
r 4
.4
su
P
P
le
m
e
n
tA
r
y 
m
At
e
r
iA
l
su
pp
le
m
en
ta
ry
 t
ab
le
 4
.4
.1
. M
in
im
al
ly
 a
dj
us
te
d 
as
so
ci
at
io
ns
 b
et
w
ee
n 
fa
t i
nt
ak
e,
 a
t t
he
 e
xp
en
se
 o
f c
ar
bo
hy
dr
at
es
, a
t a
ge
 1
 y
ea
r a
nd
 c
ar
di
om
et
ab
ol
ic
 
he
al
th
 a
t 6
 y
ea
rs
 o
f a
ge
.
Fa
t i
nt
ak
e,
 p
er
 5
E%
BF
%
(S
D
S)
n=
29
11
SB
P
(S
D
S)
n=
28
43
D
BP
(S
D
S)
n=
28
43
H
D
L
(S
D
S)
n=
20
08
In
su
lin
(S
D
S)
n=
19
98
Tr
ia
cy
lg
ly
ce
ro
l
(S
D
S)
n=
20
03
C
ar
di
om
et
ab
ol
ic
 ri
sk
 
fa
ct
or
 sc
or
e
n=
18
96
to
ta
l f
at
 in
ta
ke
-0
.0
07
(-
0.
03
6;
0.
02
2)
0.
01
9
(-
0.
01
5;
0.
05
3)
-0
.0
02
(-
0.
03
5;
0.
03
0)
0.
02
6
(-
0.
01
4;
0.
06
6)
-0
.0
15
(-
0.
05
5;
0.
02
6)
-0
.0
24
(-
0.
06
4;
0.
01
6)
-0
.0
73
(-
0.
17
6;
0.
03
0)
 
sf
A
 in
ta
ke
-0
.0
73
(-
0.
19
6;
0.
05
0)
0.
07
4
(0
.0
00
;0
.1
48
)*
0.
07
9
(-
0.
04
9;
0.
20
7)
0.
04
8
(-
0.
03
5;
0.
13
1)
-0
.1
65
(-
0.
24
9;
-0
.0
81
)*
-0
.0
35
(-
0.
11
9;
0.
04
9)
-0
.2
81
(-
0.
49
7;
0.
06
6)
 
m
u
fA
 in
ta
ke
0.
05
3
(-
0.
09
9;
0.
20
6)
-0
.0
81
(-
0.
25
6;
0.
09
3)
-0
.1
38
(-
0.
30
8;
0.
03
2)
-0
.0
27
(-
0.
13
0;
0.
07
7)
0.
18
0
(0
.0
76
;0
.2
85
)*
0.
01
1
(-
0.
09
3;
0.
11
5)
0.
13
2
(-
0.
40
6;
0.
67
0)
 
P
u
fA
 in
ta
ke
-0
.0
50
(-
0.
18
9;
0.
09
0)
0.
13
7
(-
0.
02
3;
0.
29
8)
0.
14
9
(-
0.
00
6;
0.
30
5)
0.
04
1
(-
0.
12
0;
0.
20
2)
-0
.0
71
(-
0.
17
60
;0
.0
35
)
-0
.0
43
(-
0.
14
0;
0.
05
3)
-0
.0
08
(-
0.
48
9;
 0
.4
73
)
Va
lu
es 
ar
e b
as
ed
 o
n 
lin
ea
r r
eg
re
ssi
on
 m
od
els
 a
nd
 re
fle
ct 
di
ffe
re
nc
es 
(9
5%
 C
I)
 in
 ca
rd
io
m
et
ab
ol
ic 
ou
tco
m
es 
(a
ge
 a
nd
 se
x 
ad
ju
ste
d 
SD
-sc
or
es)
 a
nd
 ca
rd
io
m
et
ab
ol
ic 
ris
k 
fa
cto
r s
co
re
 p
er
 5
 E
%
 in
cr
ea
se 
of
 a
 sp
ec
ifi
c f
at
 in
ta
ke
, a
t t
he
 ex
pe
ns
e o
f c
ar
bo
hy
dr
at
es.
 *
 p
 <
0.
05
M
od
els
 w
er
e a
dj
us
te
d 
fo
r i
nt
ak
e o
f t
ot
al
 en
er
gy
 a
nd
 en
er
gy
 fr
om
 p
ro
te
in
 a
nd
 a
ll 
ty
pe
s o
f f
at
s (
i.e
., 
al
l e
ne
rg
y s
ou
rc
es 
ex
ce
pt
 fo
r c
ar
bo
hy
dr
at
es)
 to
 ex
am
in
e m
ac
ro
nu
tri
en
t 
su
bs
tit
ut
io
n 
eff
ec
ts.
 M
od
els
 w
er
e a
dd
iti
on
al
ly 
ad
ju
ste
d 
fo
r c
hi
ld
’s 
ag
e a
t F
FQ
, s
ex
 a
nd
 et
hn
ici
ty.
Ab
br
ev
ia
tio
ns
: S
D
S,
 S
ta
nd
ar
d 
de
vi
at
io
n 
sco
re
; S
FA
, s
at
ur
at
ed
 fa
tty
 a
cid
s; 
M
U
FA
, m
on
ou
ns
at
ur
at
ed
 fa
tty
 a
cid
s; 
PU
FA
, p
ol
yu
ns
at
ur
at
ed
 fa
tty
 a
cid
s; 
BF
, b
od
y f
at
; S
BP
, 
sy
sto
lic
 b
lo
od
 p
re
ssu
re
; D
BP
, d
ia
sto
lic
 b
lo
od
 p
re
ssu
re
; H
D
L,
 h
ig
h-
de
ns
ity
-li
po
pr
ot
ein
; E
, e
ne
rg
y.
278
Chapter 4.4
su
pp
le
m
en
ta
ry
 t
ab
le
 4
.4
.2
. A
dj
us
te
d 
as
so
ci
at
io
ns
 b
et
w
ee
n 
fa
t i
nt
ak
e,
 a
t t
he
 e
xp
en
se
 o
f c
ar
bo
hy
dr
at
es
, a
t a
ge
 1
 a
nd
 c
ar
di
om
et
ab
ol
ic
 h
ea
lth
 a
t a
ge
 6
 
ye
ar
s i
n 
D
ut
ch
 c
hi
ld
re
n 
on
ly.
Fa
t i
nt
ak
e,
 p
er
 5
E%
BF
%
(S
D
S)
n=
29
11
SB
P
(S
D
S)
n=
28
43
D
BP
(S
D
S)
n=
28
43
H
D
L
(S
D
S)
n=
20
08
In
su
lin
(S
D
S)
n=
19
98
Tr
ia
cy
lg
ly
ce
ro
l
(S
D
S)
n=
20
03
C
ar
di
om
et
ab
ol
ic
 ri
sk
 
fa
ct
or
 sc
or
e
n=
18
96
to
ta
l f
at
 in
ta
ke
-0
.0
24
(-
0.
05
8;
0.
00
9)
0.
01
9
(-
0.
02
4;
0.
06
3)
-0
.0
20
(-
0.
06
3;
0.
02
2)
0.
01
1
(-
0.
04
2;
0.
06
4)
0.
01
7
(-
0.
03
5;
0.
06
9)
-0
.0
41
(-
0.
09
4;
0.
01
2)
-0
.0
64
(-
0.
19
3;
0.
06
4)
 
sf
A
 in
ta
ke
-0
.0
73
(-
0.
21
1;
0.
06
4)
0.
06
7
(-
0.
11
5;
0.
24
8)
0.
03
6
(-
0.
14
0;
0.
21
1)
0.
07
7
(-
0.
13
8;
0.
29
2)
-0
.1
25
(-
0.
33
7;
0.
08
6)
-0
.0
31
(-
0.
24
6;
0.
18
4)
-0
.2
73
(-
0.
80
0;
0.
25
4)
 
m
u
fA
 in
ta
ke
0.
01
9
(-
0.
15
0;
0.
18
9)
-0
.0
65
(-
0.
29
0;
0.
15
9)
-0
.1
36
(-
0.
35
3;
0.
08
0)
-0
.0
93
(-
0.
36
2;
0.
17
6)
0.
24
1
(-
0.
02
4;
0.
50
6)
-0
.0
54
(-
0.
32
4;
0.
21
6)
0.
18
2
(-
0.
47
5;
0.
84
0)
 
P
u
fA
 in
ta
ke
-0
.0
72
(-
0.
23
1;
0.
08
8)
0.
09
6
(-
0.
11
2;
0.
30
4)
0.
11
6
(-
0.
08
4;
0.
31
7)
0.
13
1
(-
0.
12
2;
0.
38
4)
-0
.1
71
(-
0.
42
0;
0.
07
8)
-0
.0
55
(-
0.
30
9;
0.
19
9)
-0
.3
21
(-
0.
94
5;
0.
30
3)
Va
lu
es 
ar
e b
as
ed
 o
n 
m
ul
tiv
ar
ia
bl
e l
in
ea
r r
eg
re
ssi
on
 m
od
els
 a
nd
 re
fle
ct 
di
ffe
re
nc
es 
(9
5%
 C
I)
 in
 ca
rd
io
m
et
ab
ol
ic 
ou
tco
m
es 
(a
ge
 a
nd
 se
x 
ad
ju
ste
d 
SD
-sc
or
es)
 a
nd
 ca
rd
io
-
m
et
ab
ol
ic 
ris
k 
fa
cto
r s
co
re
 p
er
 5
 E
%
 h
ig
he
r i
nt
ak
e o
f a
 sp
ec
ifi
c f
at
 in
ta
ke
, a
t t
he
 ex
pe
ns
e o
f c
ar
bo
hy
dr
at
es.
M
od
els
 w
er
e a
dj
us
te
d 
fo
r i
nt
ak
e o
f t
ot
al
 en
er
gy
 a
nd
 en
er
gy
 fr
om
 p
ro
te
in
 a
nd
 a
ll 
ty
pe
s o
f f
at
s (
i.e
., 
al
l e
ne
rg
y s
ou
rc
es 
ex
ce
pt
 fo
r c
ar
bo
hy
dr
at
es)
 to
 ex
am
in
e m
ac
ro
nu
tri
en
t 
su
bs
tit
ut
io
n 
eff
ec
ts.
 M
od
els
 w
er
e a
dd
iti
on
al
ly 
ad
ju
ste
d 
fo
r a
ge
 a
t F
FQ
, s
ex
, e
th
ni
cit
y, 
m
at
er
na
l e
du
ca
tio
n,
 h
ou
seh
ol
d 
in
co
m
e, 
pa
rit
y, 
m
at
er
na
l B
M
I, 
m
at
er
na
l a
ge
, s
m
ok
-
in
g 
du
rin
g 
pr
eg
na
nc
y, 
dr
in
ki
ng
 a
lco
ho
l d
ur
in
g 
pr
eg
na
nc
y, 
br
ea
stf
ee
di
ng
, b
irt
h 
w
eig
ht
, s
cr
ee
n 
tim
e a
nd
 p
la
yi
ng
 sp
or
ts 
at
 6
 ye
ar
s o
f a
ge
.
Ab
br
ev
ia
tio
ns
: S
D
S,
 S
ta
nd
ar
d 
de
vi
at
io
n 
sco
re
; S
FA
, s
at
ur
at
ed
 fa
tty
 a
cid
s; 
M
U
FA
, m
on
ou
ns
at
ur
at
ed
 fa
tty
 a
cid
s; 
PU
FA
, p
ol
yu
ns
at
ur
at
ed
 fa
tty
 a
cid
s; 
BF
, b
od
y f
at
; S
BP
, 
sy
sto
lic
 b
lo
od
 p
re
ssu
re
; D
BP
, d
ia
sto
lic
 b
lo
od
 p
re
ssu
re
; H
D
L,
 h
ig
h-
de
ns
ity
-li
po
pr
ot
ein
; E
, e
ne
rg
y.
4.4 Fatty acid intake & growth, adiposity, and cardiometabolic health
279
Ch
ap
te
r 4
.4
supplementary table 4.4.3. Adjusted associations between fat intake, at the expense of car-
bohydrates, at the age of 1 year with fat mass index, fat-free mass index, LDL cholesterol, total 
cholesterol, and C-peptide concentrations at 6 years of age.
Fat intake, per 
5E%
Total-C
(SDS)
n=1947
LDL-C
(SDS)
n=1948
C-peptide
(SDS)
n=1939
FMI
(SDS)
n=2911
FFMI
(SDS)
n=2911
total fat 
intake
-0.007
(-0.048;0.034)
-0.006
(-0.047;0.036)
0.006
(-0.035;0.048)
-0.014
(-0.041;0.013)
-0.016
(-0.047;0.015)
sfA intake -0.092
(-0.258;0.075)
-0.085
(-0.252;0.082)
-0.145
(-0.312;0.021)
-0.023
(-0.032;0.065)
0.017
(-0.108;0.143)
mufA intake 0.058
(-0.149;0.265)
0.074
(-0.134;0.282)
0.198
(-0.008;0.405)
0.025
(-0.131;0.085)
-0.010
(-0.169;0.148)
PufA intake -0.005
(-0.198;0.187)
-0.039
(-0.232;0.154)
-0.033
(-0.226;0.159)
-0.105
(-0.112;0.162)
-0.114
(-0.260;0.033)
Values are based on multivariable linear regression models and reflect differences (95% CI) in cardio-
metabolic outcomes (age and sex adjusted SD-scores) per 5 E% higher intake of a specific fat intake, at the 
expense of carbohydrates.
Models were adjusted for intake of total energy and energy from protein and all types of fats (i.e., all energy 
sources except for carbohydrates) to examine macronutrient substitution effects. Models were additionally 
adjusted for age at FFQ, sex, ethnicity, maternal education, household income, parity, maternal BMI, 
maternal age, smoking during pregnancy, drinking alcohol during pregnancy, breastfeeding, birth weight, 
screen time and playing sports at 6 years of age.
Abbreviations: E, energy; SDS, standard deviation score; LDL, low density lipoprotein; FMI, fat mass 
index; fat-free mass index; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, poly-
unsaturated fatty acids.
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AbstrAct
Background: Folate and vitamin B12 have been reported to be associated with body composition, 
however, evidence on this association in elderly individuals is scarce. We aimed to investigate the 
associations of serum folate and vitamin B12 levels, as well as dietary intake of folic acid and vitamin 
B12 with body composition in a large population of older persons.
Methods: We used baseline data from the B-PROOF study, a randomized controlled trial which 
included 2919 individuals aged 65 years and older with elevated homocysteine levels. Venous blood 
samples were obtained to measure serum folate, vitamin B12, HoloTC, and MMA. Dietary intake 
of folate and vitamin B12 was measured with use of a food frequency questionnaire. Height and 
weight were measured and fat mass and fat-free mass were measured with use of Dual Energy X-ray 
assessment DXA. Body mass index (BMI), fat mass index (FMI) and fat-free mass index (FFMI) were 
calculated.
Results: In linear regression models adjusted for several medical history and lifestyle variables, higher 
levels of serum folate (nmol/L) were associated with a 0.02 lower BMI (95% CI -0.04; -0.01). This 
association was stronger in participants with cardiometabolic diseases (p-interaction=0.03), and was 
mainly driven by FFMI. Higher levels of HoloTC (pmol/L) were associated with a 0.96 higher FMI 
(95%CI 0.26; 1.65) and higher MMA (μgmol/L) was associated with a 1.11 lower FMI (95%CI -1.90; 
-0.32). No associations were observed between dietary intake of folate or vitamin B12 with body 
composition.
Conclusions: In this population of elderly, higher folate levels were associated with a lower BMI. This 
association was most pronounced in participants with prevalent cardiometabolic diseases, and was 
mainly driven by FFMI. In contrast, higher levels of vitamin B12, measured by HoloTC and MMA, 
were associated with a higher FMI. Future studies should further investigate underlying mechanisms 
and long-term effects on health.
5.1 Folate and vitamin B12 & body composition
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introduction
The prevalence overweight is growing in all age categories.1 Being overweight or obese can alter the 
absorption, distribution, metabolism and/or excretion of micronutrients, which may cause several 
vitamin deficiencies.2-4 This may be particularly of importance in the elderly as this group is mainly 
at high risk of deficiency.5 For instance, vitamin B12 levels have been shown to decline with age 
and therefore prevalence of vitamin B12 deficiency and depletion is high in elderly.6 This increase in 
prevalence of vitamin B12 deficiency is caused by both inadequate dietary intake as well as malab-
sorption.7
Several studies showed that there is an association between overweight and obesity with serum 
vitamin B12 and folate.8-13 However, it is not clear in whether vitamin B deficiency is a cause or 
a consequence of obesity. It is suggested that obesity leads to malabsorption of vitamin B12 and 
folate, which causes deficiencies. On the other hand, vitamin B12 and folate deficiency due to low 
dietary intake may also lead to obesity. For example, Guananti et al. reported that vitamin B12 and 
folate intake were inversely associated with adiposity in children.14 In addition, we also observed an 
inverse association between folate intake and BMI in children from a Dutch birth cohort.15 These 
findings could be explained by the role of folate and vitamin B12 in epigenetic mechanisms. Vitamin 
B12 and folate act as co-factors in one-carbon metabolism, which is important for the forming of 
methyl donors for DNA methylation.16, 17 Deficiency of these nutrients could lead to dysregulation of 
DNA methylation and might generate metabolic disturbances, including disturbed energy and lipid 
metabolism, leading to adiposity.18, 19
To date, studies exploring the association between folate and vitamin B12 with body composition 
in older individuals have not been conducted. Furthermore, measuring overweight by BMI in elderly 
is under debate.20Aging is associated with loss of muscle mass, and therefore BMI could underestimate 
the prevalence of obesity in this population.21 To address these relations in an elderly population with 
changing body composition, the use of serum and dietary intake data simultaneously can provide a 
further insight on the relation of folate and vitamin B12 with body composition. Therefore, we aimed 
to investigate the associations of serum folate and vitamin B12 levels as well as dietary intake of folic 
acid and vitamin B12 from both food and supplements, with detailed measures of body composition 
in a large population of older persons.
mAteriAls And methods
study participants
For the present cross-sectional analyses, baseline data of the B-PROOF study (B-vitamins for the 
Prevention Of Osteoporotic Fractures) were used. The B-PROOF study is a multi-center, randomized, 
placebo-controlled, double-blind intervention study, investigating the effect of a 2-year daily oral 
vitamin B12 (500 µg) and folic acid (400 µg) supplementation on fracture incidence. The study was 
conducted in three research centers in the Netherlands: VU University Medical Center (Amster-
dam), Wageningen University (Wageningen), and Erasmus Medical Center (Rotterdam). This study 
included 2919 individuals, aged 65 years and older with elevated homocysteine levels (12 - 50 µmol/l). 
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Participants were excluded if they had a renal insufficiency (creatinine level > 150 µmol/l) or presence 
of a malignancy in the past 5 years. A detailed description of the trial has been reported elsewhere.22 
All participants gave written informed consent before the start of the study. The B-PROOF study 
has been registered in the Netherlands Trial Register (NTRNTR1333) and with ClinicalTrials.gov 
(NCT00696514). The WU Medical Ethics Committee approved the study protocol, and the Medical 
Ethics committees of Erasmus MC and VUmc gave approval for local feasibility.22
Anthropometrics measurements
Height was measured in duplicate to the nearest 0.1 cm with the participant standing erect and with-
out wearing shoes, using a stadiometer.22 Weight was measured to the nearest 0.5 kg using a calibrated 
weighing device (SECA 761) with the participant wearing light garments, empty pockets and without 
wearing shoes.22 BMI was calculated as weight in kilograms divided by square of height in meters and 
expressed as kg/m2. Participants were categorized in underweight (BMI < 20), normal weight (BMI 
20 to <25), overweight (BMI 25 to <30) and obesity (BMI ≥ 30).23
body composition
At baseline, a subsample of participants from the Amsterdam and Rotterdam region (n=1227) un-
derwent Dual Energy X-ray assessment (DXA) using the GE Lunar Prodigy device (GE Healthcare, 
USA, CV = 0.08%), (Erasmus MC) and the Hologic QDR 4500 Delphi device (Hologic Inc., USA, CV 
– 0.45%), (VuMC). The two devices were cross-calibrated by measuring a European spine phantom 
(ESP) five times on both devices and all results were adjusted accordingly. Total fat mass and total 
fat-free mass was calculated from the DXA scan.22 Fat Mass Index (FMI) and Fat-Free Mass Index 
(FFMI) was calculated as total fat mass or total fat-free mass in kilograms divided by square of height 
in meters and expressed as kg/m2.
laboratory measurements
Venous blood samples were obtained in the morning, when the participants were in a fasted state, or 
had taken a restricted breakfast. Plasma homocysteine was determined at baseline, using the Archi-
tect i2000 RS analyser (VUmc, intra assay CV – 2%, inter assay CV = 4%), HPLC method24 (WU, intra 
assay CV = 3.1%, inter assay CV = 5.9%) and LCMS/MS (EMC, CV = 3.1%). According to a cross-
calibration, outcomes of the three centers did not differ significantly. Serum folate was determined by 
imunoelectrochemiluminescence on a Roche Modular E170 (Roche, Almere, The Netherlands) (CV 
= 5.9% at 5.7 nmol/L and 2.8% at 23.4 nmol/L). Serum methylmalonic acid (MMA) was measured 
by LC-MS/MS (CV < 9%) and holo-transcobalamin (HoloTC), and was determined by the AxSYM 
analyser (Abbott Diagnostics, Hoofddorp, the Netherlands) (CV < 8%).22, 25 HoloTC was used as 
measure of vitamin B12 status, because it has been shown to better reflect vitamin B12 status than 
serum total vitamin B12.26 To isolate DNA, buffy coats were used. The MTHFR genotypes, 677CC, 
677CT or 677 TT, were determined using the Illumina Omni-express array (Illumina Inc., San Diego, 
CA, USA).
5.1 Folate and vitamin B12 & body composition
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dietary assessment
Dietary intake was estimated in a subsample, i.e. all participants of the Wageningen region (n=603), 
by a Food Frequency Questionnaire (FFQ) with a focus on macronutrients, vitamin B12, folate, 
vitamin D, and calcium. The FFQ was developed by the dietetics group of Wageningen University 
and was derived from an FFQ which was validated for energy, fat, cholesterol, folate and vitamin B12 
intake.22, 27, 28 Folic acid and vitamin B12 supplement use was defined as users or non-users.
covariates
Demographic characteristics and health status variables, which included age, sex, self-reported medi-
cal history (cardiovascular disease and diabetes), alcohol intake, smoking habits, physical activity 
(Kcal/day), education and vitamin supplement use, were determined using a structured questionnaire. 
Alcohol intake was categorized according to the Dutch method of Garretsen et al. into ‘never’, ‘light’, 
‘moderate’ and ‘excessive’ drinkers, based on the number of days per week alcohol was consumed and 
the number of glasses per time.29, 30 Smoking habits were defined as never smoked; former smoker or 
current smoker.
statistical analyses
Normal distribution for all variables was examined by visual inspection of histograms. When neces-
sary, data were transformed. Second, linear regression analysis was used to determine associations of 
serum folate, vitamin B12, HoloTC, MMA, folic acid intake, and vitamin B12 intake (from food and 
supplement) with BMI, FMI and FFMI. All the analyses were adjusted for age and sex, and for energy 
intake for the association between folic acid and vitamin B12 intake (from food and supplements) 
(model 1). Subsequently, based on literature, smoking, alcohol, PA, homocysteine, education, hyper-
tension, and hypercholesterolemia were added as fixed confounders.31, 32 In addition, the interaction 
of age, gender, prevalent cardiometabolic diseases (cardiac disease or diabetes), MTHFR with serum 
folate and serum vitamin B12 on body composition was tested in the model 2. If the P value for 
interaction was < 0.1, stratified analyses were performed. In addition, we tested whether there was 
an interaction of serum folate with serum vitamin B12, MMA and HoloTC on body composition. 
Statistical analyses were performed using the statistical software package of SPSS 21.0 (SPSS Inc., 
Chicago, Illinois, USA). P-values of < 0.05 were considered statistically significant for all the analyses 
other than the interaction analyses (<0.1).
results
Population characteristics
Population characteristics are presented in Table 5.1.1. Mean age was 74.0 years (6.5 SD) for the 
total population (n=2919), 73 years (5.7 SD) for the DXA population (n=1227) and 72.8 years (5.7 
SD) for the population with FFQ data available (n=603). Mean BMI was 27.1 kg/m2 (4.0 SD) for the 
total population, 27.0 kg/m2 (3.8 SD) for participants who underwent a DXA measurement, and 26.9 
kg/m2 (SD 3.6) for participants with FFQ data. The participants who underwent a DXA scan were 
younger; different alcohol consumption patterns (more moderate and excessive alcohol intake and 
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table 5.1.1. Population characteristics
b-Proof 
Participants (n 
=2919)
dXA-test 
Participants (n = 
1227)
ffQ participants 
(n=603)
Age (years)a 74 (6.5) 72.9 (5.7) 72.8 (5.7)
Sex
Female (%) 50 48.3 42.1 
Body Mass Index (kg/m2)a 27.1 (4.0) 27.0 (3.8) 26.9 (3.6)
Underweight (%) 0.4 0.2 0.3 
Normal weight (%) 28.6 30.4 28.4 
Overweight (%) 50.9 50.1 54.7 
Obesity (%) 20.1 19.2 16.6 
Fat NA NA
Total Fat Mass (kg) 25.5 (8.4) 
Total Fat Percentage (%) 32.4 
FMI (kg/m2) 8.9 (3.2) 
FFMI (kg/m2) 18.0 (2.2) 
Smoking (%)
Current 56.5 57.6 58.8 
Former 9.6 9.0 10.4 
Never 33.9 33.3 31.0 
Alcohol intake (%)
Light 67.4 64.1 64.2 
Moderate 28.8 31.4 32.8 
Excessive 3.4 4.0 2.5 
Very excessive 0.4 0.6 0.5 
Self-reported medical history of
Cardiac disease (%) 25.1 25 25.5 
Diabetes (%) 10.3 10.8 7.1 
Hypercholesterolemia (%) 24.7 28.5 21.2 
Measured hypertension (%) 51.5 58.8 38.6 
Homocysteine (mmol/L)b 14.4 [3.6] 14.3 [3.3] 14.0 [3.2]
Serum Folate (nmol/L)a 21.0 (11.62) 21.3 (9.3) 20.1 (17.2)
Serum Vitamin B12 (pmol/L)a 285.5 (115.95) 287.5 (115.2) 281.2 (107.9)
Holotranscobalamin (pmol/L)b 59.0 [34] 67 [40] 60.0 [34.0]
MMA (mcgmol/L)b 0.2 [0.1] 0.2 [0.1] 0.2 [0.1]
MTHFR (%)
CC 44.9 46.4 44.3 
CT 42.1 40.8 42.6 
TT 13.0 12.8 13.1 
Folic Acid supplement use (%) 16.0 16.3 11.1
Vitamin B12 supplement use (%) 16.2 16.8 11.1
5.1 Folate and vitamin B12 & body composition
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less very excessive drinkers); had a higher serum HoloTC when compared to the total B-PROOF 
population. The participants with FFQ data were also younger; less likely to have diabetes mellitus; 
had lower serum folate and vitamin B12; had lower use of folic acid and vitamin B12 supplementation; 
had higher PA and were more often high educated when compared to the total B-PROOF population. 
HoloTC was log-transformed, as this variable was non-normally distributed.
folate and vitamin b12 biomarkers and bmi
Results of the linear regression analyses of serum folate, serum vitamin B12, HoloTC, MMA, folic 
acid supplements and vitamin B12 supplements with BMI for the total population, are shown in Table 
5.1.2. Serum folate was inversely significantly associated with BMI after adjustments for covariates, 
indicating that for each nmol/L increase in serum folate, there was a 0.02 kg/m2 lower BMI (β -0.02; 
95% CI -0.04; -0.01) in the total population. Serum vitamin B12 was also inversely significantly asso-
ciated with BMI in the crude model, but this association was no longer significant after adjustment for 
covariates (β -0.001; 95% CI -0.003; 0.000 vs. β 0.000; 95% CI -0.002; 0.001) in the total population. 
HoloTC, MMA, folic acid supplements and vitamin B12 supplements were not associated with BMI 
(Table 5.1.2).
We found a significant association of HoloTC log transformed and BMI in the population with a 
DXA measurement after adjustment for covariates (β 1.37; 95% CI 0.43; 2.32). Additionally, MMA 
was significant inversely associated with BMI in this particular population (β -1.27; 95% CI -2.35; 
-0.20)(Supplementary Table 5.1.1). We found no significant associations between intake of folic acid 
and vitamin B12 (total and from food only) with BMI (Table 5.1.4).
table 5.1.1. Population characteristics (continued)
b-Proof 
Participants (n 
=2919)
dXA-test 
Participants (n = 
1227)
ffQ participants 
(n=603)
Folate intake from food (mcg/day)a NA NA 191.5 (53.9)
Vitamin B12 intake from food (mcg/day)a NA NA 4.1 (2.0)
Total activity (Kcal/day)b 550.8 [483.8] 591.2 [505.4] 586.4 [512.4]
Total energy intake (Kcal/day)a NA NA 2005.9 (473.4)
Education (%)
Low 32.1 32.5 25.9 
Middle 42.0 41.1 40.8 
High 26.0 26.4 33.3 
Region (%)
Amsterdam 26.6 34.6 0 
Rotterdam 29.4 65.4 0 
Wageningen 44.0 0 100 
aPresented as mean (SD); or b median [IQR]
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folate and vitamin b12 biomarkers and fmi and ffmi in dXA population
Results of the linear regression analyses of serum folate, serum vitamin B12, HoloTC, MMA, folic 
acid supplements and vitamin B12 supplements with FMI and FFMI for the DXA population are 
shown in Table 5.1.3. There was a significant association between HoloTC and FMI (β 0.96; 95% 
CI 0.26; 1.65) in the adjusted model, indicating that for each pmol/L increase in log transformed 
HoloTC, there was a 0.96 kg/m2 higher FMI. However, MMA was significantly inversely associated 
with FMI, indicating that for each μgmol/L increase in MMA, there was a 1.11 kg/m2 lower FMI (β 
-1.11; 95% CI -1.90; -0.32). Moreover, serum folate, serum vitamin B12, HoloTC, MMA, folic acid 
supplements and vitamin B12 supplements were not associated with FFMI.
Additional analyses
Analyses were stratified in case of a significant interaction was observed with one of the potential 
effect modifiers. Results of these stratified analyses are presented in Supplementary Table 5.1.3. We 
found a significant interaction between serum folate and cardiometabolic diseases in association with 
BMI (p-interaction=0.03) as well as FFMI (p-interaction=0.06). Stratification showed that the as-
sociation between serum folate and BMI was most pronounced in participants with cardiometabolic 
diseases compared to participants without cardiometabolic diseases. In participants with cardiometa-
bolic diseases a significant inverse association was observed between serum folate and BMI (β -0.05; 
95%CI -0.09; -0.02), whereas no significant association was observed for participants without cardio-
metabolic diseases (β -0.01; 95% CI 0.03; -0.01) (Supplementary Table 5.1.3). Similarly, there was 
an inverse association between serum folate and FFMI in participants with cardiometabolic diseases 
(β -0.03; 95% CI -0.05; -0.01), but in participants without cardiometabolic diseases, this association 
table 5.1.2. Associations between serum folate, vitamin B12, HoloTC, MMA, folic acid 
supplements and vitamin B12 supplements with BMI in Total Population (n=2919)
BMI
Model 1
β 95% CI
Model 2
β 95% CI
Serum Folate (nmol/L) -0.02 [0.03; -0.01]* -0.02 [-0.04; -0.01]*
Serum Vitamin B12 (pmol/L) -0.001 [-0.003; 0.000]* -0.001 [-0.002; 0.001]
HoloTC_loga (pmol/L) 0.53 [-0.09; 1.15] 0.61 [-0.10; 1.32]
MMA (µgmol/L) -0.26 [-0.742; 0.225] -0.68 [-1.47; 0.12]
Folic acid supplements -0.27 [-0.67; 0.12] -0.10 [-0.54; 0.34]
Vitamin B12 supplements -0.37 [-0.76; 0.03] -0.27 [-0.71; 0.17]
Values are regression coefficients and 95% CIs based on linear regression models and reflect differences in 
BMI per 1 unit increase of serum foliate, serum vitamin B12, HoloTC, MMA, folic acid supplements, 
vitamin B12 supplements;
Model 1 is adjusted for age, sex.
Model 2 is additionally adjusted for smoking, alcohol consumption, physical activity, education, hyperten-
sion and hypercholesterolemia.
alog transformed
*P-value <0.05.
5.1 Folate and vitamin B12 & body composition
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table 5.1.3. Associations between serum folate, vitamin B12, HoloTC, MMA, folic acid 
supplements and vitamin B12 supplements with FMI and FFMI in DXA population (n=1227)
FMI FFMI
Model 1
β 95% CI
Model 2
β 95% CI
Model 1
β 95% CI
Model 2
β 95% CI
Serum Folate (nmol/L) -0.004 [-0.02; 0.01] -0.002 [-0.02; 0.02] -0.009 [-0.020; 0.002] -0.01 [-0.02; 0.000]
Serum Vitamin B12 (pmol/L) 0.000 [-0.002; 0.001] -0.00 [-0.001; 0.001] 0.000 [-0.001; 0.001] 0.000 [0.001; 0.001]
HoloTC_loga (pmol/L) 0.75 [0.07; 1.42]* 0.96 [0.26; 1.65]* 0.23 [-0.19; 0.65] 0.40 [-0.03; 0.84]
MMA (µgmol/L) -0.75 [-1.53; 0.04] -1.11 [-1.90; -0.32]* -0.14 [-0.63; 0.35] -0.17 [-0.67; 0.33]
Folic acid supplements -0.03 [-0.46; 0.40] 0.17 [-0.27; 0.62] -0.18 [-0.44; 0.09] -0.11 [-0.38; 0.17]
Vitamin B12 supplements -0.18 [-0.61; 0.24] -0.05 [-0.49; 0.39] -0.19 [-0.46; 0.08] -0.11 [-0.39;0.16]
Values are regression coefficients and 95% CIs based on linear regression models and reflect differences in 
BMI per 1 unit increase of serum foliate, serum vitamin B12, HoloTC, MMA, folic acid supplements, 
vitamin B12 supplements.
Model 1 is adjusted for age, sex.
Model 2 is additionally adjusted for smoking, alcohol consumption, physical activity, education, hyperten-
sion, hypercholesterolemia.
Model 3 is additionally adjusted for diabetes and homocysteine.
alog transformed
*P-value <0.05.
table 5.1.4. Associations between serum folate, vitamin B12, HoloTC, MMA and folic acid 
intake and supplements, vitamin B12 intake and supplements with BMI in FFQ population 
(n=603)
BMI
Model 1
β 95% CI
Model 2
β 95% CI
Serum Folate (nmol/L) -0.004 [-0.02; 0.01] -0.02 [-0.06; 0.03]
Serum Vitamin B12 (pmol/L) -0.003 [-0.006; 0.000]* -0.001 [-0.005; 0.002]
HoloTC_loga (pmol/L) 0.04 [-1.26; 1.35] 0.03 [-1.74; 1.81]
MMA (µgmol/L) -0.15 [-0.76; 0.46] -0.78 [-2.99; 1.43]
Folic acid total intake (FFQ) 0.000 [-0.002; 0.001] 0.00 [-0.003; 0.002]
Vitamin B12 total intake (FFQ)a -0.84 [-2.13; 0.46] -1.06 [-2.76; 0.63]
Folic acid intake from food (FFQ) 0.005 [-0.002; 0.011] 0.007 [-0.001; 0.02]
Vitamin B12 total intake from food (FFQ) 0.03 [-0.014; 0.079] 0.07 [-0.004; 0.15]
Folic acid supplements -0.16 [-1.08; 0.75] -0.45 [-1.53; 0.64]
Vitamin B12 intake supplements -0.12 [-1.04; 0.80] -0.51 [-1.58; 0.56]
Values are regression coefficients and 95% CIs based on linear regression models and reflect differences in 
FMI per 1 unit increase of serum foliate, serum vitamin B12, HoloTC, MMA, folic acid intake (from 
food and supplements), vitamin B12 intake (from food and supplements); Model 1 is adjusted for age, sex 
(and energy intake for intake form food). Model 2 is additionally adjusted for smoking, alcohol consump-
tion, physical activity, education, hypertension and hypercholesterolemia.
alog transformed *P-value <0.05.
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was not significant (β -0.01; 95%CI 0.05; -0.01). We also observed a significant interaction between 
vitamin B12 supplement use and cardiometabolic diseases with FFMI, but stratified analyses showed 
no significant associations.
Age was found to be an effect modifier in the association between MMA and FMI (p-interac-
tion=0.03). MMA was inversely associated with FMI in the population older than 73 years (β -1.92; 
95% CI -2.90; -0.94), but not in participants younger than 73 years (β -0.07; 95% CI -1.33; 1.19). In 
addition, we found a significant interaction between sex and MMA (p=0.04) with FFMI. In women, 
an inverse association was observed between (β -0.65; 95% CI -1.26; -0.03). In contrast, a positive 
association between MMA and FFMI was observed for men, although this was non-significant (β 
0.68; 95% CI -0.20; 1.55). There was also a significant interaction between sex and vitamin B12 intake 
with BMI. A higher vitamin B12 intake was associated with a lower BMI in men (β -2.86; 95% CI 
-4.58; -1.13), but not in women.
discussion
In the current study, we investigated associations between serum levels as well as dietary intake of 
vitamin B12 and folate with body composition in elderly individuals. We observed that a higher 
level of serum folate was associated with a lower BMI. This association was most pronounced in 
participants with cardiometabolic diseases, and seemed to be driven by FFMI rather than FMI in 
this subgroup. Furthermore, HoloTC was positively associated with FMI and MMA was negatively 
associated with FMI, both suggesting that higher levels of vitamin B12 are associated with a higher 
FMI. However, we did not observe any associations between dietary intake of vitamin B12 or folate 
with body composition.
Our findings regarding folate are in line with results from several previous studies. In a cross 
sectional study among adults Kimmons et al. showed that compared with normal-weight adults, 
overweight and obese adults were more likely to have low folate levels.8 In line with this, a study by 
Mahabir et al. showed that adiposity was associated with lower serum folate levels in postmenopausal 
women.9 The inverse association we observed between folate levels and BMI was modified by the 
presence of cardiometabolic diseases. Stratified analyses showed that associations were stronger in 
participants with cardiometabolic diseases, and that this association was mainly driven by FFMI. 
However, no associations between folate levels with BMI or FFMI were observed in participants 
without cardiometabolic diseases. Possibly, our findings in participants with cardiometabolic diseases 
are a reflection of a different underlying mechanisms. Another explanation could be reverse causality. 
Changes in lifestyle that are made after disease incidence may result in an improved folate status, 
while a detrimental physical status due to cardiometabolic diseases, such as a lower FFMI may still 
be present.
In contrast to our expectations, we observed that several biomarkers of vitamin B12, including 
higher levels of HoloTC and lower levels of MMA, were associated with a higher FMI. In a previous 
study among children we observed similar detrimental associations between vitamin B12 intake and 
android-gynoid ratio.15 However, in another study among adults from a primary care-based setting 
vitamin B12 was negatively correlated with BMI.10 Considering the age of our study population, lack 
5.1 Folate and vitamin B12 & body composition
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of intrinsic factor could play a role in these findings. This could lead to malabsorption of vitamin B12, 
which could be related to other health outcomes affecting body composition. Therefore, participants 
with lower vitamin B12 levels could have lower FMI as a reflection of a detrimental physical status. 
This is supported by our results showing that the negative association for MMA with FMI is stronger 
in older participants (>73 years).
From these studies investigating levels of folate and vitamin B12 with body composition it is not 
possible to determine the temporal direction. Hypotheses has been proposed for both directions: 
folate and vitamin B12 deficiency may be a consequence of obesity due to malabsorption, but may 
also be a cause of obesity due to metabolic disturbances through insulin resistance, or epigenetic 
mechanism, such as DNA methylation.18, 19 In addition to biomarkers of folate and vitamin B12, we 
examined associations between dietary intake of folate and vitamin B12 with body composition. 
However, our results do not provide evidence that dietary intake of vitamin B12 and folate are in-
volved in the development of overweight or obesity. This is in line with a previous study in which the 
causal relationship between vitamin B12 and BMI was studied with use of a Mendelian randomiza-
tion approach. The authors reported that vitamin B12 levels were associated with BMI, however, there 
was no evidence that a higher BMI was caused by lower vitamin B12 levels.33 In line with this, in a 
study among Mexican children an inverse association was observed between folate vitamin B12 levels 
and body composition, but not with dietary intake of folate and vitamin B12.14
strengths and limitations
The current study has several strengths and limitations. An important strength is the size of the 
population included and the large amount of information available on potentially confounding fac-
tors. However, residual confounding cannot be ruled out, as in any observational study. For instance, 
the positive association between biomarkers of vitamin B12 with FMI could be due to other dietary 
factors. Considering that vitamin B12 only naturally occurs in animal products, the positive associa-
tion between vitamin B12 biomarkers and BMI could be explained by a higher animal-based diet 
accompanied with a higher caloric intake. However, we only had data available on energy intake in 
a subset, but not the total population. Therefore, we could not determine whether this association 
was explained by other dietary factors in this population. As dietary intake was only available in a 
subgroup, this may have resulted in insufficient statistical power, and therefore we may have been 
unable to detect an association between dietary intake and body composition. Furthermore, due to 
the cross-sectional nature of our data, we are not able to determine a temporal relationship of the 
associations we observed. We had several methods to measure vitamin B12 levels which provided 
better insight in potential deficiencies. For instance, HoloTC has been shown to be a more accurate to 
detect vitamin B12 deficiency compared to other methods.34 Another strength of this study was that 
detailed body composition measurements were available, in addition to the use of BMI. Although 
BMI may be practical to use as outcome of interest, this measure is limited regarding prediction of 
several health outcomes because it does not take into account body composition.35, 36 Therefore, we 
used more detailed body composition measured with DXA, including FMI and FFMI. However, we 
did not have data on distribution of body fat. This may also be of importance when predicting disease 
risk, as abdominal fat rather than gynoid fat may have different effects on health.37
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conclusion
In this population of elderly, higher folate serum levels were associated with a lower BMI. This as-
sociation was most pronounced in participants with prevalent cardiometabolic diseases, and was 
mainly driven by FFMI rather than FMI among these participants. In contrast, higher levels of 
vitamin B12, measured by HoloTC and MMA, were associated with a higher FMI. Future large-scale 
studies should further investigate underlying mechanisms and long-term effects on health.
5.1 Folate and vitamin B12 & body composition
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supplementary table 5.1.1. Associations between serum folate, vitamin B12, HoloTC, MMA, 
folic acid supplements and vitamin B12 supplements with BMI in DXA population (n=1227)
BMI
Model 1
β 95% CI
Model 2
β 95% CI
Serum Folate (nmol/L) -0.01 [-0.03; 0.01] -0.01 [-0.04; 0.01]
Serum Vitamin B12 (pmol/L) 0.000 [-0.002; 0.001] 0.000 [-0.002; 0.002]
HoloTC_loga (pmol/L) 0.98 [0.07; 1.90]* 1.37 [0.43; 2.32]*
MMA (µgmol/L) -0.88 [-1.943; 0.185] -1.27 [-2.35; -0.20]*
Folic acid supplements -0.17 [-0.75; 0.41] 0.06 [-0.54; 0.67]
Vitamin B12 supplements -0.34 [-0.91; 0.24] -0.17 [-0.76; 0.43]
Values are regression coefficients and 95% CIs based on linear regression models and reflect differences in 
BMI per 1 unit increase of serum folate, serum vitamin B12, HoloTC, MMA, folic acid supplements, 
vitamin B12 supplements;
Model 1 is adjusted for age, sex.
Model 2 is additionally adjusted for smoking, alcohol consumption, physical activity, education, hyperten-
sion and hypercholesterolemia.
alog transformed *P-value <0.05.
supplementary table 5.1.2. Associations between intake of folate and vitamin B12 and serum 
folate, vitamin B12, holoTC, MMA
Folic acid intake
β 95% CIa
Vitamin B12 intake
β 95% CIa
Serum Folate (nmol/L) 0.065 [0.060; 0.069]* NA
Serum Vitamin B12 (pmol/L) NA 1.469 [0.087; 2.851]*
HoloTC (pmol/L) NA -0.001 [-0.007; 0.005]
MMA (µgmol/L) NA 0.970 [0.479; 1.462]*
aadjusted for age and sex
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supplementary table 5.1.3. Associations between serum folate, MMA, vitamin B12 supple-
ments and vitamin B12 intake with BMI, FMI, and FFMI stratified for effect modifiers (p-
interaction < 0.10)
BMI
β 95% CI1
β 95% CI2
FMI FFMI
Serum folate cardiometabolic 
diseases(y/n)
(p-interaction 0.03)
No: -0.01 (-0.03; 0.01)
Yes: -0.05 (-0.09; -0.02)*
- cardiometabolic diseases 
(y/n)
(p-interaction 0.06)
No: -0.01 (-0.02; 0.01)
Yes: -0.03 (-0.05; -0.01)*
MMA - Age (p-interaction 0.03)
Age <73 yrs.: -0.07 (-1.33; 
1.19)
Age >73 yrs.: -1.92 (-2.90; 
-0.94)*
Sex (p-interaction 0.04)
Male: 0.68 (-0.20; 1.55)
Female: -0.65 (-1.26; 
-0.03)*
Vitamin B12 supplements - - cardiometabolic diseases 
(y/n)
 (p-interaction 0.07)
No: -0.25 (-0.55; 0.06)
Yes: 0.33 (-0.25; 0.92)
Vitamin B12 total_log Age (p-interaction 0.07)
Age <73 yrs.: -0.76 (-3.20; 
1.68)
Age >73 yrs.: -1.84 (-4.23; 
0.55)
Sex (p-interaction 0.03)
Male: -2.86 (-4.58; -1.13)*
Female: 1.63 (-1.48; 4.74)
- -
Values are regression coefficients and 95% CIs based on linear regression models and reflect differences in 
BMI, FMI, or FFMI per 1 unit increase of serum folate, serum vitamin B12, HoloTC, MMA, folic acid 
supplements, vitamin B12 supplements;
Models are adjusted for age, sex, smoking, alcohol consumption, physical activity, education, hypertension 
and hypercholesterolemia.
*P-value <0.05.
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Methyl donor nutrient intake and 
incidence of type 2 diabetes mellitus: 
results from the Nurses’ Health Study 
and Health Professionals Follow-Up 
Study.
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Methyl donor nutrient intake and incidence of type 2 diabetes mellitus: results from 
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AbstrAct
Background There is increasing evidence that DNA methylation may play a role in the development 
of diabetes. DNA methylation can be influenced by environmental factors, such as diet. These dietary 
factors include methyl donor nutrients, including vitamin B2, vitamin B6, vitamin B12, folate, and 
methionine, which are important in one-carbon metabolism. Intake of these nutrients may influence 
risk of type 2 diabetes via epigenetic changes.
Methods We included 69,949 women from the Nurses’ Health Study (1984-2012), 90,239 women 
from the Nurses’ Health Study 2 (1991-2011), and 40,539 men from the Health Professionals Follow-
Up Study (1986-2010). Dietary data were collected every 2-4 years using a semi-quantitative food 
frequency questionnaire, from which dietary intake of vitamin B2, vitamin B6, vitamin B12, folate, 
and methionine were calculated. Hazard ratios were estimated using Cox proportional hazard regres-
sion analyses with time-varying covariates.
Results We documented 8,141 cases of type 2 diabetes during 1,763,428 years of follow-up. In pooled 
multivariable-adjusted analysis, the highest quartiles of vitamin B2 and vitamin B6 were associated 
with a lower risk of type 2 diabetes compared to the lowest quartile (Q1) (HR [95% CI]: 0.90 [0.84, 
0.97], and 0.91 [0.84, 0.97], respectively). Intake of total vitamin B12 was not associated with risk of 
diabetes. However, when analyses were stratified by food source, vitamin B12 intake from food in Q5 
was associated with a higher risk of diabetes compared to Q1 (HR [95% CI]: 1.11 [1.02, 1.19], whereas 
a high B12 intake from supplements was associated with lower risk of diabetes (HR [95% CI]: 0.92 
[0.85, 0.98]). There was no significant association between folate and methionine intake and risk of 
diabetes.
Conclusion Our study suggests that higher intakes of vitamin B2 and vitamin B6 are associated with 
a lower risk of diabetes. A higher vitamin B12 intake from food seems to be associated with a higher 
risk of diabetes, which may be due to animal products.
5.2 Methyl donor nutrient intake & type 2 diabetes mellitus
307
Ch
ap
te
r 5
.2
bAckground
The prevalence of type 2 diabetes is growing worldwide and leads to a major increase in morbidity 
and mortality.1 Therefore, it is important to identify risk factors in the development of type 2 diabetes 
in order to develop targeted prevention strategies.
There is increasing evidence that DNA methylation may play a role in the development of metabolic 
disorders, including diabetes and diabetes related complications.2-4 DNA methylation can be influenced by 
environmental factors, such as diet.5 These dietary factors include methyl donor nutrients, such as folate 
and vitamin B12, which are important in one-carbon metabolism. Intake of these nutrients may influence 
risk of type 2 diabetes via epigenetic changes.6 Only a few studies have investigated the association between 
methyl donor nutrients and diabetes. Krishnaveni et al. reported that vitamin B12 deficiency in pregnant 
women was associated with risk of both gestational diabetes and diabetes after 5 years of follow up.7 In 
contrast, in a randomized controlled trial among women at high risk of CVD, Song et al. reported no 
significant effect of supplementation of vitamin B6, vitamin B12, and folate on the risk of type 2 diabetes.8 
However, in the same study a trend towards a protective effect in participants with family history of type 2 
diabetes was reported. These findings suggest that vitamin B6, vitamin B12 and folate may be beneficial for 
a specific subgroup which is predisposed to development of type 2 diabetes.
To date, no studies have been conducted on the association between the intake of methyl donor 
nutrients and risk of type 2 diabetes in adults in large prospective cohort studies. Therefore, the aim of 
this study was to investigate the association between intake of methyl donor nutrients and risk of type 
2 diabetes, and whether these associations are modified by family history of type 2 diabetes.
methods
study population
This study was embedded in three prospective cohort studies in the USA: the Nurses’ Health Study 
(NHS), Nurses’ Health Study II (NHS2), and the Health Professionals’ Follow-Up Study (HPFS). The 
NHS started in 1976 with 121,701 female nurses aged 30-55 years, the NHS2 started in 1989 with 
116,430 female nurses aged 25-42 years, and the HPFS 1986 with 51,529 male health professionals 
aged 40-75 years. In all three studies, information on lifestyle and medical history was collected by 
questionnaires at baseline and every 2 years during follow-up. The response rate per cycle was ~90% 
for all cohorts. In this study, the 1984, 1991, and 1986 cycles were baselines for NHS, NHS2, and 
HPFS, respectively, since most covariates of interest were comprehensively measured from this cycle 
onwards. Participants with type 1 diabetes or type 2 diabetes mellitus, history of gestational diabetes, 
cardiovascular disease, cancer, missing dietary data, or inadequate dietary data (adequate dietary 
information was defined as:>50 of 61 items completed, yielding 500-3500 kcal/d, for women; >60 
of 131 items completed, yielding 800-4200 kcal/d, for men). The population for analyses consisted 
of 69,949 women from the Nurses’ Health Study, 90,239 women from the Nurses’ Health Study 2, 
and 40,539 men from the Health Professionals Follow-Up Study. Study protocols for all cohorts were 
approved by the institutional review board of Brigham and Women’s Hospital and Harvard T.H. Chan 
School of Public Health and all participants provided informed consent.
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dietary assessment
Dietary data were collected every 2-4 years using a validated semi-quantitative food frequency 
questionnaire as described previously.9, 10 Participants were asked how often they consumed a serving 
of ~130 food items over the previous year. The frequency of a food item could range from “never or 
less than once/month” to “≥ 6 times/day”. Dietary intake of vitamin B2, vitamin B6, vitamin B12, 
folate, and methionine were calculated by multiplying the consumption frequency of each food by the 
nutrient content of the portion specified. Nutrient values of foods were obtained from the Harvard 
University Food composition Database, derived mainly from the US Department of Agriculture 
sources. All nutrients were adjusted for total energy intake with use of the residual method.11
Ascertainment of type 2 diabetes
Participants in all three cohorts were asked whether they were diagnosed with diabetes by a physician 
every two years. Participants who self-reported physician diagnosed diabetes were sent a supple-
mentary questionnaire to confirm diagnosis.12, 13 Participants were defined as type 2 diabetes cases 
if they met at least one of the following criteria (according to the National Diabetes Data Group)14: 
classic symptoms plus fasting blood glucose ≥7.8 mmol/L or random blood glucose ≥11.1mmol/L; 
no symptoms, but increased blood glucose levels on two different occasions (i.e. fasting blood glucose 
≥7.8 mmol/L or random blood glucose ≥11.1mmol/L); treatment with hypoglycemic drugs. Starting 
June 1998 the threshold for fasting plasma glucose was changed to ≥7.0 mmol/L.15 Starting 2010 
HbA1c ≥ 6.5% was added to the diagnosis criteria.16
covariates
At baseline height was ascertained and during follow-up information on weight, smoking, marital 
status, family history of type 2 diabetes, hypertension, hypercholesterolemia, level of physical ac-
tivity, total energy intake, alcohol consumption, and ethnicity was ascertained with use of biennial 
questionnaires. For participants from NHS and NHS2, information on postmenopausal status and 
postmenopausal hormone use, and for participants from NHS2 only information on oral contracep-
tive use was obtained.
statistical analysis
We calculated cumulative updated averages of intake of vitamin B2, vitamin B6, vitamin B12, folate 
and methionine for each cohort to better estimate long-term intakes and to reduce within-person 
variation. Missing data on dietary intake during follow-up were replaced by the cumulative average of 
previous assessments. Updating was stopped in case of a cancer or CVD event, as diet may be changed 
in response to these events. Quantiles of each nutrient were calculated to limit the influence of outli-
ers and to detect potential non-linear associations. Person time was calculated for each participant 
from questionnaire return date until type 2 diabetes diagnosis, death, or end of follow-up. Hazard 
ratios were estimated using Cox proportional hazard regression analyses with time-varying covari-
ates to assess the association between quintiles of vitamin B2, vitamin B6, vitamin B12, folate and 
methionine and risk of type 2 diabetes. Age was included as the timescale. All models were adjusted 
for smoking, marital status, family history of type 2 diabetes, hypertension, hypercholesterolemia, 
level of physical activity, total energy intake, alcohol consumption, ethnicity, and BMI. In additional 
5.2 Methyl donor nutrient intake & type 2 diabetes mellitus
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models adjustments were made for other nutritional factors, including cereal fiber, animal protein, 
and PUFA:SFA ratio. Effect modification by age, family history of diabetes, and alcohol consumption 
was tested by including cross-product terms in the models. Analysis were performed per cohort and 
then combined in meta-analysis using a fixed effects model: the Cochrane Q statistic, the I2 statistic, 
and between-study coefficient of variation were used to assess heterogeneity. All analyses were per-
formed using SAS version 9.4 for UNIX (SAS Institute).
results
The baseline characteristics of participants are presented in Table 5.2.1. 5.2Mean and median intakes 
of vitamin B2, vitamin B6, vitamin B12, and methionine remained similar between baseline and 
during follow-up (data not shown). In contrast, due to the folate fortification which was implemented 
in 1998 (Figure 5.2.1),17 median [95% range] intake of folate changed from 301.0 [230.0-474] in 1984 
to 372.0 [262.0-650.0] in 2010.
We documented 17,629 cases of type 2 diabetes during 4,454,307 years of follow-up. The associations 
between quintiles of vitamin B2, vitamin B6, vitamin B12, folate, and methionine with risk of type 
2 diabetes are presented in Tables 5.2.2-5.2.6. In pooled multivariable-adjusted analysis, the highest 
quintile(Q5) of vitamin B2 was associated with a lower risk of type 2 diabetes compared to the lowest 
quintile(Q1) (HR [95% CI]: 0.92 [0.88, 0.97]). A higher vitamin B6 was also associated with a lower risk 
of type 2 diabetes (HR [95% CI]: Q5 vs. Q1 0.93 [0.89, 0.98]). The associations for vitamin B2 and vita-
min B6 remained significant for after adjustment for several other nutrients. Intake of total vitamin B12 
was not associated with risk of diabetes. However, when analyses were stratified by food source, vitamin 
B12 intake from food in Q5 was associated with a higher risk of diabetes compared to Q1, but this was 
no longer significant after adjustment of other nutrients (HR [95% CI]: 1.05 [0.99, 1.10]). In contrast, a 
high B12 intake from supplements was associated with lower risk of diabetes (HR [95% CI] Q5 vs. Q1: 
0.94 [0.90, 0.99]). There was a tendency toward a protective association for a high folate intake on risk 
of diabetes (HR [95% CI] Q5 vs. Q1: 0.90 [0.85, 0.94]). However, this association was attenuated after 
adjustment of other nutrients (HR [95% CI] Q5 vs. Q1: 0.95 [0.90, 1.00]). A high methionine intake 
was associated with a higher risk of diabetes(HR [95% CI] Q5 vs. Q1: 1.06 [1.01, 1.11]), but this was 
explained by other nutrients (HR [95% CI] Q5 vs. Q1: 0.97 [0.86, 1.09]).
We tested interactions for sex, alcohol intake, and family history of diabetes, but none of the inter-
action terms were significant. Therefore, all results are presented for the total population. In order to 
determine whether the folic acid fortification implementation in 1998 affected the association between 
folate intake and risk of type 2 diabetes, we performed several sensitivity analyses. First, we continuously 
updated folate intake, instead of cumulatively updating, but this did not change the results (data not 
shown). Second, we separated analyses for time periods before and after 1998. From these two time 
periods, similar results were observed compared to the total follow-up period (data not shown).
310
Chapter 5.2
ta
bl
e 
5.
2.
1.
 A
ge
-s
ta
nd
ar
di
ze
d 
ch
ar
ac
te
ris
tic
s b
y 
qu
in
til
es
 o
f m
et
hy
l d
on
or
 n
ut
rie
nt
s.
b
2
b
6
b
12
fo
la
te
m
et
hi
on
in
e
Q
1
Q
 3
Q
5
Q
1
Q
3
Q
 5
Q
1
Q
3
Q
5
Q
1
Q
3
Q
 5
Q
 1
Q
3
Q
 5
n
h
s
A
ge
 (y
ea
rs
)
49
.7
6
(7
.0
7)
50
.3
0
(7
.2
0)
50
.4
9
(7
.1
4)
49
.7
3
(7
.0
3)
50
.4
2
(7
.1
5)
50
.4
4
(7
.1
5)
49
.8
8
(7
.1
0)
50
.1
2
(7
.1
4)
50
.7
2
(7
.1
4)
49
.7
4
(7
.0
6)
50
.3
3
(7
.1
5)
50
.5
6
(7
.1
9)
50
.3
1
(7
.1
7)
50
.1
7
(7
.1
1)
50
.3
5
(7
.1
3)
w
hi
te
, %
97
98
98
98
98
98
98
98
97
98
98
98
97
98
97
c
ur
re
nt
 p
os
tm
en
op
au
sa
l 
ho
rm
on
e 
us
e,
 %
24
24
26
23
24
26
23
25
26
23
24
27
25
24
25
c
ur
re
nt
 sm
ok
er
, %
26
24
23
27
23
23
25
23
24
27
23
23
26
24
23
Ph
ys
ic
al
 a
ct
iv
it
y 
(m
et
-h
/
w
k)
13
.6
1
(1
9.
94
)
14
.1
2
(2
0.
00
)
14
.8
4
(2
2.
07
)
13
.5
3
(1
9.
45
)
14
.3
4
(2
1.
05
)
15
.1
4
(2
3.
29
)
13
.9
3
(2
0.
34
)
14
.3
1
(2
1.
82
)
14
.9
1
(2
3.
51
)
13
.2
5
(2
0.
35
)
14
.2
4
(2
0.
24
)
15
.0
7
(2
3.
36
)
13
.8
8
(2
0.
27
)
14
.1
7
(2
0.
86
)
14
.9
9
(2
3.
15
)
b
m
i 
(k
g/
m
2 )
24
.7
7
(4
.5
0)
24
.8
8
(4
.5
4)
24
.7
7
(4
.6
1)
24
.8
0
(4
.5
6)
24
.9
4
(4
.6
0)
24
.7
8
(4
.6
1)
24
.7
3
(4
.5
1)
24
.8
0
(4
.5
9)
24
.9
0
(4
.6
3)
24
.9
0
(4
.6
7)
24
.8
2
(4
.5
7)
24
.7
2
(4
.5
3)
24
.5
6
(4
.4
5)
24
.8
2
(4
.5
9)
25
.1
7
(4
.7
5)
fh
 d
ia
be
te
s,
 %
28
28
27
28
29
27
28
28
28
28
28
27
28
28
28
h
yp
er
te
ns
io
n,
 %
8
8
8
7
8
7
8
8
8
8
8
7
8
8
8
h
yp
er
ch
ol
es
te
ro
le
m
ia
, %
3
3
4
3
3
4
4
3
3
3
3
4
3
3
4
A
h
ei
 sc
or
e
46
.9
1
(1
0.
86
)
47
.6
1
(1
0.
49
)
48
.7
4
(1
1.
05
)
46
.5
0
(1
0.
68
)
47
.9
5
(1
0.
63
)
48
.9
1
(1
1.
14
)
47
.0
5
(1
0.
81
)
47
.5
7
(1
0.
91
)
48
.9
3
(1
0.
74
)
46
.1
4
(1
0.
74
)
47
.9
9
(1
0.
63
)
48
.8
3
(1
1.
04
)
46
.7
4
(1
0.
68
)
47
.5
5
(1
0.
79
)
49
.2
0
(1
0.
89
)
en
er
gy
 in
ta
ke
 (k
ca
l/
d)
15
30
(4
93
)
18
87
(5
39
)
17
04
(5
34
)
15
61
(5
09
)
18
99
(5
29
)
16
91
(5
26
)
16
36
(5
41
)
18
69
(5
53
)
16
27
(5
14
)
16
38
(5
37
)
17
96
(5
29
)
16
59
(4
98
)
17
05
(5
62
)
17
74
(5
28
)
16
93
(5
22
)
A
lc
oh
ol
 in
ta
ke
 (g
/d
)
9.
06
4
(1
4.
32
3)
5.
64
5
(9
.7
45
)
6.
61
5
(1
1.
19
3)
7.
47
5
(1
2.
22
0)
6.
39
5
(1
1.
15
5)
6.
73
9
(1
1.
30
1)
7.
72
4
(1
2.
92
9)
7.
13
7
(1
2.
03
6)
6.
05
8
(1
0.
14
5)
7.
38
8
(1
3.
00
2)
6.
76
7
(1
0.
77
0)
6.
46
2
(1
0.
64
1)
9.
81
2
(1
6.
15
0)
6.
71
4
(1
0.
35
8)
4.
58
8
(7
.4
83
)
V
it
am
in
 b
2 
in
ta
ke
 
(m
g/
d)
1.
14
2
(0
.1
50
)
2.
00
1
(0
.1
66
)
13
.3
0
(1
1.
62
)
1.
36
8
(0
.4
81
)
1.
95
9
(0
.6
35
)
12
.4
5
(1
2.
10
)
1.
62
9
(3
.2
30
)
4.
22
0
(4
.3
86
)
8.
15
8
(1
2.
12
2)
2.
35
2
(3
.4
08
)
3.
28
3
(4
.1
11
)
8.
17
0
(1
1.
69
6)
3.
57
7
(6
.1
45
)
4.
11
2
(6
.6
22
)
5.
08
2
(7
.9
12
)
V
it
am
in
 b
6 
in
ta
ke
 
(m
g/
d)
3.
66
2
(1
7.
65
9)
4.
13
9
(1
5.
50
4)
27
.5
7
(4
6.
21
)
1.
29
8
(0
.1
88
)
2.
12
6
(0
.1
92
)
38
.6
3
(5
3.
25
)
4.
52
1
(1
9.
39
3)
9.
09
7
(2
5.
65
0)
17
.3
5
(3
8.
71
)
4.
34
8
(1
8.
15
8)
6.
65
6
(2
1.
91
0)
21
.2
3
(4
2.
51
)
7.
85
7
(2
5.
73
7)
8.
96
5
(2
6.
85
9)
12
.1
3
(3
2.
74
)
5.2 Methyl donor nutrient intake & type 2 diabetes mellitus
311
Ch
ap
te
r 5
.2
ta
bl
e 
5.
2.
1.
 A
ge
-s
ta
nd
ar
di
ze
d 
ch
ar
ac
te
ris
tic
s b
y 
qu
in
til
es
 o
f m
et
hy
l d
on
or
 n
ut
rie
nt
s. 
(c
on
tin
ue
d)
b
2
b
6
b
12
fo
la
te
m
et
hi
on
in
e
Q
1
Q
 3
Q
5
Q
1
Q
3
Q
 5
Q
1
Q
3
Q
5
Q
1
Q
3
Q
 5
Q
 1
Q
3
Q
 5
V
it
am
in
 b
12
 in
ta
ke
 
(m
cg
/d
)
4.
64
6
(2
.4
57
)
10
.6
4
(5
.2
8)
20
.7
1
(3
2.
91
)
6.
41
4
(4
.6
90
)
9.
77
9
(5
.5
58
)
20
.2
5
(3
2.
79
)
3.
43
2
(0
.7
22
)
8.
84
6
(1
.4
96
)
25
.6
9
(3
0.
53
)
6.
83
9
(4
.6
80
)
9.
84
3
(8
.1
95
)
20
.4
1
(2
9.
48
)
8.
36
2
(1
7.
86
7)
11
.3
7
(1
4.
38
)
15
.2
3
(1
7.
36
)
fo
la
te
 in
ta
ke
 (m
cg
/d
)
21
5.
3
(7
2.
1)
31
8.
5
(9
3.
2)
55
0.
1
(3
29
.6
)
21
3.
3
(6
9.
6)
32
3.
4
(8
2.
7)
56
9.
2
(3
26
.6
)
24
4.
6
(9
1.
9)
39
7.
7
(1
82
.8
)
55
9.
2
(3
09
.1
)
17
8.
5
(2
8.
1)
30
2.
9
(2
1.
4)
76
5.
1
(2
14
.0
)
34
3.
8
(2
27
.0
)
37
9.
2
(2
20
.0
)
43
0.
8
(2
53
.6
)
m
et
hi
on
in
e 
in
ta
ke
 (g
/d
)
1.
47
3
(0
.3
34
)
1.
76
0
(0
.3
32
)
1.
73
6
(0
.3
96
)
1.
48
9
(0
.3
02
)
1.
77
3
(0
.3
57
)
1.
74
1
(0
.3
97
)
1.
40
1
(0
.2
83
)
1.
70
3
(0
.3
65
)
1.
83
8
(0
.3
96
)
1.
55
8
(0
.3
47
)
1.
70
8
(0
.3
51
)
1.
73
9
(0
.3
91
)
1.
18
2
(0
.1
35
)
1.
64
9
(0
.0
50
)
2.
21
5
(0
.2
57
)
n
h
s2
A
ge
 (y
ea
rs
)
36
.4
9
(4
.6
5)
36
.1
3
(4
.6
1)
35
.8
3
(4
.7
3)
36
.1
6
(4
.6
7)
36
.3
0
(4
.5
8)
35
.8
3
(4
.7
4)
36
.3
1
(4
.6
1)
36
.2
2
(4
.6
1)
35
.7
7
(4
.7
7)
36
.0
9
(4
.6
9)
36
.4
6
(4
.5
6)
35
.3
7
(4
.7
6)
36
.0
5
(4
.7
5)
36
.0
4
(4
.6
3)
36
.3
2
(4
.6
0)
w
hi
te
, %
95
97
97
96
97
97
97
97
96
95
97
97
96
97
96
c
ur
re
nt
 o
c 
us
e,
 %
12
11
9
12
11
8
12
11
10
12
11
8
12
11
10
c
ur
re
nt
 sm
ok
er
, %
18
10
11
17
10
11
13
12
12
18
10
9
15
12
11
Ph
ys
ic
al
 a
ct
iv
it
y 
(m
et
-h
/
w
k)
17
.6
8
(2
4.
62
)
20
.7
8
(2
6.
75
)
23
.7
8
(3
0.
61
)
16
.2
2
(2
3.
01
)
22
.0
2
(2
7.
30
)
23
.9
5
(3
0.
69
)
19
.9
0
(2
6.
34
)
20
.1
1
(2
6.
96
)
22
.9
0
(3
0.
13
)
15
.7
7
(2
2.
37
)
22
.2
7
(2
7.
59
)
23
.9
9
(3
0.
73
)
20
.9
8
(2
9.
34
)
20
.0
4
(2
5.
89
)
22
.6
8
(2
8.
63
)
b
m
i 
(k
g/
m
2 )
24
.5
6
(5
.6
0)
24
.5
8
(5
.1
4)
24
.2
8
(4
.9
0)
24
.6
1
(5
.6
6)
24
.5
4
(5
.1
4)
24
.3
5
(4
.8
7)
24
.1
4
(5
.2
3)
24
.7
8
(5
.3
9)
24
.4
5
(5
.0
0)
25
.0
6
(5
.8
5)
24
.2
9
(4
.9
8)
24
.2
5
(4
.8
3)
23
.6
5
(5
.0
1)
24
.3
8
(5
.0
5)
25
.5
2
(5
.5
6)
fh
 d
ia
be
te
s,
 %
35
34
33
34
34
34
34
35
34
35
34
33
32
34
36
h
yp
er
te
ns
io
n,
 %
7
5
6
7
6
6
6
6
6
7
6
6
5
6
7
h
yp
er
ch
ol
es
te
ro
le
m
ia
, %
15
13
14
14
14
15
14
14
14
16
13
14
13
14
16
en
er
gy
 in
ta
ke
 (k
ca
l/
d)
45
.1
0
(1
1.
01
)
47
.3
9
(1
0.
55
)
49
.8
1
(1
1.
04
)
41
.9
1
(9
.7
6)
49
.8
4
(1
0.
55
)
50
.3
9
(1
1.
23
)
47
.2
7
(1
1.
52
)
47
.1
0
(1
0.
67
)
48
.8
4
(1
0.
66
)
42
.0
7
(9
.6
1)
49
.6
8
(1
0.
64
)
50
.3
6
(1
0.
97
)
45
.3
4
(1
1.
98
)
46
.6
9
(1
0.
28
)
51
.6
7
(1
0.
12
)
A
lc
oh
ol
 in
ta
ke
 (g
/d
)
16
39
(5
38
)
19
03
(5
37
)
17
15
(5
35
)
16
49
(5
44
)
18
89
(5
45
)
17
40
(5
49
)
16
82
(5
45
)
18
73
(5
52
)
17
04
(5
39
)
17
04
(5
48
)
18
36
(5
47
)
16
84
(5
14
)
17
75
(5
84
)
18
18
(5
40
)
17
36
(5
26
)
V
it
am
in
 b
2 
in
ta
ke
 
(m
g/
d)
3.
67
3
(7
.1
57
)
2.
82
2
(5
.3
18
)
2.
84
4
(5
.9
18
)
3.
00
2
(6
.1
73
)
3.
20
5
(6
.0
66
)
2.
98
6
(6
.0
71
)
3.
39
6
(6
.7
56
)
3.
12
8
(5
.9
29
)
2.
75
5
(5
.5
13
)
3.
11
9
(6
.5
21
)
3.
31
2
(6
.0
75
)
2.
61
6
(5
.2
51
)
3.
81
6
(8
.0
05
)
3.
14
7
(5
.6
27
)
2.
41
4
(4
.5
38
)
312
Chapter 5.2
ta
bl
e 
5.
2.
1.
 A
ge
-s
ta
nd
ar
di
ze
d 
ch
ar
ac
te
ris
tic
s b
y 
qu
in
til
es
 o
f m
et
hy
l d
on
or
 n
ut
rie
nt
s. 
(c
on
tin
ue
d)
b
2
b
6
b
12
fo
la
te
m
et
hi
on
in
e
Q
1
Q
 3
Q
5
Q
1
Q
3
Q
 5
Q
1
Q
3
Q
5
Q
1
Q
3
Q
 5
Q
 1
Q
3
Q
 5
V
it
am
in
 b
6 
in
ta
ke
 
(m
g/
d)
1.
40
3
(0
.1
76
)
2.
30
5
(0
.1
72
)
11
.2
1
(1
6.
38
)
1.
61
4
(0
.4
39
)
2.
24
7
(0
.6
43
)
10
.7
3
(1
6.
49
)
1.
71
3
(1
.2
86
)
2.
80
2
(2
.3
01
)
9.
26
1
(1
6.
81
8)
1.
98
2
(2
.3
44
)
2.
83
3
(3
.2
99
)
8.
08
2
(1
5.
63
2)
3.
89
9
(9
.3
92
)
3.
88
4
(7
.9
99
)
4.
48
2
(9
.0
86
)
V
it
am
in
 b
12
 in
ta
ke
 
(m
cg
/d
)
3.
50
5
(1
5.
92
9)
4.
34
6
(1
5.
84
6)
22
.0
1
(4
1.
37
)
1.
58
9
(0
.2
00
)
2.
57
5
(0
.2
25
)
31
.1
3
(5
0.
36
)
4.
13
1
(1
7.
73
7)
5.
80
3
(1
9.
64
2)
17
.7
3
(3
7.
83
)
3.
77
6
(1
6.
01
1)
6.
26
7
(2
1.
41
5)
16
.7
2
(3
7.
05
)
8.
15
9
(2
6.
11
1)
7.
69
6
(2
3.
90
3)
9.
33
3
(2
6.
79
1)
fo
la
te
 in
ta
ke
 (m
cg
/d
)
4.
65
3
(1
.8
44
)
7.
95
2
(4
.6
11
)
19
.6
2
(2
4.
52
)
5.
43
6
(3
.5
04
)
7.
49
9
(4
.4
07
)
18
.6
9
(2
4.
61
)
3.
49
5
(0
.7
11
)
7.
42
7
(0
.4
95
)
22
.7
2
(2
4.
08
)
5.
71
4
(3
.8
41
)
7.
68
9
(6
.7
03
)
17
.9
2
(2
2.
64
)
8.
36
6
(1
3.
31
4)
9.
75
2
(1
4.
29
4)
11
.5
5
(1
3.
26
)
m
et
hi
on
in
e 
in
ta
ke
 (g
/d
)
25
8.
3
(7
6.
4)
37
1.
1
(1
03
.2
)
82
8.
9
(3
71
.6
)
24
9.
8
(6
7.
8)
38
4.
1
(9
4.
9)
82
5.
3
(3
83
.5
)
29
4.
6
(1
01
.3
)
39
4.
5
(1
74
.6
)
81
0.
1
(3
71
.9
)
21
7.
7
(3
2.
8)
37
4.
8
(3
0.
8)
95
1.
3
(2
73
.4
)
46
0.
9
(2
98
.2
)
47
5.
3
(2
83
.5
)
50
2.
9
(3
04
.4
)
en
er
gy
 in
ta
ke
 (k
ca
l/
d)
1.
85
2
(0
.4
21
)
2.
11
5
(0
.4
02
)
2.
08
9
(0
.4
50
)
1.
78
4
(0
.3
43
)
2.
14
9
(0
.4
33
)
2.
08
3
(0
.4
62
)
1.
78
0
(0
.4
17
)
2.
11
5
(0
.4
05
)
2.
13
4
(0
.4
51
)
1.
96
9
(0
.4
41
)
2.
04
9
(0
.4
13
)
2.
06
9
(0
.4
44
)
1.
47
0
(0
.1
95
)
2.
01
4
(0
.0
57
)
2.
64
9
(0
.2
86
)
h
P
fs
A
ge
51
.4
0
(9
.0
2)
53
.0
9
(9
.6
4)
53
.8
8
(9
.6
0)
50
.9
9
(9
.0
2)
53
.7
2
(9
.6
7)
54
.1
2
(9
.6
1)
51
.8
1
(9
.4
7)
52
.8
5
(9
.4
1)
53
.8
6
(9
.4
3)
51
.7
0
(9
.1
7)
53
.2
3
(9
.5
7)
54
.1
1
(9
.5
4)
52
.9
3
(9
.7
5)
52
.6
9
(9
.4
5)
53
.7
3
(9
.3
6)
w
hi
te
, %
93
96
95
95
95
95
94
96
95
94
95
95
94
96
95
c
ur
re
nt
 sm
ok
er
, %
11
9
9
14
6
9
8
9
11
14
7
8
11
9
8
Ph
ys
ic
al
 a
ct
iv
it
y 
(m
et
-h
/
w
k)
18
.5
3
(2
5.
84
)
21
.3
7
(2
9.
79
)
23
.6
4
(3
1.
12
)
16
.5
0
(2
2.
81
)
22
.9
2
(3
3.
03
)
24
.3
1
(3
2.
34
)
21
.6
3
(2
8.
98
)
21
.0
7
(2
7.
48
)
22
.2
9
(3
0.
98
)
16
.2
9
(2
5.
46
)
22
.8
5
(3
2.
87
)
25
.0
4
(3
3.
36
)
21
.4
9
(3
2.
41
)
20
.9
9
(2
6.
29
)
21
.9
6
(3
0.
83
)
b
m
i 
(k
g/
m
2 )
25
.5
8
(3
.2
4)
25
.4
7
(3
.2
7)
25
.1
1
(3
.1
4)
25
.6
5
(3
.3
2)
25
.4
3
(3
.2
8)
25
.0
9
(3
.1
3)
25
.1
8
(3
.1
4)
25
.5
5
(3
.4
0)
25
.5
3
(3
.4
8)
25
.8
2
(3
.5
1)
25
.4
2
(3
.2
1)
25
.0
8
(3
.2
4)
25
.0
3
(3
.1
6)
25
.4
0
(3
.1
1)
25
.9
3
(3
.5
8)
fh
 d
ia
be
te
s,
 %
19
21
21
19
20
20
19
20
20
19
20
20
19
21
21
h
yp
er
te
ns
io
n,
 %
21
17
20
18
19
20
20
18
19
20
18
20
18
19
21
h
yp
er
ch
ol
es
te
ro
le
m
ia
, %
11
8
12
8
10
12
12
9
10
9
10
12
9
10
12
en
er
gy
 in
ta
ke
 (k
ca
l/
d)
50
.8
7
(1
1.
67
)
51
.5
5
(1
1.
06
)
55
.0
5
(1
1.
72
)
47
.0
7
(1
0.
39
)
54
.7
1
(1
0.
90
)
56
.1
1
(1
1.
69
)
53
.1
0
(1
2.
08
)
51
.4
0
(1
1.
26
)
53
.8
6
(1
1.
15
)
46
.6
1
(1
0.
52
)
53
.9
6
(1
0.
83
)
56
.1
8
(1
1.
41
)
48
.9
9
(1
1.
55
)
52
.5
1
(1
1.
26
)
56
.0
4
(1
0.
95
)
5.2 Methyl donor nutrient intake & type 2 diabetes mellitus
313
Ch
ap
te
r 5
.2
ta
bl
e 
5.
2.
1.
 A
ge
-s
ta
nd
ar
di
ze
d 
ch
ar
ac
te
ris
tic
s b
y 
qu
in
til
es
 o
f m
et
hy
l d
on
or
 n
ut
rie
nt
s. 
(c
on
tin
ue
d)
b
2
b
6
b
12
fo
la
te
m
et
hi
on
in
e
Q
1
Q
 3
Q
5
Q
1
Q
3
Q
 5
Q
1
Q
3
Q
5
Q
1
Q
3
Q
 5
Q
 1
Q
3
Q
 5
A
lc
oh
ol
 in
ta
ke
 (g
/d
)
17
70
(5
53
)
21
52
(6
39
)
19
64
(6
16
)
17
76
(5
72
)
21
38
(6
32
)
19
44
(6
05
)
19
21
(6
05
)
20
87
(6
22
)
19
08
(6
01
)
18
93
(6
15
)
20
62
(6
21
)
19
21
(5
84
)
19
71
(6
31
)
20
29
(6
13
)
19
62
(6
30
)
V
it
am
in
 b
2 
in
ta
ke
 
(m
g/
d)
14
.1
6
(1
7.
88
)
9.
88
3
(1
3.
97
6)
11
.7
4
(1
5.
87
)
12
.1
9
(1
6.
31
)
10
.8
0
(1
4.
49
)
11
.5
0
(1
5.
46
)
12
.5
5
(1
7.
22
)
11
.4
1
(1
5.
17
)
10
.3
8
(1
4.
11
)
13
.0
7
(1
7.
95
)
10
.8
0
(1
4.
26
)
10
.7
8
(1
4.
24
)
16
.8
0
(2
1.
65
)
10
.9
7
(1
3.
84
)
7.
47
5
(9
.8
70
)
V
it
am
in
 b
6 
in
ta
ke
 
(m
g/
d)
1.
41
7
(0
.1
73
)
2.
38
9
(0
.2
00
)
16
.6
2
(1
8.
28
)
1.
64
9
(1
.2
70
)
2.
35
5
(0
.7
46
)
15
.9
3
(1
8.
71
)
2.
26
0
(4
.4
14
)
3.
78
6
(4
.0
09
)
11
.6
1
(1
9.
62
)
2.
99
3
(4
.5
83
)
3.
70
4
(4
.5
32
)
10
.9
5
(1
8.
79
)
4.
61
9
(8
.9
48
)
5.
02
8
(9
.1
36
)
6.
04
5
(1
2.
23
4)
V
it
am
in
 b
12
 in
ta
ke
 
(m
cg
/d
)
2.
31
6
(7
.4
13
)
3.
41
2
(9
.4
63
)
28
.0
5
(4
5.
88
)
1.
58
3
(0
.2
00
)
2.
67
4
(0
.2
22
)
32
.7
4
(4
8.
66
)
3.
91
5
(1
4.
24
4)
5.
96
4
(1
7.
94
9)
19
.9
6
(4
1.
17
)
3.
46
2
(1
1.
76
5)
5.
46
6
(1
6.
86
7)
22
.2
1
(4
3.
17
)
7.
63
9
(2
3.
16
1)
8.
13
9
(2
3.
11
4)
11
.1
9
(3
1.
45
)
fo
la
te
 in
ta
ke
 (m
cg
/d
)
6.
37
1
(2
.6
75
)
11
.4
5
(6
.3
4)
22
.5
3
(3
6.
02
)
7.
85
9
(4
.7
72
)
10
.0
6
(5
.6
2)
22
.7
7
(3
5.
77
)
4.
94
8
(1
.1
37
)
9.
46
8
(0
.4
99
)
29
.3
0
(3
5.
58
)
8.
60
1
(5
.5
15
)
10
.3
7
(6
.8
5)
21
.8
1
(3
3.
22
)
10
.2
5
(1
2.
82
)
12
.4
2
(1
2.
50
)
15
.2
7
(2
5.
59
)
m
et
hi
on
in
e 
in
ta
ke
 (g
/d
)
29
0.
5
(9
2.
1)
40
8.
6
(1
14
.1
)
69
1.
1
(4
10
.6
)
27
3.
8
(8
1.
9)
41
8.
2
(9
8.
5)
74
3.
1
(4
03
.8
)
34
4.
4
(1
19
.8
)
40
3.
1
(1
63
.1
)
72
5.
3
(4
01
.3
)
23
5.
6
(3
5.
6)
38
8.
1
(2
4.
1)
93
0.
7
(2
75
.9
)
45
1.
7
(2
69
.3
)
47
4.
8
(2
62
.5
)
51
0.
5
(3
04
.1
)
en
er
gy
 in
ta
ke
 (k
ca
l/
d)
2.
09
6
(0
.4
01
)
2.
31
7
(0
.3
76
)
2.
29
1
(0
.4
26
)
2.
02
8
(0
.3
37
)
2.
35
0
(0
.3
91
)
2.
30
5
(0
.4
28
)
2.
06
6
(0
.3
83
)
2.
28
2
(0
.3
71
)
2.
36
9
(0
.4
28
)
2.
16
9
(0
.4
30
)
2.
27
7
(0
.3
85
)
2.
28
2
(0
.4
17
)
1.
71
0
(0
.1
73
)
2.
22
9
(0
.0
55
)
2.
82
2
(0
.2
76
)
314
Chapter 5.2
table 5.2.2. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of vitamin B2
Q1 Q2 Q3 Q4 Q5
nhs
Total vitamin B2(mcg/d)
Median 1.5 2 2.7 4.5 10.6
Cases/person-years 1,728/347,616 1,727/357,685 1,662/352,678 1,569/352,563 1,455/352,887
Model 1 1 0.98 (0.91, 1.04) 0.94(0.87, 1.00) 0.88 (0.83, 0.95) 0.81 (0.76, 0.87)
Model 2 1 0.93 (0.87, 0.99) 0.92 (0.84, 0.98) 0.90 (0.84, 0.97) 0.87 (0.81, 0.93)
Model 3 1 0.95 (0.89, 1.02) 0.95 (0.88, 1.01) 0.94 (0.87, 1.01) 0.90 (0.84, 0.97)
Vitamin B2 from food (mcg/d)
Median 1.2 1.4 1.6 1.8 2.2
Cases/person-years 1,749/347,085 1,680/355,479 1,593/346,420 1,581/363,583 1,538/350,861
Model 4 1 0.91 (0.85,0.98) 0.91 (0.85, 0.98) 0.93 (0.87, 0.996) 0.85 (0.79, 0.92)
Model 5 1 0.93 (0.86, 0.99) 0.93 (0.86, 0.999) 0.95 (0.88, 1.03) 0.88 (0.81, 0.95)
Vitamin B2 from supplements (mcg/d)
Median 0 0.1 0.3 1.7 9.3
Cases/person-years 2,075/389,974 1,707/322,319 1,478/344,911 1,498/353,500 1,383/352,725
Model 6 1 0.94 (0.88, 1.01) 0.98 (0.92, 1.05) 0.96 (0.89, 1.03) 0.92 (0.89, 0.99)
Model 7 1 0.96 (0.89, 1.03) 0.995 (0.93, 1.07) 0.97 (0.90, 1.03) 0.91 (0.85, 0.98)
nhs ii
Total vitamin B2(mcg/d)
Median 1.6 2.1 2.7 3.9 16
Cases/person-years 1,462/361,387 1,209/364,647 1,130/363,958 1,080/364,306 1,168/365,126
Model 1 1 0.84 (0.78, 0.91) 0.79 (0.73, 0.86) 0.77 (0.71, 0.83) 0.78 (0.72, 0.84)
Model 2 1 0.90 (0.83, 0.96) 0.89 (0.82, 0.96) 0.90 (0.84, 0.98) 0.93 (0.85, 1.00)
Model 3 1 0.92 (0.85, 0.99) 0.92 (0.85, 0.99) 0.93 (0.86, 1.01) 0.96 (0.88, 1.03)
Vitamin B2 from food (mcg/d)
Median 1.4 1.7 1.9 2.1 2.5
Cases/person-years 1,515/360,779 1,283/365,758 1,229/364,291 1,112/364,686 910/363,910
Model 4 1 0.90 (0.83, 0.97) 0.90 (0.84, 0.98) 0.85 (0.78, 0.92) 0.78 (0.72, 0.85)
Model 5 1 0.90 (0.84, 0.98) 0.91 (0.78, 0.93) 0.85 (0.78, 0.93) 0.78 (0.71, 0.86)
Vitamin B2 from supplements (mcg/d)
Median 0 0.2 0.7 1.6 10.1
Cases/person-years 1,389/407,950 1,127/317,401 1,200/364,806 1,144/364,202 1,189/365,064
Model 6 1 0.87 (0.80, 0.94) 0.93 (0.86, 1.01) 0.95 (0.88, 1.03) 0.98 (0.90, 1.06)
Model 7 1 0.87 (0.80, 0.95) 0.93 (0.86, 1.01) 0.95 (0.88, 1.03) 0.97 (0.89, 1.05)
hPfs
Total vitamin B2 (mcg/d)
Median 1.57 2.06 2.69 4.13 13.01
Cases/person-years 729/173,610 752/174,265 655/174,658 681/174,346 622/174,579
Model 1 1 1.01 (0.91, 1.12) 0.87 (0.78, 0.97) 0.90 (0.81, 0.998) 0.82 (0.73, 0.91)
5.2 Methyl donor nutrient intake & type 2 diabetes mellitus
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table 5.2.2. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of vitamin B2 
(continued)
Q1 Q2 Q3 Q4 Q5
Model 2 1 1.02 (0.92, 1.13) 0.90 (0.80, 0.998) 0.94 (0.85, 1.05) 0.88 (0.79, 0.99)
Model 3 1 1.05 (0.94, 1.16) 0.92 (0.82, 1.03) 0.97 (0.87, 1.08) 0.91 (0.82, 1.02)
Vitamin B2 from food (mcg/d)
Median 1.47 1.73 1.94 2.18 2.59
Cases/person-years 717/173,562 656/174,986 707/174,544 709/174,255 650/174,109
Model 4 1 0.90 (0.81,0.999) 0.96 (0.86, 1.06) 0.94 (0.85, 1.05) 0.84 (0.75, 0.94)
Model 5 1 0.91 (0.81, 1.01) 0.97 (0.87, 1.09) 0.95 (0.85, 1.07) 0.84 (0.75, 0.95)
Vitamin B2 from supplements (mcg/d)
Median 1.69 1.99 2.22 2.47 2.92
Cases/person-years 781/200,534 665/146,833 707/175,029 668/174,460 618/174,601
Model 6 1 1.11 (0.98, 1.25) 1.04 (0.93, 1.17) 1.00 (0.90, 1.12) 0.97 (0.87, 1.08)
Model 7 1 1.12 (0.999, 1.26) 1.07 (0.95, 1.19) 1.02 (0.91, 1.14) 0.97 (0.87, 1.08)
Pooled
Total vitamin B2(mcg/d)
Model 1 1 0.93 (0.89, 0.98)* 0.87 (0.83, 0.91)* 0.84 (0.81, 0.88)* 0.80 (0.77, 0.84)
Model 2 1 0.94 (0.89, 0.98)  0.90 (0.86, 0.95) 0.91 (0.87, 0.95) 0.89 (0.85, 0.94)
Model 3 1 0.96 (0.91, 1.00) 0.93 (0.89, 0.98)  0.94 (0.90, 0.99)  0.92 (0.88, 0.97)
Vitamin B2 from food (mcg/d)
Model 4 1 0.91 (0.86, 0.95) 0.92 (0.87, 0.96)  0.90 (0.86, 0.94) 0.82 (0.79, 0.87)
Model 5 1 0.91 (0.87, 0.96) 0.93 (0.89, 0.98)  0.92 (0.87, 0.96) 0.84 (0.79, 0.88)
Vitamin B2from supplements (mcg/d)
Model 6 1  0.94 (0.90, 0.99)* 0.97 (0.93, 1.02)  0.97 (0.92, 1.01)  0.95 (0.91, 1.00)
Model 7 1 0.95 (0.91, 1.00)* 0.99 (0.94, 1.03)  0.97 (0.93, 1.02) 0.94 (0.90, 0.99)
Model 1: adjusted for age (continuously).
Model 2: model 1 + ethnicity (caucasian, black, or other), smoking (never, past, current: 1-14, 15-24, or 
≥25 cigarettes/day), marital status (currently married, widowed, divorced or separated, or never married), 
family history of type 2 diabetes (yes/no), hypertension(yes/no), hypercholesterolemia (yes/no), postmeno-
pausal status and hormone use(premenopausal, or if postmenopausal, never, current, or past postmeno-
pausal hormone use), total energy intake (quintiles), level of physical activity (<3, 3-9, 9-18, 18-27, or 
≥27 MET-h/week), alcohol consumption (0, 0.1-5, 5-10, 10-15, or ≥15 g/day), and BMI (<21, 21-23, 
23-25, 25-27, 27-30, 30-33, 33-35, 35-40, or ≥40 kg/m2).
Model 3: model 2 + intake of cereal fiber (quintiles), animal protein (quintiles), and PUFA:SFA ratio 
(quintiles).
Model 4: model 2 + multivitamin use (yes/no).
Model 5: model 3 + multivitamin use (yes/no).
Model 6: model 2 + AHEI index: (quintiles).
Model 7: model 3 + AHEI index: (quintiles).
* p-Value for Q-statistic <0.05, indicating statistically significant heterogeneity among the three cohorts
316
Chapter 5.2
table 5.2.3. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of vitamin B6
Q1 Q2 Q3 Q4 Q5
nhs
Total vitamin B6(mcg/d)
Median 1.6 2.3 3.1 4.8 24.4
Cases/person-years 1,777/356,303 1,702/349,303 1,649/350,357 1,521/353,413 1,492/353,641
Model 1 1 0.94 (0.88, 1.01) 0.91 (0.85, 0.97) 0.83 (0.78, 0.89) 0.81 (0.76, 0.87)
Model 2 1 0.93 (0.86, 0.99) 0.94 (0.88, 1.01) 0.90 (0.84, 0.96) 0.87 (0.81, 0.94)
Model 3 1 0.94 (0.88, 1.01) 0.97 (0.90, 1.04) 0.93 (0.87, 0.999) 0.91 (0.84, 0.97)
Vitamin B6 from food (mcg/d)
Median 1.3 1.6 1.7 1.9 2.3
Cases/person-years 1,749/347,085 1,680/355,479 1,593/346,420 1,581/363,583 1,538/350,861
Model 4 1 0.98 (0.91, 1.05) 0.98 (0.91, 1.05) 0.98 (0.92, 1.06) 0.92 (0.86, 0.99)
Model 5 1 0.99 (0.92, 1.06) 0.995 (0.92, 1.07) 1.02 (0.95, 1.10) 0.98 (0.90, 1.06)
Vitamin B6 from supplements (mcg/d)
Median 0 0.1 0.4 2 16
Cases/person-years 2,016/379,056 1,703/323,397 1,557/354,942 1,456/353,018 1,409/353,015
Model 6 1 0.95 (0.88, 1.02) 1.01 (0.94, 1.08) 0.94 (0.88, 1.01) 0.94 (0.87, 1.01)
Model 7 1 0.96 (0.89, 1.03) 1.02 (0.95, 1.09) 0.95 (0.88, 1.02) 0.93 (0.86, 0.99)
nhs ii
Total vitamin B6(mcg/d)
Median 1.8 2.3 3.1 4.6 23.6
Cases/person-years 1,352/355,812 1,201/368,418 1,189/368,953 1,109/360,367 1,198/365,874
Model 1 1 0.88 (0.81, 0.95) 0.86 (0.80, 0.93) 0.83 (0.76, 0.90) 0.85 (0.79, 0.90)
Model 2 1 0.92 (0.85, 0.999) 0.94 (0.87, 1.02) 0.94 (0.87, 1.02) 0.98 (0.90, 1.06)
Model 3 1 0.93 (0.86, 1.01) 0.96 (0.88, 1.04) 0.96 (0.88, 1.04) 1.00 (0.92, 1.08)
Vitamin B6 from food (mcg/d)
Median 1.6 1.9 2.1 2.3 2.6
Cases/person-years 1,320/363,342 1,197/363,468 1,209/363,681 1,180/364,435 1,143/364,497
Model 4 1 0.96 (0.88, 1.03) 0.995 (0.91, 1.08) 0.94 (0.86, 1.01) 0.97 (0.89, 1.05)
Model 5 1 0.95 (0.88, 1.03) 0.995 (0.91, 1.08) 0.94 (0.86, 1.03) 0.98 (0.89, 1.07)
Vitamin B6 from supplements (mcg/d)
Median 0 0.3 1 2.3 21.6
Cases/person-years 1,382/404,010 1,143/324,332 1,236/361,770 1,101/364,168 1,187/365,144
Model 6 1 0.88 (0.81, 0.96) 0.94 (0.87, 1.02) 0.92 (0.85, 1.00) 0.98 (0.90, 1.06)
Model 7 1 0.88 (0.81, 0.96) 0.94 (0.87, 1.02) 0.92 (0.85, 0.995) 0.96 (0.89, 1.04)
hPfs
Total vitamin B6 (mcg/d)
Median 1.8 2.3 3.1 4.6 18.9
Cases/person-years 757/168,808 698/179,817 680/173,644 690/174,365 614/174,822
Model 1 1 0.87 (0.78, 0.96) 0.85 (0.76, 0.94) 0.85 (0.77, 0.95) 0.75 (0.68, 0.84)
5.2 Methyl donor nutrient intake & type 2 diabetes mellitus
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table 5.2.3. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of vitamin B6 
(continued)
Q1 Q2 Q3 Q4 Q5
Model 2 1 0.89 (0.80, 0.98) 0.89 (0.80, 0.99) 0.92 (0.83, 1.03) 0.84 (0.75, 0.93)
Model 3 1 0.90(0.81, 0.998) 0.92 (0.82, 1.02) 0.95 (0.85, 1.06) 0.87 (0.77, 0.97)
Vitamin B6 from food (mcg/d)
Median 1.7 2 2.2 2.5 2.9
Cases/person-years 744/173,742 736/174,214 671/174,699 630/175,051 658/173,751
Model 4 1 0.98 (0.88, 1.08) 0.90 (0.81, 0.995) 0.86 (0.77, 0.96) 0.93 (0.84, 1.04)
Model 5 1 0.97 (0.88, 1.08) 0.90 (0.80, 1.00) 0.87 (0.77, 0.98) 0.96 (0.85, 1.08)
Vitamin B6 from supplements (mcg/d)
Median 0 0.1 0.6 2.2 16.3
Cases/person-years 783/197,397 682/149,920 692/175,026 663/174,321 619/174,792
Model 6 1 1.09 (0.97, 1.22) 1.00 (0.90, 1.12) 0.97 (0.87, 1.08) 0.95 (0.85, 1.06)
Model 7 1 1.10 (0.98, 1.23) 1.02 (0.91, 1.14) 0.96 (0.88, 1.10) 0.95 (0.85, 1.06)
Pooled
Total vitamin B6(mcg/d)
Model 1 1  0.91 (0.87, 0.95) 0.88 (0.84, 0.92) 0.84 (0.80, 0.87) 0.81 (0.78, 0.85)
Model 2 1 0.92 (0.88, 0.96) 0.93 (0.89, 0.97) 0.92 (0.88, 0.96) 0.90 (0.86, 0.95)*
Model 3 1 0.93 (0.89, 0.98) 0.96 (0.91, 1.00)  0.95 (0.90, 0.99) 0.93 (0.89, 0.98)
Vitamin B6 from food (mcg/d)
Model 4 1 0.97 (0.93, 1.02) 0.97 (0.92, 1.01) 0.94 (0.90, 0.99) 0.94 (0.89, 0.99)
Model 5 1 0.97 (0.93, 1.02) 0.98 (0.93, 1.03) 0.96 (0.91, 1.01) 0.97 (0.92, 1.03)
Vitamin B6 from supplements (mcg/d)
Model 6 1 0.95 (0.90, 0.99)* 0.98 (0.94, 1.03) 0.94 (0.90, 0.99) 0.95 (0.91, 1.00)
Model 7 1 0.95 (0.91, 1.00)* 0.99 (0.94, 1.04) 0.94 (0.90, 0.99) 0.94 (0.90, 0.99)
Model 1: adjusted for age (continuously).
Model 2: model 1 + ethnicity (caucasian, black, or other), smoking (never, past, current: 1-14, 15-24, or 
≥25 cigarettes/day), marital status (currently married, widowed, divorced or separated, or never married), 
family history of type 2 diabetes (yes/no), hypertension(yes/no), hypercholesterolemia (yes/no), postmeno-
pausal status and hormone use(premenopausal, or if postmenopausal, never, current, or past postmeno-
pausal hormone use), total energy intake (quintiles), level of physical activity (<3, 3-9, 9-18, 18-27, or 
≥27 MET-h/week), alcohol consumption (0, 0.1-5, 5-10, 10-15, or ≥15 g/day), and BMI (<21, 21-23, 
23-25, 25-27, 27-30, 30-33, 33-35, 35-40, or ≥40 kg/m2).
Model 3: model 2 + intake of cereal fiber (quintiles), animal protein (quintiles), and PUFA:SFA ratio 
(quintiles).
Model 4: model 2 + multivitamin use (yes/no).
Model 5: model 3 + multivitamin use (yes/no).
Model 6: model 2 + AHEI index: (quintiles).
Model 7: model 3 + AHEI index: (quintiles).
* p-Value for Q-statistic <0.05, indicating statistically significant heterogeneity among the three cohorts
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table 5.2.4. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of vitamin B12
Q1 Q2 Q3 Q4 Q5
nhs
Total vitamin B12(mcg/d)
Median 5 7.7 10 13 21
Cases/person-years 1,543/353,584 1,582/346,079 1,649/360,818 1,715/351,210 1,652/351,736
Model 1 1 1.04 (0.97, 1.12) 1.04 (0.97, 1.12) 1.10 (1.02, 1.17) 1.04 (0.97, 1.12)
Model 2 1 1.00 (0.93, 1.07) 1.01 (0.94, 1.08) 1.05 (0.98, 1.12) 1.00 (0.94, 1.08)
Model 3 1 1.00 (0.93, 1.08) 1.01 (0.94, 1.09) 1.05 (0.98, 1.13) 1.01 (0.94, 1.09)
Vitamin B12 from food (mcg/d)
Median 3.6 4.8 6 8 13.2
Cases/person-years 1,415/351,919 1,519/356,411 1,552/350,468 1,519/353,045 2,136/351,585
Model 4 1 0.98 (0.91, 1.06) 1.06 (0.99, 1.14) 1.08 (1.01, 1.16) 1.12 (1.04, 1.20)
Model 5 1 0.98 (0.91, 1.06) 1.06 (0.98, 1.14) 1.08 (1.00, 1.17) 1.11 (1.02, 1.19)
Vitamin B12 from supplements (mcg/d)
Median 0 0.2 0.9 3.9 8.6
Cases/person-years 1,946/365,271 1,682/338,434 1,736/353,930 1,447/352,380 1,330/353,414
Model 6 1 0.97 (0.90, 1.04) 0.97 (0.91, 1.04) 0.97 (0.91, 1.04) 0.92 (0.86, 0.99)
Model 7 1 0.97 (0.91, 1.04) 0.98 (0.91, 1.05) 0.98 (0.91, 1.05) 0.92 (0.85, 0.98)
nhs ii
Total vitamin B12(mcg/d)
Median 4.5 6.4 8.5 12 24
Cases/person-years 1,182/361,038 1,197/376,576 1,192/349,340 1,253/367,927 1,225/364,543
Model 1 1 1.03 (0.94, 1.12) 1.04 (0.96, 1.13) 1.04 (0.96, 1.12) 0.99 (0.91, 1.07)
Model 2 1 0.98 (0.90, 1.06) 0.999 (0.92, 1.08) 0.997 (0.92, 1.08) 0.99 (0.91, 1.07)
Model 3 1 0.98 (0.90, 1.06) 1.00 (0.92, 1.09) 1.00 (0.92, 1.09) 0.99 (0.91, 1.08)
Vitamin B12 from food (mcg/d)
Median 3.7 4.7 5.6 6.6 9.2
Cases/person-years 1,050/365,697 1,104/363,186 1,213/357,920 1,321/369,028 1,361/363,591
Model 4 1 0.94 (0.86, 1.02) 0.99 (0.91, 1.08) 1.01 (0.93, 1.09) 1.01 (0.93, 1.10)
Model 5 1 0.93 (0.85, 1.02) 0.97 (0.89, 1.06) 0.98 (0.90, 1.08) 0.98 (0.89, 1.07)
Vitamin B12 from supplements (mcg/d)
Median 0 0.7 2.2 5 15.9
Cases/person-years 1,381/407,570 1,108/309,418 1,162/373,191 1,200/363,351 1,198/365,894
Model 6 1 0.91 (0.84, 0.99) 0.95 (0.88, 1.03) 0.98 (0.91, 1.06) 0.99 (0.91, 1.06)
Model 7 1 0.92 (0.84, 0.99) 0.96 (0.88, 1.04) 0.98 (0.91, 1.06) 0.97 (0.90, 1.05)
hPfs
Total vitamin B12 (mcg/d)
Median 5.5 8 10.5 14.5 25.6
Cases/person-years 620/178,826 701/170,745 688/168,366 771/179,272 659/174,247
Model 1 1 1.15 (1.03, 1.28) 1.11 (0.99, 1.24) 1.18 (1.06, 1.31) 1.02 (0.91, 1.14)
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table 5.2.4. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of vitamin B12 
(continued)
Q1 Q2 Q3 Q4 Q5
Model 2 1.07 (0.96, 1.19) 1.03 (0.93, 1.15) 1.10 (0.99, 1.22) 0.95 (0.85, 1.08)
Model 3 1.05 (0.94, 1.17) 1.02 (0.91, 1.14) 1.08 (0.97, 1.20) 0.93 (0.83, 1.04)
Vitamin B12 from food (mcg/d)
Median 4.5 6 7.3 9.1 13.8
Cases/person-years 717/173,562 656/174,986 707/174,544 709/174,255 650/174,109
Model 4 1 1.11 (0.99, 1.25) 1.08 (0.96,1.21) 1.19 (1.07, 1.33) 1.09 (0.97, 1.22)
Model 5 1 1.10 (0.98, 1.24) 1.06 (0.94, 1.19) 1.15 (1.02, 1.30) 1.03 (0.91, 1.16)
Vitamin B12 from supplements (mcg/d)
Median 0 0.3 1.4 4.9 13.9
Cases/person-years 775/194,562 647/152,239 700/174,114 691/175,592 626/174,950
Model 6 1 0.998 (0.89, 1.12) 0.997 (0.89, 1.11) 1.01 (0.91, 1.13) 0.95 (0.85, 1.05)
Model 7 1 1.01 (0.90, 1.12) 1.00 (0.90, 1.12) 1.03 (0.92, 1.14) 0.95 (0.85, 1.06)
Pooled
Total vitamin B12(mcg/d)
Model 1 1  1.06 (1.01, 1.11) 1.05 (1.01, 1.11) 1.09 (1.04, 1.14) 1.02 (0.97, 1.07)
Model 2 1  1.01 (0.96, 1.05) 1.01 (0.96, 1.06)  1.04 (0.99, 1.09) 0.99 (0.94, 1.04)
Model 3 1 1.00 (0.96, 1.05)  1.01 (0.96, 1.06)  1.04 (0.99, 1.09) 0.99 (0.94, 1.04)
Vitamin B12 from food (mcg/d)
Model 4 1 0.99 (0.94, 1.04) 1.04 (0.99, 1.09) 1.08 (1.02, 1.13)*  1.07 (1.02, 1.13)
Model 5 1  0.98 (0.93, 1.04) 1.03 (0.97, 1.08)  1.06 (1.00, 1.12)  1.05 (0.99, 1.10)
Vitamin B12 from supplements (mcg/d)
Model 6 1  0.95 (0.91, 1.00) 0.97 (0.93, 1.02) 0.98 (0.94, 1.03)  0.95 (0.91, 1.00)
Model 7 1  0.96 (0.91, 1.01) 0.98 (0.93, 1.02) 0.99 (0.94, 1.04) 0.94 (0.90, 0.99)
Model 1: adjusted for age (continuously).
Model 2: model 1 + ethnicity (caucasian, black, or other), smoking (never, past, current: 1-14, 15-24, or 
≥25 cigarettes/day), marital status (currently married, widowed, divorced or separated, or never married), 
family history of type 2 diabetes (yes/no), hypertension(yes/no), hypercholesterolemia (yes/no), postmeno-
pausal status and hormone use(premenopausal, or if postmenopausal, never, current, or past postmeno-
pausal hormone use), total energy intake (quintiles), level of physical activity (<3, 3-9, 9-18, 18-27, or 
≥27 MET-h/week), alcohol consumption (0, 0.1-5, 5-10, 10-15, or ≥15 g/day), and BMI (<21, 21-23, 
23-25, 25-27, 27-30, 30-33, 33-35, 35-40, or ≥40 kg/m2).
Model 3: model 2 + intake of cereal fiber (quintiles), animal protein (quintiles), and PUFA:SFA ratio 
(quintiles).
Model 4: model 2 + multivitamin use (yes/no).
Model 5: model 3 + multivitamin use (yes/no).
Model 6: model 2 + AHEI index: (quintiles).
Model 7: model 3 + AHEI index: (quintiles).
* p-Value for Q-statistic <0.05, indicating statistically significant heterogeneity among the three cohorts
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table 5.2.5. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of folate
Q1 Q2 Q3 Q4 Q5
nhs
Total folate (mcg/d)
Median 212 284 363 474 659
Cases/person-years 1,840/350,315 1,770/352,055 1,598/353,694 1,530/353,706 1,403/353,659
Model 1 1 0.94 (0.88, 1.00) 0.84 (0.78, 0.90) 0.80 (0.75, 0.86) 0.73 (0.68, 0.78)
Model 2 1 0.996 (0.93, 1.06) 0.94 (0.87, 1.00) 0.91 (0.85, 0.98) 0.89 (0.83, 0.96)
Model 3 1 1.03 (0.96, 1.10) 0.98 (0.91, 1.05) 0.96 (0.90, 1.03) 0.95 (0.88, 1.02)
Folate from food (mcg/d)
Median 190.7 239.5 277.5 230 393.7
Cases/person-years 2,007/350,888 1,715/352,983 1,626/352,631 1,498/353,277 1,295/353,649
Model 4 1 0.996 (0.93, 1.07) 0.995 (0.93, 1.07) 0.97 (0.90, 1.04) 0.92 (0.85, 0.99)
Model 5 1 1.03 (0.96, 1.10) 1.05 (0.97, 1.12) 1.03 (0.96, 1.11) 1.00 (0.93, 1.08)
Folate from supplements (mcg/d)
Median 0 4.5 18.5 169.5 379.6
Cases/person-years 1,932/376,167 1,819/323,703 1,723/357,408 1,189/353,242 1,478/352,908
Model 6 1 0.98 (0.91, 1.05) 0.97 (0.90, 1.04) 0.91 (0.85, 0.98) 0.94 (0.87, 1.01)
Model 7 1 0.99 (0.92, 1.06) 0.98 (0.92, 1.06) 0.92 (0.86, 0.99) 0.94 (0.87, 1.01)
nhs ii
Total folate (mcg/d)
Median 239.0 318.0 415.0 575.0 821.0
Cases/person-years 1,563/361,937 1,219/363,705 1,161/364,140 1,164/364,834 942/364,808
Model 1 1 0.77 (0.71, 0.83) 0.73 (0.68, 0.79) 0.74 (0.69, 0.80) 0.63 (0.58, 0.68)
Model 2 1 0.92 (0.86, 0.995) 0.93 (0.86, 0.999) 0.95 (0.88, 1.02) 0.88 (0.81, 0.96)
Model 3 1 0.95 (0.88, 1.02) 0.96 (0.88, 1.04) 0.99 (0.91, 1.07) 0.92 (0.85, 1.00)
Folate from food (mcg/d)
Median 231.3 290.3 331.7 377.7 465.1
Cases/person-years 1,665/360,362 1,325/363,925 1,188/365,151 1,073/364,235 798/365,751
Model 4 1 0.94 (0.88, 1.01) 0.95 (0.88, 1.02) 0.93 (0.86, 1.01) 0.84 (0.77, 0.92)
Model 5 1 0.97 (0.90, 1.04) 0.99 (0.91, 1.07) 0.99 (0.91, 1.08) 0.91 (0.82, 1.00)
Folate from supplements (mcg/d)
Median 0 2 28.8 142.2 356
Cases/person-years 1,271/418,391 1,288/312,310 1,221/361,331 1,219/365,171 1,050/362,221
Model 6 1 0.94 (0.86, 1.03) 0.997 (0.91, 1.09) 1.01 (0.93, 1.10) 0.97 (0.87, 1.10)
Model 7 1 0.95 (0.86, 1.03) 1.00 (0.92, 1.10) 1.01 (0.93, 1.10) 0.96 (0.88, 1.05)
hPfs
Total folate (mcg/d)
Median 272 360.7 451.5 606.7 862.7
Cases/person-years 784/172,569 728/174,366 675/174,716 628/175,143 624/174,662
Model 1 1  0.91 (0.82, 1.00) 0.83 (0.75, 0.92) 0.77 (0.69, 0.85) 0.75 (0.68, 0.83)
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table 5.2.5. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of folate (con-
tinued)
Q1 Q2 Q3 Q4 Q5
Model 2 1 0.98 (0.88, 1.08) 0.94 (0.85, 1.05) 0.88 (0.79, 0.98) 0.92 (0.83, 1.03)
Model 3 1 1.02 (0.92, 1.13) 0.999 (0.90, 1.11) 0.94 (0.84, 1.05) 0.99 (0.89, 1.11)
Folate from food (mcg/d)
Median 253 313.6 359.2 412.4 508
Cases/person-years 819/172,813 724/174,098 652/175,009 677/174,510 567/175,026
Model 4 1 0.94 (0.85, 1.04) 0.86 (0.77, 0.95) 0.93 (0.84, 1.03) 0.85 (0.76, 0.95)
Model 5 1 0.96 (0.87, 1.07) 0.91 (0.81, 1.01) 0.998 (0.90, 1.11) 0.93 (0.83, 1.05)
Folate from supplements (mcg/d)
Median 0 8.58 38.2 216 435.4
Cases/person-years 823/217,120 591/128,956 724/176,160 655/174,906 646/174,314
Model 6 1 1.07 (0.95, 1.21) 1.10 (0.98, 1.23) 1.03 (0.92, 1.15) 1.01 (0.91, 1.13)
Model 7 1 1.09 (0.96, 1.23) 1.12 (0.98, 1.25) 1.05 (0.94, 1.17) 1.02 (0.91, 1.13)
Pooled
Total folate (mcg/d)
Model 1 1 0.87 (0.83, 0.91)* 0.80 (0.76, 0.83)*  0.77 (0.74, 0.81) 0.70 (0.66, 0.73)*
Model 2 1 0.97 (0.92, 1.01) 0.93 (0.89, 0.98) 0.92 (0.88, 0.96) 0.90 (0.85, 0.94)
Model 3 1 1.00 (0.95, 1.04) 0.98 (0.93, 1.02) 0.97 (0.92, 1.01) 0.95 (0.90, 1.00)
Folate from food (mcg/d)
Model 4 1 0.97 (0.92, 1.01) 0.95 (0.91, 1.00) 0.95 (0.90, 0.99) 0.88 (0.84, 0.92)
Model 5 1 0.99 (0.95, 1.04) 1.00 (0.95, 1.05) 1.01 (0.96, 1.06) 0.96 (0.91, 1.01)
Folate from supplements (mcg/d)
Model 6 1 0.98 (0.93, 1.03) 1.00 (0.95, 1.05) 0.97 (0.92, 1.02) 0.96 (0.92, 1.01)
Model 7 1 0.99 (0.94, 1.04) 1.01 (0.97, 1.07) 0.98 (0.93, 1.02) 0.96 (0.92, 1.01)
Model 1: adjusted for age (continuously).
Model 2: model 1 + ethnicity (caucasian, black, or other), smoking (never, past, current: 1-14, 15-24, or 
≥25 cigarettes/day), marital status (currently married, widowed, divorced or separated, or never married), 
family history of type 2 diabetes (yes/no), hypertension(yes/no), hypercholesterolemia (yes/no), postmeno-
pausal status and hormone use(premenopausal, or if postmenopausal, never, current, or past postmeno-
pausal hormone use), total energy intake (quintiles), level of physical activity (<3, 3-9, 9-18, 18-27, or 
≥27 MET-h/week), alcohol consumption (0, 0.1-5, 5-10, 10-15, or ≥15 g/day), and BMI (<21, 21-23, 
23-25, 25-27, 27-30, 30-33, 33-35, 35-40, or ≥40 kg/m2).
Model 3: model 2 + intake of cereal fiber (quintiles), animal protein (quintiles), and PUFA:SFA ratio 
(quintiles).
Model 4: model 2 + multivitamin use (yes/no).
Model 5: model 3 + multivitamin use (yes/no).
Model 6: model 2 + AHEI index: (quintiles).
Model 7: model 3 + AHEI index: (quintiles).
* p-Value for Q-statistic <0.05, indicating statistically significant heterogeneity among the three cohorts
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table 5.2.6. Hazard ratios (95% CIs) for type 2 diabetes according to quintiles of methionine
Q1 Q2 Q3 Q4 Q5
nhs
Methionine (mcg/d)
Median 1.4 1.6 1.7 1.8 2
Cases/person-years 1,264/347,134 1,426/354,669 1,590/358,789 1,766/351,334 2,095/351,502
Model 1 1 1.11 (1.03, 1.20) 1.23 (1.14, 1.32) 1.38 (1.28, 1.48) 1.63 (1.51, 1.74)
Model 2 1 1.02 (0.94, 1.10) 1.03 (0.95, 1.11) 1.04 (0.95, 1.12) 1.03 (0.96, 1.11)
Model 3 1 1.01 (0.90, 1.13) 0.97 (0.84, 1.11) 0.98 (0.83, 1.16) 0.95 (0.78, 1.15)
nhs ii
Methionine (mcg/d)
Median 1.5 1.8 1.9 2.1 2.4
Cases/person-years 927/364,771 994/364,213 1,128/364,059 1,261/365,380 1,739/361,000
Model 1 1 1.08 (0.99, 1.18) 1.23 (1.13, 1.34) 1.37 (1.26, 1.49) 1.86 (1.72, 2.01)
Model 2 1 0.95 (0.87, 1.04) 0.98 (0.89, 1.07) 0.98 (0.90, 1.07) 1.06 (0.98, 1.15)
Model 3 1 0.92 (0.81, 1.04) 0.96 (0.82, 1.13) 0.95 (0.78, 1.14) 1.03 (0.82, 1.28)
hPfs
Methionine (mcg/d)
Median 1.8 2 2.2 2.4 2.6
Cases/person-years 578/173,892 581/175,037 664/174,833 698/173,990 918/173,704
Model 1 1 1.01 (0.90, 1.13) 1.14 (1.02, 1.28) 1.20 (1.07, 1.34) 1.57 (1.41, 1.74)
Model 2 1 0.92 (0.87, 1.09) 0.98 (0.87, 1.09) 0.97 (0.86, 1.08) 1.10 (0.99, 1.23)
Model 3 1 0.92 (0.79, 1.06) 0.94 (0.79, 1.12) 0.86 (0.71, 1.06) 0.92 (0.72, 1.16)
Pooled
Methionine (mcg/d)
Model 1 1  1.08 (1.03, 1.14) 1.21 (1.15, 1.27) 1.34 (1.27, 1.40)  1.69 (1.61, 1.77)*
Model 2 1  0.98 (0.93, 1.03)  1.00 (0.95, 1.05) 1.00 (0.96, 1.06) 1.06 (1.01, 1.11)
Model 3 1 0.95 (0.89, 1.03) 0.96 (0.87, 1.05)  0.94 (0.84, 1.04)  0.97 (0.86, 1.09)
Model 1: adjusted for age (continuously).
Model 2: model 1 + ethnicity (caucasian, black, or other), smoking (never, past, current: 1-14, 15-24, or 
≥25 cigarettes/day), marital status (currently married, widowed, divorced or separated, or never married), 
family history of type 2 diabetes (yes/no), hypertension(yes/no), hypercholesterolemia (yes/no), postmeno-
pausal status and hormone use(premenopausal, or if postmenopausal, never, current, or past postmeno-
pausal hormone use), total energy intake (quintiles), level of physical activity (<3, 3-9, 9-18, 18-27, or 
≥27 MET-h/week), alcohol consumption (0, 0.1-5, 5-10, 10-15, or ≥15 g/day), and BMI (<21, 21-23, 
23-25, 25-27, 27-30, 30-33, 33-35, 35-40, or ≥40 kg/m2).
Model 3: model 2 + intake of cereal fiber (quintiles), animal protein (quintiles), and PUFA:SFA ratio 
(quintiles).
* p-Value for Q-statistic <0.05, indicating statistically significant heterogeneity among the three cohorts
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discussion
Our study suggests that higher intakes of vitamin B2 and vitamin B6 are associated with a lower risk 
of diabetes. A higher folate intake seemed to be associated with a lower risk of diabetes, but this was 
explained by intake of other nutrients. A higher vitamin B12 intake from supplements was associated 
with a lower risk of diabetes. In contrast, higher intake of vitamin B12 from food seems to be associ-
ated with a higher risk of diabetes, which may be due to animal products. There was no association 
between methionine intake and risk of diabetes.
We hypothesized that nutrients involved in one-carbon metabolism may influence the risk of type 
2 diabetes through changes in DNA methylation. Of these nutrients, only vitamin B2 and vitamin B6 
showed a protective association with the risk of type 2 diabetes. However, total intake of folate and 
methionine did not seem to be associated with risk of type 2 diabetes. The lack of findings on folate in 
contrast with findings from previous studies. In a case-control study, Nilsson et al. identified 251 CpG 
sites that were differentially methylated, of which the majority was hypomethylated, in diabetes cases 
compared to controls. The difference in DNA methylation could be explained by folate levels as these 
were positively correlated with the identified CpG sites, and folate levels were lower in participant 
with diabetes.18 Results from this study suggest that the association between folate and diabetes may 
be mediated through changes in DNA methylation. Our null- findings for folate and vitamin B12 are 
in line with findings from a randomized controlled trial among women at high risk of CVD, where 
no significant effects of supplementation of vitamin B6, vitamin B12, and folate on the risk of type 2 
 
figure 5.2.1. Median folate intake from 1984-2010
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diabetes were observed.8 They did observe a reduction in diabetes risk among women with a family 
history of diabetes. Therefore, we tested in our study population whether associations differed for par-
ticipant with family history of diabetes. However, no significant interaction was observed, suggesting 
that there was no difference for these groups in association between methyl donor nutrient intake and 
risk of type 2 diabetes. Possibly, the protective association observed for vitamin B2 and vitamin B6 
on diabetes risk are mediated through one-carbon metabolism, and consequently differential DNA 
methylation. Another explanation would be that these vitamins lower the risk of diabetes through 
other mechanisms, as vitamin B2 and vitamin B6 have been proposed to improve glucose metabolism 
and inflammation markers.19 So far, not many epidemiological studies have been conducted on the 
association between vitamin B2 and diabetes, but findings from clinical and animal studies suggest 
that vitamin B2 may decrease risk of diabetes through reduced inflammation, oxidative stress, and 
hyperglycemia.20, 21 Results from animal studies suggest that supplementation of vitamin B2 may be 
beneficial for glucose and insulin metabolism, but also reduce diabetic complications.21, 22 In a clinical 
study Bialy et al. showed that treatment of adipocyte-macrophage co-cultures with vitamin B2 lead 
to a reduction of pro-inflammatory factors and an increase of anti-inflammatory factors.23 Our find-
ings regarding vitamin B6 may be explained by its role in glucose metabolism. In an animal study, 
Maessen at al. reported that intervention with pyridoxine, a vitamin B6 analog, improved glucose me-
tabolism and insulin resistance in obese mice.24 In an intervention study among overweight and obese 
subjects, pyridoxine together with leucine had an improving effect on insulin sensitivity.25 In addition, 
an increase in advanced glycation end products (AGEs) may lead to diabetes related complications. 
As vitamin B6 has anti-AGEs properties, it may be a therapeutic target for diabetes complications.26
Strengths of this study include the large sample size with a high follow-up rate and its prospective 
design, which allowed us to asses diet before disease onset. Furthermore, the repeated dietary data 
enabled us to calculate cumulative average to represent a long-term diet, which have less measure-
ment error than estimated nutrient intake from single assessment.27 We also had detailed information 
on nutrients from different sources and a wide range of information on lifestyle factors and other co-
variates, minimizing the chance of confounding. However, several limitations should be considered. 
Due to the observational nature of the study-design, residual confounding cannot be excluded. Since 
dietary intake is self-reported, it is prone to measurement errors. There was low variation in vitamin 
intake, limiting the ability to detect associations for extreme high or extreme low intakes. Our study 
population was socioeconomic homogeneous, which may enhance internal validity, however it also 
reduces external validity. Therefore, results need to be replicated in a more representative group of 
the total population.
Findings from this study suggest that higher intakes of vitamin B2 and vitamin B6 are associated 
with a lower risk of type 2 diabetes. Higher intake of vitamin B12 from supplements was also associ-
ated with a lower diabetes risk, whereas a higher vitamin B12 intake from food seems to be associated 
with a higher risk of diabetes, which may be due to animal products. Future studies are needed to 
replicate these findings in other populations.
5.2 Methyl donor nutrient intake & type 2 diabetes mellitus
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AbstrAct
Background: Substitution of macronutrients may affect the risk of coronary heart disease (CHD) in 
different manners. Therefore, the aim of this study is to investigate the relationship of macronutrient 
intake and CHD, by taking into account single macronutrient subgroups and different substitutions, 
in a large prospective cohort study in the Netherlands.
Methods: This study was performed in 5,905 participants from The Rotterdam Study, a population-
based cohort study. Macronutrient intake was measured with use of a semi-quantitative food 
frequency questionnaire (FFQ). Incidence of CHD was ascertained through medical records. Cox 
proportional hazard regression analyses were used to study the association between intakes of mac-
ronutrients and CHD incidence.
Results: In multivariable-adjusted models plant protein was inversely associated with incident CHD 
at the expense of animal protein (HR of 0.54; 95%CI 0.30 - 0.97) as well as at the expense of saturated 
fat (HR of 0.56; 95%CI 0.33 - 0.98). Furthermore, animal protein was related to an increased risk of 
incident CHD at the expense of plant protein (HR of 1.64; 95%CI 1.01 - 2.68). However, total protein 
intake showed no association with CHD. Carbohydrates, fat and their subgroups were not associated 
with CHD incidence at the expense of any other macronutrient.
Conclusion: Findings from this population-based prospective cohort study suggest that a higher 
plant protein intake at the expense of either animal protein or saturated fat is associated with a lower 
risk of CHD. These findings support the current guidelines that recommend a dietary pattern provid-
ing more plant-based and less animal-based food.
5.3 Macronutrient intake & CHD
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introduction
Cardiovascular diseases (CVD) remain the leading global cause of death and its prevalence is still 
rising.1, 2 As coronary heart diseases (CHD) account for the major part of this amount, identifying 
determinants influencing CHD events is of importance.3
One of the major determinants for CHD is nutrition. The role of macronutrients in relation to 
CHD has been studied extensively, however, inconsistent findings have been reported. Although 
high intakes of saturated fatty acids (SFA) are generally considered a risk factor for CHD, a recent 
systematic reported that intake of SFAs is not associated with CHD.4 However, replacement of SFAs 
with other macronutrients was not taken into account. Another systematic review showed that this 
association depended on the nutrients for which it was substituted. No association was observed 
between SFAs and CHD when replaced by carbohydrates or monounsaturated fatty acids (MUFA), 
but when replaced by polyunsaturated fatty acids (PUFA) a lower risk in CHD was observed.5 These 
results suggest that the composition of the nutritional intake rather than single nutrients may be 
important in the interplay between diet and CHD risk. Besides SFA, other macronutrients and their 
subtypes have been studied in relation to CHD. In a prospective cohort study following 29,017 post-
menopausal women from Iowa for 15 years an isoenergetic replacement of carbohydrates or animal 
protein by vegetable protein decreased CHD mortality by 30 % among women with the highest protein 
intake.6 Within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 21,955 male smokers 
between 50 and 69 years a replacement of SFA and transfat with carbohydrates showed a decreased 
risk for CHD, whereas the replacement of MUFA with carbohydrates resulted in an increased risk.7
Hence, the macronutrient composition of the diet rather than single macronutrients is of impor-
tance when studying the association between nutrition and CHD risk. Nevertheless, studies focusing 
on all macronutrients and its interplay have not been carried out so far. Therefore, the aim of this 
study is to investigate the relationship of macronutrient intake and CHD, by taking into account 
single macronutrient subgroups and substitution in this association, in a large prospective cohort 
study in the Netherlands.
methods
The rotterdam study
The current analysis was embedded in the Rotterdam study, a population-based prospective cohort 
study in the city of Rotterdam, the Netherlands. As a response to the demographic changes of the 
population, this follow-up study aimed to evaluate the occurrence and progression of chronic diseases 
and their risk factors that are frequent in elderly persons. The first cohort started in 1990 (RS-I) and 
included participants of 55 years or over, living in the well-defined Ommoord district of Rotterdam. 
Until September 1993 all residents of this suburb matching the criteria (n=10,215) were invited and 
7,983 people responded (response of 78%). In 2000, a second cohort (RS-II) started with persons that 
became 55 years or those of 55 years or over that migrated into this district since the start of the study. 
Of the initially 4,472 invited persons, 3,011 responded (response of 67%). A further extension of the 
study (RS-III) was initiated in 2006, of the 6,057 invited subjects aged 45-54 years, 3,932 responded 
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(65% response). In total 14,926 subjects are included in the Rotterdam study, with an overall response 
of 72%. Briefly, examinations of the participants were administered at baseline enrollment including 
a home interview (2h) by a trained research assistant and physically examinations (5h) as well as 
dietary assessment at the research center in their district. All participants gave written informed con-
sent and the medical ethics committee of the Erasmus Medical Center and The Netherlands Ministry 
of Health, Welfare and Sports approved the study protocol.8
study population
To evaluate the association of the intake of macronutrients and coronary heart disease, data from 
subjects who responded to the study center at baseline from RS-I (n=7,983), RS-II (n=3,011) and RS-
III (n=3,932) of the Rotterdam study were used. Of all 14,926 participants we excluded 5,225 because 
of incomplete dietary data. In these cases diet was not assessed mainly because of exclusion of subjects 
suspected of dementia, logistic reasons, implausible reported dietary intake, not returned FFQ, or 
because dietitians considered reports unreliable. Furthermore, we excluded 86 subjects because of 
missing follow-up data, or no informed consent on CHD, and 3,710 because of a history or missing 
data of CHD, stroke, or diabetes mellitus at baseline, which left 5,905 participants for current analysis 
(Figure 5.3.1).
dietary assessment
Dietary intake of macronutrients for RS-I and RS-II was assessed in a two-step approach. At baseline, 
participants completed a self-administered questionnaire about the type of food and drinks consumed 
at least twice a month during the preceding year, as well as about dietary habits, supplement use and 
prescribed diets. Based on these data, subjects underwent a standardized interview supervised by a 
trained dietitian during their next visit in the research center after completing a checklist about their 
nutritional intake using 170-item semi-quantitative food frequency questionnaires (FFQ) to assess 
the amount and frequency in times per day, week, or month of their nutritional intake. The FFQ 
included 13 food groups and additional questions on prescribed diets, supplementary use, dietary 
habits and took seasonal variations in fruit, vegetable, and fish intakes into account.9 In RS-III, sub-
jects completed a self-administered but more comprehensive FFQ containing of 389 items, based on 
a validated FFQ for Dutch adults that also took into account preparation methods.10, 11 Portion sizes in 
both FFQs were expressed in standardized household measures (e.g., spoon or cup) and natural units 
(e.g., piece of fruit or slice of bread). To derive total energy and nutrient intakes per day the received 
dietary data were linked to the Dutch Food Composition Table of 1993 for RS-I and RS-II,12 and to 
the Dutch Food Composition Table of 2006 for RS-III.13
Ascertainment of chd
The primary endpoint of this study was incident CHD after the standardized home interview of each 
individual participant at baseline. CHD was defined as a fatal or non-fatal myocardial infarction (MI), 
a surgical or percutaneous myocardial revascularization procedure, or fatal CHD.14 Information on 
incident CHD was obtained through automated linkage of the study database to medical reports of 
general practitioners and hospitals in the research area. Data from participants with general practi-
tioners outside the study area was obtained through annual collection of their medical records. All 
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data on potential events were independently adjudicated by two research physicians and subsequently 
reviewed by a medical specialist in cardiovascular disease, whose judgment was considered decisive. 
Follow-up information for CHD was available until January 1, 2012.
Assessment of covariates
Information on sociodemographic data, current health status, medical history, medication use, and 
health behavior was obtained during a home visit by a trained research assistant using a structured 
questionnaire. Educational level of the subjects was categorized as low (primary education), interme-
diate (secondary general or vocational education), or high (higher vocational education or university). 
Smoking behavior was classifi ed in never, former, or current. Data on physical activity were obtained 
through combinations of an adapted version of the Zutphen Physical Activity Questionnaire and the 
LASA Physical Activity Questionnaire.15, 16 Because of diff erently extended data generation for physi-
cal activity between the three cohorts, z-scores were calculated to obtain comparable data. Height and 
weight of the participants were obtained during physical examinations at the research center while 
wearing indoor clothes without shoes. Body mass index (BMI) was calculated as weight divided by 
height squared (kg/m²). Blood pressure was measured in duplicate at the right brachial artery using 
a random-zero sphygmomanometer with the participant sitting quietly for at least fi ve minutes. Th e 
mean of both measurements was calculated. Participants were categorized as hypertensive when they 
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figure 5.3.1. Flow chart of participants included for analysis
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had a systolic blood pressure ≥140 mmHg, and/or a diastolic blood pressure ≥90 mmHg, and/or use 
of antihypertensive medication. Information on prevalent diseases at baseline was obtained during 
the standardized home interview and reviewed by a study physician using medical records, during 
physical examinations at the research center and through linkage with data from the Nationwide 
Medical Registry (LMR, Utrecht, the Netherlands).14 Current medication use was assessed during the 
baseline home interview and was coded in accordance with the Anatomical Therapeutic Chemical 
(ATC) classification system.14 Subjects were defined as prevalent type 2 diabetes cases if they had 
a serum glucose concentration ≥ 11.1 mmol/L before or 2 h after a 75-g glucose load or used anti-
diabetic medication. Stroke was defined as a combination of symptoms showing rapidly developing 
clinical signs of cerebral impairment for at least 24 h or leading to death caused by vascular origin 
17. Serum total cholesterol was assessed in non-fasting blood samples with an automated enzymatic 
method using Roche CHODPAP reagent agent.
statistical analysis
To assess the associations between macronutrients and CHD incidence, a cox (proportional haz-
ards) regression was used. Therefore, person years were calculated starting from the date of baseline 
examinations until January 1, 2012, or first CHD event, last contact or death. Taking into account 
the first occurring event, hazard ratios (HRs) were calculated with 95% confidence intervals (CI) 
for CHD incidence. For evaluation of the association between intakes of macronutrients and CHD 
incidence, total amounts of the macronutrients carbohydrates, fat and protein as well as their sub-
groups, i.e. mono- and disaccharides, polysaccharides, animal and plant protein, MUFA, PUFA, and 
SFA were included in the analysis. In order to account for confounding effects of total energy intake 
and substitutional influences of other macronutrients nutrient density substitution models were cre-
ated.18 In these models intakes of all nutrients that contribute to the total amount of energy intake 
were included, except for one. Intakes of g per day were calculated for 5% of total energy intake and 
included in the same model, at the expense of one nutrient (i.e. the nutrient left out of the model). 
Therefore, coefficients can be interpreted as a 5E% higher intake at the expense of the nutrient left 
out. Subsequently, three models were constructed including selections of confounders based on lit-
erature. The first crude model was adjusted for the energy adjusted macronutrients except one, total 
energy intake, age, sex, and study cohort. The second model was additionally adjusted for education, 
smoking, physical activity. And the third fully adjusted model included additionally BMI, hyperten-
sion and antihypertensive use, lipid reducing medication, serum cholesterol and postmenopausal 
status. In order to reduce bias due to missing data and increase statistical power multiple imputation 
(n=5 imputations) was implemented using the predictive mean matching method. All analyses were 
executed with IBM SPSS Statistics for Windows, version 21.0, software (IBM Corporation, Armonk, 
New York).
results
Baseline characteristics of the study population are shown in Table 5.3.1. The total population con-
sists of 5,905 with the highest number of participants in RS-I (n=2,717) followed by RS-III (n=2,303) 
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and the fewest in RS-II (n=885). Mean ± SD age of subjects in RS-I was 65.3 ± 6.7 years, subjects in 
RS-II had a mean age of 62.8 ± 7.6 years, and in RS-III 56.7 ± 6.3 years. The person years of follow up 
since baseline differed between the cohorts depending on the start of the study with a mean of 19.3 ± 
4.9 person years in RS-I, 13.8 ± 3.2 years in RS-II and 7.5 ± 1.3 years in RS-III. During this time 410 
(15.0 %) CHD events in RS-I, 64 (7.2 %) in RS-II and 35 (1.5 %) in RS-III occurred.
Table 5.3.2 presents the associations between total, plant and animal protein intake at the expense 
of the other macronutrients with the incidence of CHD. In fully adjusted models (model 3), intake 
of plant protein was negatively associated with incident CHD when consumed at the expense of 
animal protein (HR of 0.54; 95%CI 0.30 - 0.97) or SFA (HR of 0.56; 95%CI 0.33 - 0.98), but not at the 
expense of the other macronutrients. Animal protein intake was positively associated with incident 
CHD when consumed at the expense of plant protein (HR of 1.64; 95%CI 1.01 - 2.68), but not at 
the expense of other macronutrients. Total protein intake was not related to CHD incidence when 
consumed at the expense of fat or carbohydrates and its subgroups.
Associations between total carbohydrate, mono- and disaccharide and polysaccharide intake and 
CHD incidence of the fully adjusted models are shown in Table 5.3.3. No association was found for 
mono- and disaccharides at the expense of polysaccharides (HR of 0.92; 95%CI 0.80 - 1.07). Intake of 
total carbohydrates, mono- and disaccharides and polysaccharides were not related to CHD incidence 
when consumed at the expense of protein or fat and its subgroups.
table 5.3.2. Association between incident CHD and total, plant and animal protein intake at 
the expense of the other macronutrients and their subgroups
total Protein
HRa (95% CIb)
Plant Protein
HRa (95% CIb)
Animal Protein
HRa (95% CIb)
expense of
-Plant Protein / / 1.643 (1.007 - 2.682)*
-Animal Protein / 0.541 (0.302 - 0.967)* /
total fat 1.080 (0.903 - 1.292) 0.587 (0.341 - 1.012) 1.131 (0.943 - 1.358)
-Saturated Fat 0.940 (0.727 - 1.216) 0.563 (0.325 - 0.976)* 1.045 (0.792 - 1.380)
-Mono-Unsaturated Fat 1.293 (0.974 - 1.715) 0.697 (0.362 - 1.344) 1.279 (0.962 - 1.700)
-Poly-Unsaturated Fat 1.041 (0.827 - 1.310) 0.572 (0.312 - 1.052) 1.058 (0.840 - 1.332)
total carbohydrates 1.092 (0.917 - 1.299) 0.717 (0.443 - 1.163) 1.098 (0.921 - 1.309)
-Mono- and Disaccharides 1.089 (0.914 - 1.299) 0.610 (0.342 - 1.088) 1.123 (0.938 - 1.346)
-Polysaccharides 1.105 (0.909 - 1.342) 0.564 (0.288 - 1.105) 1.038 (0.846 - 1.275)
aHazard ratio (HR) estimated from Cox proportional hazard regression model. bConfidence interval 
of the estimated HR. Multivariate model were adjusted for macronutrients, energy intake (continu-
ous, in kcal/day), age (continuous), sex (reference = male), cohort (RS-I, RS-II, RS-III), education 
(low, intermediate, high), smoking (current, former, never), physical activity (continuous), BMI 
(continuous), hypertension or antihypertensive use, lipid reducing medication, serum cholesterol 
(continuous), postmenopausal status. *p<0.05.
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Table 5.3.4 presents the associations between total, MUFA, PUFA, and SFA intake with incident 
CHD. MUFA was not related to CHD at the expense of SFA (HR of 0.81; 95%CI 0.53 - 1.24) or PUFA 
(HR of 0.82; 95%CI 0.59 - 1.14). PUFA was not related to CHD at the expense of SFA (HR of 0.99; 
95%CI 0.77 - 1.28) or MUFA(HR of 1.21; 95%CI 0.88 - 1.65), as well as SFA showed no association at 
the expense of MUFA (HR of 1.22; 95%CI 0.82 - 1.82) or PUFA (HR of 1.02; 95%CI 0.79 - 1.32). Fur-
thermore, total, MUFA, PUFA and SFA intake were not related to CHD incidence when consumed at 
the expense of any of the other examined macronutrients.
table 5.3.3. Association between incident CHD and total carbohydrates, mono- and disaccha-
rides and polysaccharides at the expense of the other macronutrients and their subgroups
total carbohydrates
HRa (95% CIb)
mono- and disaccharides
HRa (95% CIb)
Polysaccharides
HRa (95% CIb)
expense of
-Mono- and Disaccharides / / 1.084 (0.934 - 1.258)
-Polysaccharides / 0.924 (0.796 - 1.072) /
total Protein 0.928 (0.780 - 1.104) 0.925 (0.773 - 1.107) 0.912 (0.748 - 1.112)
-Plant Protein 1.367 (0.917 - 2.038) 1.463 (0.898 - 2.384) 1.560 (0.885 - 2.749)
-Animal Protein 0.916 (0.771 - 1.089) 0.893 (0.745 - 1.070) 0.968 (0.789 - 1.188)
total fat 0.990 (0.916 - 1.069) 1.001 (0.919 - 1.089) 1.103 (0.951 - 1.279)
-Saturated Fat 0.859 (0.694 - 1.063) 0.930 (0.736 - 1.175) 1.009 (0.771 - 1.320)
-Mono-Unsaturated Fat 1.186 (0.954 - 1.475) 1.141 (0.911 - 1.429) 1.236 (0.968 - 1.577)
-Poly-Unsaturated Fat 0.953 (0.794 - 1.143) 0.941 (0.784 - 1.129) 1.021 (0.816 - 1.276)
aHazard ratio (HR) estimated from Cox proportional hazard regression model. bConfidence interval 
of the estimated HR. Multivariate model were adjusted for macronutrients, energy intake (continu-
ous, in kcal/day), age (continuous), sex (reference = male), cohort (RS-I, RS-II, RS-III), education 
(low, intermediate, high), smoking (current, former, never), physical activity (continuous), BMI 
(continuous), hypertension or antihypertensive use, lipid reducing medication, serum cholesterol 
(continuous), postmenopausal status. *p<0.05.
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discussion
In this population-based study among 5,905 Dutch persons aged 45 or older, plant protein was 
inversely associated with incident CHD at the expense of animal protein as well as at the expense of 
SFA. Furthermore, animal protein was related to an increased risk of incident CHD at the expense of 
plant protein. However, total protein intake showed no association with CHD. Carbohydrates, fat and 
their subgroups were not associated with CHD incidence at the expense of any other macronutrient.
Findings of the present study show that higher plant protein intake is related to a lower CHD 
risk. This beneficial association might be driven by reducing CHD risk factors. Postulated effects of 
an increased dietary protein intake are a weight loss due to a greater satiety and lower subsequent 
energy intake, improved lipid and lipoprotein profile by decreasing triacylglycerol and oxidized LDL 
cholesterol and reduced blood pressure.19-21 However, these findings remain controversial and seem to 
depend on the dietary source of protein as a critical determinant of the outcome. A systematic review 
focusing on the protein source has shown beneficial effects on blood pressure for plant protein, and 
no association for animal protein.22 Similarly, a review of observational and interventional studies 
regarding CVD risk underlines the favorable effects of a diet containing mainly plant-derived protein 
sources as well as unprocessed animal-based protein foods that are low in SFA,23 which is in line with 
the present study. However, no significant association was observed between total protein intake and 
CHD risk. Due to the opposite directions in which plant and animal protein are associated with CHD 
risk, it is possible that both protein subgroups outweigh each other, resulting in a null-association 
for total protein intake. In line with several previous studies, we observed that a higher plant protein 
intake at the expense of SFA was associated with lower CHD incidence.6, 24 Beneficial effects by replac-
ing SFA in the diet have also been shown in former studies. In contrast to the present study, this 
association was evaluated in replacing SFA by PUFAs as reported in a pooled analysis of 11 European 
and American cohort studies, which analyzed the association of MUFAs, PUFAs and carbohydrates 
with CHD. However, carbohydrate subgroups and dietary protein intake were not included in the 
analysis.5 Another study combining data from the Nurses´ Health Study following 84,628 women and 
Health Professionals Follow-up Study following 42,908 men took different sources of carbohydrates 
into account and found that both PUFAs and high-quality carbohydrates are associated with a de-
creased risk of CHD if they replace dietary SFA.25
Strengths of this study contain the prospective study design with extensive data collection, allow-
ing the adjustment for many possible confounders and a long follow-up period. Furthermore, in this 
study we used a comprehensive approach that combines all macronutrients, including subgroups and 
evaluated all possible combinations of substitution by each other in association with CHD incidence. 
Due to application of the nutrient density substitution model, the amount of energy intake as well 
as influencing effects of other nutrients were taken into account and allow a more practical inter-
pretation of the results.18 A limitation of this study is the observational nature, therefore, no causal 
relationship can be concluded. Furthermore, residual confounding cannot be ruled out, as in any 
observational study. Moreover, using an FFQ relies on self-report an can lead to measurement error. 
Therefore, it may not have been possible to estimate accurate absolute amounts of nutritional intakes 
Nevertheless, this instrument has been shown to be an appropriate method for ranking individuals by 
their nutritional intakes in epidemiologic studies and has been validated against 15 24-h food records 
5.3 Macronutrient intake & CHD
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among participants in the Rotterdam Study obtaining good correlations between both methods.9, 26 
A further limitation of this study consists in the lack of repeated data on dietary intakes. Changes in 
the diet between baseline measurement and the outcome could not be assessed and included in the 
analysis. Furthermore, the generalizability of these results should be taken into account. As subjects 
with prevalent CHD, stroke and diabetes at baseline were excluded from the analysis suggesting a 
higher risk of developing CHD in these groups, the evaluated study population is a relatively healthy 
group. Therefore, results can only be generalized to a relatively healthy older population.
In conclusion, findings from this population based prospective cohort study suggest that a higher 
plant protein intake at the expense of either animal protein or SFA is associated with a lower risk 
of CHD. This is in line with current dietary guidelines that recommend a shift towards a higher 
plant-based diet and lower animal-based diet. The current study has shown substitutional associa-
tions of macronutrients and contributes to an evaluation of the whole diet in context of CHD risk. 
Nevertheless, further studies that investigate the underlying mechanisms are needed.
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Aims
The aim of this thesis was to investigate the interplay between nutritional factors, DNA methylation, 
and cardiometabolic risk factors and diseases in children as well as adults. We were mainly interested 
in nutrients that are known to be involved in DNA methylation through their role in the one-carbon 
metabolism, including vitamin B2, vitamin B6, vitamin B12, folate, and methionine. Other nutrients 
that may be involved in DNA methylation were examined as well, such as protein and fatty acids. The 
cardiometabolic risk factors of interest for both children and adults were body composition and lipid 
levels. Additionally, in adults we explored CHD events and type 2 diabetes.
mAin findings 
Chapter 2: Nutrition and DNA methylation
In the past years, there has been an increasing interest in the effect of nutrition on DNA methyla-
tion.1-3 Altered DNA methylation may have an effect on several cardiometabolic outcomes; the role 
of nutrition in this mechanism may therefore be of importance in strategies for prevention and treat-
ment of several chronic diseases.4 Results from animal studies have shown promising results,5-7 and 
the past decade there has been an incredible increase in publications of human studies on this topic as 
well. However, findings from studies in humans on the role of nutrition in DNA methylation are still 
inconsistent.1 In order to gain more insight in effects of several nutrients on DNA methylation across 
the life-course in humans, a clear overview of the current evidence is of importance. Identifying 
which nutrients affect DNA methylation of which CpG sites will provide insight in the mechanisms 
that are responsible for the effect of nutrition on several health outcomes. The aim of this chapter 
was to systematically review the literature on the associations between different nutrients with DNA 
methylation in humans across all stages of the life course (Chapter 2.1). The majority of the publica-
tions included in this review explored the role of methyl donor nutrients, including folate and other 
B-vitamins, and fatty acids in DNA methylation. The literature review showed that several nutrients, 
including folate, fatty acids, and vitamin D, are associated with DNA methylation on a global, gene-
specific, or genome-wide level. However, the directions of these associations are inconsistent. Further 
large-scale studies of high quality are needed to elucidate the role of nutrition in DNA methylation.
Chapter 3: DNA methylation and cardiometabolic health
DNA methylation has been linked to several health outcomes, including cardiometabolic factors such 
as dyslipidemia and obesity. There is promising evidence that DNA methylation is related to choles-
terol and triacylglycerol. In order to obtain a better understanding of the role of DNA methylation on 
dyslipidemia, a comprehensive overview of the current evidence is of importance. Therefore, we con-
ducted a systematic review on studies investigating the association between DNA methylation (global, 
gene-specific, and genome-wide) and lipid levels (triacylglycerol, total cholesterol, LDL-cholesterol, 
and HDL-cholesterol) (Chapter 3.1). In this review we included 31 publications, based on 23 unique 
studies. There were no consistent associations observed for global DNA methylation and lipid levels. 
Gene-specific and genome-wide studies showed significant associations between lipid levels and DNA 
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methylation at ABCG1, CPT1A, SREBF1, TNNT1, MIR33B, and TNIP, which were replicated. Of all 
studies included in our review, only three performed an EWAS.8-10 As a hypothesis-free approach was 
used in these types of studies, replication is important. Therefore, we performed an EWAS on lipid 
levels using data from the Rotterdam Study (Chapter 3.2). In this EWAS we replicated previously 
reported associations for methylation of ABCG1, CPT1A, and SREBF1 with triacylglycerol and HDL-
cholesterol.9, 10 In addition, we observed a novel association between DNA methylation of a CpG site 
near DHCR24 and HDL-cholesterol. The DHCR24 gene encodes for 3-hydroxysterol-24 reductase, 
a cholesterol biosynthesis enzyme that catalyzes the conversion of desmosterol to cholesterol.11, 12 
Furthermore, we studied the association between DNA methylation and anthropological measures, 
such as BMI and waist circumference. We conducted an EWAS on BMI and WC in the Rotterdam 
Study and replicated these results in the ARIC study (Chapter 3.3). We identified and replicated 12 
CpG sites associated with BMI and 13 CpG sites associated with WC. These included several CpG 
sites known to be related to cardiometabolic outcomes, such as ABCG1 and CPT1A. In addition 
to these known CpG sites, we identified two novel CpG sites related to both BMI and WC, namely 
MSI2 and LARS2. MSI2 encodes RNA-binding proteins and plays a central role in posttranscriptional 
gene regulation,13 and has been suggested to be associated with eating behaviors.14 LARS2 encodes 
an enzyme that catalyzes aminoacylation of mitochondrial tRNALeu and may be linked to bipolar 
disorder.15, 16 Considering that bipolar disorder is associated with obesity, overweight, and abdominal 
obesity,17 methylation of MSI2 and LARS2 could play a role in disturbances in eating behaviors, and 
consequently can affect BMI and WC. In conclusion, in our EWASs we replicated previously reported 
associations between DNA methylation and cardiometabolic outcomes, but also identified novel CpG 
sites related to lipids and obesity-related traits. 
Chapter 4: Nutrition and cardiometabolic health in children 
In chapter 4 we studied the associations between several nutrients, which may be involved in DNA 
methylation and cardiometabolic outcomes in children. Some of these nutrients are known to be 
directly involved in the one-carbon metabolism, such as vitamin B6, vitamin B12 and folate. Besides 
these nutrients, other nutrients, including protein and fatty acids, have been suggested to affect 
DNA methylation as well. These nutrients could therefore also be associated with cardiometabolic 
health in children through epigenetic mechanisms. In Chapter 4.1 we started by investigating the 
association between the known methyl donor nutrients, including vitamin B6, vitamin B12, folate 
and methionine with body composition. We observed that high intake of folic acid at the age of 1 
year was associated with a lower weight and BMI at the age of 6 years, whereas a high methionine 
intake was associated with an unfavorable body composition, including a higher BMI and body fat 
percentage. Furthermore, we studied the association between protein intake ate the age at 1 year 
with repeatedly measured growth and detailed body composition. We observed that a higher protein 
intake, in particular animal protein, at 1 year was associated with a higher height, weight, and BMI, up 
to the age of 9 years (Chapter 4.2), and we found that the positive association between protein intake 
and BMI was driven by a higher fat mass index (Chapter 4.3). Intake of fat or fatty acids at the age of 
1 year, however, were not associated with these growth and body composition outcomes or with other 
aspects of cardiometabolic health in childhood (Chapter 4.4). 
6.1 General discussion
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Chapter 5: Nutrition and cardiometabolic health in adults 
The aim of this chapter was to investigate associations between nutrition and cardiometabolic health 
in different large cohort studies adults. First, we studied the association of folate and vitamin B12 
levels with body composition in the B-PROOF study (Chapter 5.1). We observed that higher levels 
of folate were associated with a lower BMI. This association was most pronounced in participants 
with prevalent cardiometabolic diseases, and was mainly driven by FFMI rather than FMI among 
these participants. In contrast, higher levels of vitamin B12, measured by HoloTC and MMA, were 
associated with a higher FMI. Second, we studied the role of methyl donor nutrients and the risk 
of diabetes using data from the Nurses’ Health Study and Health Professionals Follow-up Study 
(Chapter 5.2). We observed that higher intake of vitamin B2 and vitamin B6 was associated with a 
lower risk of type II diabetes. This association was attenuated slightly, but remained significant, after 
adjustment of several sociodemographic and lifestyle covariates. Higher intake of vitamin B12 from 
supplements was also associated with a lower diabetes risk, whereas a higher vitamin B12 intake from 
food seems to be associated with a higher risk of diabetes, which may be due to animal products. 
Finally, we investigated the association between macronutrient intake and the risk of CHD (Chapter 
5.3). Although we observed no association between total protein intake and risk of CHD, when we 
separated analyses for animal and vegetable protein we observed significant associations in opposite 
directions. A higher animal protein intake was associated with a higher risk of CHD, whereas a higher 
plant protein intake was associated with a lower risk of CHD. The discrepancy in findings for animal 
and plant protein could be due to a difference in amino acid composition. Certain amino acids, such 
as methionine and lysine, may affect DNA methylation, and consequently cardiometabolic health.3 
methodologicAl considerAtions
Study design & study populations 
For the studies in this thesis data from different cohorts were used. The majority of the studies in-
cluded in this thesis were carried out in two Dutch population-based prospective cohort studies: The 
Generation R Study and the Rotterdam Study. The Generation R Study included offspring of women 
from Rotterdam who were recruited during pregnancy. Data on follow up in early childhood was 
available up to the age of 9 years. The Rotterdam Study included residents from Ommoord, aged 
45 years and older. In addition, for a few studies in this thesis we used data from the Nurses’ Health 
Study, Nurses’ Health Study II, Health Professionals Follow-Up Study, ARIC, and B-PROOF Study. 
All the data we used from these studies were of observational nature. When interpreting the results of 
our studies, both internal validity and external validity should be considered. Internal validity refers 
to the accuracy of the measurements of the variables of interest in our studies. Regarding internal 
validity, three different types of bias should be taken into account, i.e. selection bias, information 
bias, and confounding. The specific types of information bias and confounding will be discussed per 
variable of interest separately later in this chapter. Selection bias occurs when associations between 
the exposure and outcome of interest are different for the population that participate in the study and 
the population that was eligible for inclusion, but did not participate. In this thesis, the studied popu-
lations tented toward a selection of a more healthy population with a higher social-economic status. 
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However, previous studies have shown that selective non-participation at baseline are not likely to be 
related to future risk of diseases and therefore do not strongly influence associations, making bias due 
to selection unlikely.18 Nevertheless, it may affect the external validity of our results, which should 
be taken into account when extrapolating our findings. External validity, or generalizability, means 
to what extent findings can be extrapolated to the population of interest. In order to determine the 
generalizability of findings, one should always take into account the source population that is used 
to select subjects included in the studies. There are some differences in external validity between 
cohorts included in this thesis, as the Generation R Study and Rotterdam Study are both population-
based cohort studies, whereas the Nurses’ Health Study and Health Professionals Follow-Up Study 
exclusively consist of health professionals. These different source populations have several strengths 
and limitations. For example, the internal validity of studies including health professionals may be 
higher, as this is a well-educated group of health professionals and may be more capable of estimating 
their health behaviors, such as diet, as opposed to the general population. However, findings from 
these studies may not be generalizable to the total population. In contrast, the population-based stud-
ies may have a higher external validity, but internal validation may not be as high compared to the 
cohorts involving health professionals. 
DNA methylation 
For our studies involving DNA methylation, we used an epigenome-wide association study approach. 
This method provides the opportunity to identify novel CpG sites that are involved in regulation 
of a wide range of phenotypes, in our case, cardiometabolic health. Nevertheless, with this type of 
approach caution must be taken when interpreting the results. As EWAS follows a hypothesis-free ap-
proach, significant findings from these types of studies could be the result of false positives. This type 
of error, also known as Type I error, can be caused by multiple testing. Considering the high number 
of tests being carried out, the generally used cut-off of a p-value of <0.05 is not desirable as this would 
result in a high number of chance findings. One way of dealing with this issue is the use of the Bonfer-
roni correction, i.e. dividing the cut-off for statistical significance (e.g. P<0.05) by number of test that 
are carried out.  This limits the possibility of false-positive findings. However, this method is also 
considered to be too conservative as the number of effective tests may not be as high as the number of 
CpGs studied, due to the correlations among CpGs.19 This correction may therefore be too stringent, 
which may lead to false-negative findings, also known as Type II error. Usually, this is caused by lack 
of power, mainly due to a small sample size. A common approach to overcome this power issue is 
the collaborations between studies. Furthermore, hypothesis-free approaches are in fact generating 
a hypothesis that need replication. Therefore, to ensure that our findings are true-positives, we made 
use of a discovery and a replication cohort. In the discovery cohort, we apply the EWAS approach, 
which fulfills hypothesis-generating purposes. Consequently, we investigate whether the significant 
results from the discovery cohort were also associated within the replication cohort, serving as a 
hypothesis-testing purpose. When findings replicate across two different cohorts, the chance that this 
is due to Type I error is minimal. Two different types of replication are usually applied, internal rep-
lication (within same study population) or external replication (across different study populations). 
When an internal replication is applied, populations of the discovery and replication cohorts are from 
the same source population and thus more homogeneous, making it less likely that associations will 
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be distorted by cohort-specific differences. When external replication is applied, heterogeneity across 
studies may limit the possibility to replicate findings across cohorts. On the other hand, external 
replication provides the opportunity to explore whether identified CpG sites replicate across different 
populations. In contrast to genetics, DNA methylation is dynamic over time and prone to change in 
response to environmental factors. Therefore, it is crucial to consider potential confounders when 
exploring the association between DNA methylation and cardiometabolic outcomes. Considering 
this, we adjusted our analyses for lifestyle factors, such as smoking, which has been shown to be 
strongly associated with DNA methylation.20 Furthermore, the DNA methylation profile varies across 
different cell types. Therefore, confounding by differences in cell types should be taken into account 
when analyzing DNA methylation. Since whole blood was used for DNA methylation measurements, 
we adjusted all our models for leukocyte proportions,21 as these are strongly correlated with DNA 
methylation. In addition, DNA methylation measurements are subject to batch effects. Therefore, we 
included technical covariates, i.e. array number and position on array, in our models.
Nutrition assessments  
The dietary intake data from all cohorts used in this thesis were measured using FFQs. The strength 
of using an FFQ is its ability to measure habitual intake and that they are easily completed by 
participants, making them particularly appealing for large-scale studies. Limitations of the FFQ 
are that it is self-reported and it is therefore prone to measurement error, which may result in to 
misclassification of the exposure. In general, subjects tend to overestimate healthy food items, such 
as fruits and vegetables, but underestimate unhealthy products.22, 23 If these measurement errors are 
non-differential, i.e. these are random and not related to the outcome of interest, this may attenuate 
associations between nutrient intake and the outcome of interest. However, misclassification could 
also be differential, i.e. it is related to the outcome of interest. For instance, obese subjects are more 
likely to underreport their food intake, especially fat intake.24 Due to measurement error, it is not 
feasible to estimate the exact amount of intake of a certain nutrient with use of an FFQ. However, 
it has been shown to be a good method for ranking participants by intake of nutrients, making it 
a suitable method to examine associations with health outcomes.25 The FFQs used in our studies 
were evaluated against other methods that measure dietary intake which demonstrated the ability to 
adequately rank participants according to their intake. In the first two cohorts of the Rotterdam Study 
dietary intake was assessed with an FFQ of 170 food items. This FFQ was validated against fifteen 24h 
food records and four 24h urinary urea excretion samples in a subsample of 80 participants of the 
Rotterdam Study. Pearson’s correlations for nutrient intakes with the food records ranged between 
0.44 and 0.85 and Spearman’s correlation for protein intake against urinary urea was 0.67.26 For the 
third cohort, dietary intake was assessed using a self-administered 389 item semi quantitative FFQ. 
This FFQ was previously validated in two other Dutch populations using a 9-day dietary record27 
and a 4 week dietary history,28 which showed Pearson’s correlations for intakes of different nutrients 
varying from 0.40 to 0.86. In The Generation R Study the FFQ was validated against three 24h-recalls, 
obtained by trained nutritionists, in a representative sample of 32 Dutch children aged 14 months.29 
Intraclass correlation coefficients for nutrient intakes ranged from 0.36 to 0.74.30 The FFQ was only 
validated for Dutch children, while we had a multi-ethnic study population. Therefore, we performed 
sensitivity analyses in Dutch children only, which showed that all results were similar to those of the 
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total study population. In our study populations the variation of intakes of nutrients was relatively 
low. This made it difficult to detect an association between dietary intake of certain nutrients and any 
of the cardiometabolic outcomes evaluated. Considering that intake of many nutrients are correlated 
with total energy intake, associations with cardiometabolic outcomes may be confounded by energy 
intake. To account for this potential bias, we adjusted our nutrients of interest for energy using two 
methods: the residual method and the macronutrient substitution model.31 Besides the adjustment 
for energy intake, these methods will also reduce the measurement error.25, 32 In addition to energy 
intake, we adjusted for several medical, demographic and lifestyle variables. However, as in all obser-
vational studies, residual confounding may still be present. 
Cardiometabolic health
For the studies included in this thesis our outcomes of interest consisted of various cardiometabolic 
risk factors in both children and adults, including body composition and lipid levels. In addition, 
in adults we studied incidence of cardiometabolic diseases, i.e. diabetes and coronary heart disease. 
When studying disease incidence as an outcome of interest, a large sample size is needed to provide 
sufficient statistical power and enable us to detect associations. On the other hand, studying cardio-
metabolic risk factors as outcome of interest requires less power, and provides the opportunity to 
investigate underlying mechanisms. Furthermore, by identifying determinants of risk factors, early 
preventive measures can be taken, i.e. before disease incidence occurs. Nevertheless, the extent to 
which cardiometabolic diseases can be predicted by biomarkers and risk factors should be taken into 
account. Obesity, defined as having a BMI of >30, is one of the major risk factors for cardiometabolic 
diseases.33 Therefore, we aimed to study determinants that lead to an increase of BMI. This will not 
only provide insights in potential preventive strategies for reducing obesity, it may consequently pre-
vent diabetes and CHD. The use of BMI as outcome of interest is practical and low in costs, making it 
ideal for large-scale studies. However, this measure is limited regarding prediction of cardiometabolic 
health because it does not take into account body composition or distribution of body fat.34, 35 A 
higher fat mass is detrimental for cardiometabolic health, whereas a higher fat-free mass is associated 
with beneficial cardiometabolic health.36 Furthermore, distribution of body fat is of importance when 
predicting cardiometabolic health. Abdominal fat may lead to an increased risk of cardiometabolic 
diseases, but this may not be the case for gynoid fat. One solution could be waist circumference or 
waist-to-hip ratio, as these measurements provide a better estimate of abdominal fat.37 However, us-
ing detailed measures of body composition is preferred over indirect measures.38 Therefore, a strength 
of our studies is the assessment of body composition and distribution of body fat with the use of DXA. 
By making a distinction between fat mass and fat-free mass, which may have different effects on later 
health outcomes, we were able to show that the positive association between protein intake and BMI 
was mainly driven by FMI. Still, to what extent body composition during childhood predicts future 
risk of cardiometabolic diseases could be debated, as it is more challenging to demonstrate this due 
to the time-lapse. Nevertheless, previous studies have shown that cardiometabolic risk factors most 
certainly track from childhood to adulthood and increase the risk of cardiometabolic diseases.39-41 
Hence, targeting factors associated with cardiometabolic health during childhood could be a good 
strategy to prevent later cardiometabolic diseases. 
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clinical implications and directions for future research 
Considering that our studies are based on observational data, the possibility to determine a causal 
relation is limited. However, some of our results confirm previously reported effects shown in trials. 
The causal effect of a higher protein intake in early childhood on a higher weight and BMI has been 
confirmed in a randomized controlled trial among 1138 children comparing the effect of higher- and 
lower-protein formula during the first year of life on growth up to 6 years of age.42, 43 Our findings 
regarding protein intake and growth and body composition, confirms these results. In addition, we 
have shown that this association persists up to the age of 9 years. Furthermore, the association be-
tween a higher animal protein intake and BMI was driven by a higher fat mass and not fat-free mass. 
This increase of fat mass in response to animal protein could lead to detrimental health outcomes in 
later life. Promoting a lower protein intake, especially animal protein, in early life could be an effective 
strategy to prevent childhood adiposity, and consequently lower the risk of cardiometabolic diseases 
later in life. In line with this, in adults higher animal protein intake may also lead to unfavorable 
cardiometabolic health, as it was associated with a higher risk of CHD. In contrast, plant protein was 
associated with a lower risk. These findings are in line with current guidelines stating that consump-
tion of animal-based food items should be limited. Furthermore, findings from our studies suggest 
that higher intakes of certain methyl donor nutrients, including vitamin B2, vitamin B6, and folate 
are associated with favorable cardiometabolic health outcomes, such as a lower BMI and lower risk 
of type 2 diabetes. However, evidence from epidemiological studies is still scarce, thus future studies 
are needed to replicate these findings in other populations. In contrast to our hypothesis, a higher 
intake of total vitamin B12 was associated with unfavorable cardiometabolic health outcomes in both 
children and adults. Since vitamin B12 naturally occurs in animal products, this could explain these 
unexpected findings. Interestingly, when we separated our analyses for vitamin B12 from foods and 
supplements in relation to type 2 diabetes (chapter 5.2), results were in opposite direction. A higher 
vitamin B12 intake from food was associated with a higher risk of type 2 diabetes, whereas a higher 
intake of vitamin B12 from supplements was associated with a lower risk of type 2 diabetes. This 
suggests that the detrimental associations we observe for vitamin B12 may indeed be due to the foods 
in which it is present: animal based food. This could be elucidated by implementing randomized 
controlled trials with vitamin B12 supplementation, in which the food source of vitamin B12 not an 
issue.  
One of the mechanisms that may mediate the association between nutrition and cardiometabolic 
health is DNA methylation. In our studies on DNA methylation and cardiometabolic risk factors we 
have replicated several CpG sites, which were also previously reported by several studies, namely 
ABCG1, CPT1A, and SREBF1. These CpG sites could be used as a marker to predict risk of cardio-
metabolic diseases and may act as therapeutic targets. Future studies should further investigate how 
nutrition, including methyl donor nutrients, affect DNA methylation at these CpG sites. In other 
cases, our findings create new hypotheses, such as methylation of DHCR24 that was associated with 
HDL-C. Although it is biologically plausible that this CpG site plays a role in cholesterol metabolism, 
replication is still required to confirm whether this newly identified CpG sites is indeed associated 
with HDL-C. Furthermore, the use of different study designs are required to determine potential 
causality, for instance with the use of the Mendelian randomization approach.44, 45 As we did not have 
any longitudinal information on DNA methylation, we could not examine DNA methylation changes 
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over time. In addition, when investigating DNA methylation at a genome-wide level a large sample 
size is required to obtain sufficient statistical power. Therefore, collaboration of cohort studies in 
consortia is required to achieve this. 
conclusion 
In conclusion, findings from this thesis suggest that higher intakes of protein, especially animal 
protein, may be detrimental for cardiometabolic health in children as well as adults. Furthermore, 
we observed that intake of some methyl donor nutrients, such as vitamin B2, vitamin B6, and folate, 
could be beneficial for cardiometabolic health. Epigenetic mechanisms may be involved in these as-
sociations, as some of these nutrients have been shown to be associated with DNA methylation. In 
addition, we have identified and replicated CpG sites involved in cardiometabolic pathways which 
were differentially methylated in relation to cardiometabolic risk factors. These CpG sites might 
serve as biomarkers to identify subjects at high risk of cardiometabolic diseases and could be used as 
therapeutic targets. Still, further large-scale studies are needed to replicate these findings and further 
elucidate the role of nutrition in DNA methylation and its effects on cardiometabolic health. 
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summAry
Chapter 1 provides a general introduction on nutrition, DNA methylation and cardiometabolic 
health and a description of the studies on which this thesis is based. 
In Chapter 2 we discuss the associations between nutrition and DNA methylation. Chapter 2.1 
provides an overview of the current evidence on the associations between different nutrients with 
DNA methylation in humans across all stages of the life course (i.e. during pregnancy, infancy, child-
hood, adolescence, and adulthood). In this systematic review we identified 3774 references, of which 
98 studies met all inclusion criteria. The majority examined associations in adults and folate was the 
main nutrient of interest. Several candidate gene and epigenome-wide association studies reported 
differential DNA methylation of CpG sites in response to folate (e.g. IGF2, H19, HOX), fatty acids 
(e.g. PPRAGC1A, TNFα), and vitamin D (CYP24A1). Some of these observed associations were spe-
cific to life course stage (e.g. IGF2 in early life) and tissue (e.g. opposite directions for PPRAGC1A in 
muscle vs. fat tissue). To date, promising results have been reported in the field of nutrition and DNA 
methylation in humans at different stages across the life-course. Especially for nutrients known to be 
involved in one-carbon metabolism, such as folate, but also others, such as fatty acids and vitamin D. 
Studies on other nutrients, such as other macronutrients and several minerals are still scarce. Further 
large-scale studies of high quality are needed to expand our understanding on the role of nutrition in 
DNA methylation and its effects on health and disease. 
In Chapter 3 we discuss the associations of DNA methylation and cardiometabolic risk factors. 
Chapter 3.1 provides an overview of studies investigating the association between DNA methylation 
(global, gene-specific, and genome-wide) and lipid levels (triacylglycerol, total cholesterol, LDL-
cholesterol, and HDL-cholesterol). In this systematic review we included 31 publications, based on 
23 unique studies. There were no consistent associations observed for global DNA methylation and 
lipid levels. Gene-specific and genome-wide studies showed significant associations between lipid 
levels and DNA methylation at ABCG1, CPT1A, SREBF1, TNNT1, MIR33B, and TNIP, which were 
replicated. In Chapter 3.2 presents results of an EWAS on lipid levels in the Rotterdam Study. In 
this EWAS we replicated previously reported associations for methylation of ABCG1, CPT1A, and 
SREBF1 with triacylglycerol or HDL-cholesterol. In addition, we observed a novel association 
between DNA methylation of a CpG site near DHCR24 and HDL-cholesterol. The DHCR24 gene 
encodes for 3-hydroxysterol-24 reductase, a cholesterol biosynthesis enzyme that catalyzes the con-
version of desmosterol to cholesterol. Chapter 3.3 presents the findings of an EWAS on BMI and WC 
in the Rotterdam Study and replication of these findings in a USA-based study. We identified and 
replicated 12 CpG sites associated with BMI and 13 CpG sites associated with WC. These included 
several CpG sites, which are known to be related to cardiometabolic outcomes, such as ABCG1 and 
CPT1A. In addition to these known CpG sites, we identified two novel CpG sites related to both BMI 
and WC, namely MSI2 and LARS2. MSI2 encodes RNA-binding proteins and plays a central role in 
posttranscriptional gene regulation, and has been suggested to be associated with eating behaviors. 
LARS2 encodes an enzyme that catalyzes aminoacylation of mitochondrial tRNALeu and may be 
linked to bipolar disorder. 
Chapter 4 focuses on associations of nutrition in early childhood with cardiometabolic health 
in children at school age from The Generation R Study. Chapter 4.1 describes associations between 
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intake of methyl donor nutrients, including vitamin B6, vitamin B12, folate, and methionine with 
growth and body composition. We observed that high intake of folic acid at the age of 1 year was 
associated with a lower weight and BMI at the age of 6 years, whereas a high methionine intake 
was associated with an unfavorable body composition, including a higher BMI and fat percentage. 
Chapter 4.2 shows the association between protein intake with repeatedly measured growth. We ob-
served that a higher protein intake, in particular animal protein, at 1 year was associated with a higher 
height, weight, and BMI, up to the age of 9 years. Chapter 4.3 presents associations between protein 
intake with detailed body composition. We found that the positive association between protein intake 
and BMI was driven by a higher fat mass index. Chapter 4.4 describes associations between different 
types of fatty acids with body composition and cardiometabolic health in childhood. Intake of fat or 
fatty acids at the age of 1 year, however, were not associated with body composition or with other 
aspects of cardiometabolic health in childhood.
Chapter 5 focuses on associations between nutrition and cardiometabolic health in adults. Chapter 
5.1 presents the association between folate and vitamin B12 with body composition in the B-PROOF 
study. higher folate levels were associated with a lower BMI. This association was most pronounced 
in participants with prevalent cardiometabolic diseases, and was mainly driven by FFMI. In Chapter 
5.2 we studied the role of methyl donor nutrients and the risk of diabetes using data from the Nurses’ 
Health Study, Nurses’ Health Study II, and Health Professionals Follow-Up Study. We observed that 
higher intakes of vitamin B2 and vitamin B6 are associated with a lower risk of diabetes. This associa-
tion was attenuated slightly, but remained significant, after adjustment of several sociodemographic 
and lifestyle covariates. Chapter 5.3 presents the association between macronutrient intake and the 
risk of CHD in The Rotterdam Study. Although we observed no association between total protein 
intake, when we separated analyses for animal and vegetable protein we observed significant associa-
tions in opposite directions. A higher animal protein intake was associated with a higher risk of CHD, 
whereas a higher plant protein intake was associated with a lower risk of CHD. Carbohydrates, fat and 
their subgroups were not associated with CHD incidence at the expense of any other macronutrient.
In Chapter 6, interpretation of the main findings are discussed as well as the methodological 
considerations, implications, and recommendation for future studies. 
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In Hoofdstuk 1 van dit proefschrift wordt een algemene introductie van voeding, DNA methylatie 
en cardiometabole gezondheid gegeven en worden de studies waarop dit proefschrift is gebaseerd 
beschreven.  
In Hoofdstuk 2 beschrijft de associaties tussen voeding en DNA methylatie. Hoofdstuk 2.1 geeft 
een overzicht van het huidige bewijs van de associaties tussen verschillende nutriënten met DNA 
methylatie. In dit systematische literatuuronderzoek hebben we 3774 referenties geïdentificeerd, 
waarvan 98 aan alle inclusiecriteria voldeden. De meerderheid onderzocht de associaties in vol-
wassenen. Van alle nutriënten was foliumzuur het meest bestudeerd. Meerdere gen-specifieke en 
epigenoom-brede associatie studies rapporteerden differentiële DNA methylatie van CpG sites in 
relatie tot foliumzuur (o.a. IGF2, H19, HOX), vetzuren (e.g. PPRAGC1A, TNFα), en vitamine D 
(CYP24A1). Een aantal van deze geobserveerde associaties waren specifiek voor bepaalde levensloop-
fases, zoals IGF2 in het vroege levensstadium. Daarnaast waren sommige associaties specifiek voor 
weefsels, zo werden associaties geobserveerd tussen vetinname en methylatie van PPRAGC1A, maar 
deze waren in tegengestelde richtingen voor vetweefsel en spierweefsel. Veelbelovende resultaten zijn 
gerapporteerd op het gebied van voeding en DNA methylatie in mensen op verschillende momenten 
van de levensloop. Vooral voor nutriënten waarvan bekend is dat deze betrokken zijn in het “one-
carbon metabolism”, zoals foliumzuur, maar ook voor andere nutriënten, zoals vetzuren en vitamine 
D. Studies die zich richten op andere nutriënten, zoals andere macronutriënten en verschillende 
mineralen zijn schaars. Verdere grootschalige studies van hoge kwaliteit zijn nodig om onze kennis te 
vergoten van de rol van voeding in DNA methylatie en de effecten hiervan op gezondheid en ziekte. 
In Hoofdstuk 3 worden de associaties tussen DNA methylatie en cardiometabole risicofactoren 
besproken. Hoofdstuk 3.1 geeft een overzicht van de studies die de associatie tussen DNA methylatie, 
zowel globaal, gen-specifiek en epigenoom-breed, met lipide gehalte (inclusief triglyceride, totaal cho-
lesterol, LDL-cholesterol en HDL-cholesterol). In dit systematische literatuuronderzoek includeerden 
we 31 publicaties, gebaseerd op 23 unieke studies. Er waren geen consistente associaties geobserveerd 
voor globale DNA methylatie en lipide gehalte. Gen-specifieke en epigenoom-brede studies lieten 
significante associaties zien tussen lipide gehalte en DNA methylatie op  ABCG1, CPT1A, SREBF1, 
TNNT1, MIR33B en TNIP. Deze bevindingen werden ook gerepliceerd. Hoofdstuk 3.2 presenteert 
de resultaten van een epigenoom-brede associatie studie op lipide gehalte. In deze studie hebben 
we eerder gerapporteerde resultaten gerepliceerd voor methylatie van ABCG1, CPT1A en SREBF1 
met triglyceriden of HDL-cholesterol. Daarnaast observeerden we een nieuwe associatie tussen 
methylatie van een CpG-site die gelokaliseerd is bij DHCR24 en HDL-cholesterol. Het DHCR24 gen 
codeert voor 3-hydroxysterol-24 reductase, een cholesterolbiosynthese enzym dat de omzetting van 
desmosterol naar cholesterol katalyseert. In Hoofdstuk 3.3 presenteren we de bevindingen van een 
epigenoom-brede associatie studie op BMI en middelomtrek in de Rotterdam Study en replicatie 
van deze bevindingen in een VS-gebaseerde studie. We identificeerden en repliceerden 12 CpG sites 
geassocieerd met BMI en 13 CpG sites geassocieerd met middelomtrek. Tot deze bevindingen hoor-
den enkele CpG sites waarvan bekend is dat deze geassocieerd zijn met cardiometabole uitkomsten, 
zoals ABGG1 en CPT1A. Hiernaast identificeerden we twee nieuwe CpG sites welke beide gerelateerd 
waren aan BMI en middelomtrek, namelijk MSI2 en LARS2. MSI2 codeert voor RNA-bindende pro-
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teïnen en speelt een belangrijke rol in posttranscriptionele genregulatie, en is mogelijk geassocieerd 
met eetgedrag. LARS2 codeert voor een enzym dat de aminoacylatie van mitochondriale tRNALeu 
katalyseert en is mogelijk gerelateerd aan bipolaire stoornis.
Hoofdstuk 4 richt zich op de associatie tussen voeding in de vroege jeugd en cardiometabole ge-
zondheid in kinderen op schoolleeftijd van de Generation R Study. In Hoofdstuk 4.1 worden associa-
ties tussen inname van methyl donor nutriënten, inclusief vitamine B6, vitamine B12, foliumzuur, en 
methionine met groei en lichaamssamenstelling beschreven. We observeerden dat een hoge inname 
van foliumzuur op de leeftijd van 1 jaar geassocieerd was met een ongunstige lichaamssamenstelling, 
inclusief een hogere BMI en vetpercentage. Hoofstuk 4.2 laat de associaties zien tussen eiwitinname 
en herhaaldelijk gemeten groei. We observeerden dat een hogere eiwitinname, met name dierlijk ei-
wit, op 1 jaar geassocieerd was met een hogere lengte, gewicht en BMI tot en met de leeftijd van 9 jaar. 
Hoofdstuk 4.3 presenteert de associaties tussen eiwitinname en gedetailleerde lichaamssamenstelling. 
We vonden dat de positieve associatie tussen eiwitinname en BMI voornamelijk werd gedreven door 
een hogere vetmassa. Hoofdstuk 4.4 beschrijft de associaties tussen verschillende soorten vetzuren 
met lichaamssamenstelling en cardiometabole gezondheid in kinderen. Echter was de inname van 
vet of vetzuren op de leeftijd van 1 jaar niet geassocieerd met groei, lichaamssamenstelling of andere 
aspecten van cardiometabole gezondheid. 
Hoofdstuk 5 richt zich op de associatie tussen voeding en cardiometabole gezondheid in volwas-
senen. Hoofdstuk 5.1 presenteert de associaties tussen bloedwaarde van foliumzuur en vitamine 
B12 met lichaamssamenstelling in de B-PROOF Study. We observeerden dat hogere waarden van 
foliumzuur geassocieerd waren met een lagere BMI. Deze associatie was het sterkst in deelnemers 
met cardiometabole ziekten, en werd voornamelijk gedreven door vetvrije massa. In Hoofdstuk 
5.2 bestudeerden we de rol van methyl donor nutriënten en het risico op diabetes met gebruik van 
de data van de Nurses’ Health Study, Nurses’ Health Study II, and Health Professionals Follow-Up 
Study. We observeerden dat een hogere inname van vitamine B2 en vitamine B6 geassocieerd was 
met een verlaging op het risico van type II diabetes. Deze associatie was enigszins verzwakt, maar 
bleef significant na het adjusteren voor verschillende sociodemografische en levensstijl-covariaten. 
Hoofdstuk 5.3 presenteert de associatie tussen inname van macronutriënten en het risico op CHD 
in de Rotterdam Study. Alhoewel we geen associatie observeerden voor totale eiwitinname, waren 
dierlijk en plantaardig eiwit in tegenovergestelde richtingen geassocieerd met CHD. Een hogere in-
name van dierlijk eiwit was geassocieerd met een hoger risico op CHD, terwijl een hogere inname 
van plantaardig eiwit geassocieerd was met een lager risico op CHD. Koolhydraten, vetten, en de 
subgroepen hiervan waren niet geassocieerd met CHD incidentie ten koste van een van de andere 
macronutriënten. 
In Hoofdstuk 6 worden de interpretaties van de belangrijkste bevindingen besproken en de 
methodologische aspecten, implicaties en aanbevelingen voor vervolgstudies. 
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York and Boston as well. I hope we can explore more cities together this way in the future! Mirjam, 
thank you for all you valuable help! To my students: Wendy, Rafaelle, Carolin, and Ehab. Thank you 
for all your hard work, it was great supervising each of you.
A special thank you to Frank Hu for hosting me at the department of Nutrition at the Harvard School 
of Public Health. Shilpa, thank you for all your help and insightful meetings during my stay. Ambika, 
thank you very much for helping me get started with the analyses in SAS. If it wasn’t for you, I would 
probably still be trying to work out the errors in my program! Also, thank you to the rest of the 
group; it was great working with you. My thanks also goes out to all my other colleagues from Boston: 
Jordi and Martha (whose story is probably the academic equivalent of a fairytale), Jacky, Ane, Sarah, 
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Manja, Geng, Gang, Shafqat, Hassan, Jiantoa, Yanping, and Reem. And to my group of colleagues who 
made everyone wonder whether there were any people at Harvard who did not come from Erasmus: 
Klodian, Josje, Jana, Layal, Sirwan, Daniel, Frank, and Tim, thank you for all the nice lunches, coffee 
breaks, dinners, and the occasional beer(s). Boston would not have been as much fun without you. 
Ook wil ik graag mijn voormalig begeleiders bedanken die mij op weg naar dit promotietraject hebben 
geholpen. Anke, mijn afstudeerstage bij B-PROOF was mijn introductie in de wetenschap. Bedankt 
voor je begeleiding gedurende deze periode, dit heeft mij ongetwijfeld een goede start geboden. Edith, 
dankjewel voor de kans te starten bij ErasmusAGE. Iets wat begon als een master thesis, is uiteindelijk 
een proefschrift geworden. Bedankt voor je hulp en aanmoediging hier in verder te gaan. 
Vincent en Mathilde, bedankt dat jullie mijn paranimfen willen zijn! Vincent, bruh, “Started from 
the bottom, now we’re here”. Opgegroeid in dezelfde wijk, op dezelfde middelbare school gezeten, 
al kruisten onze paden niet tot een paar jaar geleden. Maar al snel was het duidelijk – vooral na de 
development of the infamous BraunJen-method in R – wij zijn een top-team! En misschien kunnen 
Bacon en Dikkie Dik ons team versterken in de toekomst. Math, van samen op de middelbare school, 
naar samen de NIHES master, en uiteindelijk beide op naar de PhD. Ik vond het echt gezellig toen 
je ook hier op de afdeling kwam werken, en vind het supertof dat je verder bent gegaan met een 
promotietraject hebt dat echt bij je past. Ik ben blij dat je naast me zult staan tijdens mijn verdediging!
Mijn lieve vriendinnen, Cait, Joyce, Ils, Jess, Jos, Mees, en Mir, bedankt voor alle nodige afleiding in 
de vorm van gezellige dinnerdates, stapavondjes en weekendjes weg. Ook gaat mijn dank uit naar 
mijn hockeyteams, zowel voormalig dames 3 van OMHC als het bedrijfshockeyteam bij Erasmus MC, 
die altijd voor zeer welkome sportieve afleiding en gezelligheid hebben gezorgd. 
Mijn lieve familie, inclusief alle Braunies, Peterse, Bosmans, Wulfjes, en alle “koude kant” die daarbij 
hoort, waar ik zo ontzettend veel bewondering voor heb. Met wat vast een collectief record moet 
zijn in tegenslagen, weten jullie toch altijd moed en veerkracht te tonen. Nick, bedankt voor alle 
schaakpotjes die je toch elke keer weer met me aangaat ondanks dat ik je zelden weet te verslaan. Ik 
ga mijn best doen in de toekomst een gelijkwaardige tegenstander te worden, of op zijn minst een 
uitdaging te bieden! Ik ben zo trots op je dat je besloten hebt verder te studeren en voel me vereerd dat 
je altijd aan mij denkt als je daar een ingewikkelde vraag erover hebt (ookal kan ik ze de helft van de 
tijd niet beantwoorden). Steph, bedankt voor het o zo vaak zitting nemen als test publiek als ik weer 
een presentatie moest voorbereiden. Jouw enige taak was dan ook “alleen maar geïnteresseerd kijken”, 
en wat doe je dat altijd goed! Bedankt voor je instant begrip voor alles wat ik doe en zeg. Hiermee lukt 
het ons altijd, tot grootste ergernis en onbegrip van anderen om ons heen, hele gesprekken te voeren 
met halve woorden en afgebroken zinnen. Ik ben blij dat (ondanks we niet meer samen wonen) we 
nog steeds onze mojo hebben. Eddy, fijn om je bij de familie te hebben. Bedankt dat je zo’n goede 
invloed op mijn lieve zus bent – we hebben haar nog nooit zo snel een keuken zien opruimen – en op 
de rest van ons, volgens mij was onze vakantie in Thailand het meest actief toen we met jullie aan het 
reizen waren. Mam, bedankt voor alle enthousiaste aanmoediging en vrijheid die je ons hebt gegeven 
om onze eigen weg te vinden. En de enorme woordenschat die je ons hebt bijgebracht. De meerder-
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heid zal niemand ooit doorgaans in een zin gebruiken (behalve jij dan natuurlijk), maar mochten ze 
die ene keer aan bod komen, dan ben ik op de hoogte! 
Aan mijn schoonfamilie, zowel de Henneps als Dubois. In het bijzonder Carmen, Wendel, en – voor 
altijd in onze herrinnering – Ruben (al zal dit voor mij altijd “meneer” blijven), bedankt dat jullie me 
altijd thuis hebben laten voelen. Carmen, dankuwel voor alle saoto soep, pom, moksi alesi, nasi, bami, 
roti, bakabana, pitjel, en noem maar op. Ik kijk elke week weer uit naar uw traditionele zondagse 
maaltijden, ze geven me altijd de boost die ik nodig heb om weer vol goede moed de week in te gaan. 
Soso lobi!  
Lieve dikkie, ik weet niet hoe ik moet beginnen je te bedanken voor alle steun die je me hebt gegeven. 
Ik weet niet hoe ik het zonder je had overleefd. Bedankt voor je eindeloze support in alles wat ik doe, 
je onzelfzuchtigheid hier in, je geduld (die ik soms misschien iets teveel op de proef stel), en dat je 
me aan het einde van de dag altijd weer aan het lachen weet te krijgen. Je bent awesome ;) Waar heb 
ik je toch aan verdiend! 
En dan sluit ik dit dankwoord af met degene waarbij het allemaal begon. Lieve papa, wat heb ik jou 
de afgelopen jaren gemist. Ironisch genoeg denk ik dat een van de redenen dat ik jou miste, dezelfde 
reden is dat het succesvol afronden van mijn proefschrift gelukt is. Zonder al jouw wijze lessen was 
dit proefschrift nooit tot stand gekomen. Je hebt ons altijd aangemoedigd vragen te stellen, en nog 
belangrijker, te beantwoorden! Want als we het niet weten, “dan zoeken we het toch op?”. Op de 
strenge regel van tijdens het eten niet van tafel mogen, was er een uitzondering: als de encyclopedie 
of de Dikke van Dale er bij gehaald moest worden. Ik geloof dat hier de ontwikkeling van mijn weten-
schappelijke nieuwsgierigheid is ontstaan. Dit is slechts een klein voorbeeld, hiernaast heb ik nog zo 
ontzettend veel waarvoor ik je wil bedanken, dat de laatste paragraaf van mijn dankwoord minstenst 
de lengte van mijn proefschrift zou kunnen krijgen (wat ik geheel terecht zou vinden, maar geen mens 
die dat leest). Dus laat ik het samenvatten:
Pap, bedankt voor ALLES! 
(p.s. dankzij jouw briljante golfbal oplossing ben ik mijn sleutels al 15 jaar niet meer verloren!)
“Netheid is voor de dommen, het genie beheerst de chaos”
– Albert Einstein
